<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25174599</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1827-6806</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>15</Volume>
<Issue>7-8</Issue>
<PubDate>
<MedlineDate>2014 Jul-Aug</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Giornale italiano di cardiologia (2006)</Title>
<ISOAbbreviation>G Ital Cardiol (Rome)</ISOAbbreviation>
</Journal>
<ArticleTitle>[Preventive medicine and alcohol consumption].</ArticleTitle>
<Pagination>
<MedlinePgn>452-3</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1714/1596.17426</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Testino</LastName>
<ForeName>Gianni</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Patussi</LastName>
<ForeName>Valentino</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Scafato</LastName>
<ForeName>Emanuele</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>ita</Language>
<PublicationTypeList>
<PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
<VernacularTitle>Medicina preventiva e consumo di alcol.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>Italy</Country>
<MedlineTA>G Ital Cardiol (Rome)</MedlineTA>
<NlmUniqueID>101263411</NlmUniqueID>
<ISSNLinking>1827-6806</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000428">Alcohol Drinking</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001145">Arrhythmias, Cardiac</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002318">Cardiovascular Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006293">Health Promotion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007558">Italy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D011315">Preventive Medicine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020521">Stroke</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25087655</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-8392</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>45</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Human pathology</Title>
<ISOAbbreviation>Hum. Pathol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.</ArticleTitle>
<Pagination>
<MedlinePgn>1918-27</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.humpath.2014.05.015</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0046-8177(14)00235-4</ELocationID>
<Abstract>
<AbstractText>Recently, cancer therapies have been supplemented by vascular endothelial growth factor (VEGF) inhibitors as anti-angiogenic agents. However, kidney-related adverse reactions associated with these agents clinically manifest as hypertension and proteinuria, the most severe form being thrombotic microangiopathy (TMA). We present the spectrum of pathological features in VEGF inhibitor-associated kidney disease. Clinicopathological findings of kidney disease were retrospectively studied in 5 cancer patients treated with anti-VEGF agents. Although 4 cases received bevacizumab (anti-VEGF-A), one was given sorafenib (small molecule tyrosine kinase inhibitor affecting VEGF-R2). All patients presented with acute kidney injury, hypertension, and/or proteinuria. All kidney biopsies showed recent and chronic endothelial injury of varying severity and vascular sclerosis, including 2 with typical active features of TMA. Furthermore, acute tubular injury with focal necrosis was seen in all cases. While administration of VEGF inhibitor was discontinued in 4 cases, it was resumed for 5 more doses, following steroid therapy in 1 case. Cessation of VEGF inhibitor therapy was successful in reversing anemia and led to improvement of hypertension and proteinuria in 4 of the 5 cases. One case with TMA progressed to end-stage renal disease. A range of renal pathologic lesions secondary to endothelial injury are noted often accompanied by acute tubular damage following anti-VEGF therapy, the most severe being TMA. While most of the clinical manifestations are reversible with discontinuation of therapy, the role of other nephrotoxic chemotherapeutic agents in enhancing renal injury including severe TMA and other host factors with possible poor outcome should be considered. </AbstractText>
<CopyrightInformation>Copyright Â© 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Usui</LastName>
<ForeName>Joichi</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Weill Cornell Medical College, Cornell University, New York, New York, 10065; Department of Nephrology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, 305-8575, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Glezerman</LastName>
<ForeName>Ilya G</ForeName>
<Initials>IG</Initials>
<AffiliationInfo>
<Affiliation>Renal Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, 10065.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Salvatore</LastName>
<ForeName>Steven P</ForeName>
<Initials>SP</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Weill Cornell Medical College, Cornell University, New York, New York, 10065.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chandran</LastName>
<ForeName>Chandra B</ForeName>
<Initials>CB</Initials>
<AffiliationInfo>
<Affiliation>Nephrology Division, Department of Medicine, St. Joseph's Regional Medical Center, Paterson, New Jersey, 07503.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Flombaum</LastName>
<ForeName>Carlos D</ForeName>
<Initials>CD</Initials>
<AffiliationInfo>
<Affiliation>Renal Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, 10065.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Seshan</LastName>
<ForeName>Surya V</ForeName>
<Initials>SV</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Weill Cornell Medical College, Cornell University, New York, New York, 10065. Electronic address: svs2002@med.cornell.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Hum Pathol</MedlineTA>
<NlmUniqueID>9421547</NlmUniqueID>
<ISSNLinking>0046-8177</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010671">Phenylurea Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>25X51I8RD4</RegistryNumber>
<NameOfSubstance UI="D009536">Niacinamide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>2S9ZZM9Q9V</RegistryNumber>
<NameOfSubstance UI="C469428">bevacizumab</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9ZOQ3TZI87</RegistryNumber>
<NameOfSubstance UI="C471405">sorafenib</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058186">Acute Kidney Injury</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020533">Angiogenesis Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007668">Kidney</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007674">Kidney Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009536">Niacinamide</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010671">Phenylurea Compounds</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011507">Proteinuria</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057049">Thrombotic Microangiopathies</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042461">Vascular Endothelial Growth Factor A</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Acute tubular injury</Keyword>
<Keyword MajorTopicYN="N">Proteinuria</Keyword>
<Keyword MajorTopicYN="N">Renal failure</Keyword>
<Keyword MajorTopicYN="N">Thrombotic microangiopathy</Keyword>
<Keyword MajorTopicYN="N">Vascular endothelial growth factor inhibitor</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25129326</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1474-547X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>384</Volume>
<Issue>9945</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
<Day>30</Day>
</PubDate>
</JournalIssue>
<Title>Lancet</Title>
<ISOAbbreviation>Lancet</ISOAbbreviation>
</Journal>
<ArticleTitle>Obesity: a certain and avoidable cause of cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>727-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(14)61172-7</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0140-6736(14)61172-7</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Campbell</LastName>
<ForeName>Peter T</ForeName>
<Initials>PT</Initials>
<AffiliationInfo>
<Affiliation>Epidemiology Research Program, American Cancer Society, Atlanta, GA 30303, USA. Electronic address: peter.campbell@cancer.org.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016420">Comment</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Lancet</MedlineTA>
<NlmUniqueID>2985213R</NlmUniqueID>
<ISSNLinking>0140-6736</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentOn">
<RefSource>Lancet. 2014 Aug 30;384(9945):755-65</RefSource>
<PMID Version="1">25129328</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015992">Body Mass Index</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25129328</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1474-547X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>384</Volume>
<Issue>9945</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
<Day>30</Day>
</PubDate>
</JournalIssue>
<Title>Lancet</Title>
<ISOAbbreviation>Lancet</ISOAbbreviation>
</Journal>
<ArticleTitle>Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5Â·24 million UK adults.</ArticleTitle>
<Pagination>
<MedlinePgn>755-65</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(14)60892-8</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0140-6736(14)60892-8</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">High body-mass index (BMI) predisposes to several site-specific cancers, but a large-scale systematic and detailed characterisation of patterns of risk across all common cancers adjusted for potential confounders has not previously been undertaken. We aimed to investigate the links between BMI and the most common site-specific cancers.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">With primary care data from individuals in the Clinical Practice Research Datalink with BMI data, we fitted Cox models to investigate associations between BMI and 22 of the most common cancers, adjusting for potential confounders. We fitted linear then non-linear (spline) models; investigated effect modification by sex, menopausal status, smoking, and age; and calculated population effects.</AbstractText>
<AbstractText Label="FINDINGS" NlmCategory="RESULTS">5Â·24 million individuals were included; 166,955 developed cancers of interest. BMI was associated with 17 of 22 cancers, but effects varied substantially by site. Each 5 kg/m(2) increase in BMI was roughly linearly associated with cancers of the uterus (hazard ratio [HR] 1Â·62, 99% CI 1Â·56-1Â·69; p&lt;0Â·0001), gallbladder (1Â·31, 1Â·12-1Â·52; p&lt;0Â·0001), kidney (1Â·25, 1Â·17-1Â·33; p&lt;0Â·0001), cervix (1Â·10, 1Â·03-1Â·17; p=0Â·00035), thyroid (1Â·09, 1Â·00-1Â·19; p=0Â·0088), and leukaemia (1Â·09, 1Â·05-1Â·13; pâ¤0Â·0001). BMI was positively associated with liver (1Â·19, 1Â·12-1Â·27), colon (1Â·10, 1Â·07-1Â·13), ovarian (1Â·09, 1.04-1.14), and postmenopausal breast cancers (1Â·05, 1Â·03-1Â·07) overall (all p&lt;0Â·0001), but these effects varied by underlying BMI or individual-level characteristics. We estimated inverse associations with prostate and premenopausal breast cancer risk, both overall (prostate 0Â·98, 0Â·95-1Â·00; premenopausal breast cancer 0Â·89, 0Â·86-0Â·92) and in never-smokers (prostate 0Â·96, 0Â·93-0Â·99; premenopausal breast cancer 0Â·89, 0Â·85-0Â·94). By contrast, for lung and oral cavity cancer, we observed no association in never smokers (lung 0Â·99, 0Â·93-1Â·05; oral cavity 1Â·07, 0Â·91-1Â·26): inverse associations overall were driven by current smokers and ex-smokers, probably because of residual confounding by smoking amount. Assuming causality, 41% of uterine and 10% or more of gallbladder, kidney, liver, and colon cancers could be attributable to excess weight. We estimated that a 1 kg/m(2) population-wide increase in BMI would result in 3790 additional annual UK patients developing one of the ten cancers positively associated with BMI.</AbstractText>
<AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">BMI is associated with cancer risk, with substantial population-level effects. The heterogeneity in the effects suggests that different mechanisms are associated with different cancer sites and different patient subgroups.</AbstractText>
<AbstractText Label="FUNDING" NlmCategory="BACKGROUND">National Institute for Health Research, Wellcome Trust, and Medical Research Council.</AbstractText>
<CopyrightInformation>Copyright Â© 2014 Bhaskaran et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bhaskaran</LastName>
<ForeName>Krishnan</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Non-Communicable Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, UK. Electronic address: krishnan.bhaskaran@lshtm.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Douglas</LastName>
<ForeName>Ian</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Department of Non-Communicable Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Forbes</LastName>
<ForeName>Harriet</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Non-Communicable Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>dos-Santos-Silva</LastName>
<ForeName>Isabel</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Department of Non-Communicable Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Leon</LastName>
<ForeName>David A</ForeName>
<Initials>DA</Initials>
<AffiliationInfo>
<Affiliation>Department of Non-Communicable Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Smeeth</LastName>
<ForeName>Liam</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Non-Communicable Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, UK; Farr Institute of Health Informatics Research, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>098504</GrantID>
<Agency>Wellcome Trust</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<Agency>Wellcome Trust</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Lancet</MedlineTA>
<NlmUniqueID>2985213R</NlmUniqueID>
<ISSNLinking>0140-6736</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Epidemiol. 2011 Nov 15;174(10):1127-39</RefSource>
<PMID Version="1">21984660</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Natl Cancer Inst. 2012 May 16;104(10):778-89</RefSource>
<PMID Version="1">22457475</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS Med. 2012;9(4):e1001200</RefSource>
<PMID Version="1">22606070</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Oncol. 2012 Jul;23(7):1665-71</RefSource>
<PMID Version="1">22228452</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lancet. 2012 Jul 21;380(9838):219-29</RefSource>
<PMID Version="1">22818936</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Epidemiol. 2012 Aug;41(4):1060-72</RefSource>
<PMID Version="1">22531127</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Epidemiol. 2012 Oct;36(5):425-9</RefSource>
<PMID Version="1">22727737</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>N Engl J Med. 2011 Mar 3;364(9):829-41</RefSource>
<PMID Version="1">21366474</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Epidemiol Biomarkers Prev. 2010 Dec;19(12):3119-30</RefSource>
<PMID Version="1">21030602</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Stat Med. 2010 Dec 10;29(28):2920-31</RefSource>
<PMID Version="1">20842622</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Natl Cancer Inst. 2010 Mar 17;102(6):391-400</RefSource>
<PMID Version="1">20208017</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Br J Clin Pharmacol. 2010 Jan;69(1):4-14</RefSource>
<PMID Version="1">20078607</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Epidemiol. 2009 Aug 1;170(3):297-307</RefSource>
<PMID Version="1">19478235</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2008 Jul 10;26(20):3395-402</RefSource>
<PMID Version="1">18612154</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arch Physiol Biochem. 2008 Feb;114(1):71-83</RefSource>
<PMID Version="1">18465361</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lancet. 2008 Feb 16;371(9612):569-78</RefSource>
<PMID Version="1">18280327</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Breast Cancer Res. 2012;14(3):R76</RefSource>
<PMID Version="1">22583394</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Gynecol Oncol. 2012 May;125(2):330-5</RefSource>
<PMID Version="1">22330614</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Natl Cancer Inst. 2000 Nov 15;92(22):1831-6</RefSource>
<PMID Version="1">11078760</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Public Health Nutr. 2002 Aug;5(4):561-5</RefSource>
<PMID Version="1">12186665</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>N Engl J Med. 2003 Apr 24;348(17):1625-38</RefSource>
<PMID Version="1">12711737</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Natl Cancer Inst. 2003 Aug 20;95(16):1244-8</RefSource>
<PMID Version="1">12928351</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lancet. 2004 Jan 10;363(9403):157-63</RefSource>
<PMID Version="1">14726171</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Pharmacoepidemiol Drug Saf. 2004 Jul;13(7):437-41</RefSource>
<PMID Version="1">15269927</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Epidemiology. 2004 Sep;15(5):615-25</RefSource>
<PMID Version="1">15308962</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Br J Cancer. 2006 Aug 7;95(3):366-70</RefSource>
<PMID Version="1">16832414</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMJ. 2007 Dec 1;335(7630):1134</RefSource>
<PMID Version="1">17986716</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2303-11</RefSource>
<PMID Version="1">24127414</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Cancer Prev. 2013 Nov;22(6):492-505</RefSource>
<PMID Version="1">23591454</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Pharmacoepidemiol Drug Saf. 2013 Feb;22(2):168-75</RefSource>
<PMID Version="1">23239282</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>Lancet. 2014 Aug 30;384(9945):727-8</RefSource>
<PMID Version="1">25129326</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015992">Body Mass Index</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D006113">Great Britain</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016016">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012306">Risk</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4151483</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25174744</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0767-0974</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>30</Volume>
<Issue>8-9</Issue>
<PubDate>
<MedlineDate>2014 Aug-Sep</MedlineDate>
</PubDate>
</JournalIssue>
<Title>MÃ©decine sciences : M/S</Title>
<ISOAbbreviation>Med Sci (Paris)</ISOAbbreviation>
</Journal>
<ArticleTitle>[HDAC5 inhibition: a tool to stop cancer cell immortality].</ArticleTitle>
<Pagination>
<MedlinePgn>730-2</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1051/medsci/20143008005</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Polese</LastName>
<ForeName>Catherine</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Laboratoire de recherche sur les mÃ©tastases, groupe HDAC, UniversitÃ© de LiÃ¨ge, Institut deÂ pathologie B23, B-4000 LiÃ¨ge (Sart-Tilman), Belgique - Adresse actuelle : Signalisation et interaction des protÃ©ines, GIGA-R (B34), avenue de l'HÃ´pital, 1, B-4000 LiÃ¨ge, Belgique.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mottet</LastName>
<ForeName>Denis</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Laboratoire de recherche sur les mÃ©tastases, groupe HDAC, UniversitÃ© de LiÃ¨ge, Institut deÂ pathologie B23, B-4000 LiÃ¨ge (Sart-Tilman), Belgique - Adresse actuelle : Signalisation et interaction des protÃ©ines, GIGA-R (B34), avenue de l'HÃ´pital, 1, B-4000 LiÃ¨ge, Belgique.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType UI="D016433">News</PublicationType>
</PublicationTypeList>
<VernacularTitle>Inhiber HDAC5: un outil pour couper court Ã  l'immortalitÃ© des cellules cancÃ©reuses.</VernacularTitle>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>France</Country>
<MedlineTA>Med Sci (Paris)</MedlineTA>
<NlmUniqueID>8710980</NlmUniqueID>
<ISSNLinking>0767-0974</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002843">Chromatin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D056572">Histone Deacetylase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.1.98</RegistryNumber>
<NameOfSubstance UI="C404500">HDAC5 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.1.98</RegistryNumber>
<NameOfSubstance UI="D006655">Histone Deacetylases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002843">Chromatin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056572">Histone Deacetylase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006655">Histone Deacetylases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059505">Telomere Homeostasis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25174748</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0767-0974</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>30</Volume>
<Issue>8-9</Issue>
<PubDate>
<MedlineDate>2014 Aug-Sep</MedlineDate>
</PubDate>
</JournalIssue>
<Title>MÃ©decine sciences : M/S</Title>
<ISOAbbreviation>Med Sci (Paris)</ISOAbbreviation>
</Journal>
<ArticleTitle>[Regulation of immunological visibility by the EGF receptor].</ArticleTitle>
<Pagination>
<MedlinePgn>742-4</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1051/medsci/20143008009</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Vantourout</LastName>
<ForeName>Pierre</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Peter Gorer Department of Immunobiology, King's College London, London, Royaume-Uni - London Research Institute, Cancer Research UK, London, Royaume-Uni.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hayday</LastName>
<ForeName>Adrian</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Peter Gorer Department of Immunobiology, King's College London, London, Royaume-Uni - London Research Institute, Cancer Research UK, London, Royaume-Uni - Medical Research Council Centre for Transplantation Biology, London, Royaume-Uni - Comprehensive Biomedical Research Centre of Guy's and St Thomas' Hospitals and King's College London, Great Maze Pond, SE1Â 9RT London, Royaume-Uni.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType UI="D016433">News</PublicationType>
</PublicationTypeList>
<VernacularTitle>RÃ©gulation de la visibilitÃ© immunologique par leÂ rÃ©cepteur de l'EGF.</VernacularTitle>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>France</Country>
<MedlineTA>Med Sci (Paris)</MedlineTA>
<NlmUniqueID>8710980</NlmUniqueID>
<ISSNLinking>0767-0974</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C527085">KLRK1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055655">NK Cell Lectin-Like Receptor Subfamily K</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017951">Antigen Presentation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007113">Immunity, Innate</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008214">Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055655">NK Cell Lectin-Like Receptor Subfamily K</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020871">RNA Stability</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011958">Receptor, Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013312">Stress, Physiological</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019139">Tumor Escape</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25174752</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0767-0974</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>30</Volume>
<Issue>8-9</Issue>
<PubDate>
<MedlineDate>2014 Aug-Sep</MedlineDate>
</PubDate>
</JournalIssue>
<Title>MÃ©decine sciences : M/S</Title>
<ISOAbbreviation>Med Sci (Paris)</ISOAbbreviation>
</Journal>
<ArticleTitle>[Bacterial infections as seen from the eukaryotic genome: DNA double strand breaks, inflammation and cancer].</ArticleTitle>
<Pagination>
<MedlinePgn>758-64</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1051/medsci/20143008013</ELocationID>
<Abstract>
<AbstractText>An increasing number of studies report that infection by pathogenic bacteria alters the host genome, producing highly hazardous DNA double strand breaks for the eukaryotic cell. Even when DNA repair occurs, it often leaves "scars" on chromosomes that might generate genomic instability at the next cell division. Chronic intestinal inflammation promotes the expansion of genotoxic bacteria in the intestinal microbiote which in turn triggers tumor formation and colon carcinomas. Bacteria act at the level of the host DNA repair machinery. They also highjack the host cell cycle to allow themselves time for replication in an appropriate reservoir. However, except in the case of bacteria carrying the CDT nuclease, the molecular mechanisms responsible for DNA lesions are not well understood, even if reactive oxygen species released during infection make good candidates. </AbstractText>
<CopyrightInformation>Â© 2014 mÃ©decine/sciences â Inserm.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lemercier</LastName>
<ForeName>Claudie</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Inserm UMR_S 1038, biologie Ã  grande Ã©chelle (BGE), 38054 Grenoble, France - CEA, institut de recherches en technologies et sciences pour le vivant (iRTSV), BEG, 38054 Grenoble, France - UniversitÃ© Grenoble-Alpes, 38000 Grenoble, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<VernacularTitle>Les infections bactÃ©riennes vues du gÃ©nome eucaryote - cassures double-brin, inflammation et cancer.</VernacularTitle>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>France</Country>
<MedlineTA>Med Sci (Paris)</MedlineTA>
<NlmUniqueID>8710980</NlmUniqueID>
<ISSNLinking>0767-0974</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001424">Bacterial Infections</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D053903">DNA Breaks, Double-Stranded</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004260">DNA Repair</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004926">Escherichia coli</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000472">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005057">Eukaryotic Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016678">Genome</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016480">Helicobacter pylori</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000472">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25174754</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0767-0974</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>30</Volume>
<Issue>8-9</Issue>
<PubDate>
<MedlineDate>2014 Aug-Sep</MedlineDate>
</PubDate>
</JournalIssue>
<Title>MÃ©decine sciences : M/S</Title>
<ISOAbbreviation>Med Sci (Paris)</ISOAbbreviation>
</Journal>
<ArticleTitle>[Pin1: a multi-talented peptidyl prolyl cis-trans isomerase and a promising therapeutic target for human cancers].</ArticleTitle>
<Pagination>
<MedlinePgn>772-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1051/medsci/20143008015</ELocationID>
<Abstract>
<AbstractText>Post-translational modifications are critical to modulate protein function. A post-translational mechanism, peptidyl prolyl cis-trans isomerisation, plays a key role in protein regulation. Pin1 is a ubiquitous peptidyl prolyl cis-trans isomerase conserved from Archae to Human. This enzyme binds and isomerizes phospho-serine/threonine-proline motifs. This process can induce conformational change in protein targets and modulates their activity, cellular localization, phosphorylation state, stability and/or protein-protein interactions. Pin1 activity regulates proteins involved in cell proliferation, pluripotency or cellular invasion. Pin1 is overexpressed in several human cancers and contributes to tumorigenesis. Its inactivation constitutes a promising therapeutic strategy. </AbstractText>
<CopyrightInformation>Â© 2014 mÃ©decine/sciences â Inserm.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Marsolier</LastName>
<ForeName>Justine</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Sorbonne Paris CitÃ©, universitÃ© Paris Diderot, UMR7216 CNRS, ÃpigÃ©nÃ©tique et destin cellulaire, Laboratoire plasticitÃ© des phÃ©notypes cellulaires, 35, rue HÃ©lÃ¨ne Brion, case courrier 7042, 75013 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Weitzman</LastName>
<ForeName>Jonathan B</ForeName>
<Initials>JB</Initials>
<AffiliationInfo>
<Affiliation>Sorbonne Paris CitÃ©, universitÃ© Paris Diderot, UMR7216 CNRS, ÃpigÃ©nÃ©tique et destin cellulaire, Laboratoire plasticitÃ© des phÃ©notypes cellulaires, 35, rue HÃ©lÃ¨ne Brion, case courrier 7042, 75013 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<VernacularTitle>Pin1: une peptidyl-prolyl cis-trans isomÃ©rase multifonctionnelle et une cible anticancÃ©reuse prometteuse.</VernacularTitle>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>France</Country>
<MedlineTA>Med Sci (Paris)</MedlineTA>
<NlmUniqueID>8710980</NlmUniqueID>
<ISSNLinking>0767-0974</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C098989">NIMA-interacting peptidylprolyl isomerase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 5.2.1.8</RegistryNumber>
<NameOfSubstance UI="D019696">Peptidylprolyl Isomerase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002471">Cell Transformation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004791">Enzyme Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000639">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019696">Peptidylprolyl Isomerase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25174755</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0767-0974</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>30</Volume>
<Issue>8-9</Issue>
<PubDate>
<MedlineDate>2014 Aug-Sep</MedlineDate>
</PubDate>
</JournalIssue>
<Title>MÃ©decine sciences : M/S</Title>
<ISOAbbreviation>Med Sci (Paris)</ISOAbbreviation>
</Journal>
<ArticleTitle>[Ferroptosis, a new form of cell death relevant to the medical treatment of cancer].</ArticleTitle>
<Pagination>
<MedlinePgn>779-83</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1051/medsci/20143008016</ELocationID>
<Abstract>
<AbstractText>Ferroptosis is a form of cell death that has recently been reported during exposure to erastin, a chemical compound identified in a screen for molecules able to kill cancer cells carrying an active Ras oncogene. In cells exposed to inducers of ferroptosis, a catastrophic alteration of the cellular redox metabolism occurs, resulting in massive lipid peroxidation in the plasma membrane and loss of cell viability. We present our recent observations suggesting that sorafenib, the only medical treatment with proven efficacy against hepatocellular carcinoma, induces ferroptosis, a new anti-oncogenic mode of action of this drug. The discovery of ferroptosis sheds light on the critical adaptations of the redox metabolism in cancer cells. It might also foster the discovery of new biomarkers and innovative approaches for the treatment of cancer. </AbstractText>
<CopyrightInformation>Â© 2014 mÃ©decine/sciences â Inserm.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lachaier</LastName>
<ForeName>Emma</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>EA 4666, universitÃ© de Picardie Jules Verne, Amiens, France - service de biochimie, centre de biologie humaine (CBH), CHU Amiens Sud, 80054 Salouel Cedex, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Louandre</LastName>
<ForeName>Christophe</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>EA 4666, universitÃ© de Picardie Jules Verne, Amiens, France - service de biochimie, centre de biologie humaine (CBH), CHU Amiens Sud, 80054 Salouel Cedex, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ezzoukhry</LastName>
<ForeName>Zakaria</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Inserm U1053, universitÃ© de Bordeaux Segalen, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Godin</LastName>
<ForeName>Corinne</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>EA 4666, universitÃ© de Picardie Jules Verne, Amiens, France - service de biochimie, centre de biologie humaine (CBH), CHU Amiens Sud, 80054 Salouel Cedex, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>MaziÃ¨re</LastName>
<ForeName>Jean-Claude</ForeName>
<Initials>JC</Initials>
<AffiliationInfo>
<Affiliation>service de biochimie, centre de biologie humaine (CBH), CHU Amiens Sud, 80054 Salouel Cedex, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chauffert</LastName>
<ForeName>Bruno</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>EA 4666, universitÃ© de Picardie Jules Verne, Amiens, France - service d'oncologie mÃ©dicale, CHU Amiens, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Galmiche</LastName>
<ForeName>Antoine</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>EA 4666, universitÃ© de Picardie Jules Verne, Amiens, France - service de biochimie, centre de biologie humaine (CBH), CHU Amiens Sud, 80054 Salouel Cedex, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<VernacularTitle>La ferroptose, uneÂ nouvelle forme de mort cellulaire applicable au traitement mÃ©dical des cancers.</VernacularTitle>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>France</Country>
<MedlineTA>Med Sci (Paris)</MedlineTA>
<NlmUniqueID>8710980</NlmUniqueID>
<ISSNLinking>0767-0974</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C477224">erastin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015227">Lipid Peroxidation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010084">Oxidation-Reduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010879">Piperazines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25174758</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0767-0974</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>30</Volume>
<Issue>8-9</Issue>
<PubDate>
<MedlineDate>2014 Aug-Sep</MedlineDate>
</PubDate>
</JournalIssue>
<Title>MÃ©decine sciences : M/S</Title>
<ISOAbbreviation>Med Sci (Paris)</ISOAbbreviation>
</Journal>
<ArticleTitle>[CTIP2, a multifunctional protein: cellular physiopathology and therapeutic implications].</ArticleTitle>
<Pagination>
<MedlinePgn>797-802</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1051/medsci/20143008019</ELocationID>
<Abstract>
<AbstractText>The transcription factor CTIP2 (BCL11B) is a multifunctional protein involved in numerous cell physiological processes. To date, many molecular mechanisms underlying this process have been discovered, which highlighted the importance of the epigenetic regulation of genes and the regulation of the elongation factor P-TEFb. Furthermore studies of the deregulation of CTIP2 showed the association of CTIP2 to numerous pathologies including cancer and cardiac hypertrophy. A better comprehension of the physiopathology of these diseases might lead to the design of therapeutical strategies intending to prevent CTIP2 deregulation. Moreover, CTIP2 and its associated proteins constitute potential targets in strategies aiming to reduce and/or purge HIV-1 cell reservoirs. </AbstractText>
<CopyrightInformation>Â© 2014 mÃ©decine/sciences â Inserm.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Le Douce</LastName>
<ForeName>Valentin</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Institut de parasitologie etÂ deÂ pathologie tropicale, EA7292, universitÃ© de Strasbourg, Strasbourg, France - IUT de Schiltigheim, 1 allÃ©e d'AthÃ¨nes, Schiltigheim, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cherrier</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of protein -interactions and signaling, -universitÃ© de LiÃ¨ge, LiÃ¨ge, Belgique.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Riclet</LastName>
<ForeName>RaphaÃ«l</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Institut de parasitologie etÂ deÂ pathologie tropicale, EA7292, universitÃ© de Strasbourg, Strasbourg, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rohr</LastName>
<ForeName>Olivier</ForeName>
<Initials>O</Initials>
<AffiliationInfo>
<Affiliation>Institut de parasitologie etÂ deÂ pathologie tropicale, EA7292, universitÃ© de Strasbourg, Strasbourg, France - IUT de Schiltigheim, 1 allÃ©e d'AthÃ¨nes, Schiltigheim, France - Institut universitaire de France, 103, boulevard Saint-Michel, 75005 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schwartz</LastName>
<ForeName>Christian</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Institut de parasitologie etÂ deÂ pathologie tropicale, EA7292, universitÃ© de Strasbourg, Strasbourg, France - IUT de Schiltigheim, 1 allÃ©e d'AthÃ¨nes, Schiltigheim, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<VernacularTitle>CTIP2, une protÃ©ine multifonctionnelle - implication en physiopathologie cellulaire et en thÃ©rapeutique.</VernacularTitle>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>France</Country>
<MedlineTA>Med Sci (Paris)</MedlineTA>
<NlmUniqueID>8710980</NlmUniqueID>
<ISSNLinking>0767-0974</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C479740">BCL11B protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.-</RegistryNumber>
<NameOfSubstance UI="D042925">Positive Transcriptional Elongation Factor B</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000163">Acquired Immunodeficiency Syndrome</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006332">Cardiomegaly</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044127">Epigenesis, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015658">HIV Infections</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015497">HIV-1</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D058990">Molecular Targeted Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042925">Positive Transcriptional Elongation Factor B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012097">Repressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025521">Tumor Suppressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017735">Virus Latency</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25174759</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0767-0974</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>30</Volume>
<Issue>8-9</Issue>
<PubDate>
<MedlineDate>2014 Aug-Sep</MedlineDate>
</PubDate>
</JournalIssue>
<Title>MÃ©decine sciences : M/S</Title>
<ISOAbbreviation>Med Sci (Paris)</ISOAbbreviation>
</Journal>
<ArticleTitle>[Why is it difficult to implement biomedical policy? the case of the CancÃ©ropÃ´les, the French cancer organizations].</ArticleTitle>
<Pagination>
<MedlinePgn>803-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1051/medsci/20143008020</ELocationID>
<Abstract>
<AbstractText>This article examines the new organizations in cancer research in France called cancÃ©ropÃ´les and created in 2003, whose mission is to coordinate actors from industry, research and clinical fields. Our research is based on a study of cancÃ©ropÃ´les which embraces an evolutionary perspective on cluster formation and development. Our analysis reveals that although clear differences exist between them, our sample of the three established CancÃ©ropÃ´les display similar patterns of unsuccessful cases. Eventually, the identification of mechanisms that reduce their action in the cancer research environment raises questions about the factors that may influence any public action to a reconfiguration of the French biomedical sector. </AbstractText>
<CopyrightInformation>Â© 2014 mÃ©decine/sciences â Inserm.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>VÃ©zian</LastName>
<ForeName>Audrey</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Centre de sociologie des organisations, CNRS et Sciences Po Paris, 19, rue AmÃ©lie, 75007 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>L'action mitigÃ©e des cancÃ©ropÃ´les - les raisons de l'abandon d'une politique biomÃ©dicale ambitieuse.</VernacularTitle>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>France</Country>
<MedlineTA>Med Sci (Paris)</MedlineTA>
<NlmUniqueID>8710980</NlmUniqueID>
<ISSNLinking>0767-0974</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Med Sci (Paris). 2014 Oct;30(10):925</RefSource>
<PMID Version="1">25311029</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035843">Biomedical Research</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000458">organization &amp; administration</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D005602">France</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009369">Neoplasms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D011640">Public Policy</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25174760</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0767-0974</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>30</Volume>
<Issue>8-9</Issue>
<PubDate>
<MedlineDate>2014 Aug-Sep</MedlineDate>
</PubDate>
</JournalIssue>
<Title>MÃ©decine sciences : M/S</Title>
<ISOAbbreviation>Med Sci (Paris)</ISOAbbreviation>
</Journal>
<ArticleTitle>[From exome sequencing to avatar creation: towards Â«Â precision oncologyÂ Â»?].</ArticleTitle>
<Pagination>
<MedlinePgn>809-11</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1051/medsci/20143008021</ELocationID>
<Abstract>
<AbstractText>According to recent reports, the success rate of targeted therapy directed by "actionable mutations" found in tumour DNA is rather low (10 to 20%). Interesting attempts have been made to improve this by establishing mouse "avatars" and testing drugs on them. The first results are promising, but the clinical utility of this expensive and cumbersome approach needs to be ascertained by more extensive testing. </AbstractText>
<CopyrightInformation>Â© 2014 mÃ©decine/sciences â Inserm.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jordan</LastName>
<ForeName>Bertrand</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>UMR 7268 ADÃS, Aix-Marseille UniversitÃ©/EFS/CNRS, Espace Ã©thique mÃ©diterranÃ©en, HÃ´pital d'adultes La Timone, 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France - CoReBio PACA, case 901, parc scientifique de Luminy, 13288 Marseille Cedex 09, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>De l'exome Ã  l'avatar: vers une Â« oncologie de prÃ©cision Â» ? - Chroniques gÃ©nomiques.</VernacularTitle>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>France</Country>
<MedlineTA>Med Sci (Paris)</MedlineTA>
<NlmUniqueID>8710980</NlmUniqueID>
<ISSNLinking>0767-0974</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059472">Exome</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018014">Gene Transfer Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000639">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017422">Sequence Analysis, DNA</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25131830</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1474-1784</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>13</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Nature reviews. Drug discovery</Title>
<ISOAbbreviation>Nat Rev Drug Discov</ISOAbbreviation>
</Journal>
<ArticleTitle>Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.</ArticleTitle>
<Pagination>
<MedlinePgn>673-91</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nrd4360</ELocationID>
<Abstract>
<AbstractText>Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters. Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small molecules. This Review discusses the role of altered expression and/or function of one class of epigenetic regulators--histone deacetylases (HDACs)--and their role in cancer, neurological diseases and immune disorders. We highlight the development of small-molecule HDAC inhibitors and their use in the laboratory, in preclinical models and in the clinic.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Falkenberg</LastName>
<ForeName>Katrina J</ForeName>
<Initials>KJ</Initials>
<AffiliationInfo>
<Affiliation>Cancer Therapeutics Program, The Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne 3002, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Johnstone</LastName>
<ForeName>Ricky W</ForeName>
<Initials>RW</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Therapeutics Program, The Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne 3002, Victoria, Australia. [2] Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville 3052, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nat Rev Drug Discov</MedlineTA>
<NlmUniqueID>101124171</NlmUniqueID>
<ISSNLinking>1474-1776</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D056572">Histone Deacetylase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.1.98</RegistryNumber>
<NameOfSubstance UI="D006655">Histone Deacetylases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044127">Epigenesis, Genetic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056572">Histone Deacetylase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006655">Histone Deacetylases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007154">Immune System Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009422">Nervous System Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25178695</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>20</Day>
</DateCompleted>
<Article PubModel="Electronic-Print">
<Journal>
<ISSN IssnType="Electronic">1460-2105</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>106</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Journal of the National Cancer Institute</Title>
<ISOAbbreviation>J. Natl. Cancer Inst.</ISOAbbreviation>
</Journal>
<ArticleTitle>A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis.</ArticleTitle>
<Pagination>
<MedlinePgn>dju200</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/jnci/dju200</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">dju200</ELocationID>
<Abstract>
<AbstractText>Tumor-infiltrating leukocytes are often induced by the cancer microenvironment to display a protumor, proangiogenic phenotype. This "polarization" has been described for several myeloid cells, in particular macrophages. Natural killer (NK) cells represent another population of innate immune cells able to infiltrate tumors. The role of NK in tumor progression and angiogenesis has not yet been fully investigated. Several studies have shown that tumor-infiltrating NK (here referred to as "TINKs") and tumor-associated NK (altered peripheral NK cells, which here we call "TANKs") are compromised in their ability to lysew tumor cells. Recent data have suggested that they are potentially protumorigenic and can also acquire a proangiogenic phenotype. Here we review the properties of TINKs and TANKs and compare their activities to that of NK cells endowed with a physiological proangiogenic phenotype, in particular decidual NK cells. We speculate on the potential origins of TINKs and TANKs and on the immune signals involved in their differentiation and polarization. The TINK and TANK phenotype has broad implications in the immune response to tumors, ranging from a deficient control of cancer and cancer stem cells to an altered crosstalk with other relevant players of the immune response, such as dendritic cells, to induction of cancer angiogenesis. With this recently acquired knowledge that has not yet been put into perspective, we point out new potential avenues for therapeutic intervention involving NK cells as a target or an ally in oncology. </AbstractText>
<CopyrightInformation>Â© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bruno</LastName>
<ForeName>Antonino</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Scientific and Technology Park, IRCCS MultiMedica, Milano, Italy (AB, DMN); Department of Human Pathology, University of Messina, Messina, Italy (GF); Department of Research and Statistics, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy (AA); Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy (DMN).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ferlazzo</LastName>
<ForeName>Guido</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Scientific and Technology Park, IRCCS MultiMedica, Milano, Italy (AB, DMN); Department of Human Pathology, University of Messina, Messina, Italy (GF); Department of Research and Statistics, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy (AA); Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy (DMN).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Albini</LastName>
<ForeName>Adriana</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Scientific and Technology Park, IRCCS MultiMedica, Milano, Italy (AB, DMN); Department of Human Pathology, University of Messina, Messina, Italy (GF); Department of Research and Statistics, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy (AA); Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy (DMN).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Noonan</LastName>
<ForeName>Douglas M</ForeName>
<Initials>DM</Initials>
<AffiliationInfo>
<Affiliation>Scientific and Technology Park, IRCCS MultiMedica, Milano, Italy (AB, DMN); Department of Human Pathology, University of Messina, Messina, Italy (GF); Department of Research and Statistics, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy (AA); Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy (DMN).</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Natl Cancer Inst</MedlineTA>
<NlmUniqueID>7503089</NlmUniqueID>
<ISSNLinking>0027-8874</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003713">Dendritic Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007167">Immunotherapy</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007694">Killer Cells, Natural</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D016246">Lymphocytes, Tumor-Infiltrating</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009389">Neovascularization, Pathologic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25087755</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-8421</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>274</Volume>
<Issue>1-2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Journal of neuroimmunology</Title>
<ISOAbbreviation>J. Neuroimmunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Non-stiff anti-amphiphysin syndrome: clinical manifestations and outcome after immunotherapy.</ArticleTitle>
<Pagination>
<MedlinePgn>209-14</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jneuroim.2014.07.011</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0165-5728(14)00226-4</ELocationID>
<Abstract>
<AbstractText>Amphiphysin antibody causes paraneoplastic stiff-person syndrome and can also result in a variety of neurological manifestations. Here, we investigated the clinical spectrum of 20 patients with non-stiff anti-amphiphysin syndrome and their responses to immunotherapy. The most common neurological manifestation was limbic encephalitis (n=10), followed by dysautonomia (n=9), and cerebellar dysfunction (n=6). Cancer was detected in only seven patients. Intravenous immunoglobulin or steroid treatment was effective in most patients, but three improved only after rituximab treatment. Our study suggests that anti-amphiphysin syndrome can manifest as non-stiff encephalomyelitis and is only partially associated with cancer. Active immunotherapy, including rituximab, would be beneficial. </AbstractText>
<CopyrightInformation>Copyright Â© 2014 Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Moon</LastName>
<ForeName>Jangsup</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea; Program in Neuroscience, Seoul National University College of Medicine, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Soon-Tae</ForeName>
<Initials>ST</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea; Program in Neuroscience, Seoul National University College of Medicine, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shin</LastName>
<ForeName>Jung-Won</ForeName>
<Initials>JW</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea; Program in Neuroscience, Seoul National University College of Medicine, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Byun</LastName>
<ForeName>Jung-Ick</ForeName>
<Initials>JI</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea; Program in Neuroscience, Seoul National University College of Medicine, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lim</LastName>
<ForeName>Jung-Ah</ForeName>
<Initials>JA</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea; Program in Neuroscience, Seoul National University College of Medicine, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shin</LastName>
<ForeName>Yong-Won</ForeName>
<Initials>YW</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea; Program in Neuroscience, Seoul National University College of Medicine, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Tae-Joon</ForeName>
<Initials>TJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea; Program in Neuroscience, Seoul National University College of Medicine, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Keon-Joo</ForeName>
<Initials>KJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea; Program in Neuroscience, Seoul National University College of Medicine, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Kyung-Il</ForeName>
<Initials>KI</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Seoul Paik Hospital, Inje University College of Medicine, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jung</LastName>
<ForeName>Keun-Hwa</ForeName>
<Initials>KH</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea; Program in Neuroscience, Seoul National University College of Medicine, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jung</LastName>
<ForeName>Ki-Young</ForeName>
<Initials>KY</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea; Program in Neuroscience, Seoul National University College of Medicine, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Sang Kun</ForeName>
<Initials>SK</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea; Program in Neuroscience, Seoul National University College of Medicine, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chu</LastName>
<ForeName>Kon</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea; Program in Neuroscience, Seoul National University College of Medicine, Seoul, South Korea. Electronic address: stemcell.snu@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>J Neuroimmunol</MedlineTA>
<NlmUniqueID>8109498</NlmUniqueID>
<ISSNLinking>0165-5728</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058846">Antibodies, Monoclonal, Murine-Derived</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C092560">rituximab</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>147954-52-7</RegistryNumber>
<NameOfSubstance UI="C075637">amphiphysin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058846">Antibodies, Monoclonal, Murine-Derived</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001323">Autoantibodies</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002526">Cerebellar Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004679">Encephalomyelitis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016756">Immunoglobulins, Intravenous</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007155">Immunologic Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020363">Limbic Encephalitis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009419">Nerve Tissue Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054969">Primary Dysautonomias</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016750">Stiff-Person Syndrome</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Anti-amphiphysin antibody</Keyword>
<Keyword MajorTopicYN="N">Immunotherapy</Keyword>
<Keyword MajorTopicYN="N">Paraneoplastic neurological syndrome</Keyword>
<Keyword MajorTopicYN="N">Stiff-person syndrome</Keyword>
<Keyword MajorTopicYN="N">rituximab</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25181900</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1068-8838</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>88</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Hospitals &amp; health networks / AHA</Title>
<ISOAbbreviation>Hosp Health Netw</ISOAbbreviation>
</Journal>
<ArticleTitle>Fear factor. Patient navigators are growing in number.</ArticleTitle>
<Pagination>
<MedlinePgn>24</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kreimer</LastName>
<ForeName>Susan</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016433">News</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Hosp Health Netw</MedlineTA>
<NlmUniqueID>9312077</NlmUniqueID>
<ISSNLinking>1068-8838</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000223">Adaptation, Psychological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D001294">Attitude to Health</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005239">Fear</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000451">nursing</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D024802">Nurse's Role</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009723">Nurse-Patient Relations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009859">Oncology Nursing</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000458">organization &amp; administration</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D062526">Patient Navigation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000458">organization &amp; administration</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25180996</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1439-4413</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>139</Volume>
<Issue>37</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Deutsche medizinische Wochenschrift (1946)</Title>
<ISOAbbreviation>Dtsch. Med. Wochenschr.</ISOAbbreviation>
</Journal>
<ArticleTitle>[Safety of biologic therapy - results from the German biologics register RABBIT].</ArticleTitle>
<Pagination>
<MedlinePgn>1817-20</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0034-1370252</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Strangfeld</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Programmbereich Epidemiologie, Deutsches Rheuma-Forschungszentrum Berlin.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zink</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Programmbereich Epidemiologie, Deutsches Rheuma-Forschungszentrum Berlin.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>ger</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<VernacularTitle>Sicherheit unter Biologika - Ergebnisse aus dem deutschen Biologika-Register RABBIT.</VernacularTitle>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Dtsch Med Wochenschr</MedlineTA>
<NlmUniqueID>0006723</NlmUniqueID>
<ISSNLinking>0012-0472</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001688">Biological Products</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016907">Adverse Drug Reaction Reporting Systems</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018501">Antirheumatic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001172">Arthritis, Rheumatoid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001688">Biological Products</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015897">Comorbidity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005938">Glucocorticoids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006333">Heart Failure</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009203">Myocardial Infarction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009894">Opportunistic Infections</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D012042">Registries</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012306">Risk</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020521">Stroke</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016019">Survival Analysis</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23957903</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1930-7810</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Health psychology : official journal of the Division of Health Psychology, American Psychological Association</Title>
<ISOAbbreviation>Health Psychol</ISOAbbreviation>
</Journal>
<ArticleTitle>Pain, depression, and fatigue: loneliness as a longitudinal risk factor.</ArticleTitle>
<Pagination>
<MedlinePgn>948-57</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1037/a0034012</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Pain, depression, and fatigue function as a symptom cluster and thus may share common risk factors. Interpersonal relationships clearly influence health, suggesting that loneliness may promote the development of the pain, depression, and fatigue symptom cluster. We hypothesized that loneliness would be related to concurrent symptom cluster levels and increases in symptom cluster levels over time.</AbstractText>
<AbstractText Label="METHOD" NlmCategory="METHODS">We utilized two observational studies with distinct longitudinal samples. Study 1 was a sample of cancer survivors and benign controls (N = 115) assessed annually for 2 years. Study 2 was a sample of older adults caring for a spouse with dementia (caregivers) and non-caregiver controls (N = 229) assessed annually for 4 years. Participants completed annual measures assessing loneliness, pain, depression, and fatigue.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Across both samples, lonelier participants experienced more concurrent pain, depression, and fatigue and larger increases in symptom cluster levels from one year to the next than less lonely participants. Sleep quality did not mediate the results in either study. All analyses were adjusted for relevant demographic and health variables.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Two longitudinal studies with different populations demonstrated that loneliness was a risk factor for the development of the pain, depression, and fatigue symptom cluster over time. The current research helps identify people most at risk for pain, depression, and fatigue, and lays the groundwork for research about their diagnosis and treatment. These data also highlight the health risks of loneliness; pain, depression, and fatigue often accompany serious illness and place people at risk for poor health and mortality.</AbstractText>
<CopyrightInformation>(PsycINFO Database Record (c) 2014 APA, all rights reserved).</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jaremka</LastName>
<ForeName>Lisa M</ForeName>
<Initials>LM</Initials>
<AffiliationInfo>
<Affiliation>Institute for Behavioral Medicine Research.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Andridge</LastName>
<ForeName>Rebecca R</ForeName>
<Initials>RR</Initials>
<AffiliationInfo>
<Affiliation>College of Public Health.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fagundes</LastName>
<ForeName>Christopher P</ForeName>
<Initials>CP</Initials>
<AffiliationInfo>
<Affiliation>Institute for Behavioral Medicine Research.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Alfano</LastName>
<ForeName>Catherine M</ForeName>
<Initials>CM</Initials>
<AffiliationInfo>
<Affiliation>National Cancer Institute.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Povoski</LastName>
<ForeName>Stephen P</ForeName>
<Initials>SP</Initials>
<AffiliationInfo>
<Affiliation>Comprehensive Cancer Center.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lipari</LastName>
<ForeName>Adele M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo>
<Affiliation>Comprehensive Cancer Center.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Agnese</LastName>
<ForeName>Doreen M</ForeName>
<Initials>DM</Initials>
<AffiliationInfo>
<Affiliation>Comprehensive Cancer Center.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Arnold</LastName>
<ForeName>Mark W</ForeName>
<Initials>MW</Initials>
<AffiliationInfo>
<Affiliation>Comprehensive Cancer Center.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Farrar</LastName>
<ForeName>William B</ForeName>
<Initials>WB</Initials>
<AffiliationInfo>
<Affiliation>Comprehensive Cancer Center.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yee</LastName>
<ForeName>Lisa D</ForeName>
<Initials>LD</Initials>
<AffiliationInfo>
<Affiliation>Comprehensive Cancer Center.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Carson</LastName>
<ForeName>William E</ForeName>
<Initials>WE</Initials>
<Suffix>3rd</Suffix>
<AffiliationInfo>
<Affiliation>Comprehensive Cancer Center.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bekaii-Saab</LastName>
<ForeName>Tanios</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Comprehensive Cancer Center.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Martin</LastName>
<ForeName>Edward W</ForeName>
<Initials>EW</Initials>
<Suffix>Jr</Suffix>
<AffiliationInfo>
<Affiliation>Comprehensive Cancer Center.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schmidt</LastName>
<ForeName>Carl R</ForeName>
<Initials>CR</Initials>
<AffiliationInfo>
<Affiliation>Comprehensive Cancer Center.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kiecolt-Glaser</LastName>
<ForeName>Janice K</ForeName>
<Initials>JK</Initials>
<AffiliationInfo>
<Affiliation>Institute for Behavioral Medicine Research.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>AG011585</GrantID>
<Acronym>AG</Acronym>
<Agency>NIA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA131029</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>K05 CA172296</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>M01 RR000034</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>M01RR0034</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA131029</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>UL1 RR025755</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>UL1RR025755</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D064888">Observational Study</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Health Psychol</MedlineTA>
<NlmUniqueID>8211523</NlmUniqueID>
<ISSNLinking>0278-6133</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017028">Caregivers</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003704">Dementia</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003863">Depression</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005221">Fatigue</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016014">Linear Models</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008132">Loneliness</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008137">Longitudinal Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D009820">Ohio</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010146">Pain</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017741">Survivors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013577">Syndrome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS520999 [Available on 09/01/15]</OtherID>
<OtherID Source="NLM">PMC3992976 [Available on 09/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23977875</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1930-7810</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Health psychology : official journal of the Division of Health Psychology, American Psychological Association</Title>
<ISOAbbreviation>Health Psychol</ISOAbbreviation>
</Journal>
<ArticleTitle>Longitudinal changes in clusters of cancer patients over an 18-month period.</ArticleTitle>
<Pagination>
<MedlinePgn>1012-22</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1037/a0033497</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Cross-sectional studies in cancer have revealed the presence of clusters of symptoms (e.g., gastrointestinal, emotional) and of patients (e.g., low or high levels of symptoms), but not much is known about their longitudinal evolution. In addition, their relationships with medical factors (e.g., cancer sites, treatments) and possible consequences (e.g., functioning) have yet to be established. This prospective study assessed the presence of clusters of patients in 828 participants scheduled to undergo surgery for cancer.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">The patients completed the Hospital Anxiety and Depression Scale, the Insomnia Severity Index, the Multidimensional Fatigue Inventory, the EORTC Quality-of-Life-Questionnaire-C30, and a physical symptoms questionnaire at baseline and 2, 6, 10, 14, and 18 months later.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Cluster analyses identified between five and eight clusters of patients depending on the time point. The "Low Symptoms" cluster was the most common (24.8 to 35.0% of the sample), whereas one with predominant nausea and vomiting symptoms was among the least common (1.6 to 3.5%). Significant differences were found between cancer sites, treatment regimens, quality of life, and functioning scores. Prostate cancer patients and those treated by surgery only were overrepresented in the "Low" cluster, whereas breast cancer patients were more likely to fall into the "Moderate - Night Sweats" cluster. Clusters with more severe psychological symptoms were associated with lower functioning and quality of life.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study revealed distinct clusters of patients that varied in number during cancer treatments. Findings also identified some clusters associated with lower quality of life and functioning, which should receive more clinical attention.</AbstractText>
<CopyrightInformation>(PsycINFO Database Record (c) 2014 APA, all rights reserved).</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Trudel-Fitzgerald</LastName>
<ForeName>Claudia</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>School of Psychology, UniversitÃ© Laval.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Savard</LastName>
<ForeName>JosÃ©e</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>School of Psychology, UniversitÃ© Laval.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ivers</LastName>
<ForeName>Hans</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>School of Psychology, UniversitÃ© Laval.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>MOP-69073</GrantID>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Health Psychol</MedlineTA>
<NlmUniqueID>8211523</NlmUniqueID>
<ISSNLinking>0278-6133</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000704">Analysis of Variance</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059186">Chemoradiotherapy, Adjuvant</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015897">Comorbidity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003430">Cross-Sectional Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005221">Fatigue</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008569">Memory Disorders</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009325">Nausea</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011581">Psychological Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D011788">Quality of Life</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D011792">Quebec</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011795">Questionnaires</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018434">Sickness Impact Profile</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D012893">Sleep Disorders</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013577">Syndrome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24588629</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1930-7810</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Health psychology : official journal of the Division of Health Psychology, American Psychological Association</Title>
<ISOAbbreviation>Health Psychol</ISOAbbreviation>
</Journal>
<ArticleTitle>Precancer risk perceptions predict postcancer subjective well-being.</ArticleTitle>
<Pagination>
<MedlinePgn>1023-32</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1037/hea0000074</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The present study used longitudinal data to explore whether subjective well-being in cancer survivors was related to predisease judgments of their likelihood of getting cancer.</AbstractText>
<AbstractText Label="METHOD" NlmCategory="METHODS">Subjective well-being was assessed in terms of affective well-being (frequency of positive and negative affective states) and satisfaction with one's life overall. The sample consisted of 158 participants in the National Survey of Midlife Development in the U.S. (MIDUS) who developed cancer during the 8-10 years between the first and second waves of the survey (average time since diagnosis = 3.37 years; SD = 2.48), and 3,243 control participants who reported no history of cancer at either wave.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Controlling for demographic variables and well-being at Wave 1, the effect of cancer on well-being depended on whether, prior to being diagnosed, people judged themselves to be at low or high risk of cancer. For those perceiving a high risk, a cancer diagnosis had a modest but significant negative impact on affect and life satisfaction, whereas no negative impact emerged for those perceiving a low risk. Similar effects were not observed for heart attack risk perceptions, or for measures of trait optimism or depression, suggesting that the effect was domain-specific.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Low precancer risk perceptions were associated with long-term benefits for subjective well-being in people who developed cancer.</AbstractText>
<CopyrightInformation>(PsycINFO Database Record (c) 2014 APA, all rights reserved).</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Persoskie</LastName>
<ForeName>Alexander</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Behavioral Research Program, National Cancer Institute.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ferrer</LastName>
<ForeName>Rebecca A</ForeName>
<Initials>RA</Initials>
<AffiliationInfo>
<Affiliation>Behavioral Research Program, National Cancer Institute.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nelson</LastName>
<ForeName>Wendy L</ForeName>
<Initials>WL</Initials>
<AffiliationInfo>
<Affiliation>Behavioral Research Program, National Cancer Institute.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Klein</LastName>
<ForeName>William M P</ForeName>
<Initials>WM</Initials>
<AffiliationInfo>
<Affiliation>Behavioral Research Program, National Cancer Institute.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P01 AG020166</GrantID>
<Acronym>AG</Acronym>
<Agency>NIA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Health Psychol</MedlineTA>
<NlmUniqueID>8211523</NlmUniqueID>
<ISSNLinking>0278-6133</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004198">Disease Susceptibility</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006306">Health Surveys</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008137">Longitudinal Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D010549">Personal Satisfaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D011788">Quality of Life</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D055500">Resilience, Psychological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018570">Risk Assessment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017741">Survivors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24681695</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>21</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1468-2044</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>99</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Archives of disease in childhood</Title>
<ISOAbbreviation>Arch. Dis. Child.</ISOAbbreviation>
</Journal>
<ArticleTitle>Abandonment of childhood cancer treatment in Western Kenya.</ArticleTitle>
<Pagination>
<MedlinePgn>609-14</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The most important reason for childhood cancer treatment failure in low-income countries is treatment abandonment.</AbstractText>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to explore reasons for childhood cancer treatment abandonment and assess the clinical condition of these children.</AbstractText>
<AbstractText Label="DESIGN" NlmCategory="METHODS">This was a descriptive study using semistructured questionnaires. Home visits were conducted to interview families of childhood cancer patients, diagnosed between January 2007 and January 2009, who had abandoned treatment at the Moi Teaching and Referral Hospital (MTRH).</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Between January 2007 and January 2009, 222 children were newly diagnosed with a malignancy at MTRH. Treatment outcome was documented in 180 patients. Of these 180 patients, 98 (54%) children abandoned treatment. From December 2011 until August 2012, 53 (54%) of the 98 families were contacted. Due to lack of contact information, 45 families were untraceable. From 53 contacted families, 46 (87%) families agreed to be interviewed. Reasons for abandonment were reported by 26 families, and they were diverse. Most common reasons were financial difficulties (46%), inadequate access to health insurance (27%) and transportation difficulties (23%). Most patients (72%) abandoned treatment after the first 3 months had been completed. Of the 46 children who abandoned treatment, 9 (20%) were still alive: 6 (67%) of these children looked healthy and 3 (33%) ill. The remaining 37 (80%) children had passed away.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Prevention of childhood cancer treatment abandonment requires improved access to health insurance, financial or transportation support, proper parental education, psychosocial guidance and ameliorated communication skills of healthcare providers.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Njuguna</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mostert</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Slot</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Langat</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Skiles</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sitaresmi</LastName>
<ForeName>M N</ForeName>
<Initials>MN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>van de Ven</LastName>
<ForeName>P M</ForeName>
<Initials>PM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Musimbi</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Muliro</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vreeman</LastName>
<ForeName>R C</ForeName>
<Initials>RC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kaspers</LastName>
<ForeName>G J L</ForeName>
<Initials>GJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Arch Dis Child</MedlineTA>
<NlmUniqueID>0372434</NlmUniqueID>
<ISSNLinking>0003-9888</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002662">Child Health Services</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000191">economics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006297">Health Services Accessibility</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007630">Kenya</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010290">Parents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010349">Patient Compliance</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011795">Questionnaires</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012959">Socioeconomic Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25185410</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1433-6510</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>60</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Clinical laboratory</Title>
<ISOAbbreviation>Clin. Lab.</ISOAbbreviation>
</Journal>
<ArticleTitle>Capillary electrophoresis based on the nucleic acid detection in the application of human disease diagnosis.</ArticleTitle>
<Pagination>
<MedlinePgn>1253-68</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>As the post-genome era comes, one of the trends of future medical developments is the timely diagnosis and prevention of diseases. The analysis of nucleic acid can diagnose the diseases accurately at gene level which can eliminate all kinds of false positive and negative results from phenotype and prescribe the individual prevention or therapy. As a result, a high-throughput test tool is needed for the analyses of a large number of clinical nucleic acid samples. Capillary electrophoresis (CE) has the advantages of high-efficiency, high-speed, microscale, automation, high-throughput, and cleanliness which can meet the medical requirements that mass data and a large number of samples need to be analyzed, leading CE to be the new technology considered for clinical disease diagnosis. This review puts the focus on the application of CE in clinical disease diagnosis. Meanwhile, it also gives a brief introduction of the drawbacks and future development of CE.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lian</LastName>
<ForeName>Dong-Sheng</ForeName>
<Initials>DS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Shu-Jin</ForeName>
<Initials>SJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Clin Lab</MedlineTA>
<NlmUniqueID>9705611</NlmUniqueID>
<ISSNLinking>1433-6510</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009696">Nucleic Acids</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001424">Bacterial Infections</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003141">Communicable Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004194">Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019075">Electrophoresis, Capillary</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D030342">Genetic Diseases, Inborn</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005838">Genotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009696">Nucleic Acids</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016133">Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24740872</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1535-3699</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>239</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Experimental biology and medicine (Maywood, N.J.)</Title>
<ISOAbbreviation>Exp. Biol. Med. (Maywood)</ISOAbbreviation>
</Journal>
<ArticleTitle>A strategy for integrating essential three-dimensional microphysiological systems of human organs for realistic anticancer drug screening.</ArticleTitle>
<Pagination>
<MedlinePgn>1240-54</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1177/1535370214525295</ELocationID>
<Abstract>
<AbstractText>Cancer is one of the leading causes of morbidity and mortality around the world. Despite some success, traditional anticancer drugs developed to reduce tumor growth face important limitations primarily due to undesirable bone marrow and cardiovascular toxicity. Many drugs fail in clinical development after showing promise in preclinical trials, suggesting that the available in vitro and animal models are poor predictors of drug efficacy and toxicity in humans. Thus, novel models that more accurately mimic the biology of human organs are necessary for high-throughput drug screening. Three-dimensional (3D) microphysiological systems can utilize induced pluripotent stem cell technology, tissue engineering, and microfabrication techniques to develop tissue models of human tumors, cardiac muscle, and bone marrow on the order of 1âmm(3) in size. A functional network of human capillaries and microvessels to overcome diffusion limitations in nutrient delivery and waste removal can also nourish the 3D microphysiological tissues. Importantly, the 3D microphysiological tissues are grown on optically clear platforms that offer non-invasive and non-destructive image acquisition with subcellular resolution in real time. Such systems offer a new paradigm for high-throughput drug screening and will significantly improve the efficiency of identifying new drugs for cancer treatment that minimize cardiac and bone marrow toxicity.</AbstractText>
<CopyrightInformation>Â© 2014 by the Society for Experimental Biology and Medicine.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Heylman</LastName>
<ForeName>Christopher</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Biomedical Engineering, University of California, Irvine, CA 92697, USA The Edwards Lifesciences Center for Advanced Cardiovascular Technology, University of California, Irvine, CA 92697, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sobrino</LastName>
<ForeName>Agua</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shirure</LastName>
<ForeName>Venktesh S</ForeName>
<Initials>VS</Initials>
<AffiliationInfo>
<Affiliation>Department of Biomedical Engineering, University of California, Irvine, CA 92697, USA The Edwards Lifesciences Center for Advanced Cardiovascular Technology, University of California, Irvine, CA 92697, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hughes</LastName>
<ForeName>Christopher Cw</ForeName>
<Initials>CC</Initials>
<AffiliationInfo>
<Affiliation>Department of Biomedical Engineering, University of California, Irvine, CA 92697, USA The Edwards Lifesciences Center for Advanced Cardiovascular Technology, University of California, Irvine, CA 92697, USA Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>George</LastName>
<ForeName>Steven C</ForeName>
<Initials>SC</Initials>
<AffiliationInfo>
<Affiliation>Department of Biomedical Engineering, University of California, Irvine, CA 92697, USA The Edwards Lifesciences Center for Advanced Cardiovascular Technology, University of California, Irvine, CA 92697, USA Department of Chemical Engineering and Materials Science, University of California, Irvine, CA 92697, USA Department of Medicine, University of California, Irvine, CA 92697, USA scgeorge@uci.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>1UH2TR000481-01</GrantID>
<Acronym>TR</Acronym>
<Agency>NCATS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 CA062203</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA180122</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>UH2 TR000481</GrantID>
<Acronym>TR</Acronym>
<Agency>NCATS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>04</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Exp Biol Med (Maywood)</MedlineTA>
<NlmUniqueID>100973463</NlmUniqueID>
<ISSNLinking>1535-3699</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Drug Metab Dispos. 2013 Mar;41(3):562-7</RefSource>
<PMID Version="1">23238784</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Med Toxicol. 2013 Mar;9(1):25-33</RefSource>
<PMID Version="1">22648527</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Angiogenesis. 2013 Apr;16(2):289-95</RefSource>
<PMID Version="1">23203441</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lab Chip. 2013 Apr 21;13(8):1489-500</RefSource>
<PMID Version="1">23440068</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Integr Biol (Camb). 2013 Sep;5(9):1119-29</RefSource>
<PMID Version="1">23644926</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arch Toxicol. 2013 Aug;87(8):1581-93</RefSource>
<PMID Version="1">23728527</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55</RefSource>
<PMID Version="1">23707608</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Cardiol. 2013 Sep 30;168(2):680-7</RefSource>
<PMID Version="1">23639459</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Anticancer Res. 1985 Jan-Feb;5(1):101-10</RefSource>
<PMID Version="1">3888044</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 1999 Nov 1;59(21):5529-35</RefSource>
<PMID Version="1">10554030</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2000 Aug 15;60(16):4324-7</RefSource>
<PMID Version="1">10969769</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2000 Sep 14;407(6801):249-57</RefSource>
<PMID Version="1">11001068</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Crit Rev Oncol Hematol. 2000 Nov-Dec;36(2-3):141-57</RefSource>
<PMID Version="1">11033303</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Natl Cancer Inst. 2001 Feb 21;93(4):266-76</RefSource>
<PMID Version="1">11181773</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2001 Apr 1;61(7):2866-9</RefSource>
<PMID Version="1">11306460</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Anticancer Res. 2000 Nov-Dec;20(6D):5155-64</RefSource>
<PMID Version="1">11326688</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Br J Cancer. 2001 May 18;84(10):1424-31</RefSource>
<PMID Version="1">11355958</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Annu Rev Biomed Eng. 1999;1:241-63</RefSource>
<PMID Version="1">11701489</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2002 Jun 7;296(5574):1883-6</RefSource>
<PMID Version="1">11976409</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2002 Jun 15;62(12):3387-94</RefSource>
<PMID Version="1">12067980</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Biotechnol. 2002 Nov;20(11):1067-8</RefSource>
<PMID Version="1">12410239</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2002 Feb;2(2):83-90</RefSource>
<PMID Version="1">12635171</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Gynecol Oncol. 2003 Aug;90(2):297-304</RefSource>
<PMID Version="1">12893190</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Pancreas. 2004 Jan;28(1):38-44</RefSource>
<PMID Version="1">14707728</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2004 Jan 15;10(2):415-27</RefSource>
<PMID Version="1">14760060</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2004 Feb 15;64(4):1331-7</RefSource>
<PMID Version="1">14973050</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Treat Rev. 2004 Apr;30(2):181-91</RefSource>
<PMID Version="1">15023436</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochim Biophys Acta. 2004 Jul 5;1692(2-3):103-19</RefSource>
<PMID Version="1">15246682</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Bone Joint Surg Am. 2004 Jul;86-A(7):1541-58</RefSource>
<PMID Version="1">15252108</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Carcinog. 2004 Dec;41(4):207-20</RefSource>
<PMID Version="1">15468292</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Natl Cancer Inst. 1971 Jan;46(1):113-20</RefSource>
<PMID Version="1">5101993</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Exp Cell Res. 1971 Apr;65(2):433-8</RefSource>
<PMID Version="1">4928803</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Physiol Rev. 2006 Jan;86(1):279-367</RefSource>
<PMID Version="1">16371600</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Mol Cell Biol. 2006 Mar;7(3):211-24</RefSource>
<PMID Version="1">16496023</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2006 May;6(5):392-401</RefSource>
<PMID Version="1">16572188</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochem Biophys Res Commun. 2006 Jul 21;346(1):268-75</RefSource>
<PMID Version="1">16756953</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2006 Aug;6(8):583-92</RefSource>
<PMID Version="1">16862189</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Natl Cancer Inst. 2006 Aug 16;98(16):1118-28</RefSource>
<PMID Version="1">16912264</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Physiol Lung Cell Mol Physiol. 2006 Dec;291(6):L1277-85</RefSource>
<PMID Version="1">16891397</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2006 Dec 1;66(23):11238-46</RefSource>
<PMID Version="1">17114237</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Trends Cell Biol. 2007 Jan;17(1):44-50</RefSource>
<PMID Version="1">17141502</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2007 May;7(5):332-44</RefSource>
<PMID Version="1">17457301</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2007 Aug 10;25(23):3525-33</RefSource>
<PMID Version="1">17687157</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cancer Ther. 2007 Sep;6(9):2505-14</RefSource>
<PMID Version="1">17766839</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Acta Biomater. 2008 Mar;4(2):256-63</RefSource>
<PMID Version="1">17936097</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2008 Mar 15;111(6):3131-6</RefSource>
<PMID Version="1">18174379</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochem Biophys Res Commun. 2008 Sep 5;373(4):555-60</RefSource>
<PMID Version="1">18590705</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Matrix Biol. 2008 Jul;27(6):573-85</RefSource>
<PMID Version="1">18411046</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Trends Mol Med. 2008 Aug;14(8):333-40</RefSource>
<PMID Version="1">18614399</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neoplasia. 2008 Oct;10(10):1105-19</RefSource>
<PMID Version="1">18813359</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Pharm. 2008 Sep-Oct;5(5):849-62</RefSource>
<PMID Version="1">18680382</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2008 Nov;8(11):851-64</RefSource>
<PMID Version="1">18846101</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Transl Med. 2008;6:57</RefSource>
<PMID Version="1">18844982</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncol Rep. 2008 Dec;20(6):1465-71</RefSource>
<PMID Version="1">19020729</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Br J Cancer. 2009 Jan 27;100(2):311-4</RefSource>
<PMID Version="1">19165199</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2009 Apr 2;28(13):1570-83</RefSource>
<PMID Version="1">19234490</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Lett. 2009 Aug 8;280(2):145-53</RefSource>
<PMID Version="1">19111391</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Am Coll Cardiol. 2009 Jun 16;53(24):2231-47</RefSource>
<PMID Version="1">19520246</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Respir Cell Mol Biol. 2009 Sep;41(3):297-304</RefSource>
<PMID Version="1">19151317</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13582-7</RefSource>
<PMID Version="1">21808026</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biomaterials. 2009 Oct;30(30):6076-85</RefSource>
<PMID Version="1">19695694</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2009 Nov 25;139(5):891-906</RefSource>
<PMID Version="1">19931152</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Natl Cancer Inst. 2010 Jan 6;102(1):14-25</RefSource>
<PMID Version="1">20007921</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Surg Oncol. 2010 Jan;36(1):72-7</RefSource>
<PMID Version="1">19577877</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Pharmacol Ther. 2010 Feb;125(2):196-218</RefSource>
<PMID Version="1">19874849</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Anticancer Agents Med Chem. 2010 Jan;10(1):92-102</RefSource>
<PMID Version="1">19912104</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Breast Cancer Res Treat. 2010 Jul;122(1):35-43</RefSource>
<PMID Version="1">19701706</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Tissue Eng Part A. 2010 Feb;16(2):585-94</RefSource>
<PMID Version="1">19737050</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMC Med. 2010;8:27</RefSource>
<PMID Version="1">20492690</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Dev Cell. 2010 Jun 15;18(6):884-901</RefSource>
<PMID Version="1">20627072</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FASEB J. 2010 Aug;24(8):2739-51</RefSource>
<PMID Version="1">20371616</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Cardiol. 2010 Sep 24;144(1):3-15</RefSource>
<PMID Version="1">20399520</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Assay Drug Dev Technol. 2010 Oct;8(5):581-90</RefSource>
<PMID Version="1">20662735</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cardiol. 2010 Oct;7(10):564-75</RefSource>
<PMID Version="1">20842180</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Neurol. 2010 Dec;6(12):657-66</RefSource>
<PMID Version="1">21060341</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Biol. 2011 Jan 15;214(Pt 2):337-46</RefSource>
<PMID Version="1">21177953</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>JPEN J Parenter Enteral Nutr. 2011 Jan;35(1):74-90</RefSource>
<PMID Version="1">21224434</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Expert Opin Pharmacother. 2011 Apr;12(6):851-63</RefSource>
<PMID Version="1">21254862</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2011;6(4):e18037</RefSource>
<PMID Version="1">21483779</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2011 Apr 21;472(7343):303-4</RefSource>
<PMID Version="1">21512566</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biomed Microdevices. 2011 Aug;13(4):753-8</RefSource>
<PMID Version="1">21556741</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Physiol Rev. 2011 Jul;91(3):1071-121</RefSource>
<PMID Version="1">21742796</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Treat Rev. 2011 Oct;37(6):487-93</RefSource>
<PMID Version="1">21689887</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 1976 Jun;36(6):1853-82</RefSource>
<PMID Version="1">773531</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Phys Physiol Meas. 1989 Aug;10(3):187-217</RefSource>
<PMID Version="1">2697487</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Sci Am. 1994 Jul;271(1):58-65</RefSource>
<PMID Version="1">8066425</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12378-82</RefSource>
<PMID Version="1">7528920</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Med. 1997 Feb;3(2):177-82</RefSource>
<PMID Version="1">9018236</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 1997 May 15;89(10):3596-606</RefSource>
<PMID Version="1">9160664</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 1998 May 15;91(10):3527-61</RefSource>
<PMID Version="1">9572988</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14821-6</RefSource>
<PMID Version="1">9843973</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18024-9</RefSource>
<PMID Version="1">15601776</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2005 Jan 7;307(5706):58-62</RefSource>
<PMID Version="1">15637262</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Tissue Eng. 2005 Jan-Feb;11(1-2):257-66</RefSource>
<PMID Version="1">15738680</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2005 May 1;23(13):2900-2</RefSource>
<PMID Version="1">15860848</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncology (Williston Park). 2005 Apr;19(4 Suppl 3):7-16</RefSource>
<PMID Version="1">15934498</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Cardiol Rep. 2013 May;15(5):362</RefSource>
<PMID Version="1">23512625</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>IEEE Trans Biomed Eng. 2013 Mar;60(3):682-90</RefSource>
<PMID Version="1">23380852</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Semin Oncol. 2013 Apr;40(2):156-67</RefSource>
<PMID Version="1">23540741</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochem Biophys Res Commun. 2013 May 17;434(4):773-8</RefSource>
<PMID Version="1">23602898</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Med. 2013 Jun;19(6):669-71</RefSource>
<PMID Version="1">23744143</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lab Chip. 2013 Aug 7;13(15):2990-8</RefSource>
<PMID Version="1">23723013</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2013 Jul 18;499(7458):295-300</RefSource>
<PMID Version="1">23868258</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Tissue Eng Part C Methods. 2013 Sep;19(9):730-7</RefSource>
<PMID Version="1">23320912</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lab Chip. 2013 Sep 21;13(18):3496-511</RefSource>
<PMID Version="1">23828456</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Antioxid Redox Signal. 2011 Nov 1;15(9):2543-63</RefSource>
<PMID Version="1">21457105</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncotarget. 2011 Oct;2(10):797-809</RefSource>
<PMID Version="1">22006582</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Pflugers Arch. 2012 Feb;463(2):365-76</RefSource>
<PMID Version="1">22075718</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMC Cancer. 2012;12:4</RefSource>
<PMID Version="1">22217342</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Physiol Heart Circ Physiol. 2012 Feb 15;302(4):H983-91</RefSource>
<PMID Version="1">22140046</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Pharm Sci. 2012 Apr;101(4):1337-54</RefSource>
<PMID Version="1">22213383</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2012 Mar 1;72(5):1270-9</RefSource>
<PMID Version="1">22253229</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncotarget. 2012 Jan;3(1):107-11</RefSource>
<PMID Version="1">22403741</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Crit Rev Oncol Hematol. 2012 Apr;82(1):51-77</RefSource>
<PMID Version="1">21908200</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Intern Emerg Med. 2012 Apr;7(2):113-31</RefSource>
<PMID Version="1">22161318</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Best Pract Res Clin Obstet Gynaecol. 2012 Jun;26(3):379-90</RefSource>
<PMID Version="1">22281514</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Cardiol Rev. 2011 Nov;7(4):221-33</RefSource>
<PMID Version="1">22758623</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Physiol Rev. 2012 Jul;92(3):1005-60</RefSource>
<PMID Version="1">22811424</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mammary Gland Biol Neoplasia. 2012 Jun;17(2):103-10</RefSource>
<PMID Version="1">22573197</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2012;7(9):e46391</RefSource>
<PMID Version="1">23050024</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Acta Biomater. 2012 Dec;8(12):4357-64</RefSource>
<PMID Version="1">22842035</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Exp Cell Res. 2013 Jan 1;319(1):75-87</RefSource>
<PMID Version="1">23022396</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lab Chip. 2013 Jan 7;13(1):81-9</RefSource>
<PMID Version="1">23090158</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20443-8</RefSource>
<PMID Version="1">23169660</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018929">Cell Culture Techniques</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000295">instrumentation</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D004354">Drug Screening Assays, Antitumor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000295">instrumentation</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D039904">Pluripotent Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D023822">Tissue Engineering</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000295">instrumentation</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS583273</OtherID>
<OtherID Source="NLM">PMC4156538</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Three-dimensional microphysiological systems</Keyword>
<Keyword MajorTopicYN="N">anticancer drugs</Keyword>
<Keyword MajorTopicYN="N">bone marrow</Keyword>
<Keyword MajorTopicYN="N">cardiac tissue</Keyword>
<Keyword MajorTopicYN="N">tumor</Keyword>
<Keyword MajorTopicYN="N">vasculature</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25030480</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1535-3699</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>239</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Experimental biology and medicine (Maywood, N.J.)</Title>
<ISOAbbreviation>Exp. Biol. Med. (Maywood)</ISOAbbreviation>
</Journal>
<ArticleTitle>Tissue-engineered microenvironment systems for modeling human vasculature.</ArticleTitle>
<Pagination>
<MedlinePgn>1264-71</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1177/1535370214539228</ELocationID>
<Abstract>
<AbstractText>The high attrition rate of drug candidates late in the development process has led to an increasing demand for test assays that predict clinical outcome better than conventional 2D cell culture systems and animal models. Government agencies, the military, and the pharmaceutical industry have started initiatives for the development of novel in-vitro systems that recapitulate functional units of human tissues and organs. There is growing evidence that 3D cell arrangement, co-culture of different cell types, and physico-chemical cues lead to improved predictive power. A key element of all tissue microenvironments is the vasculature. Beyond transporting blood the microvasculature assumes important organ-specific functions. It is also involved in pathologic conditions, such as inflammation, tumor growth, metastasis, and degenerative diseases. To provide a tool for modeling this important feature of human tissue microenvironments, we developed a microfluidic chip for creating tissue-engineered microenvironment systems (TEMS) composed of tubular cell structures. Our chip design encompasses a small chamber that is filled with an extracellular matrix (ECM) surrounding one or more tubular channels. Endothelial cells (ECs) seeded into the channels adhere to the ECM walls and grow into perfusable tubular tissue structures that are fluidically connected to upstream and downstream fluid channels in the chip. Using these chips we created models of angiogenesis, the blood-brain barrier (BBB), and tumor-cell extravasation. Our angiogenesis model recapitulates true angiogenesis, in which sprouting occurs from a "parent" vessel in response to a gradient of growth factors. Our BBB model is composed of a microvessel generated from brain-specific ECs within an ECM populated with astrocytes and pericytes. Our tumor-cell extravasation model can be utilized to visualize and measure tumor-cell migration through vessel walls into the surrounding matrix. The described technology can be used to create TEMS that recapitulate structural, functional, and physico-chemical elements of vascularized human tissue microenvironments in vitro.</AbstractText>
<CopyrightInformation>Â© 2014 by the Society for Experimental Biology and Medicine.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tourovskaia</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Nortis, Inc., Seattle, WA 98195, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fauver</LastName>
<ForeName>Mark</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Nortis, Inc., Seattle, WA 98195, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kramer</LastName>
<ForeName>Gregory</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Nortis, Inc., Seattle, WA 98195, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Simonson</LastName>
<ForeName>Sara</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Nortis, Inc., Seattle, WA 98195, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Neumann</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Nortis, Inc., Seattle, WA 98195, USA neumann@nortisbio.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>1R43CA144469-01</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>1R43HL107040-01A1</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>1R43NS070440-01</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>1UH2TR000504-01</GrantID>
<Acronym>TR</Acronym>
<Agency>NCATS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Exp Biol Med (Maywood)</MedlineTA>
<NlmUniqueID>100973463</NlmUniqueID>
<ISSNLinking>1535-3699</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001812">Blood-Brain Barrier</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002196">Capillaries</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018929">Cell Culture Techniques</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000295">instrumentation</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018920">Coculture Techniques</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000295">instrumentation</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042783">Endothelial Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D046210">Microfluidic Analytical Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000098">blood supply</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009389">Neovascularization, Pathologic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D023822">Tissue Engineering</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000295">instrumentation</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Microfluidic device</Keyword>
<Keyword MajorTopicYN="N">body-on-chip</Keyword>
<Keyword MajorTopicYN="N">microenvironment</Keyword>
<Keyword MajorTopicYN="N">microphysiological system</Keyword>
<Keyword MajorTopicYN="N">microvasculature</Keyword>
<Keyword MajorTopicYN="N">organ-on-chip</Keyword>
<Keyword MajorTopicYN="N">tissue engineering</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25184678</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>20</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1549-5477</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>17</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Genes &amp; development</Title>
<ISOAbbreviation>Genes Dev.</ISOAbbreviation>
</Journal>
<ArticleTitle>ZBTB7A acts as a tumor suppressor through the transcriptional repression of glycolysis.</ArticleTitle>
<Pagination>
<MedlinePgn>1917-28</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1101/gad.245910.114</ELocationID>
<Abstract>
<AbstractText>Elevated glycolysis is a common metabolic trait of cancer, but what drives such metabolic reprogramming remains incompletely clear. We report here a novel transcriptional repressor-mediated negative regulation of glycolysis. ZBTB7A, a member of the POK (POZ/BTB and KrÃ¼ppel) transcription repressor family, directly binds to the promoter and represses the transcription of critical glycolytic genes, including GLUT3, PFKP, and PKM. Analysis of The Cancer Genome Atlas (TCGA) data sets reveals that the ZBTB7A locus is frequently deleted in many human tumors. Significantly, reduced ZBTB7A expression correlates with up-regulation of the glycolytic genes and poor survival in colon cancer patients. Remarkably, while ZBTB7A-deficient tumors progress exceedingly fast, they exhibit an unusually heightened sensitivity to glycolysis inhibition. Our study uncovers a novel tumor suppressor role of ZBTB7A in directly suppressing glycolysis. </AbstractText>
<CopyrightInformation>Â© 2014 Liu et al.; Published by Cold Spring Harbor Laboratory Press.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Xue-Song</ForeName>
<Initials>XS</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Haines</LastName>
<ForeName>Jenna E</ForeName>
<Initials>JE</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mehanna</LastName>
<ForeName>Elie K</ForeName>
<Initials>EK</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Genet</LastName>
<ForeName>Matthew D</ForeName>
<Initials>MD</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ben-Sahra</LastName>
<ForeName>Issam</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Asara</LastName>
<ForeName>John M</ForeName>
<Initials>JM</Initials>
<AffiliationInfo>
<Affiliation>Division of Signal Transduction, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Manning</LastName>
<ForeName>Brendan D</ForeName>
<Initials>BD</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yuan</LastName>
<ForeName>Zhi-Min</ForeName>
<Initials>ZM</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA; zyuan@hsph.harvard.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01CA085679</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA125144</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA167814</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Genes Dev</MedlineTA>
<NlmUniqueID>8711660</NlmUniqueID>
<ISSNLinking>0890-9369</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C485514">ZBTB7A protein, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D016147">Genes, Tumor Suppressor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006019">Glycolysis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045325">HCT116 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061986">MCF-7 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4197949 [Available on 03/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">GLUT3</Keyword>
<Keyword MajorTopicYN="N">PFKP</Keyword>
<Keyword MajorTopicYN="N">PKM</Keyword>
<Keyword MajorTopicYN="N">ZBTB7A</Keyword>
<Keyword MajorTopicYN="N">glycolysis</Keyword>
<Keyword MajorTopicYN="N">tumor suppressor</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25187579</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>29</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1535-1386</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>96</Volume>
<Issue>17</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>3</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of bone and joint surgery. American volume</Title>
<ISOAbbreviation>J Bone Joint Surg Am</ISOAbbreviation>
</Journal>
<ArticleTitle>Cancer risk from bone morphogenetic protein exposure in spinal arthrodesis.</ArticleTitle>
<Pagination>
<MedlinePgn>1417-22</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2106/JBJS.M.01190</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The U.S. Food and Drug Administration reported a higher incidence of cancer in patients who had spinal arthrodesis and were exposed to a high dose of recombinant human bone morphogenetic protein-2 (rhBMP-2) compared with the control group in a randomized controlled trial. The purpose of this study was to determine the risk of cancer after spinal arthrodesis with BMP.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively analyzed the incidence of cancer in 467,916 Medicare patients undergoing spinal arthrodesis from 2005 to 2010. Patients with a preexisting diagnosis of cancer were excluded. The average follow-up duration was 2.85 years for the BMP group and 2.94 years for the control group. The main outcome measure was the relative risk of developing new malignant lesions after spinal arthrodesis with or without exposure to BMP.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The relative risk of developing cancer after BMP exposure was 0.938 (95% confidence interval [95% CI]: 0.913 to 0.964), which was significant. In the BMP group, 5.9% of the patients developed an invasive cancer compared with 6.5% of the patients in the control group. The relative risk of developing cancer after BMP exposure was 0.98 in males (95% CI: 0.94 to 1.02) and 0.93 (95% CI: 0.90 to 0.97) in females. The control group showed a higher incidence of each type of cancer except pancreatic cancer.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Recent clinical use of BMP was not associated with a detectable increase in the risk of cancer within a mean 2.9-year time window.</AbstractText>
<AbstractText Label="LEVEL OF EVIDENCE" NlmCategory="METHODS">Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.</AbstractText>
<CopyrightInformation>Copyright Â© 2014 by The Journal of Bone and Joint Surgery, Incorporated.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kelly</LastName>
<ForeName>Mick P</ForeName>
<Initials>MP</Initials>
<AffiliationInfo>
<Affiliation>Department of Orthopedics and Rehabilitation, University of Wisconsin School of Medicine and Public Health, UWMF Centennial Building, 1685 Highland Avenue, 6th Floor, Madison, WI 53705-2281. E-mail address for M.P. Kelly: Mpkelly3@wisc.edu. E-mail address for P.A. Anderson: Anderson@ortho.wisc.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Savage</LastName>
<ForeName>Jason W</ForeName>
<Initials>JW</Initials>
<AffiliationInfo>
<Affiliation>Department of Orthopaedic Surgery, Northwestern University Feinberg School of Medicine, NMH/Arkes Family Pavilion 13th Floor, 676 North Saint Clair, Chicago, IL 60611. E-mail address for J.W. Savage: jsavage@nmff.org. E-mail address for W.K. Hsu: whsu@nmff.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bentzen</LastName>
<ForeName>SÃ¸ren M</ForeName>
<Initials>SM</Initials>
<AffiliationInfo>
<Affiliation>Departments of Human Oncology, Medical Physics, and Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, K4/314 Clinical Sciences Center, 600 Highland Avenue, Madison, WI 53792-4675. E-mail address: Bentzen@humonc.wisc.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hsu</LastName>
<ForeName>Wellington K</ForeName>
<Initials>WK</Initials>
<AffiliationInfo>
<Affiliation>Department of Orthopaedic Surgery, Northwestern University Feinberg School of Medicine, NMH/Arkes Family Pavilion 13th Floor, 676 North Saint Clair, Chicago, IL 60611. E-mail address for J.W. Savage: jsavage@nmff.org. E-mail address for W.K. Hsu: whsu@nmff.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ellison</LastName>
<ForeName>Scott A</ForeName>
<Initials>SA</Initials>
<AffiliationInfo>
<Affiliation>PearlDiver Technologies, Inc., P.O. Box 1765, Warsaw, IN 46581. E-mail address: scott@pearldiverinc.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Anderson</LastName>
<ForeName>Paul A</ForeName>
<Initials>PA</Initials>
<AffiliationInfo>
<Affiliation>Department of Orthopedics and Rehabilitation, University of Wisconsin School of Medicine and Public Health, UWMF Centennial Building, 1685 Highland Avenue, 6th Floor, Madison, WI 53705-2281. E-mail address for M.P. Kelly: Mpkelly3@wisc.edu. E-mail address for P.A. Anderson: Anderson@ortho.wisc.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Bone Joint Surg Am</MedlineTA>
<NlmUniqueID>0014030</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055396">Bone Morphogenetic Protein 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019485">Bone Morphogenetic Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C499469">recombinant human bone morphogenetic protein-2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017677">Age Distribution</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055396">Bone Morphogenetic Protein 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019485">Bone Morphogenetic Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016001">Confidence Intervals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015994">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006278">Medicare</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011237">Predictive Value of Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011994">Recombinant Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018570">Risk Assessment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018426">SEER Program</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017678">Sex Distribution</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013122">Spinal Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013123">Spinal Fusion</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016212">Transforming Growth Factor beta</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4144318 [Available on 09/03/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24096485</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>05</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>36</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>4</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>Targeting cancer stem cells to suppress acquired chemotherapy resistance.</ArticleTitle>
<Pagination>
<MedlinePgn>4451-63</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2013.411</ELocationID>
<Abstract>
<AbstractText>Acquired resistance has curtailed cancer survival since the dawn of the chemotherapy age more than half a century ago. Although the application of stem cell (SC) concepts to cancer captured the imagination of scientists for many years, only the last decade has yielded substantial evidence that cancer SCs (CSCs) contribute to chemotherapy resistance. Recent studies suggest that the functional and molecular properties of CSCs constitute therapeutic opportunities to improve the efficacy of chemotherapy. Here we review how these properties have stimulated combination strategies that suppress acquired resistance across a spectrum of malignancies. The clinical implementation of these strategies promises to rejuvenate the effort against an enduring challenge. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Vidal</LastName>
<ForeName>S J</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Pathology, Mount Sinai Icahn School of Medicine, New York, NY, USA [2] Columbia University College of Physicians and Surgeons, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rodriguez-Bravo</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Molecular Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Galsky</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Oncology Department, Tisch Cancer Institute, Mount Sinai Icahn School of Medicine, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cordon-Cardo</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Mount Sinai Icahn School of Medicine, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Domingo-Domenech</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Mount Sinai Icahn School of Medicine, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>10</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009374">Neoplasms, Experimental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014411">Neoplastic Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059016">Tumor Microenvironment</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25188959</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0954-7762</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>110</Volume>
<Issue>32-33</Issue>
<PubDate>
<MedlineDate>2014 Aug 6-19</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Nursing times</Title>
<ISOAbbreviation>Nurs Times</ISOAbbreviation>
</Journal>
<ArticleTitle>Cancer nurse designs patient-friendly unit.</ArticleTitle>
<Pagination>
<MedlinePgn>5</MedlinePgn>
</Pagination>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016433">News</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nurs Times</MedlineTA>
<NlmUniqueID>0423236</NlmUniqueID>
<ISSNLinking>0954-7762</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002173">Cancer Care Facilities</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000458">organization &amp; administration</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D004739">England</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D005160">Facility Design and Construction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000451">nursing</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009859">Oncology Nursing</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000364">manpower</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25188961</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0954-7762</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>110</Volume>
<Issue>32-33</Issue>
<PubDate>
<MedlineDate>2014 Aug 6-19</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Nursing times</Title>
<ISOAbbreviation>Nurs Times</ISOAbbreviation>
</Journal>
<ArticleTitle>Cancer charity creates live chat nurse service.</ArticleTitle>
<Pagination>
<MedlinePgn>7</MedlinePgn>
</Pagination>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016433">News</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nurs Times</MedlineTA>
<NlmUniqueID>0423236</NlmUniqueID>
<ISSNLinking>0954-7762</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D002608">Charities</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D006113">Great Britain</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D020407">Internet</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000451">nursing</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009723">Nurse-Patient Relations</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25189052</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1181-912X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>24</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Season>Summer</Season>
</PubDate>
</JournalIssue>
<Title>Canadian oncology nursing journal = Revue canadienne de nursing oncologique</Title>
<ISOAbbreviation>Can Oncol Nurs J</ISOAbbreviation>
</Journal>
<ArticleTitle>Taking an "upstream" approach in the care of dying cancer patients: the case for a palliative approach.</ArticleTitle>
<Pagination>
<MedlinePgn>144-53</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Advances in technology and drug therapy have resulted in cancer patients living longer with malignant disease. However, most of these patients will face the end of life much sooner than the general population. Adopting a "palliative approach" is one innovation that has the potential to promote anticipatory planning and promote enhanced end-of-life care. Yet, in much of the western world, this upstream orientation has rarely been achieved. An emphasis on providing palliative care late in the illness trajectory has resulted in many challenges for the care of people with advanced cancer. We highlight a nursing research initiative, The Initiative for a Palliative Approach in Nursing: Evidence and Leadership (iPANEL), that aims to develop evidence to inform the integration of a palliative approach into the care of people with advancing chronic life-limiting conditions. Oncology nurses have an important role to play in facilitating a palliative approach, transforming the ways in which cancer patients are cared for within our health care system.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Stajduhar</LastName>
<ForeName>Kelli I</ForeName>
<Initials>KI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tayler</LastName>
<ForeName>Carolyn</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Canada</Country>
<MedlineTA>Can Oncol Nurs J</MedlineTA>
<NlmUniqueID>9300792</NlmUniqueID>
<ISSNLinking>1181-912X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D002170">Canada</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007857">Leadership</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000451">nursing</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009859">Oncology Nursing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D010166">Palliative Care</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25189053</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1181-912X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>24</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Season>Summer</Season>
</PubDate>
</JournalIssue>
<Title>Canadian oncology nursing journal = Revue canadienne de nursing oncologique</Title>
<ISOAbbreviation>Can Oncol Nurs J</ISOAbbreviation>
</Journal>
<ArticleTitle>"I can't sleep!": gathering the evidence for an innovative intervention for insomnia in cancer patients.</ArticleTitle>
<Pagination>
<MedlinePgn>154-65</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Sleep-wake disturbances, in particular insomnia, are experienced by 30%-75% of oncology patients, yet no effective interventions have been designed to address this distressing symptom in the ambulatory setting. In response to an identified gap in care, I share the development and evaluation of an innovative sleep intervention designed specifically for the ambulatory setting. Preliminary findings, as well as an informative blueprint for conducting point-of-care research, are described. As a "bedside" nurse it is possible and within our moral imperative and social justice mandate to take action to find evidence-informed solutions to improve care for populations of patients experiencing gaps in care. The "I" used throughout the article refers to the lead author Surya.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Absolon</LastName>
<ForeName>Nancy A</ForeName>
<Initials>NA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Truant</LastName>
<ForeName>Tracy L</ForeName>
<Initials>TL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Balneaves</LastName>
<ForeName>Lynda G</ForeName>
<Initials>LG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Goodwin</LastName>
<ForeName>Frankie</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cashman</LastName>
<ForeName>Rosemary L</ForeName>
<Initials>RL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wong</LastName>
<ForeName>Margurite E</ForeName>
<Initials>ME</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Witmans</LastName>
<ForeName>Manisha B</ForeName>
<Initials>MB</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<Language>fre</Language>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Canada</Country>
<MedlineTA>Can Oncol Nurs J</MedlineTA>
<NlmUniqueID>9300792</NlmUniqueID>
<ISSNLinking>1181-912X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D002170">Canada</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019317">Evidence-Based Medicine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010865">Pilot Projects</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007319">Sleep Initiation and Maintenance Disorders</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25189054</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1181-912X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>24</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Season>Summer</Season>
</PubDate>
</JournalIssue>
<Title>Canadian oncology nursing journal = Revue canadienne de nursing oncologique</Title>
<ISOAbbreviation>Can Oncol Nurs J</ISOAbbreviation>
</Journal>
<ArticleTitle>Rethinking assumptions about cancer survivorship.</ArticleTitle>
<Pagination>
<MedlinePgn>166-8, 174-7</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>A growing body of research informed by theories and methods in the social sciences and humanities indicates that certain problematic messages are commonly embedded in popular and oncological representations of cancer. Becoming more aware of these underlying messages has the potential to improve the ways clinicians think about and manage cancer. (Note: A written response to this article appears in Truant, Kohli, &amp; Stephens (2014), Response to "Rethinking Assumptions about Cancer Survivorship": A Nursing Disciplinary Perspective, Canadian Oncology Nursing Journal, Vol. 24, Issue 3, p. 169).</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ristovski-Slijepcevic</LastName>
<ForeName>Svetlana</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bell</LastName>
<ForeName>Kirsten</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<Language>fre</Language>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Canada</Country>
<MedlineTA>Can Oncol Nurs J</MedlineTA>
<NlmUniqueID>9300792</NlmUniqueID>
<ISSNLinking>1181-912X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D002170">Canada</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017741">Survivors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25189055</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1181-912X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>24</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Season>Summer</Season>
</PubDate>
</JournalIssue>
<Title>Canadian oncology nursing journal = Revue canadienne de nursing oncologique</Title>
<ISOAbbreviation>Can Oncol Nurs J</ISOAbbreviation>
</Journal>
<ArticleTitle>Response to "Rethinking assumptions about cancer survivorship": a nursing disciplinary perspective.</ArticleTitle>
<Pagination>
<MedlinePgn>169-73, 178-83</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>In response to our social science and humanities colleagues' paper, Rethinking Assumptions about Cancer Survivorship (Ristovski-Slijepcevic &amp; Bell. [2014]. CONJ, 24(3), p. 166), we offer a nursing disciplinary perspective on some of the dominant messages purported to underpin cancer survivorship. We illuminate points of disjuncture within their paper, using nursing's disciplinary lens to describe and explain the complexities inherent in the cancer survivorship experience and its implications for clinical practice. Opportunities for collaboration with our social science and humanities colleagues are outlined to foster synergistic knowledge development that will, ultimately, improve the care of those living with, through, and beyond cancer.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Truant</LastName>
<ForeName>Tracy L</ForeName>
<Initials>TL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kohli</LastName>
<ForeName>Jagbir K</ForeName>
<Initials>JK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stephens</LastName>
<ForeName>Jennifer M L</ForeName>
<Initials>JM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Canada</Country>
<MedlineTA>Can Oncol Nurs J</MedlineTA>
<NlmUniqueID>9300792</NlmUniqueID>
<ISSNLinking>1181-912X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002983">Clinical Competence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000451">nursing</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009723">Nurse-Patient Relations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017741">Survivors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25189056</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1181-912X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>24</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Season>Summer</Season>
</PubDate>
</JournalIssue>
<Title>Canadian oncology nursing journal = Revue canadienne de nursing oncologique</Title>
<ISOAbbreviation>Can Oncol Nurs J</ISOAbbreviation>
</Journal>
<ArticleTitle>Contribution of the pivot nurse in oncology to the experience of receiving a diagnosis of cancer by the patient and their loved ones.</ArticleTitle>
<Pagination>
<MedlinePgn>189-93, 184-8</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The announcement of a cancer diagnosis represents a difficult situation for the patient, their loved ones and professionals (Reich, Vennin &amp; BelkacÃ©mie, 2008). Until now, few studies have described nurses' contribution to this critical moment along the care trajectory (Tobin, 2012) and even fewer, the contribution of the pivot nurse in oncology (OPN) or infirmiÃ¨re pivot en oncologie (PNO) as this specialist is called in Quebec. This study aims to document the OPN's contribution to the cancer experience of the patient and their loved ones, from the time the diagnosis is communicated to the period immediately following (four to six weeks). Fourteen PNOs from a Montreal university health centre took part in two individual interviews. Results show that PNOs offer personalized support which draws on their expertise to better understand the experience lived by patients and their loved ones, and adapt their interventions according to their needs and the timing of these interventions. These results support issuing three recommendations for nursing practice in the areas of PNOs; development of expertise, interprofessional collaboration and environment.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Leboeuf</LastName>
<ForeName>IrÃ¨ne</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lachapelle</LastName>
<ForeName>Dominique</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dubois</LastName>
<ForeName>Sylvie</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Genest</LastName>
<ForeName>Catherine</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Canada</Country>
<MedlineTA>Can Oncol Nurs J</MedlineTA>
<NlmUniqueID>9300792</NlmUniqueID>
<ISSNLinking>1181-912X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000451">nursing</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009723">Nurse-Patient Relations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009859">Oncology Nursing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D011368">Professional-Family Relations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D011792">Quebec</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25189058</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1181-912X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>24</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Season>Summer</Season>
</PubDate>
</JournalIssue>
<Title>Canadian oncology nursing journal = Revue canadienne de nursing oncologique</Title>
<ISOAbbreviation>Can Oncol Nurs J</ISOAbbreviation>
</Journal>
<ArticleTitle>Developing interdisciplinary research partnerships within the clinical setting.</ArticleTitle>
<Pagination>
<MedlinePgn>204-6</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Singh-Carlson</LastName>
<ForeName>Savitri</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sherriff</LastName>
<ForeName>Colleen</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Trevillion</LastName>
<ForeName>Kris</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wong</LastName>
<ForeName>Frances</ForeName>
<Initials>F</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Canada</Country>
<MedlineTA>Can Oncol Nurs J</MedlineTA>
<NlmUniqueID>9300792</NlmUniqueID>
<ISSNLinking>1181-912X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D035843">Biomedical Research</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D003299">Cooperative Behavior</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007391">International Cooperation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000451">nursing</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D010348">Patient Care Team</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25189059</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1181-912X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>24</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Season>Summer</Season>
</PubDate>
</JournalIssue>
<Title>Canadian oncology nursing journal = Revue canadienne de nursing oncologique</Title>
<ISOAbbreviation>Can Oncol Nurs J</ISOAbbreviation>
</Journal>
<ArticleTitle>MASCC Oral Agent Teaching Tool (MOATT): yesterday, today and tomorrow.</ArticleTitle>
<Pagination>
<MedlinePgn>207-10</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lemonde</LastName>
<ForeName>Manon</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Canada</Country>
<MedlineTA>Can Oncol Nurs J</MedlineTA>
<NlmUniqueID>9300792</NlmUniqueID>
<ISSNLinking>1181-912X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D004496">Education, Continuing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000451">nursing</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D012955">Societies, Medical</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25190726</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Electronic-Print">
<Journal>
<ISSN IssnType="Electronic">1460-2105</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>106</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Journal of the National Cancer Institute</Title>
<ISOAbbreviation>J. Natl. Cancer Inst.</ISOAbbreviation>
</Journal>
<ArticleTitle>Adult cancer clinical trials that fail to complete: an epidemic?</ArticleTitle>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/jnci/dju229</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">dju229</ELocationID>
<Abstract>
<AbstractText>The number and diversity of cancer therapeutics in the pipeline has increased over the past decade due to an enhanced understanding of cancer biology and the identification of novel therapeutic targets. At the same time, the cost of bringing new drugs to market and the regulatory burdens associated with clinical drug development have progressively increased. The finite number of eligible patients and limited financial resources available to evaluate promising new therapeutics represent rate-limiting factors in the effort to translate preclinical discoveries into the next generation of standard therapeutic approaches. Optimal use of resources requires understanding and ultimately addressing inefficiencies in the cancer clinical trials system. Prior analyses have demonstrated that a large proportion of trials initiated by the National Cancer Institute (NCI) Cooperative Group system are never completed. While NCI Cooperative Group trials are important, they represent only a small proportion of all cancer clinical trials performed. Herein, we explore the problem of cancer clinical trials that fail to complete within the broader cancer clinical trials enterprise. Among 7776 phase II-III adult cancer clinical trials initiated between 2005-2011, we found a seven-year cumulative incidence of failure to complete of approximately 20% (95% confidence interval = 18% to 22%). Nearly 48000 patients were enrolled in trials that failed to complete. These trials likely contribute little to the scientific knowledge base, divert resources and patients from answering other critical questions, and represent a barrier to progress. </AbstractText>
<CopyrightInformation>Â© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Stensland</LastName>
<ForeName>Kristian D</ForeName>
<Initials>KD</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology (KDS, SJH) and Department of Medicine (KDS, AL, RH, NR, PB, WKO, MDG), Division of Hematology/Oncology, Tisch Cancer Institute and Department of Pathology (RBM) and Institute for Translational Epidemiology (RBM, PB) and Department of Medicine (JW), Divisions of General Internal Medicine and Pulmonary and Critical Care, Icahn School of Medicine, Mount Sinai, NY.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>McBride</LastName>
<ForeName>Russell B</ForeName>
<Initials>RB</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology (KDS, SJH) and Department of Medicine (KDS, AL, RH, NR, PB, WKO, MDG), Division of Hematology/Oncology, Tisch Cancer Institute and Department of Pathology (RBM) and Institute for Translational Epidemiology (RBM, PB) and Department of Medicine (JW), Divisions of General Internal Medicine and Pulmonary and Critical Care, Icahn School of Medicine, Mount Sinai, NY.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Latif</LastName>
<ForeName>Asma</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology (KDS, SJH) and Department of Medicine (KDS, AL, RH, NR, PB, WKO, MDG), Division of Hematology/Oncology, Tisch Cancer Institute and Department of Pathology (RBM) and Institute for Translational Epidemiology (RBM, PB) and Department of Medicine (JW), Divisions of General Internal Medicine and Pulmonary and Critical Care, Icahn School of Medicine, Mount Sinai, NY.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wisnivesky</LastName>
<ForeName>Juan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology (KDS, SJH) and Department of Medicine (KDS, AL, RH, NR, PB, WKO, MDG), Division of Hematology/Oncology, Tisch Cancer Institute and Department of Pathology (RBM) and Institute for Translational Epidemiology (RBM, PB) and Department of Medicine (JW), Divisions of General Internal Medicine and Pulmonary and Critical Care, Icahn School of Medicine, Mount Sinai, NY.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hendricks</LastName>
<ForeName>Ryan</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology (KDS, SJH) and Department of Medicine (KDS, AL, RH, NR, PB, WKO, MDG), Division of Hematology/Oncology, Tisch Cancer Institute and Department of Pathology (RBM) and Institute for Translational Epidemiology (RBM, PB) and Department of Medicine (JW), Divisions of General Internal Medicine and Pulmonary and Critical Care, Icahn School of Medicine, Mount Sinai, NY.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Roper</LastName>
<ForeName>Nitin</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology (KDS, SJH) and Department of Medicine (KDS, AL, RH, NR, PB, WKO, MDG), Division of Hematology/Oncology, Tisch Cancer Institute and Department of Pathology (RBM) and Institute for Translational Epidemiology (RBM, PB) and Department of Medicine (JW), Divisions of General Internal Medicine and Pulmonary and Critical Care, Icahn School of Medicine, Mount Sinai, NY.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Boffetta</LastName>
<ForeName>Paolo</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology (KDS, SJH) and Department of Medicine (KDS, AL, RH, NR, PB, WKO, MDG), Division of Hematology/Oncology, Tisch Cancer Institute and Department of Pathology (RBM) and Institute for Translational Epidemiology (RBM, PB) and Department of Medicine (JW), Divisions of General Internal Medicine and Pulmonary and Critical Care, Icahn School of Medicine, Mount Sinai, NY.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hall</LastName>
<ForeName>Simon J</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology (KDS, SJH) and Department of Medicine (KDS, AL, RH, NR, PB, WKO, MDG), Division of Hematology/Oncology, Tisch Cancer Institute and Department of Pathology (RBM) and Institute for Translational Epidemiology (RBM, PB) and Department of Medicine (JW), Divisions of General Internal Medicine and Pulmonary and Critical Care, Icahn School of Medicine, Mount Sinai, NY.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oh</LastName>
<ForeName>William K</ForeName>
<Initials>WK</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology (KDS, SJH) and Department of Medicine (KDS, AL, RH, NR, PB, WKO, MDG), Division of Hematology/Oncology, Tisch Cancer Institute and Department of Pathology (RBM) and Institute for Translational Epidemiology (RBM, PB) and Department of Medicine (JW), Divisions of General Internal Medicine and Pulmonary and Critical Care, Icahn School of Medicine, Mount Sinai, NY.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Galsky</LastName>
<ForeName>Matthew D</ForeName>
<Initials>MD</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology (KDS, SJH) and Department of Medicine (KDS, AL, RH, NR, PB, WKO, MDG), Division of Hematology/Oncology, Tisch Cancer Institute and Department of Pathology (RBM) and Institute for Translational Epidemiology (RBM, PB) and Department of Medicine (JW), Divisions of General Internal Medicine and Pulmonary and Critical Care, Icahn School of Medicine, Mount Sinai, NY matthew.galsky@mssm.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Natl Cancer Inst</MedlineTA>
<NlmUniqueID>7503089</NlmUniqueID>
<ISSNLinking>0027-8874</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000639">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D055808">Drug Discovery</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057239">Early Termination of Clinical Trials</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000706">statistics &amp; numerical data</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000639">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054547">National Cancer Institute (U.S.)</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035842">Research Subjects</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24916140</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-8321</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>29</Volume>
<Issue>11</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Psychology &amp; health</Title>
<ISOAbbreviation>Psychol Health</ISOAbbreviation>
</Journal>
<ArticleTitle>Young women's construction of their post-cancer fertility.</ArticleTitle>
<Pagination>
<MedlinePgn>1341-60</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/08870446.2014.932790</ELocationID>
<Abstract>
<AbstractText>Younger women diagnosed with cancer often face compromised fertility as a result of their treatment. However, previous research has adopted a biomedical model of fertility and utilised hypothetico-deductive research methods which have not allowed for full exploration of women's subjectivity. This study explored younger women's construction of their fertility post-cancer, and their discussions of fertility with healthcare professionals, from a social constructionist epistemology. Semi-structured one-to-one interviews were conducted with eight women aged 18-26, across a variety of cancer types. Foucaultian Discourse Analysis identified three subject positions associated with fertility concerns: 'Inadequate woman: Accepting the motherhood mandate'; 'Adequate woman: Resisting the motherhood mandate'; and 'Survival of the fittest: Woman as genetically defective'. Implications of these subject positions included feelings of inadequacy, fear and devastation; feeling undesirable to romantic partners; and concern about passing on cancer-positive genes. In describing healthcare professional interactions, women adopted positions of 'Satisfied patient'; 'Passive recipient patient'; or 'Resisting the passive patient position'. Accounts of inadequate information provision were associated with anger and frustration, whereas feeling adequately informed was associated with satisfaction at making decisions about fertility preservation. These results suggest that fertility is of importance to young women cancer survivors, and that compromised fertility can negatively impact subjectivity. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dryden</LastName>
<ForeName>Amy</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>a Centre for Health Research , University of Western Sydney , Penrith , Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ussher</LastName>
<ForeName>Jane M</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Perz</LastName>
<ForeName>Janette</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Psychol Health</MedlineTA>
<NlmUniqueID>8807983</NlmUniqueID>
<ISSNLinking>0887-0446</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D001294">Attitude to Health</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003142">Communication</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003657">Decision Making</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D005298">Fertility</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010549">Personal Satisfaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010817">Physician-Patient Relations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D036301">Qualitative Research</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017741">Survivors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Foucaultian Discourse Analysis (FDA)</Keyword>
<Keyword MajorTopicYN="N">cancer</Keyword>
<Keyword MajorTopicYN="N">fertility</Keyword>
<Keyword MajorTopicYN="N">health professionals</Keyword>
<Keyword MajorTopicYN="N">young women</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24676897</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>15</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1573-2649</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>23</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation</Title>
<ISOAbbreviation>Qual Life Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Danish population-based reference data for the EORTC QLQ-C30: associations with gender, age and morbidity.</ArticleTitle>
<Pagination>
<MedlinePgn>2183-93</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s11136-014-0675-y</ELocationID>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">General population reference data are useful in the interpretation of health-related quality of life (HRQoL) results, but for the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30), such data have been published for only seven countries. In 1992, Danish general population data were collected from women only for EORTC QLQ-C30 version 1. Since no Danish reference data exists for men and women for the QLQ-C30 version 3.0, the aims of this study were to generate such data and to investigate the associations between EORTC QLQ-C30 outcomes and age, gender and morbidity, as well as trends over time.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">An age- and gender-stratified random sample of 3,080 Danes was drawn from the Danish Civil Registration System. The EORTC QLQ-C30 was administered electronically and by mail along with a short questionnaire concerning socio-demographics/morbidity.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Responses were obtained from 1,832 individuals (60.1% of 3,009 eligible individuals). Response rates varied across age groups, ranging from 41.9% (20-29 years) to 76.1% (70-79 years). The majority of subscales were strongly associated with age and morbidity. Between genders only small, but clinically meaningful and statistically significant differences were found in five out of fifteen scales. When comparing Danish women 20 years ago and today, a tendency toward slightly improved function/reduced symptoms was observed, but the differences were small and statistically significant in only three subscales.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study is the first to present Danish general population reference values for the EORTC QLQ-C30 version 3.0. Age and morbidity are important potential confounders that must be taken into account in HRQoL studies.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Juul</LastName>
<ForeName>Therese</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Section for Colorectal and Mamma-Endocrine Surgery, Department of Surgery, Aarhus University Hospital, Aarhus, Denmark, therjuul@rm.dk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Petersen</LastName>
<ForeName>Morten Aagaard</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Holzner</LastName>
<ForeName>Bernhard</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Laurberg</LastName>
<ForeName>SÃ¸ren</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Christensen</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>GrÃ¸nvold</LastName>
<ForeName>Mogens</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Qual Life Res</MedlineTA>
<NlmUniqueID>9210257</NlmUniqueID>
<ISSNLinking>0962-9343</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000367">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D003718">Denmark</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006305">Health Status Indicators</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009017">Morbidity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011594">Psychometrics</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000592">standards</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011795">Questionnaires</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000592">standards</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012016">Reference Values</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24687566</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>15</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1573-2649</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>23</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation</Title>
<ISOAbbreviation>Qual Life Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Using Rasch analysis to examine the distress thermometer's cut-off scores among a mixed group of patients with cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>2257-65</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s11136-014-0673-0</ELocationID>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The distress thermometer (DT) is commonly used in cancer care to improve detection of distress. The DT's recommended cut-off score of 4 or 5 has typically been established using the Hospital Anxiety and Depression Scale (HADS) by receiver operating characteristic curve analysis. The present analysis complements these studies by critically examining the use of the HADS to identify the DT's cut-off score and corroborating the DT's cut-off scores using item response theory (Rasch analysis).</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">The DT and HADS were completed by 340 patients with cancer. Rasch dimensionality analysis was performed on the HADS-Total, and test characteristic curves were examined to equate the DT and the HADS subscales. Identified DT cut-off scores were then examined for their sensitivity and specificity.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Rasch analysis did not support the unidimensionality of HADS-Total. The test characteristic curves indicated that a cut-off score of â¥8 on the HADS-Anxiety and HADS-Depression subscales was equivalent to a score of 6 and 7 on the DT, respectively. However, a DT cut-off score of 5 resulted in the best balance between sensitivity and specificity across the HADS-Anxiety and HADS-Depression subscales.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite being a popular practice, the present findings did not support combining the HADS-Anxiety and HADS-Depression subscales to identify the DT's cut-off score. Furthermore, these results inform the use of the DT as a preliminary screening tool and suggest that when a single screen is used, a DT cut-off score of 6 or 7 might be more appropriate than the typical cut-off score of 4.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lambert</LastName>
<ForeName>Sylvie D</ForeName>
<Initials>SD</Initials>
<AffiliationInfo>
<Affiliation>Ingram School of Nursing, McGill University, Wilson Hall, 3506 Sherbrooke Street, Montreal, H3A 2A7, Canada, sylvie.lambert@mcgill.ca.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pallant</LastName>
<ForeName>Julie F</ForeName>
<Initials>JF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Clover</LastName>
<ForeName>Kerrie</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Britton</LastName>
<ForeName>Benjamin</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>King</LastName>
<ForeName>Madeleine T</ForeName>
<Initials>MT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Carter</LastName>
<ForeName>Gregory</ForeName>
<Initials>G</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>04</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Qual Life Res</MedlineTA>
<NlmUniqueID>9210257</NlmUniqueID>
<ISSNLinking>0962-9343</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001007">Anxiety</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003863">Depression</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011594">Psychometrics</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012372">ROC Curve</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013315">Stress, Psychological</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24729054</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>15</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1573-2649</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>23</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation</Title>
<ISOAbbreviation>Qual Life Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Assessing quality of life in young adult cancer survivors: development of the Survivorship-Related Quality of Life scale.</ArticleTitle>
<Pagination>
<MedlinePgn>2213-24</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s11136-014-0682-z</ELocationID>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Scientific advances in treatments and outcomes for those diagnosed with cancer in late adolescence and early adulthood depend, in part, on the availability of adequate assessment tools to measure health-related quality of life (HRQOL) for survivors in this age group. Domains especially relevant to late adolescence and young adulthood (LAYA; e.g., education and career, committed romantic relationships, worldview formation) are typically overlooked in studies assessing the impact of cancer, usually more appropriate for middle-aged or older survivors. Current HRQOL measures also tend to assess issues that are salient during or shortly after treatment rather than reflecting life years after treatment.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">To develop a new measure to better capture the experience of LAYA cancer survivors in longer-term survivorship (the LAYA Survivorship-Related Quality of Life measure, LAYA-SRQL), we completed an extensive measure development process. After a literature review and focus groups with LAYA cancer survivors, we generated items and ran confirmatory factor and reliability analyses using a sample of 292 LAYA cancer survivors. We then examined validity using existing measures of physical and mental health, quality of life, and impact of cancer.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The final model consisted of two domains (satisfaction and impact), each consisting of ten factors: existential/spirituality, coping, relationship, dependence, vitality, health care, education/career, fertility, intimacy/sexuality, and cognition/memory. Confirmatory factor analysis and validity analyses indicated that the LAYA-SRQL is a psychometrically sound instrument with good validity.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The LAYA-SRQL fills an important need in survivorship research, providing a way to assess HRQOL in LAYAs in a developmentally informed way.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Crystal L</ForeName>
<Initials>CL</Initials>
<AffiliationInfo>
<Affiliation>University of Connecticut, Storrs, CT, USA, crystal.park@uconn.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wortmann</LastName>
<ForeName>Jennifer H</ForeName>
<Initials>JH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hale</LastName>
<ForeName>Amy E</ForeName>
<Initials>AE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cho</LastName>
<ForeName>Dalnim</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Blank</LastName>
<ForeName>Thomas O</ForeName>
<Initials>TO</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>04</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Qual Life Res</MedlineTA>
<NlmUniqueID>9210257</NlmUniqueID>
<ISSNLinking>0962-9343</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006305">Health Status Indicators</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008603">Mental Health</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008960">Models, Psychological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011594">Psychometrics</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017741">Survivors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24894504</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1367-4811</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>30</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Bioinformatics (Oxford, England)</Title>
<ISOAbbreviation>Bioinformatics</ISOAbbreviation>
</Journal>
<ArticleTitle>Mirsynergy: detecting synergistic miRNA regulatory modules by overlapping neighbourhood expansion.</ArticleTitle>
<Pagination>
<MedlinePgn>2627-35</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/bioinformatics/btu373</ELocationID>
<Abstract>
<AbstractText Label="MOTIVATION" NlmCategory="BACKGROUND">Identification of microRNA regulatory modules (MiRMs) will aid deciphering aberrant transcriptional regulatory network in cancer but is computationally challenging. Existing methods are stochastic or require a fixed number of regulatory modules.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We propose Mirsynergy, an efficient deterministic overlapping clustering algorithm adapted from a recently developed framework. Mirsynergy operates in two stages: it first forms MiRMs based on co-occurring microRNA (miRNA) targets and then expands each MiRM by greedily including (excluding) mRNAs into (from) the MiRM to maximize the synergy score, which is a function of miRNA-mRNA and gene-gene interactions. Using expression data for ovarian, breast and thyroid cancer from The Cancer Genome Atlas, we compared Mirsynergy with internal controls and existing methods. Mirsynergy-MiRMs exhibit significantly higher functional enrichment and more coherent miRNA-mRNA expression anti-correlation. Based on Kaplan-Meier survival analysis, we proposed several prognostically promising MiRMs and envisioned their utility in cancer research.</AbstractText>
<AbstractText Label="AVAILABILITY AND IMPLEMENTATION" NlmCategory="METHODS">Mirsynergy is implemented/available as an R/Bioconductor package at www.cs.utoronto.ca/â¼yueli/Mirsynergy.html.</AbstractText>
<CopyrightInformation>Â© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Yue</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Computer Science, The Donnelly Centre, University of Toronto, Toronto, Ontario M5S 3E1, Canada, College of Information Science and Engineering, Hunan University, Changsha, Hunan, 410082, China and Banting and Best Department of Medical Research and Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S 3E1, Canada Department of Computer Science, The Donnelly Centre, University of Toronto, Toronto, Ontario M5S 3E1, Canada, College of Information Science and Engineering, Hunan University, Changsha, Hunan, 410082, China and Banting and Best Department of Medical Research and Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S 3E1, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liang</LastName>
<ForeName>Cheng</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Computer Science, The Donnelly Centre, University of Toronto, Toronto, Ontario M5S 3E1, Canada, College of Information Science and Engineering, Hunan University, Changsha, Hunan, 410082, China and Banting and Best Department of Medical Research and Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S 3E1, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wong</LastName>
<ForeName>Ka-Chun</ForeName>
<Initials>KC</Initials>
<AffiliationInfo>
<Affiliation>Department of Computer Science, The Donnelly Centre, University of Toronto, Toronto, Ontario M5S 3E1, Canada, College of Information Science and Engineering, Hunan University, Changsha, Hunan, 410082, China and Banting and Best Department of Medical Research and Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S 3E1, Canada Department of Computer Science, The Donnelly Centre, University of Toronto, Toronto, Ontario M5S 3E1, Canada, College of Information Science and Engineering, Hunan University, Changsha, Hunan, 410082, China and Banting and Best Department of Medical Research and Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S 3E1, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Luo</LastName>
<ForeName>Jiawei</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Computer Science, The Donnelly Centre, University of Toronto, Toronto, Ontario M5S 3E1, Canada, College of Information Science and Engineering, Hunan University, Changsha, Hunan, 410082, China and Banting and Best Department of Medical Research and Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S 3E1, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Zhaolei</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Computer Science, The Donnelly Centre, University of Toronto, Toronto, Ontario M5S 3E1, Canada, College of Information Science and Engineering, Hunan University, Changsha, Hunan, 410082, China and Banting and Best Department of Medical Research and Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S 3E1, Canada Department of Computer Science, The Donnelly Centre, University of Toronto, Toronto, Ontario M5S 3E1, Canada, College of Information Science and Engineering, Hunan University, Changsha, Hunan, 410082, China and Banting and Best Department of Medical Research and Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S 3E1, Canada Department of Computer Science, The Donnelly Centre, University of Toronto, Toronto, Ontario M5S 3E1, Canada, College of Information Science and Engineering, Hunan University, Changsha, Hunan, 410082, China and Banting and Best Department of Medical Research and Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S 3E1, Canada.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Bioinformatics</MedlineTA>
<NlmUniqueID>9808944</NlmUniqueID>
<ISSNLinking>1367-4803</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D000465">Algorithms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001665">Binding Sites</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016000">Cluster Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019295">Computational Biology</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004843">Epistasis, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D053263">Gene Regulatory Networks</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059467">Transcriptome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25047832</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5549</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Molecular and cellular biology</Title>
<ISOAbbreviation>Mol. Cell. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells.</ArticleTitle>
<Pagination>
<MedlinePgn>3675-88</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/MCB.00595-14</ELocationID>
<Abstract>
<AbstractText>Cyclin-dependent kinase 7 (CDK7) activates cell cycle CDKs and is a member of the general transcription factor TFIIH. Although there is substantial evidence for an active role of CDK7 in mRNA synthesis and associated processes, the degree of its influence on global and gene-specific transcription in mammalian species is unclear. In the current study, we utilize two novel inhibitors with high specificity for CDK7 to demonstrate a restricted but robust impact of CDK7 on gene transcription in vivo and in in vitro-reconstituted reactions. We distinguish between relative low- and high-dose responses and relate them to distinct molecular mechanisms and altered physiological responses. Low inhibitor doses cause rapid clearance of paused RNA polymerase II (RNAPII) molecules and sufficed to cause genome-wide alterations in gene expression, delays in cell cycle progression at both the G1/S and G2/M checkpoints, and diminished survival of human tumor cells. Higher doses and prolonged inhibition led to strong reductions in RNAPII carboxyl-terminal domain (CTD) phosphorylation, eventual activation of the p53 program, and increased cell death. Together, our data reason for a quantitative contribution of CDK7 to mRNA synthesis, which is critical for cellular homeostasis. </AbstractText>
<CopyrightInformation>Copyright Â© 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kelso</LastName>
<ForeName>Timothy W R</ForeName>
<Initials>TW</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Cellular and Molecular Biology, Institute of Molecular Tumor Biology, Westfalian Wilhelms University Muenster, Muenster, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Baumgart</LastName>
<ForeName>Karen</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Cellular and Molecular Biology, Institute of Molecular Tumor Biology, Westfalian Wilhelms University Muenster, Muenster, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Eickhoff</LastName>
<ForeName>Jan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Lead Discovery Center GmbH, Dortmund, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Albert</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Cellular and Molecular Biology, Institute of Molecular Tumor Biology, Westfalian Wilhelms University Muenster, Muenster, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Antrecht</LastName>
<ForeName>Claudia</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Cellular and Molecular Biology, Institute of Molecular Tumor Biology, Westfalian Wilhelms University Muenster, Muenster, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lemcke</LastName>
<ForeName>Sarah</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Cellular and Molecular Biology, Institute of Molecular Tumor Biology, Westfalian Wilhelms University Muenster, Muenster, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Klebl</LastName>
<ForeName>Bert</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Lead Discovery Center GmbH, Dortmund, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Meisterernst</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Cellular and Molecular Biology, Institute of Molecular Tumor Biology, Westfalian Wilhelms University Muenster, Muenster, Germany meistere@uni-muenster.de.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Cell Biol</MedlineTA>
<NlmUniqueID>8109087</NlmUniqueID>
<ISSNLinking>0270-7306</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000592924">BS-181</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000592925">LDC3140</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000592926">LDC4297</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011687">Purines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014227">Triazines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C104586">roscovitine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.22</RegistryNumber>
<NameOfSubstance UI="D018844">Cyclin-Dependent Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.22</RegistryNumber>
<NameOfSubstance UI="C066067">cyclin-dependent kinase-activating kinase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.7.-</RegistryNumber>
<NameOfSubstance UI="D012319">RNA Polymerase II</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002453">Cell Cycle</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018844">Cyclin-Dependent Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006367">HeLa Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011687">Purines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011720">Pyrazoles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011743">Pyrimidines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012319">RNA Polymerase II</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014227">Triazines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4187722 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25047840</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5549</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Molecular and cellular biology</Title>
<ISOAbbreviation>Mol. Cell. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Polycomb repressive complex 2 and H3K27me3 cooperate with H3K9 methylation to maintain heterochromatin protein 1Î± at chromatin.</ArticleTitle>
<Pagination>
<MedlinePgn>3662-74</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/MCB.00205-14</ELocationID>
<Abstract>
<AbstractText>Methylation of histone H3 on lysine 9 or 27 is crucial for heterochromatin formation. Previously considered hallmarks of, respectively, constitutive and facultative heterochromatin, recent evidence has accumulated in favor of coexistence of these two marks and their cooperation in gene silencing maintenance. H3K9me2/3 ensures anchorage at chromatin of heterochromatin protein 1Î± (HP1Î±), a main component of heterochromatin. HP1Î± chromoshadow domain, involved in dimerization and interaction with partners, has additional but still unclear roles in HP1Î± recruitment to chromatin. Because of previously suggested links between polycomb repressive complex 2 (PRC2), which catalyzes H3K27 methylation, and HP1Î±, we tested whether PRC2 may regulate HP1Î± abundance at chromatin. We found that the EZH2 and SUZ12 subunits of PRC2 are required for HP1Î± stability, as knockdown of either protein led to HP1Î± degradation. Similar results were obtained upon overexpression of H3K27me2/3 demethylases. We further showed that binding of HP1Î±/Î²/Î³ to H3K9me3 peptides is greatly increased in the presence of H3K27me3, and this is dependent on PRC2. These data fit with recent proteomic studies identifying PRC2 as an indirect H3K9me3 binder in mouse tissues and suggest the existence of a cooperative mechanism of HP1Î± anchorage at chromatin involving H3 methylation on both K9 and K27 residues. </AbstractText>
<CopyrightInformation>Copyright Â© 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Boros</LastName>
<ForeName>Joanna</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Genetic and Epigenetic Alterations of Genomes, de Duve Institute, Catholic University of Louvain, Brussels, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Arnoult</LastName>
<ForeName>Nausica</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Genetic and Epigenetic Alterations of Genomes, de Duve Institute, Catholic University of Louvain, Brussels, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stroobant</LastName>
<ForeName>Vincent</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Ludwig Institute for Cancer Research, Brussels Branch, and de Duve Institute, Catholic University of Louvain, Brussels, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Collet</LastName>
<ForeName>Jean-FranÃ§ois</ForeName>
<Initials>JF</Initials>
<AffiliationInfo>
<Affiliation>WELBIO and de Duve Institute, Catholic University of Louvain, Brussels, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Decottignies</LastName>
<ForeName>Anabelle</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Genetic and Epigenetic Alterations of Genomes, de Duve Institute, Catholic University of Louvain, Brussels, Belgium anabelle.decottignies@uclouvain.be.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Cell Biol</MedlineTA>
<NlmUniqueID>8109087</NlmUniqueID>
<ISSNLinking>0270-7306</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002843">Chromatin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002868">Chromosomal Proteins, Non-Histone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006657">Histones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>107283-02-3</RegistryNumber>
<NameOfSubstance UI="C066725">heterochromatin-specific nonhistone chromosomal protein HP-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.1.1.43</RegistryNumber>
<NameOfSubstance UI="D063151">Polycomb Repressive Complex 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.25.1</RegistryNumber>
<NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002453">Cell Cycle</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002843">Chromatin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002868">Chromosomal Proteins, Non-Histone</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006657">Histones</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008745">Methylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008958">Models, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063151">Polycomb Repressive Complex 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046988">Proteasome Endopeptidase Complex</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055550">Protein Stability</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4187721 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25195393</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1438-3276</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>156</Volume>
<Issue>14</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
<Day>21</Day>
</PubDate>
</JournalIssue>
<Title>MMW Fortschritte der Medizin</Title>
<ISOAbbreviation>MMW Fortschr Med</ISOAbbreviation>
</Journal>
<ArticleTitle>[Practice guideline. Breakthrough pain therapy is a balancing act].</ArticleTitle>
<Pagination>
<MedlinePgn>27</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Meissner</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>ger</Language>
<PublicationTypeList>
<PublicationType UI="D016433">News</PublicationType>
</PublicationTypeList>
<VernacularTitle>Praxisleitlinie. Durchbruchschmerz-Therapie ist eine Gratwanderung.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>MMW Fortschr Med</MedlineTA>
<NlmUniqueID>100893959</NlmUniqueID>
<ISSNLinking>1438-3276</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000286">Administration, Sublingual</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000701">Analgesics, Opioid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059390">Breakthrough Pain</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003299">Cooperative Behavior</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D005858">Germany</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D033183">Interdisciplinary Communication</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059408">Pain Management</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010348">Patient Care Team</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017410">Practice Guidelines as Topic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25047399</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1572-0241</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>109</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>The American journal of gastroenterology</Title>
<ISOAbbreviation>Am. J. Gastroenterol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Incidence of malignancies in diagnosed celiac patients: a population-based estimate.</ArticleTitle>
<Pagination>
<MedlinePgn>1471-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/ajg.2014.194</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The association between celiac disease and malignancies is well recognized. In Finland, the prevalence of clinically diagnosed adult celiac disease is 0.6%. In this large, population-based cohort, we aimed at a realistic projection of the cancer risk.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">In the period 2002-2011, the register comprised 32,439 adult celiac patients. This was linked with the Finnish Cancer Registry, which covers over 98% of diagnosed malignancies. The standardized incidence ratio (SIR) was calculated for the malignancies, on the basis of incidence figures for the whole population. A time-stratified analysis was made in celiac patients diagnosed after 2004 (n=11,991). Lifestyle factors, including smoking habits and obesity, were not obtainable.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The overall incidence ratio of malignant diseases was not increased (SIR 0.94; 95% confidence intervals 0.89-0.98), but it was â¥5 years from the diagnosis of celiac disease (1.31, 1.04-1.63). The SIRs for non-Hodgkin lymphoma (NHL; 1.94; 1.62-2.29), small-intestinal cancer (4.29; 2.83-6.24), colon cancer (1.35; 1.13-1.58), and basal cell carcinoma of the skin (1.13; 1.03-1.22) were increased, whereas those for lung cancer (0.60; 0.48-0.74), pancreatic cancer (0.73; 0.53-0.97), bladder cancer (0.53; 0.35-0.77), renal cancer (0.72; 0.51-0.99), and breast cancer (0.70; 0.62-0.79) were decreased. SIR for NHL immediately after the diagnosis of celiac disease was 2.56 (1.37-4.38).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There was no increased SIR of cancer in the whole series, but SIR was increased after 5 years from the diagnosis of celiac disease. The risk of breast and lung cancers was decreased. The risk of small-intestinal cancer and NHL was increased, but to a lesser extent than previously described.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ilus</LastName>
<ForeName>Tuire</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital and University of Tampere, Tampere, Finland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kaukinen</LastName>
<ForeName>Katri</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital and University of Tampere, Tampere, Finland [2] Department of Medicine, SeinÃ¤joki Central Hospital, SeinÃ¤joki, Finland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Virta</LastName>
<ForeName>Lauri J</ForeName>
<Initials>LJ</Initials>
<AffiliationInfo>
<Affiliation>Research Department, The Social Insurance Institution, Turku, Finland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pukkala</LastName>
<ForeName>Eero</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>1] Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland [2] School of Health Sciences, University of Tampere, Tampere, Finland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Collin</LastName>
<ForeName>Pekka</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital and University of Tampere, Tampere, Finland.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Gastroenterol</MedlineTA>
<NlmUniqueID>0421030</NlmUniqueID>
<ISSNLinking>0002-9270</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002446">Celiac Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D005387">Finland</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015994">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008228">Lymphoma, Non-Hodgkin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012042">Registries</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25043653</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1542-4863</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>64</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2014 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>CA: a cancer journal for clinicians</Title>
<ISOAbbreviation>CA Cancer J Clin</ISOAbbreviation>
</Journal>
<ArticleTitle>Oncologists and primary care physicians infrequently provide survivorship care plans.</ArticleTitle>
<Pagination>
<MedlinePgn>291-2</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3322/caac.21240</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Barton</LastName>
<ForeName>Mary Kay</ForeName>
<Initials>MK</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016420">Comment</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>CA Cancer J Clin</MedlineTA>
<NlmUniqueID>0370647</NlmUniqueID>
<ISSNLinking>0007-9235</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentOn">
<RefSource>J Clin Oncol. 2014 May 20;32(15):1578-85</RefSource>
<PMID Version="1">24752057</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008134">Long-Term Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008495">Medical Oncology</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D010347">Patient Care Planning</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D010818">Physician's Practice Patterns</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D011320">Primary Health Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017741">Survivors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25043971</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1542-4863</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>64</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2014 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>CA: a cancer journal for clinicians</Title>
<ISOAbbreviation>CA Cancer J Clin</ISOAbbreviation>
</Journal>
<ArticleTitle>Palliative radiotherapy at the end of life: a critical review.</ArticleTitle>
<Pagination>
<MedlinePgn>296-310</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3322/caac.21242</ELocationID>
<Abstract>
<AbstractText>When delivered with palliative intent, radiotherapy can help to alleviate a multitude of symptoms related to advanced cancer. In general, time to symptom relief is measured in weeks to months after the completion of radiotherapy. Over the past several years, an increasing number of studies have explored rates of radiotherapy use in the final months of life and have found variable rates of radiotherapy use. The optimal rate is unclear, but would incorporate anticipated efficacy in patients whose survival allows it and minimize overuse among patients with expected short survival. Clinician prediction has been shown to overestimate the length of survival in repeated studies. Prognostic indices can provide assistance with estimations of survival length and may help to guide treatment decisions regarding palliative radiotherapy in patients with potentially short survival times. This review explores the recent studies of radiotherapy near the end of life, examines general prognostic models for patients with advanced cancer, describes specific clinical circumstances when radiotherapy may and may not be beneficial, and addresses open questions for future research to help clarify when palliative radiotherapy may be effective near the end of life.</AbstractText>
<CopyrightInformation>Â© 2014 American Cancer Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jones</LastName>
<ForeName>Joshua A</ForeName>
<Initials>JA</Initials>
<AffiliationInfo>
<Affiliation>Assistant Professor, Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lutz</LastName>
<ForeName>Stephen T</ForeName>
<Initials>ST</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chow</LastName>
<ForeName>Edward</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Johnstone</LastName>
<ForeName>Peter A</ForeName>
<Initials>PA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>CA Cancer J Clin</MedlineTA>
<NlmUniqueID>0370647</NlmUniqueID>
<ISSNLinking>0007-9235</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000532">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000532">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D010166">Palliative Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016019">Survival Analysis</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">palliative care</Keyword>
<Keyword MajorTopicYN="N">radiation oncology</Keyword>
<Keyword MajorTopicYN="N">radiotherapy</Keyword>
<Keyword MajorTopicYN="N">survival.</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25104502</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1542-4863</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>64</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2014 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>CA: a cancer journal for clinicians</Title>
<ISOAbbreviation>CA Cancer J Clin</ISOAbbreviation>
</Journal>
<ArticleTitle>MicroRNAome genome: a treasure for cancer diagnosis and therapy.</ArticleTitle>
<Pagination>
<MedlinePgn>311-36</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3322/caac.21244</ELocationID>
<Abstract>
<AbstractText>The interplay between abnormalities in genes coding for proteins and noncoding microRNAs (miRNAs) has been among the most exciting yet unexpected discoveries in oncology over the last decade. The complexity of this network has redefined cancer research as miRNAs, produced from what was once considered "genomic trash," have shown to be crucial for cancer initiation, progression, and dissemination. Naturally occurring miRNAs are very short transcripts that never produce a protein or amino acid chain, but act by regulating protein expression during cellular processes such as growth, development, and differentiation at the transcriptional, posttranscriptional, and/or translational level. In this review article, miRNAs are presented as ubiquitous players involved in all cancer hallmarks. The authors also describe the most used methods to detect their expression, which have revealed the identity of hundreds of miRNAs dysregulated in cancer cells or tumor microenvironment cells. Furthermore, the role of miRNAs as hormones and as reliable cancer biomarkers and predictors of treatment response is discussed. Along with this, the authors explore current strategies in designing miRNA-targeting therapeutics, as well as the associated challenges that research envisions to overcome. Finally, a new wave in molecular oncology translational research is introduced: the study of long noncoding RNAs.</AbstractText>
<CopyrightInformation>Â© 2014 American Cancer Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Berindan-Neagoe</LastName>
<ForeName>Ioana</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Department of Functional Genomics, The Oncology Institute, Research Center for Functional Genomics, Biomedicine and Translational Medicine, Department of Immunology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Monroig</LastName>
<ForeName>Paloma del C</ForeName>
<Initials>Pdel C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pasculli</LastName>
<ForeName>Barbara</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Calin</LastName>
<ForeName>George A</ForeName>
<Initials>GA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>CA Cancer J Clin</MedlineTA>
<NlmUniqueID>0370647</NlmUniqueID>
<ISSNLinking>0007-9235</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014408">Tumor Markers, Biological</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016678">Genome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014408">Tumor Markers, Biological</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">cancer.</Keyword>
<Keyword MajorTopicYN="N">diagnosis</Keyword>
<Keyword MajorTopicYN="N">microRNA</Keyword>
<Keyword MajorTopicYN="N">therapy</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24853866</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-0142</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>120</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Cancer</Title>
<ISOAbbreviation>Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Ambulatory cancer and US general population reference values and cutoff scores for the functional assessment of cancer therapy.</ArticleTitle>
<Pagination>
<MedlinePgn>2902-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.28758</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Health-related quality of life (HRQOL) measures are commonly used in oncology research. Interest in their use for monitoring or screening is increasing. The Functional Assessment of Cancer Therapy (FACT) is one of the most widely used HRQOL instruments. Consequently, oncology researchers and practitioners have an increasing need for reference values for the Functional Assessment of Cancer Therapy-General (FACT-G) and its 7-item rapid version, the Functional Assessment of Cancer Therapy-General 7 (FACT-G7), to compare FACT scores across specific subgroups of patients in research trials and practice. The objectives of this study are to provide 1) reference values from a sample of the general US adult population and a sample of adults diagnosed with cancer and 2) cutoff scores for quality of life.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">A sample of the general US population (Nâ=â1075) and a sample of patients with cancer from 12 studies (Nâ=â5065) were analyzed. Cutoff scores were established using distribution- and anchor-based methods. Mean values for the cancer sample were analyzed by performance status, cancer type, and disease status. Also, t tests and established criteria for meaningful differences were used to compare values.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">FACT-G and FACT-G7 scores in the general US population sample and cancer sample were generally comparable. Among the sample of patients with cancer, FACT-G and FACT-G7 scores worsened with declining performance status and increasing disease status.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data will aid interpretation of the magnitude and meaning of FACT scores, and allow for comparisons of scores across studies.</AbstractText>
<CopyrightInformation>Â© 2014 American Cancer Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pearman</LastName>
<ForeName>Timothy</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yanez</LastName>
<ForeName>Betina</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Peipert</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wortman</LastName>
<ForeName>Katy</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Beaumont</LastName>
<ForeName>Jennifer</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cella</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 CA 157809</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer</MedlineTA>
<NlmUniqueID>0374236</NlmUniqueID>
<ISSNLinking>0008-543X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D000553">Ambulatory Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D006304">Health Status</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009367">Neoplasm Staging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010361">Patients</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011795">Questionnaires</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012016">Reference Values</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012107">Research Design</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">health-related quality of life</Keyword>
<Keyword MajorTopicYN="N">oncology</Keyword>
<Keyword MajorTopicYN="N">patient-reported outcomes</Keyword>
<Keyword MajorTopicYN="N">reference values</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24898093</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-0142</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>120</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Cancer</Title>
<ISOAbbreviation>Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Factors associated with high burden in caregivers of older adults with cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>2927-35</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.28765</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Older adults with cancer are vulnerable to functional decline, which places greater onus on caregivers. Few studies have prospectively examined burden in caregivers of older cancer patients. The objective of this study was to determine the factors associated with high caregiver burden.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">In total, 100 caregivers of patients aged â¥65 years with cancer, who were recruited at a single institution, completed questionnaires gauging their perception of the patient's physical, emotional, and social health. The association between these items, cancer-related factors, sociodemographic factors, and caregiver burden (measured using the Caregiver Strain Index [CSI]) was determined through multivariate analysis.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The median patient age was 70 years (range, 65-91 years), 70% of patients had advanced disease, and 98% were receiving treatment. Caregivers were mostly women (73%), spouses (68%), and lived with the patient (79%). The median amount of care provided was 10 hours per week. The mean CSI score (Â± standard deviation) was 3.1âÂ±â3.2. Most caregivers (75%) reported some burden, with 15% reporting high caregiver burden (CSI score, â¥7). In multivariate analysis, employed caregivers (odds ratio, 4.5; 95% confidence interval, 1.1-18.4; Pâ=â.04) and those caring for patients who required more help with instrumental activities of daily living (Older Americans Resources and Services-Instrumental Activities of Daily Living score, &lt;12 of a possible 14; odds ratio, 12.4; 95% confidence interval, 2.4-62.5; Pâ&lt;â.001) were more likely to experience high caregiver burden (CSI score, â¥7).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Caregiver burden is common in those who care for older cancer patients. High burden is more likely in employed caregivers and in those who care for patients who require increased functional assistance. Further studies are needed to determine the unique challenges experienced by caregivers of older adults with cancer and potential interventions to alleviate burden in these caregivers.</AbstractText>
<CopyrightInformation>Â© 2014 American Cancer Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hsu</LastName>
<ForeName>Tina</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Loscalzo</LastName>
<ForeName>Matthew</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ramani</LastName>
<ForeName>Rupal</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Forman</LastName>
<ForeName>Stephen</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Popplewell</LastName>
<ForeName>Leslie</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Clark</LastName>
<ForeName>Karen</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Katheria</LastName>
<ForeName>Vani</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Feng</LastName>
<ForeName>Tao</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Strowbridge</LastName>
<ForeName>Rex</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rinehart</LastName>
<ForeName>Redmond</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Smith</LastName>
<ForeName>Dan</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Matthews</LastName>
<ForeName>Keith</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dillehunt</LastName>
<ForeName>Jeff</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hurria</LastName>
<ForeName>Arti</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R21 AG041489</GrantID>
<Acronym>AG</Acronym>
<Agency>NIA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21 AG041489</GrantID>
<Acronym>AG</Acronym>
<Agency>NIA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer</MedlineTA>
<NlmUniqueID>0374236</NlmUniqueID>
<ISSNLinking>0008-543X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017028">Caregivers</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015577">Geriatric Assessment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000451">nursing</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010865">Pilot Projects</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D013315">Stress, Psychological</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS586562 [Available on 09/15/15]</OtherID>
<OtherID Source="NLM">PMC4159406 [Available on 09/15/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">aged</Keyword>
<Keyword MajorTopicYN="N">caregivers</Keyword>
<Keyword MajorTopicYN="N">neoplasms</Keyword>
<Keyword MajorTopicYN="N">prospective studies</Keyword>
<Keyword MajorTopicYN="N">psychological</Keyword>
<Keyword MajorTopicYN="N">stress</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25196660</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1097-0142</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>120</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Cancer</Title>
<ISOAbbreviation>Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Nanotech advancements: scientists harness nanotechnology to better diagnose and treat cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>2781-3</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.28982</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Printz</LastName>
<ForeName>Carrie</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016433">News</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer</MedlineTA>
<NlmUniqueID>0374236</NlmUniqueID>
<ISSNLinking>0008-543X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D036103">Nanotechnology</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24692097</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-0215</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>135</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>International journal of cancer. Journal international du cancer</Title>
<ISOAbbreviation>Int. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Risk of cancer in patients with medically diagnosed hay fever or allergic rhinitis.</ArticleTitle>
<Pagination>
<MedlinePgn>2397-403</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.28873</ELocationID>
<Abstract>
<AbstractText>Data on allergic conditions as risk or protective factors for cancer are controversial probably because most studies have used self-reported data on mixed groups of allergies in a case-control setting. We define cancer risks in medically diagnosed hay fever/allergic rhinitis patients in a nationwide cohort study. A total of 138,723 hay fever/allergic rhinitis patients were identified from three Swedish health care databases and standardized incidence ratios (SIRs) were calculated for subsequent cancers identified from the Swedish Cancer Registry. Overall cancer risk was not changed (SIR 1.03). For individual cancers, the highest SIR was observed for nasal cancer (SIR 2.63), followed by testicular (1.46) and endocrine tumors (1.42), and kidney (1.31), prostate (1.18) and breast (1.11) cancers. The results were consistent in the three sources of data and all SIRs were above unity, albeit mainly not statistically significant. The SIRs for nervous system tumors were above unity and of borderline significance. SIRs were decreased for esophageal (0.50), liver (0.62) and lung (0.78) cancers, and the three sources of data agreed in the direction of the effect. The increased risks for testicular, renal, prostate and endocrine cancers may be explained by immunological mechanisms. Excess risk for these cancer accounts for a significant population attributable fraction. Nervous system cancers showed a borderline increase and none of the histological types were significantly decreased, providing strong evidence against the published case-control studies, which have reported protective effects. The reasons for the reduced risks for esophageal, liver and lung cancer remain to be explained. </AbstractText>
<CopyrightInformation>Â© 2014 UICC.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hemminki</LastName>
<ForeName>Kari</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Center for Primary Health Care Research, Lund University, MalmÃ¶, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>FÃ¶rsti</LastName>
<ForeName>Asta</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fallah</LastName>
<ForeName>Mahdi</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sundquist</LastName>
<ForeName>Jan</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sundquist</LastName>
<ForeName>Kristina</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ji</LastName>
<ForeName>Jianguang</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>04</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Int J Cancer</MedlineTA>
<NlmUniqueID>0042124</NlmUniqueID>
<ISSNLinking>0020-7136</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015994">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012042">Registries</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D065631">Rhinitis, Allergic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012221">Rhinitis, Allergic, Perennial</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006255">Rhinitis, Allergic, Seasonal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D013548">Sweden</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">allergic rhinitis</Keyword>
<Keyword MajorTopicYN="N">cancer risk</Keyword>
<Keyword MajorTopicYN="N">hay fever</Keyword>
<Keyword MajorTopicYN="N">immune disturbance</Keyword>
<Keyword MajorTopicYN="N">standardized incidence ratio</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24706491</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-0215</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>135</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>International journal of cancer. Journal international du cancer</Title>
<ISOAbbreviation>Int. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Cancer beyond organ and tissue specificity: next-generation-sequencing gene mutation data reveal complex genetic similarities across major cancers.</ArticleTitle>
<Pagination>
<MedlinePgn>2362-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.28882</ELocationID>
<Abstract>
<AbstractText>Cancer medicine relies on the paradigm that cancer is an organ- and tissue-specific disease, which is the basis for classifying tumors. With the extensive genomic information now available on tumors it is possible to conduct analyses to reveal common genetic features across cancer types and to explore whether the established anatomy-based tumor classification is actually reflected on the genetic level, which might provide important guides to new therapeutic directions. Here, we have conducted an extensive analysis of the genetic similarity of tumors from 14 major cancer entities using somatic mutation data from 4,796 cases available through The Cancer Genome Atlas (TCGA) based on all available genes as well as different cancer-related gene sets. Our analysis provides a systematic account of the genetic similarity network for major cancer types and shows that in about 43% of the cases on average, tumors of a particular anatomic site are genetically more similar to tumors from different organs and tissues (trans-similarity) than to tumors of the same origin (self-similarity). The observed similarities exist not only for carcinomas from different sites but are also present among neoplasms from different tissue origin, such as melanoma, acute myeloid leukemia, and glioblastoma. The current WHO cancer classification is therefore reflected on the genetic level by only about 57% of the tumors. These results provide a rationale to reconsider organ- and tissue-specificity in cancer and contribute to the discussion about whether personalized therapies targeting specific genetic alterations may be transferred to cancers from other anatomic sites with similar genetic properties. </AbstractText>
<CopyrightInformation>Â© 2014 UICC.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Heim</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Institute of Pathology, CharitÃ© Medical University Berlin, CharitÃ©platz 1, 10117, Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Budczies</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stenzinger</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Treue</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hufnagl</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Denkert</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dietel</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Klauschen</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>04</Month>
<Day>17</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Int J Cancer</MedlineTA>
<NlmUniqueID>0042124</NlmUniqueID>
<ISSNLinking>0020-7136</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015894">Genome, Human</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059014">High-Throughput Nucleotide Sequencing</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000145">classification</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009928">Organ Specificity</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">WHO cancer classification</Keyword>
<Keyword MajorTopicYN="N">cancer genetics</Keyword>
<Keyword MajorTopicYN="N">mutational cancer profiling</Keyword>
<Keyword MajorTopicYN="N">personalized medicine</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24723234</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-0215</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>135</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>International journal of cancer. Journal international du cancer</Title>
<ISOAbbreviation>Int. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Adherence to cancer prevention guidelines and risk of breast cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>2444-52</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.28887</ELocationID>
<Abstract>
<AbstractText>Healthy eating patterns and keeping physically active are potentially more important for chronic disease prevention than intake or exclusion of specific food items or nutrients. To this end, many health organizations routinely publish dietary and lifestyle recommendations aimed at preventing chronic disease. Using data from the Canadian National Breast Screening Study, we investigated the association between breast cancer risk and adherence to two sets of guidelines specific for cancer prevention, namely the American Cancer Society (ACS) Guidelines and the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations. At baseline, 49,613 women completed dietary and lifestyle questionnaires and height and weight measurements were taken. During a mean follow-up of 16.6 years, 2,503 incident cases of breast cancer were ascertained. Cox proportional hazard models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association of meeting each guideline, and number of guidelines met, with breast cancer risk. The two sets of guidelines yielded similar results. Specifically, adherence to all six ACS guidelines was associated with a 31% reduction in breast cancer risk when compared to subjects adhering to at most one guideline (HR=0.69; 95% CI=0.49-0.97); similarly, adherence to six or seven of the WCRF/AICR guidelines was also associated with a 31% reduction in breast cancer risk (HR=0.69; 95% CI=0.47-1.00). Under either classification, meeting each additional guideline was associated with a 4-6% reduction in breast cancer risk. These results suggest that adherence to cancer prevention guidelines is associated with a reduced risk of breast cancer.</AbstractText>
<CopyrightInformation>Â© 2014 UICC.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Catsburg</LastName>
<ForeName>Chelsea</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Miller</LastName>
<ForeName>Anthony B</ForeName>
<Initials>AB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rohan</LastName>
<ForeName>Thomas E</ForeName>
<Initials>TE</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>04</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Int J Cancer</MedlineTA>
<NlmUniqueID>0042124</NlmUniqueID>
<ISSNLinking>0020-7136</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008207">Lymphatic Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009364">Neoplasm Recurrence, Local</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009367">Neoplasm Staging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015996">Survival Rate</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">breast cancer</Keyword>
<Keyword MajorTopicYN="N">cohort</Keyword>
<Keyword MajorTopicYN="N">diet and cancer</Keyword>
<Keyword MajorTopicYN="N">guideline adherence</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25124653</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-0215</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>135</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>International journal of cancer. Journal international du cancer</Title>
<ISOAbbreviation>Int. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Oncometabolites-driven tumorigenesis: From genetics to targeted therapy.</ArticleTitle>
<Pagination>
<MedlinePgn>2237-48</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.29080</ELocationID>
<Abstract>
<AbstractText>Although the alteration of cellular metabolism in cancer was reported by Warburg in the early 1930s, a regain of interest in cancer metabolism has more recently followed the discovery of germline or somatic mutations in genes coding for metabolic enzymes (succinate dehydrogenase, fumarate hydratase and isocitrate dehydrogenase) that are associated with tumor susceptibility. Mutations in these genes are found in numerous tumor types including paragangliomas, kidney cancers, leiomyomas, glioblastomas and acute myeloid leukemia. They lead to the accumulation of so-called oncometabolites that behave as competitors of 2-oxoglutarate-dependent dioxygenases, involved in a broad spectrum of pathways such as hypoxic response and epigenetic reprogramming. Here, we review the diverse pathways affected by oncometabolites, their potential role in cancer formation, maintenance, metastasis and sensitivity to chemotherapies, as well as emerging new therapeutic strategies. </AbstractText>
<CopyrightInformation>Â© 2014 UICC.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Morin</LastName>
<ForeName>AurÃ©lie</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>INSERM, UMR970, Paris-Cardiovascular Research Center at HEGP, Paris, France; FacultÃ© de MÃ©decine, UniversitÃ© Paris Descartes, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>LetouzÃ©</LastName>
<ForeName>Eric</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gimenez-Roqueplo</LastName>
<ForeName>Anne-Paule</ForeName>
<Initials>AP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Favier</LastName>
<ForeName>Judith</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Int J Cancer</MedlineTA>
<NlmUniqueID>0042124</NlmUniqueID>
<ISSNLinking>0020-7136</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Int J Cancer. 2014 Nov 15;135(10):2235-6</RefSource>
<PMID Version="1">25132359</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002471">Cell Transformation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D055442">Metabolome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">FH</Keyword>
<Keyword MajorTopicYN="N">IDH</Keyword>
<Keyword MajorTopicYN="N">SDH</Keyword>
<Keyword MajorTopicYN="N">epigenetics</Keyword>
<Keyword MajorTopicYN="N">glioblastoma</Keyword>
<Keyword MajorTopicYN="N">hypoxia</Keyword>
<Keyword MajorTopicYN="N">metabolism</Keyword>
<Keyword MajorTopicYN="N">oncometabolite</Keyword>
<Keyword MajorTopicYN="N">paraganglioma</Keyword>
<Keyword MajorTopicYN="N">pheochromocytoma</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25132359</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-0215</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>135</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>International journal of cancer. Journal international du cancer</Title>
<ISOAbbreviation>Int. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Cancer research in France.</ArticleTitle>
<Pagination>
<MedlinePgn>2235-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.29131</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Rogers</LastName>
<ForeName>Kara</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>1115 Oak Way, Madison, WI, 53705, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lenoir</LastName>
<ForeName>Gilbert M</ForeName>
<Initials>GM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016420">Comment</PublicationType>
<PublicationType UI="D016421">Editorial</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Int J Cancer</MedlineTA>
<NlmUniqueID>0042124</NlmUniqueID>
<ISSNLinking>0020-7136</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentOn">
<RefSource>Int J Cancer. 2014 Nov 15;135(10):2237-48</RefSource>
<PMID Version="1">25124653</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002471">Cell Transformation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D055442">Metabolome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25195984</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1879-355X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>90</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>International journal of radiation oncology, biology, physics</Title>
<ISOAbbreviation>Int. J. Radiat. Oncol. Biol. Phys.</ISOAbbreviation>
</Journal>
<ArticleTitle>Around the globe--Radiation oncology in Australia.</ArticleTitle>
<Pagination>
<MedlinePgn>1-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijrobp.2014.03.044</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0360-3016(14)00401-5</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Duchesne</LastName>
<ForeName>Gillian M</ForeName>
<Initials>GM</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, Peter Mac Cancer Centre, Melbourne, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Turner</LastName>
<ForeName>Sandra L</ForeName>
<Initials>SL</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cronje</LastName>
<ForeName>Sonja</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Faculty of Radiation Oncology, Royal Australian and New Zealand College of Radiologists, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Int J Radiat Oncol Biol Phys</MedlineTA>
<NlmUniqueID>7603616</NlmUniqueID>
<ISSNLinking>0360-3016</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D001315">Australia</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002173">Cancer Care Facilities</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000458">organization &amp; administration</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003256">Consumer Participation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006297">Health Services Accessibility</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000458">organization &amp; administration</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019456">Health Transition</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020407">Internet</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000532">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018787">Radiation Oncology</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000193">education</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000458">organization &amp; administration</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000592">standards</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012955">Societies, Medical</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000458">organization &amp; administration</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25195986</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1879-355X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>90</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>International journal of radiation oncology, biology, physics</Title>
<ISOAbbreviation>Int. J. Radiat. Oncol. Biol. Phys.</ISOAbbreviation>
</Journal>
<ArticleTitle>Considerations for observational research using large data sets in radiation oncology.</ArticleTitle>
<Pagination>
<MedlinePgn>11-24</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijrobp.2014.05.013</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0360-3016(14)00611-7</ELocationID>
<Abstract>
<AbstractText>The radiation oncology community has witnessed growing interest in observational research conducted using large-scale data sources such as registries and claims-based data sets. With the growing emphasis on observational analyses in health care, the radiation oncology community must possess a sophisticated understanding of the methodological considerations of such studies in order to evaluate evidence appropriately to guide practice and policy. Because observational research has unique features that distinguish it from clinical trials and other forms of traditional radiation oncology research, the International Journal of Radiation Oncology, Biology, Physics assembled a panel of experts in health services research to provide a concise and well-referenced review, intended to be informative for the lay reader, as well as for scholars who wish to embark on such research without prior experience. This review begins by discussing the types of research questions relevant to radiation oncology that large-scale databases may help illuminate. It then describes major potential data sources for such endeavors, including information regarding access and insights regarding the strengths and limitations of each. Finally, it provides guidance regarding the analytical challenges that observational studies must confront, along with discussion of the techniques that have been developed to help minimize the impact of certain common analytical issues in observational analysis. Features characterizing a well-designed observational study include clearly defined research questions, careful selection of an appropriate data source, consultation with investigators with relevant methodological expertise, inclusion of sensitivity analyses, caution not to overinterpret small but significant differences, and recognition of limitations when trying to evaluate causality. This review concludes that carefully designed and executed studies using observational data that possess these qualities hold substantial promise for advancing our understanding of many unanswered questions of importance to the field of radiation oncology.</AbstractText>
<CopyrightInformation>Copyright Â© 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jagsi</LastName>
<ForeName>Reshma</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. Electronic address: rjagsi@med.umich.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bekelman</LastName>
<ForeName>Justin E</ForeName>
<Initials>JE</Initials>
<AffiliationInfo>
<Affiliation>Departments of Radiation Oncology and Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Aileen</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Ronald C</ForeName>
<Initials>RC</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hoffman</LastName>
<ForeName>Karen</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shih</LastName>
<ForeName>Ya-Chen Tina</ForeName>
<Initials>YC</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Section of Hospital Medicine, The University of Chicago, Chicago, Illinois.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Smith</LastName>
<ForeName>Benjamin D</ForeName>
<Initials>BD</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, Division of Radiation Oncology, and Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>James B</ForeName>
<Initials>JB</Initials>
<AffiliationInfo>
<Affiliation>Yale School of Medicine, New Haven, Connecticut.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>K07 CA163616</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>K07-CA163616</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 HS018535</GrantID>
<Acronym>HS</Acronym>
<Agency>AHRQ HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 HS020263</GrantID>
<Acronym>HS</Acronym>
<Agency>AHRQ HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21CA165092</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Int J Radiat Oncol Biol Phys</MedlineTA>
<NlmUniqueID>7603616</NlmUniqueID>
<ISSNLinking>0360-3016</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D057189">Checklist</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000592">standards</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057186">Comparative Effectiveness Research</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D016208">Databases, Factual</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004059">Diffusion of Innovation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017048">Health Care Costs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006302">Health Services Research</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006306">Health Surveys</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007345">Insurance Claim Review</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006278">Medicare</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049451">Nomograms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064887">Observational Study as Topic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000592">standards</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011364">Professional Practice</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000639">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057216">Propensity Score</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017594">Publication Bias</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018787">Radiation Oncology</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000639">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035583">Rare Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D012042">Registries</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012107">Research Design</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018426">SEER Program</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS614519 [Available on 09/01/15]</OtherID>
<OtherID Source="NLM">PMC4159773 [Available on 09/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25199215</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0893-9675</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>19</Volume>
<Issue>1-2</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Critical reviews in oncogenesis</Title>
<ISOAbbreviation>Crit Rev Oncog</ISOAbbreviation>
</Journal>
<ArticleTitle>Serendipity. Coincidence. Luck.</ArticleTitle>
<Pagination>
<MedlinePgn>15-9</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kiessling</LastName>
<ForeName>Rolf</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Crit Rev Oncog</MedlineTA>
<NlmUniqueID>8914610</NlmUniqueID>
<ISSNLinking>0893-9675</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007694">Killer Cells, Natural</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25199271</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>16</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1345-5354</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>34</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Igaku butsuri : Nihon Igaku Butsuri Gakkai kikanshi = Japanese journal of medical physics : an official journal of Japan Society of Medical Physics</Title>
<ISOAbbreviation>Igaku Butsuri</ISOAbbreviation>
</Journal>
<ArticleTitle>[Oncology PET imaging].</ArticleTitle>
<Pagination>
<MedlinePgn>3-9</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>At the beginning of this article, likening medical images to "Where is Waldo?" I indicate the concept of diagnostic process of PET/CT imaging, so that medical physics specialists could understand the role of each imaging modality and infer our distress for image diagnosis. Then, I state the present situation of PET imaging and the basics (e.g. health insurance coverage, clinical significance, principle, protocol, and pitfall) of oncology FDG-PET imaging which accounts for more than 99% of all clinical PET examinations in Japan. Finally, I would like to give a wishful prospect of oncology PET that will expand to be more cancer-specific in order to assess therapeutic effects of emerging molecular targeted drugs targeting the "hallmarks of cancer".</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Inubushi</LastName>
<ForeName>Masayuki</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>jpn</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Japan</Country>
<MedlineTA>Igaku Butsuri</MedlineTA>
<NlmUniqueID>101125977</NlmUniqueID>
<ISSNLinking>1345-5354</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0Z5B2CJX4D</RegistryNumber>
<NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005462">Fluorine Radioisotopes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019788">Fluorodeoxyglucose F18</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007564">Japan</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057054">Molecular Imaging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049268">Positron-Emission Tomography</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000639">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019275">Radiopharmaceuticals</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25035143</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>29</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-6256</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>180</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>American journal of epidemiology</Title>
<ISOAbbreviation>Am. J. Epidemiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Comparing indices of diet quality with chronic disease mortality risk in postmenopausal women in the Women's Health Initiative Observational Study: evidence to inform national dietary guidance.</ArticleTitle>
<Pagination>
<MedlinePgn>616-25</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/aje/kwu173</ELocationID>
<Abstract>
<AbstractText>Poor diet quality is thought to be a leading risk factor for years of life lost. We examined how scores on 4 commonly used diet quality indices-the Healthy Eating Index 2010 (HEI), the Alternative Healthy Eating Index 2010 (AHEI), the Alternate Mediterranean Diet (aMED), and the Dietary Approaches to Stop Hypertension (DASH)-are related to the risks of death from all causes, cardiovascular disease (CVD), and cancer among postmenopausal women. Our prospective cohort study included 63,805 participants in the Women's Health Initiative Observational Study (from 1993-2010) who completed a food frequency questionnaire at enrollment. Cox proportional hazards models were fit using person-years as the underlying time metric. We estimated multivariate hazard ratios and 95% confidence intervals for death associated with increasing quintiles of diet quality index scores. During 12.9 years of follow-up, 5,692 deaths occurred, including 1,483 from CVD and 2,384 from cancer. Across indices and after adjustment for multiple covariates, having better diet quality (as assessed by HEI, AHEI, aMED, and DASH scores) was associated with statistically significant 18%-26% lower all-cause and CVD mortality risk. Higher HEI, aMED, and DASH (but not AHEI) scores were associated with a statistically significant 20%-23% lower risk of cancer death. These results suggest that postmenopausal women consuming a diet in line with a priori diet quality indices have a lower risk of death from chronic disease.</AbstractText>
<CopyrightInformation>Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>George</LastName>
<ForeName>Stephanie M</ForeName>
<Initials>SM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ballard-Barbash</LastName>
<ForeName>Rachel</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Manson</LastName>
<ForeName>JoAnn E</ForeName>
<Initials>JE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Reedy</LastName>
<ForeName>Jill</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shikany</LastName>
<ForeName>James M</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Subar</LastName>
<ForeName>Amy F</ForeName>
<Initials>AF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tinker</LastName>
<ForeName>Lesley F</ForeName>
<Initials>LF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vitolins</LastName>
<ForeName>Mara</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Neuhouser</LastName>
<ForeName>Marian L</ForeName>
<Initials>ML</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>HHSN268201100001C</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>HHSN268201100002C</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>HHSN268201100003C</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>HHSN268201100046C</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>HHSN26820110004C</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>HHSN271201100004C</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D023362">Evaluation Studies</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D064888">Observational Study</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D023361">Validation Studies</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>17</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Epidemiol</MedlineTA>
<NlmUniqueID>7910653</NlmUniqueID>
<ISSNLinking>0002-9262</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002318">Cardiovascular Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002908">Chronic Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004032">Diet</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D038441">Diet, Mediterranean</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004522">Educational Status</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005510">Food Habits</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015438">Health Behavior</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015994">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015233">Models, Statistical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015999">Multivariate Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018673">Nutrition Policy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011159">Population Surveillance</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017698">Postmenopause</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016016">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011795">Questionnaires</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000592">standards</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016019">Survival Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016387">Women's Health</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4157698 [Available on 09/15/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">diet</Keyword>
<Keyword MajorTopicYN="N">diet quality indices</Keyword>
<Keyword MajorTopicYN="N">mortality risk</Keyword>
<Keyword MajorTopicYN="N">postmenopausal women</Keyword>
<Keyword MajorTopicYN="N">prospective cohort study</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202041</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Sono-photodynamic combination therapy: a review on sensitizers.</ArticleTitle>
<Pagination>
<MedlinePgn>4657-64</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Cancer is characterized by the dysregulation of cell signaling pathways at several steps. The majority of current anticancer therapies involve the modulation of a single target. A tumor-targeting drug-delivery system consists of a tumor detection moiety and a cytotoxic material joined directly or through a suitable linker to form a conjugate. Photodynamic therapy has been used for more than 100 years to treat tumors. One of the present goals of photodynamic therapy research is to enhance the selective targeting of tumor cells in order to reduce the risk and extension of unwanted side-effects, caused by normal cell damage. Sonodynamic therapy is a promising new treatment for patients with cancer. It treats cancer with ultrasound and sonosensitive agents. Porphyrin compounds often serve as photosensitive and sonosensitive agents. The combination of these two methods makes cancer treatment more effective. The present review provides an overview of photodynamic therapy, sonodynamic therapy, sono-photodynamic therapy and the four sensitizers which are suitable candidates for combined sono-photodynamic therapy. </AbstractText>
<CopyrightInformation>CopyrightÂ© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Sadanala</LastName>
<ForeName>Krishna Chaitanya</ForeName>
<Initials>KC</Initials>
<AffiliationInfo>
<Affiliation>Integrated Omics Institute, Wonkwang University, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chaturvedi</LastName>
<ForeName>Pankaj Kumar</ForeName>
<Initials>PK</Initials>
<AffiliationInfo>
<Affiliation>Integrated Omics Institute, Wonkwang University, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Seo</LastName>
<ForeName>You Mi</ForeName>
<Initials>YM</Initials>
<AffiliationInfo>
<Affiliation>Integrated Omics Institute, Wonkwang University, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Jeung Mo</ForeName>
<Initials>JM</Initials>
<AffiliationInfo>
<Affiliation>Integrated Omics Institute, Wonkwang University, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jo</LastName>
<ForeName>Yong Sam</ForeName>
<Initials>YS</Initials>
<AffiliationInfo>
<Affiliation>Integrated Omics Institute, Wonkwang University, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Yang Koo</ForeName>
<Initials>YK</Initials>
<AffiliationInfo>
<Affiliation>Dongsung Pharmaceuticals, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ahn</LastName>
<ForeName>Woong Shick</ForeName>
<Initials>WS</Initials>
<AffiliationInfo>
<Affiliation>Integrated Omics Institute, Wonkwang University, Seoul, South Korea ahnws4120@yahoo.co.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008027">Light</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D010778">Photochemotherapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017319">Photosensitizing Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013016">Sound</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D014464">Ultrasonic Therapy</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Photodynamic therapy</Keyword>
<Keyword MajorTopicYN="N">review</Keyword>
<Keyword MajorTopicYN="N">sensitizer</Keyword>
<Keyword MajorTopicYN="N">sono-photodynamic therapy</Keyword>
<Keyword MajorTopicYN="N">sonodynamic therapy</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202053</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Development of a novel in vivo cancer model using cell sheet engineering.</ArticleTitle>
<Pagination>
<MedlinePgn>4747-54</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="AIM" NlmCategory="OBJECTIVE">Standard in vivo cancer models entail injecting single cancer cells, but this technique is not always successful. We developed a novel cancer cell sheet by using temperature-responsive polymer poly(N-isopropyl acryl amide)-coated plates, which allow controlled attachment and detachment of living cancer cells via simple temperature changes.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Four human cancer cell lines were used to make cell sheets. The cancer cell sheets were subcutaneously transplanted into nude mice and compared regarding their tumor-forming ability with the conventional cell suspension technique.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Human cancer cell sheets were successfully transplanted into nude mice. The cancer cell sheets resulted in stable engraftment and showed a higher tumor volume determined by total flux with the IVISÂ® imaging system.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Novel cancer cell sheets are useful tools to make in vivo cancer models in mice for the assessment of anticancer therapeutics.</AbstractText>
<CopyrightInformation>CopyrightÂ© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Suzuki</LastName>
<ForeName>Ryuji</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterological Surgery, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Aruga</LastName>
<ForeName>Atsushi</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterological Surgery, Tokyo Women's Medical University, Tokyo, Japan Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, Tokyo, Japan aruga.atsushi@twmu.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kobayashi</LastName>
<ForeName>Hajime</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamato</LastName>
<ForeName>Masayuki</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamamoto</LastName>
<ForeName>Masakazu</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterological Surgery, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018929">Cell Culture Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045325">HCT116 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014407">Tumor Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cancer</Keyword>
<Keyword MajorTopicYN="N">cell sheet</Keyword>
<Keyword MajorTopicYN="N">mouse model</Keyword>
<Keyword MajorTopicYN="N">tissue engineering</Keyword>
<Keyword MajorTopicYN="N">transplantation</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202104</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Phase I study of Efatutazone, an oral PPARÎ³ agonist, in patients with metastatic solid tumors.</ArticleTitle>
<Pagination>
<MedlinePgn>5133-41</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Efatutazone is a highly selective agonist of peroxisome proliferator-activated receptor gamma (PPARÎ³), a therapeutic target for carcinogenesis.</AbstractText>
<AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">In this phase I dose-escalation study, we assessed the safety, efficacy, and pharmacokinetics of efatutazone and the recommended dose (RD) was determined in Japanese patients with metastatic solid tumors using a 3+3 design.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 13 patients were enrolled and received efatutazone at doses of 0.25 mg, 0.50 mg, and 0.75 mg bid for multiple 3-week cycles. No dose-limiting toxicities were observed, and the maximum tolerated dose was not reached. Partial response was confirmed in one patient and stable disease in three. Efatutazone exposure was almost dose-proportional. RD was determined to be 0.50 mg bid, corresponding to the RD in previous global phase I studies.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Efatutazone demonstrated acceptable toxicity and gave evidence of disease control in Japanese patients with metastatic solid tumors.</AbstractText>
<CopyrightInformation>CopyrightÂ© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Murakami</LastName>
<ForeName>Haruyasu</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan ha.murakami@scchr.jp.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ono</LastName>
<ForeName>Akira</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Takahashi</LastName>
<ForeName>Toshiaki</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Onozawa</LastName>
<ForeName>Yusuke</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tsushima</LastName>
<ForeName>Takahiro</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamazaki</LastName>
<ForeName>Kentaro</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jikoh</LastName>
<ForeName>Takahiro</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Clinical Planning Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Boku</LastName>
<ForeName>Narikazu</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan Department of Clinical Oncology, St. Marianna University School of Medicine, Kanagawa, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamamoto</LastName>
<ForeName>Nobuyuki</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biological Markers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047495">PPAR gamma</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D045162">Thiazolidinediones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>M17ILL71MC</RegistryNumber>
<NameOfSubstance UI="C510342">efatutazone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015415">Biological Markers</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047495">PPAR gamma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000819">agonists</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045162">Thiazolidinediones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Adiponectin</Keyword>
<Keyword MajorTopicYN="N">Japan</Keyword>
<Keyword MajorTopicYN="N">PPARÎ³ dose-escalation study</Keyword>
<Keyword MajorTopicYN="N">efatutazone</Keyword>
<Keyword MajorTopicYN="N">phase I trial</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25129480</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1546-170X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>20</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Nature medicine</Title>
<ISOAbbreviation>Nat. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>In vivo proteomic imaging analysis of caveolae reveals pumping system to penetrate solid tumors.</ArticleTitle>
<Pagination>
<MedlinePgn>1062-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.3623</ELocationID>
<Abstract>
<AbstractText>Technologies are needed to map and image biological barriers in vivo that limit solid tumor delivery and, ultimately, the effectiveness of imaging and therapeutic agents. Here we integrate proteomic and imaging analyses of caveolae at the blood-tumor interface to discover an active transendothelial portal to infiltrate tumors. A post-translationally modified form of annexin A1 (AnnA1) is selectively concentrated in human and rodent tumor caveolae. To follow trafficking, we generated a specific AnnA1 antibody that targets caveolae in the tumor endothelium. Intravital microscopy of caveolae-immunotargeted fluorophores even at low intravenous doses showed rapid and robust pumping across the endothelium to enter mammary, prostate and lung tumors. Within 1 h, the fluorescence signal concentrated throughout tumors to exceed the peak levels in blood. This transvascular pumping required the expression of caveolin 1 and annexin A1. Tumor uptake with other antibodies were &gt;100-fold less. This proteomic imaging strategy reveals a unique target, antibody and caveolae pumping system for solid tumor penetration. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Oh</LastName>
<ForeName>Phil</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>1] Proteogenomics Research Institute for Systems Medicine, San Diego, California, USA. [2] Sidney Kimmel Cancer Center, San Diego, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Testa</LastName>
<ForeName>Jacqueline E</ForeName>
<Initials>JE</Initials>
<AffiliationInfo>
<Affiliation>1] Proteogenomics Research Institute for Systems Medicine, San Diego, California, USA. [2] Sidney Kimmel Cancer Center, San Diego, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Borgstrom</LastName>
<ForeName>Per</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>1] Sidney Kimmel Cancer Center, San Diego, California, USA. [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Witkiewicz</LastName>
<ForeName>Halina</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>1] Proteogenomics Research Institute for Systems Medicine, San Diego, California, USA. [2] Sidney Kimmel Cancer Center, San Diego, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Yan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>1] Proteogenomics Research Institute for Systems Medicine, San Diego, California, USA. [2] Sidney Kimmel Cancer Center, San Diego, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schnitzer</LastName>
<ForeName>Jan E</ForeName>
<Initials>JE</Initials>
<AffiliationInfo>
<Affiliation>1] Proteogenomics Research Institute for Systems Medicine, San Diego, California, USA. [2] Sidney Kimmel Cancer Center, San Diego, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P01CA104898</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA115215</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA119378</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA83989</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>17</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Nat Med</MedlineTA>
<NlmUniqueID>9502015</NlmUniqueID>
<ISSNLinking>1078-8956</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021941">Caveolae</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007091">Image Processing, Computer-Assisted</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D040901">Proteomics</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24985921</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0755-4982</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>43</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Presse mÃ©dicale (Paris, France : 1983)</Title>
<ISOAbbreviation>Presse Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Fever of unknown origin in the 2000s: evaluation of 103 cases over eleven years.</ArticleTitle>
<Pagination>
<MedlinePgn>e233-40</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lpm.2014.02.026</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0755-4982(14)00285-1</ELocationID>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Despite recent diagnostic advances, a fever of unknown origin (FUO) remains a clinical challenge.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">This study reports the clinical courses and outcomes of 103 cases of FUO and evaluates the places of (18)F-Fluorodeoxyglucose positrons emission tomography ((18)FDG-PET) and molecular biology in the diagnostic approach.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">This retrospective study was carried out from 2002 to 2012 in two departments of internal medicine. The diagnosis of FUO was based on the updated criteria of Durack and Street. It included 54 men and 49 women (mean age: 57 years) in 52 of whom the final diagnosis could not be established. Among the 51 patients with final diagnosis, non-infectious inflammatory disorders were the most prevalent (61%). The other diagnoses were infectious diseases (23.5%), miscellaneous causes (10%) and malignancies (6%). (18)FDG-PET was performed in 48 patients and was contributory in 10. Molecular biology techniques were performed in 28 patients and were contributory in only one case: detection of a cytomegalovirus infection by polymerase-chain-reaction assay. At study closure, eleven patients had died, of whom five died from the disease that caused the FUO. Only two deaths among the 52 patients without diagnosis could be attributed to the feverish illness.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">As observed in the most recent case series, the rate of undiagnosed patients is increasing. The prognosis was good for undiagnosed FUO. Here, the yield of (18)FDG-PET was 21% but that of molecular biology negligible. The recourse to molecular biology seems useless unless directed by a high degree of clinical suspicion.</AbstractText>
<CopyrightInformation>Copyright Â© 2014 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Robine</LastName>
<ForeName>Adrien</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Hospices civils de Lyon, hÃ´pital de la Croix-Rousse, department of internal medicine, 69004, Lyon, France; UniversitÃ© de Lyon, 69000 Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hot</LastName>
<ForeName>Arnaud</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>UniversitÃ© de Lyon, 69000 Lyon, France; Hospices civils de Lyon, hÃ´pital Edouard-Herriot, department of internal medicine, 69003 Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Maucort-Boulch</LastName>
<ForeName>Delphine</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>UniversitÃ© de Lyon, 69000 Lyon, France; Hospices civils de Lyon, hÃ´pital Lyon-Sud, department of biostatistics, 69310 Pierre-BÃ©nite, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Iwaz</LastName>
<ForeName>Jean</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Hospices civils de Lyon, hÃ´pital Lyon-Sud, department of biostatistics, 69310 Pierre-BÃ©nite, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Broussolle</LastName>
<ForeName>Christiane</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Hospices civils de Lyon, hÃ´pital de la Croix-Rousse, department of internal medicine, 69004, Lyon, France; UniversitÃ© de Lyon, 69000 Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>SÃ¨ve</LastName>
<ForeName>Pascal</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Hospices civils de Lyon, hÃ´pital de la Croix-Rousse, department of internal medicine, 69004, Lyon, France; UniversitÃ© de Lyon, 69000 Lyon, France. Electronic address: pascal.seve@chu-lyon.fr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>France</Country>
<MedlineTA>Presse Med</MedlineTA>
<NlmUniqueID>8302490</NlmUniqueID>
<ISSNLinking>0755-4982</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004269">DNA, Bacterial</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0Z5B2CJX4D</RegistryNumber>
<NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-73-2</RegistryNumber>
<NameOfSubstance UI="D005293">Ferritins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004269">DNA, Bacterial</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004279">DNA, Viral</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005293">Ferritins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005335">Fever of Unknown Origin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019788">Fluorodeoxyglucose F18</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007239">Infection</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016133">Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049268">Positron-Emission Tomography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019275">Radiopharmaceuticals</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25204028</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0741-6245</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>32</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Mayo Clinic health letter (English ed.)</Title>
<ISOAbbreviation>Mayo Clin Health Lett</ISOAbbreviation>
</Journal>
<ArticleTitle>Mayo Clinic acquires technology to treat tumors.</ArticleTitle>
<Pagination>
<MedlinePgn>4</MedlinePgn>
</Pagination>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016433">News</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mayo Clin Health Lett</MedlineTA>
<NlmUniqueID>8507508</NlmUniqueID>
<ISSNLinking>0741-6245</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>K</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057086">High-Intensity Focused Ultrasound Ablation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24838191</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1555-7162</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>127</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>The American journal of medicine</Title>
<ISOAbbreviation>Am. J. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>Risk and prognosis of cancer in patients with nephrotic syndrome.</ArticleTitle>
<Pagination>
<MedlinePgn>871-7.e1</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amjmed.2014.05.002</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0002-9343(14)00385-4</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Nephrotic syndrome may be a marker of occult cancer, but population-based studies of this association are lacking. Therefore, we examined the risk and prognosis of cancer in patients with nephrotic syndrome.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We conducted this population-based cohort study in Denmark, including all individuals diagnosed with nephrotic syndrome between 1980 and 2010 without a preceding cancer history. We computed the 5-year risk of cancer accounting for competing risk by death and standardized incidence ratios (SIRs) of cancer in patients with nephrotic syndrome relative to the general population. We compared the 5-year mortality for patients with cancer after nephrotic syndrome with that for a cancer cohort without a history of nephrotic syndrome using Cox regression adjusted for age, gender, and comorbidity.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 4293 individuals with nephrotic syndrome, 338 developed an incident cancer during a median follow-up of 5.7 years. The 5-year risk of any cancer was 4.7% in patients with nephrotic syndrome, a 73% increased risk (SIR, 1.73; 95% confidence interval [CI], 1.55-1.92). The association was most pronounced for lung cancer, kidney cancer, lymphoma, and multiple myeloma. It was highest within 1 year of nephrotic syndrome diagnosis (SIR, 4.49; 95% CI, 3.68-5.42), but remained increased beyond 1 year (SIR, 1.34; 95% CI, 1.17-1.53). The 5-year mortality after cancer was 68.5% in patients with cancer with nephrotic syndrome and 63.4% in the cancer comparison cohort (adjusted hazard ratio, 1.20; 95% CI, 1.02-1.42).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Nephrotic syndrome is a marker of occult solid tumors and hematologic malignancies and is associated with a worsened cancer prognosis.</AbstractText>
<CopyrightInformation>Copyright Â© 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Christiansen</LastName>
<ForeName>Christian F</ForeName>
<Initials>CF</Initials>
<AffiliationInfo>
<Affiliation>Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. Electronic address: cfc@clin.au.dk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Onega</LastName>
<ForeName>Tracy</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Departments of Medicine and Community and Family Medicine and the Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, NH.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>SvÃ¦rke</LastName>
<ForeName>Claus</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>KÃ¶rmendinÃ© Farkas</LastName>
<ForeName>DÃ³ra</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jespersen</LastName>
<ForeName>Bente</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Baron</LastName>
<ForeName>John A</ForeName>
<Initials>JA</Initials>
<AffiliationInfo>
<Affiliation>Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; Department of Medicine, University of North Carolina, Chapel Hill.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>SÃ¸rensen</LastName>
<ForeName>Henrik Toft</ForeName>
<Initials>HT</Initials>
<AffiliationInfo>
<Affiliation>Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Med</MedlineTA>
<NlmUniqueID>0267200</NlmUniqueID>
<ISSNLinking>0002-9343</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D003718">Denmark</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015994">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009404">Nephrotic Syndrome</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016016">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012042">Registries</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cohort studies</Keyword>
<Keyword MajorTopicYN="N">Mortality</Keyword>
<Keyword MajorTopicYN="N">Neoplasms</Keyword>
<Keyword MajorTopicYN="N">Nephrotic syndrome</Keyword>
<Keyword MajorTopicYN="N">Prognosis</Keyword>
<Keyword MajorTopicYN="N">Risk</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25203874</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>05</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1528-1140</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>260</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Annals of surgery</Title>
<ISOAbbreviation>Ann. Surg.</ISOAbbreviation>
</Journal>
<ArticleTitle>Hospital readmissions: necessary evil or preventable target for quality improvement.</ArticleTitle>
<Pagination>
<MedlinePgn>583-9; discussion 589-91</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/SLA.0000000000000923</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate readmission rates and associated factors to identify potentially preventable readmissions.</AbstractText>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The decision to penalize hospitals for readmissions is compelling health care systems to develop processes to minimize readmissions. Research to identify preventable readmissions is critical to achieve these goals.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We performed a retrospective review of University HealthSystem Consortium database for cancer patients hospitalized from January 2010 to September 2013. Outcome measures were 7-, 14-, and 30-day readmission rates and readmission diagnoses. Hospital and disease characteristics were evaluated to evaluate relationships with readmission.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 2,517,886 patients were hospitalized for cancer treatment. Readmission rates at 7, 14, and 30 days were 2.2%, 3.7%, and 5.6%, respectively. Despite concern that premature hospital discharge may be associated with increased readmissions, a shorter initial length of stay predicted lower readmission rates. Furthermore, high-volume centers and designated cancer centers had higher readmission rates. Evaluating institutional data (N = 2517 patients) demonstrated that factors associated with higher readmission rates include discharge from a medical service, site of malignancy, and emergency primary admission. When examining readmission within 7 days for surgical services, the most common readmission diagnoses were infectious causes (46.3%), nausea/vomiting/dehydration (26.8%), and pain (6.1%).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A minority of patients after hospitalization for cancer-related therapy are readmitted with potentially preventable conditions such as nausea, vomiting, dehydration, and pain. However, most factors associated with readmission cannot be modified. In addition, high-volume centers and designated cancer centers have higher readmission rates, which may indicate that readmission rates may not be an appropriate marker for quality improvement.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Brown</LastName>
<ForeName>Erin G</ForeName>
<Initials>EG</Initials>
<AffiliationInfo>
<Affiliation>*Division of Surgical Oncology, UC Davis Cancer Center, Sacramento, CA; and â Division of Biostatistics, Department of Public Health Sciences, UC Davis School of Medicine, Sacramento, CA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Burgess</LastName>
<ForeName>Debra</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Chin-Shang</ForeName>
<Initials>CS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Canter</LastName>
<ForeName>Robert J</ForeName>
<Initials>RJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bold</LastName>
<ForeName>Richard J</ForeName>
<Initials>RJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>UL1 TR000002</GrantID>
<Acronym>TR</Acronym>
<Agency>NCATS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>UL1 TR000002</GrantID>
<Acronym>TR</Acronym>
<Agency>NCATS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Ann Surg</MedlineTA>
<NlmUniqueID>0372354</NlmUniqueID>
<ISSNLinking>0003-4932</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002173">Cancer Care Facilities</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000592">standards</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003681">Dehydration</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017048">Health Care Costs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006761">Hospitals</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000592">standards</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007239">Infection</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007902">Length of Stay</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010149">Pain, Postoperative</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010359">Patient Readmission</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000592">standards</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020250">Postoperative Nausea and Vomiting</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D058996">Quality Improvement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013514">Surgical Procedures, Operative</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013923">Thromboembolism</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS616714 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC4217287 [Available on 10/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24853181</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-1827</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>9</Day>
</PubDate>
</JournalIssue>
<Title>British journal of cancer</Title>
<ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Role of Fbxw7 in the maintenance of normal stem cells and cancer-initiating cells.</ArticleTitle>
<Pagination>
<MedlinePgn>1054-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2014.259</ELocationID>
<Abstract>
<AbstractText>In addition to the properties of self-renewal and multipotency, stem cells are characterised by their distinct cell cycle status. Somatic stem cells are maintained in a quiescent state but switch reversibly from quiescence to proliferation as needed. On the other hand, embryonic stem cells and induced pluripotent stem cells proliferate rapidly until the induction of differentiation results in inhibition of cell cycle progression. Uncovering the mechanisms underlying cell cycle control in stem cells should thus provide insight into regulation of the balance between self-renewal and differentiation, a key goal of stem cell biology. Recent research has shown that cancer-initiating cells (CICs), a cell population with stem cell-like properties in cancer, are also quiescent, with this characteristic conferring resistance to anticancer therapies that target dividing cells. Elucidation of the mechanisms of CIC quiescence might therefore be expected to provide a basis for the eradication of cancer. This review summarises our current understanding of the role of F-box and WD40 repeat domain-containing 7 (Fbxw7), a key regulator of the cell cycle, in the maintenance of normal stem cells and CICs, as well as attempts to define future challenges in this field. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Takeishi</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Fukuoka 812-8582, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nakayama</LastName>
<ForeName>K I</ForeName>
<Initials>KI</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Fukuoka 812-8582, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Cancer</MedlineTA>
<NlmUniqueID>0370635</NlmUniqueID>
<ISSNLinking>0007-0920</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D044783">F-Box Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="C513273">FBXW7 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D002453">Cell Cycle</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018797">Cell Cycle Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044783">F-Box Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014411">Neoplastic Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013234">Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044767">Ubiquitin-Protein Ligases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25203854</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0966-0461</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>23</Volume>
<Issue>16</Issue>
<PubDate>
<MedlineDate>2014 Sep 11-24</MedlineDate>
</PubDate>
</JournalIssue>
<Title>British journal of nursing (Mark Allen Publishing)</Title>
<ISOAbbreviation>Br J Nurs</ISOAbbreviation>
</Journal>
<ArticleTitle>Scalp cooling: management option for chemotherapy-induced alopecia.</ArticleTitle>
<Pagination>
<MedlinePgn>S4, S6, S8 passim</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.12968/bjon.2014.23.Sup16.S4</ELocationID>
<Abstract>
<AbstractText>Chemotherapy is increasingly being administered as a treatment for cancer and with it are a number of possible side effects. One, which has a negative impact on a patient's quality of life and their self-esteem, is that of chemotherapy-induced alopecia (CIA). A side effect of which, for some, could be prevented by the use of scalp cooling, dependent on the regimen being administered and patient choice. This article explores the issue of CIA from the patient's perspective and scalp cooling as a preventative measure, along with a review of the evidence around the risk associated with developing scalp metastases following scalp cooling. It also discusses why scalp cooling should be available for both male and female patients; along with the potential impact scalp cooling may have on clinical areas delivering chemotherapy. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Roe</LastName>
<ForeName>Helen</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Consultant Cancer Nurse/Acute Oncology Service Lead, North Cumbria University Hospitals NHS Trust.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Nurs</MedlineTA>
<NlmUniqueID>9212059</NlmUniqueID>
<ISSNLinking>0966-0461</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000505">Alopecia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006197">Hair</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000254">growth &amp; development</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007036">Hypothermia, Induced</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018579">Patient Selection</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D012535">Scalp</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012737">Sex Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Alopecia</Keyword>
<Keyword MajorTopicYN="N">Chemotherapy</Keyword>
<Keyword MajorTopicYN="N">Scalp cooling</Keyword>
<Keyword MajorTopicYN="N">Self-image</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25203320</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1878-3686</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>26</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>8</Day>
</PubDate>
</JournalIssue>
<Title>Cancer cell</Title>
<ISOAbbreviation>Cancer Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>Vulnerabilities of mutant SWI/SNF complexes in cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>309-17</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ccr.2014.07.018</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1535-6108(14)00307-9</ELocationID>
<Abstract>
<AbstractText>Cancer genome sequencing efforts have revealed the novel theme that chromatin modifiers are frequently mutated across a wide spectrum of cancers. Mutations in genes encoding subunits of SWI/SNF (BAF) chromatin remodeling complexes are particularly prevalent, occurring in 20% of all human cancers. As these are typically loss-of-function mutations and not directly therapeutically targetable, central goals have been to elucidate mechanism and identify vulnerabilities created by these mutations. Here, we discuss emerging data that these mutations lead to the formation of aberrant residual SWI/SNF complexes that constitute a specific vulnerability and discuss the potential for exploiting these dependencies in SWI/SNF mutant cancers. </AbstractText>
<CopyrightInformation>Copyright Â© 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Helming</LastName>
<ForeName>Katherine C</ForeName>
<Initials>KC</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02215, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA; Biological and Biomedical Sciences Program, Harvard Medical School, Boston, MA 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Xiaofeng</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02215, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Roberts</LastName>
<ForeName>Charles W M</ForeName>
<Initials>CW</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02215, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA. Electronic address: charles_roberts@dfci.harvard.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 CA113794</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA172152</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA113794</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA172152</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 CA105423</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer Cell</MedlineTA>
<NlmUniqueID>101130617</NlmUniqueID>
<ISSNLinking>1535-6108</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D046912">Multiprotein Complexes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D021122">Protein Subunits</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020022">Genetic Predisposition to Disease</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046912">Multiprotein Complexes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021122">Protein Subunits</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS617220 [Available on 09/08/15]</OtherID>
<OtherID Source="NLM">PMC4159614 [Available on 09/08/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25043504</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1096-9896</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>234</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of pathology</Title>
<ISOAbbreviation>J. Pathol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Boveri at 100: Boveri, chromosomes and cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>138-41</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/path.4406</ELocationID>
<Abstract>
<AbstractText>Microscopic studies of chromosomes in cells cultured from leukaemias and solid tumours have helped confirm the central tenet of Boveri's somatic mutation theory of cancer, namely that acquired chromosomal aberrations of susceptible target cells may cause their neoplastic transformation. Cancer cytogenetics - especially when used together with appropriate molecular genetic investigations of tumour parenchyma cells - offers diagnostic and prognostic information, insights into the clonal composition and evolution of neoplasms, and information about how the observed gains, losses and balanced relocations work pathogenetically. In the future, one may expect cancer cytogenetics to focus not only on how the various aberrations contribute to tumourigenesis, but also on why and how they occur, as well as on the biological meaning behind the polyclonality detected in several epithelial neoplasms. Finally, the study of different nuclear compartments during interphase may add to our understanding of how large-scale numerical and structural karyotypic aberrations may disturb normal controls of cell division and death to induce neoplastic transformation.</AbstractText>
<CopyrightInformation>Copyright Â© 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Heim</LastName>
<ForeName>Sverre</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Medical Faculty, University of Oslo and Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Norway.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D019215">Biography</PublicationType>
<PublicationType UI="D016456">Historical Article</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>J Pathol</MedlineTA>
<NlmUniqueID>0204634</NlmUniqueID>
<ISSNLinking>0022-3417</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002877">Chromosomes, Human</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003582">Cytogenetics</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D005858">Germany</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049672">History, 19th Century</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049673">History, 20th Century</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008495">Medical Oncology</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<PersonalNameSubjectList>
<PersonalNameSubject>
<LastName>Boveri</LastName>
<ForeName>Theodor</ForeName>
<Initials>T</Initials>
</PersonalNameSubject>
</PersonalNameSubjectList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Boveri</Keyword>
<Keyword MajorTopicYN="N">cancer</Keyword>
<Keyword MajorTopicYN="N">chromosome</Keyword>
<Keyword MajorTopicYN="N">cytogenetics</Keyword>
<Keyword MajorTopicYN="N">karyotype</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25043632</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1096-9896</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>234</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of pathology</Title>
<ISOAbbreviation>J. Pathol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Boveri at 100: cancer evolution, from preneoplasia to malignancy.</ArticleTitle>
<Pagination>
<MedlinePgn>146-51</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/path.4408</ELocationID>
<Abstract>
<AbstractText>In the 100 years since the publication of Boveri's manuscript, 'Concerning the origin of human tumours', we have seen many advances in our understanding of how tumours originate, develop and progress. However, reading this article now, it is possible to find conclusions, or more often predictions, of what we now consider basic tenets of tumour biology. These include predicting the stochastic nature of the malignant change and that all tumours are necessarily of clonal origin, perhaps the basis of the modern concepts of field cancerization, of tumour heterogeneity and the clonal evolution of tumours. Modern researchers rarely refer to this paper, yet as a source of ideas it must rank amongst the landmarks in tumour biology of the last 100 years.</AbstractText>
<CopyrightInformation>Copyright Â© 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wright</LastName>
<ForeName>Nicholas A</ForeName>
<Initials>NA</Initials>
<AffiliationInfo>
<Affiliation>Centre for Tumour Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>14895</GrantID>
<Agency>Cancer Research UK</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<Agency>Cancer Research UK</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D019215">Biography</PublicationType>
<PublicationType UI="D016456">Historical Article</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>J Pathol</MedlineTA>
<NlmUniqueID>0204634</NlmUniqueID>
<ISSNLinking>0022-3417</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D005858">Germany</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049672">History, 19th Century</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049673">History, 20th Century</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008495">Medical Oncology</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016609">Neoplasms, Second Primary</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D011230">Precancerous Conditions</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<PersonalNameSubjectList>
<PersonalNameSubject>
<LastName>Boveri</LastName>
<ForeName>Theodor</ForeName>
<Initials>T</Initials>
</PersonalNameSubject>
</PersonalNameSubjectList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Boveri</Keyword>
<Keyword MajorTopicYN="N">cancer</Keyword>
<Keyword MajorTopicYN="N">clonality</Keyword>
<Keyword MajorTopicYN="N">evolution</Keyword>
<Keyword MajorTopicYN="N">field cancerization</Keyword>
<Keyword MajorTopicYN="N">tumour heterogeneity</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25074498</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1096-9896</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>234</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of pathology</Title>
<ISOAbbreviation>J. Pathol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Boveri at 100: Theodor Boveri and genetic predisposition to cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>142-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/path.4414</ELocationID>
<Abstract>
<AbstractText>One hundred years have passed since the publication of Theodore Boveri's Zur Frage der Entstehung maligner Tumouren [Concerning the Origin of Malignant Tumours]. This prescient publication created the foundations for much of our understanding of the origins of cancer and in particular the genetic basis of some cancers. In his work, Boveri suggested that loss of key cellular attributes, now known as tumour suppressor genes, are a key driver event in the development of cancer and inheritance could play a role in cancer susceptibility. He also predicted that chromosomal (genomic) instability as a key hallmark of cancer. Whilst these key insights that still inform the practice of cancer genetics, they were not the main theme of Boveri's text, which was to describe the role of chromosomal abnormalities in the development of cancer. In making his case he also suggested that genetic information could be contained in distinct packages (genes) that are linearly arranged along chromosomes and that cancers arise from single cells. These remarkably accurate hypotheses add weight to the need to celebrate this landmark publication for its accurate prediction of so much that we take for granted. Here we focus on Boveri's contributions to our understanding of hereditary cancers, which, alongside the astute clinical observations of Paul Broca and Aldred Scott Warthin, were published decades before the field became respectable, yet could still inform anyone studying hereditary cancers.</AbstractText>
<CopyrightInformation>Copyright Â© 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hansford</LastName>
<ForeName>Samantha</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver General Hospital, and British Columbia Cancer Agency, Vancouver, BC, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huntsman</LastName>
<ForeName>David G</ForeName>
<Initials>DG</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D019215">Biography</PublicationType>
<PublicationType UI="D016456">Historical Article</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>J Pathol</MedlineTA>
<NlmUniqueID>0204634</NlmUniqueID>
<ISSNLinking>0022-3417</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D002869">Chromosome Aberrations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020022">Genetic Predisposition to Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D005858">Germany</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049672">History, 19th Century</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049673">History, 20th Century</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008495">Medical Oncology</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<PersonalNameSubjectList>
<PersonalNameSubject>
<LastName>Boveri</LastName>
<ForeName>Theodor</ForeName>
<Initials>T</Initials>
</PersonalNameSubject>
</PersonalNameSubjectList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">cancer</Keyword>
<Keyword MajorTopicYN="N">chromosomal theory</Keyword>
<Keyword MajorTopicYN="N">chromosome</Keyword>
<Keyword MajorTopicYN="N">genetics</Keyword>
<Keyword MajorTopicYN="N">genomic instability</Keyword>
<Keyword MajorTopicYN="N">hereditary</Keyword>
<Keyword MajorTopicYN="N">inheritance</Keyword>
<Keyword MajorTopicYN="N">tumour suppressor gene</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25122012</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1541-0048</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>104</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>American journal of public health</Title>
<ISOAbbreviation>Am J Public Health</ISOAbbreviation>
</Journal>
<ArticleTitle>Is science public health's BFF?</ArticleTitle>
<Pagination>
<MedlinePgn>1798</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2105/AJPH.2014.302209</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Brown</LastName>
<ForeName>Theodore M</ForeName>
<Initials>TM</Initials>
<AffiliationInfo>
<Affiliation>AJPH Department Editor.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016420">Comment</PublicationType>
<PublicationType UI="D016421">Editorial</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Public Health</MedlineTA>
<NlmUniqueID>1254074</NlmUniqueID>
<ISSNLinking>0090-0036</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003678">Defoliants, Chemical</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>2577AQ9262</RegistryNumber>
<NameOfSubstance UI="D015084">2,4-Dichlorophenoxyacetic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>39277-47-9</RegistryNumber>
<NameOfSubstance UI="C021608">Agent Orange</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9Q963S4YMX</RegistryNumber>
<NameOfSubstance UI="D015085">2,4,5-Trichlorophenoxyacetic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>DO80M48B6O</RegistryNumber>
<NameOfSubstance UI="D013749">Tetrachlorodibenzodioxin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentOn">
<RefSource>Am J Public Health. 2014 Oct;104(10):1862-71</RefSource>
<PMID Version="1">25121809</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentOn">
<RefSource>Am J Public Health. 2014 Oct;104(10):1912-9</RefSource>
<PMID Version="1">25121817</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentOn">
<RefSource>Am J Public Health. 2014 Oct;104(10):1860-1</RefSource>
<PMID Version="1">25122032</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentOn">
<RefSource>Am J Public Health. 2014 Oct;104(10):1833-9</RefSource>
<PMID Version="1">25122018</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentOn">
<RefSource>Am J Public Health. 2014 Oct;104(10):1894-900</RefSource>
<PMID Version="1">25122015</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015085">2,4,5-Trichlorophenoxyacetic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015084">2,4-Dichlorophenoxyacetic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018070">Biological Specimen Banks</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000458">organization &amp; administration</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035843">Biomedical Research</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000941">ethics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003678">Defoliants, Chemical</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004651">Employment</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004781">Environmental Exposure</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005389">Firearms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D036281">Genetic Research</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000941">ethics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D006291">Health Policy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006708">Homicide</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D010067">Ownership</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063766">Pediatric Obesity</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D011050">Policy Making</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012106">Research</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013749">Tetrachlorodibenzodioxin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019460">Tobacco Industry</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000458">organization &amp; administration</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D047829">Vietnam Conflict</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014948">Wounds, Gunshot</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25122032</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1541-0048</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>104</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>American journal of public health</Title>
<ISOAbbreviation>Am J Public Health</ISOAbbreviation>
</Journal>
<ArticleTitle>On Agent Orange in Vietnam.</ArticleTitle>
<Pagination>
<MedlinePgn>1860-1</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2105/AJPH.2014.302089</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Clapp</LastName>
<ForeName>Richard W</ForeName>
<Initials>RW</Initials>
<AffiliationInfo>
<Affiliation>Richard W. Clapp is with the School of Public Health, Boston University, Boston, MA. Carol Baraldi is with Independence Care System, New York, NY. Jean Grassman is with the City University of New York, New York, NY. At the time of the study, Franklin Mirer was with Hunter College, City University of New York. Daniel Robie is with York College, City University of New York. Susan Schnall is with New York University, New York, NY.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Baraldi</LastName>
<ForeName>Carole</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Grassman</LastName>
<ForeName>Jean</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mirer</LastName>
<ForeName>Franklin</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Robie</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schnall</LastName>
<ForeName>Susan</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016420">Comment</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Public Health</MedlineTA>
<NlmUniqueID>1254074</NlmUniqueID>
<ISSNLinking>0090-0036</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003678">Defoliants, Chemical</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>2577AQ9262</RegistryNumber>
<NameOfSubstance UI="D015084">2,4-Dichlorophenoxyacetic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>39277-47-9</RegistryNumber>
<NameOfSubstance UI="C021608">Agent Orange</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9Q963S4YMX</RegistryNumber>
<NameOfSubstance UI="D015085">2,4,5-Trichlorophenoxyacetic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>DO80M48B6O</RegistryNumber>
<NameOfSubstance UI="D013749">Tetrachlorodibenzodioxin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Am J Public Health. 2014 Oct;104(10):1798</RefSource>
<PMID Version="1">25122012</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentOn">
<RefSource>Am J Public Health. 2014 Oct;104(10):1857-60</RefSource>
<PMID Version="1">25208001</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015085">2,4,5-Trichlorophenoxyacetic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015084">2,4-Dichlorophenoxyacetic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003678">Defoliants, Chemical</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004781">Environmental Exposure</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013749">Tetrachlorodibenzodioxin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D047829">Vietnam Conflict</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25208001</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1541-0048</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>104</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>American journal of public health</Title>
<ISOAbbreviation>Am J Public Health</ISOAbbreviation>
</Journal>
<ArticleTitle>Agent Orange in Vietnam. 1995.</ArticleTitle>
<Pagination>
<MedlinePgn>1857-60</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2105/AJPH.2014.104101857</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dwyer</LastName>
<ForeName>J H</ForeName>
<Initials>JH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Flesch-Janys</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D019215">Biography</PublicationType>
<PublicationType UI="D016419">Classical Article</PublicationType>
<PublicationType UI="D016456">Historical Article</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Public Health</MedlineTA>
<NlmUniqueID>1254074</NlmUniqueID>
<ISSNLinking>0090-0036</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003678">Defoliants, Chemical</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>2577AQ9262</RegistryNumber>
<NameOfSubstance UI="D015084">2,4-Dichlorophenoxyacetic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>39277-47-9</RegistryNumber>
<NameOfSubstance UI="C021608">Agent Orange</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9Q963S4YMX</RegistryNumber>
<NameOfSubstance UI="D015085">2,4,5-Trichlorophenoxyacetic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>DO80M48B6O</RegistryNumber>
<NameOfSubstance UI="D013749">Tetrachlorodibenzodioxin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Am J Public Health. 2014 Oct;104(10):1860-1</RefSource>
<PMID Version="1">25122032</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015085">2,4,5-Trichlorophenoxyacetic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015084">2,4-Dichlorophenoxyacetic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003678">Defoliants, Chemical</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004781">Environmental Exposure</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049673">History, 20th Century</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013749">Tetrachlorodibenzodioxin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D047829">Vietnam Conflict</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<PersonalNameSubjectList>
<PersonalNameSubject>
<LastName>Dwyer</LastName>
<ForeName>J H</ForeName>
<Initials>JH</Initials>
</PersonalNameSubject>
<PersonalNameSubject>
<LastName>Flesch-Janys</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</PersonalNameSubject>
</PersonalNameSubjectList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24794629</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1420-9071</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>71</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Cellular and molecular life sciences : CMLS</Title>
<ISOAbbreviation>Cell. Mol. Life Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Eph- and ephrin-dependent mechanisms in tumor and stem cell dynamics.</ArticleTitle>
<Pagination>
<MedlinePgn>3685-710</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00018-014-1633-0</ELocationID>
<Abstract>
<AbstractText>The erythropoietin-producing hepatocellular (Eph) receptors comprise the largest family of receptor tyrosine kinases (RTKs). Initially regarded as axon-guidance and tissue-patterning molecules, Eph receptors have now been attributed with various functions during development, tissue homeostasis, and disease pathogenesis. Their ligands, ephrins, are synthesized as membrane-associated molecules. At least two properties make this signaling system unique: (1) the signal can be simultaneously transduced in the receptor- and the ligand-expressing cell, (2) the signaling outcome through the same molecules can be opposite depending on cellular context. Moreover, shedding of Eph and ephrin ectodomains as well as ligand-dependent and -independent receptor crosstalk with other RTKs, proteases, and adhesion molecules broadens the repertoire of Eph/ephrin functions. These integrated pathways provide plasticity to cell-microenvironment communication in varying tissue contexts. The complex molecular networks and dynamic cellular outcomes connected to the Eph/ephrin signaling in tumor-host communication and stem cell niche are the main focus of this review. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gucciardo</LastName>
<ForeName>Erika</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Research Programs Unit, Genome-Scale Biology, Biomedicum Helsinki, University of Helsinki, P.O.B. 63, 00014, Helsinki, Finland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sugiyama</LastName>
<ForeName>Nami</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lehti</LastName>
<ForeName>Kaisa</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Switzerland</Country>
<MedlineTA>Cell Mol Life Sci</MedlineTA>
<NlmUniqueID>9705402</NlmUniqueID>
<ISSNLinking>1420-682X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D036342">Ephrins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016023">Integrins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D036081">Receptors, Eph Family</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.-</RegistryNumber>
<NameOfSubstance UI="D045726">Metalloproteases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D020741">rho GTP-Binding Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016764">Cell Polarity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D036342">Ephrins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016023">Integrins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045726">Metalloproteases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014411">Neoplastic Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D036081">Receptors, Eph Family</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020741">rho GTP-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25154553</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>05</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1573-7284</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>29</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>European journal of epidemiology</Title>
<ISOAbbreviation>Eur. J. Epidemiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Fruit and vegetable intake and cause-specific mortality in the EPIC study.</ArticleTitle>
<Pagination>
<MedlinePgn>639-52</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s10654-014-9945-9</ELocationID>
<Abstract>
<AbstractText>Consumption of fruits and vegetables is associated with a lower overall mortality. The aim of this study was to identify causes of death through which this association is established. More than 450,000 participants from the European Prospective Investigation into Cancer and Nutrition study were included, of which 25,682 were reported deceased after 13 years of follow-up. Information on lifestyle, diet and vital status was collected through questionnaires and population registries. Hazard ratios (HR) with 95% confidence intervals (95% CI) for death from specific causes were calculated from Cox regression models, adjusted for potential confounders. Participants reporting consumption of more than 569 g/day of fruits and vegetables had lower risks of death from diseases of the circulatory (HR for upper fourth 0.85, 95% CI 0.77-0.93), respiratory (HR for upper fourth 0.73, 95% CI 0.59-0.91) and digestive system (HR for upper fourth 0.60, 95% CI 0.46-0.79) when compared with participants consuming less than 249 g/day. In contrast, a positive association with death from diseases of the nervous system was observed. Inverse associations were generally observed for vegetable, but not for fruit consumption. Associations were more pronounced for raw vegetable consumption, when compared with cooked vegetable consumption. Raw vegetable consumption was additionally inversely associated with death from neoplasms and mental and behavioral disorders. The lower risk of death associated with a higher consumption of fruits and vegetables may be derived from inverse associations with diseases of the circulatory, respiratory and digestive system, and may depend on the preparation of vegetables and lifestyle factors.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Leenders</LastName>
<ForeName>Max</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands, m.b.leenders@uu.nl.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Boshuizen</LastName>
<ForeName>Hendriek C</ForeName>
<Initials>HC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ferrari</LastName>
<ForeName>Pietro</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Siersema</LastName>
<ForeName>Peter D</ForeName>
<Initials>PD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Overvad</LastName>
<ForeName>Kim</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>TjÃ¸nneland</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Olsen</LastName>
<ForeName>Anja</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Boutron-Ruault</LastName>
<ForeName>Marie-Christine</ForeName>
<Initials>MC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dossus</LastName>
<ForeName>Laure</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dartois</LastName>
<ForeName>Laureen</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kaaks</LastName>
<ForeName>Rudolf</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Kuanrong</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Boeing</LastName>
<ForeName>Heiner</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bergmann</LastName>
<ForeName>Manuela M</ForeName>
<Initials>MM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Trichopoulou</LastName>
<ForeName>Antonia</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lagiou</LastName>
<ForeName>Pagona</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Trichopoulos</LastName>
<ForeName>Dimitrios</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Palli</LastName>
<ForeName>Domenico</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Krogh</LastName>
<ForeName>Vittorio</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Panico</LastName>
<ForeName>Salvatore</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tumino</LastName>
<ForeName>Rosario</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vineis</LastName>
<ForeName>Paolo</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Peeters</LastName>
<ForeName>Petra H M</ForeName>
<Initials>PH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Weiderpass</LastName>
<ForeName>Elisabete</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Engeset</LastName>
<ForeName>Dagrun</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Braaten</LastName>
<ForeName>Tonje</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Redondo</LastName>
<ForeName>Maria Luisa</ForeName>
<Initials>ML</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Agudo</LastName>
<ForeName>Antonio</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>SÃ¡nchez</LastName>
<ForeName>MarÃ­a-JosÃ©</ForeName>
<Initials>MJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Amiano</LastName>
<ForeName>Pilar</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Huerta</LastName>
<ForeName>JosÃ©-MarÃ­a</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ardanaz</LastName>
<ForeName>Eva</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Drake</LastName>
<ForeName>Isabel</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sonestedt</LastName>
<ForeName>Emily</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Johansson</LastName>
<ForeName>Ingegerd</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Winkvist</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Khaw</LastName>
<ForeName>Kay-Tee</ForeName>
<Initials>KT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wareham</LastName>
<ForeName>Nick J</ForeName>
<Initials>NJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Key</LastName>
<ForeName>Timothy J</ForeName>
<Initials>TJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bradbury</LastName>
<ForeName>Kathryn E</ForeName>
<Initials>KE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Johansson</LastName>
<ForeName>Mattias</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Licaj</LastName>
<ForeName>Idlir</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gunter</LastName>
<ForeName>Marc J</ForeName>
<Initials>MJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Murphy</LastName>
<ForeName>Neil</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Riboli</LastName>
<ForeName>Elio</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bueno-de-Mesquita</LastName>
<ForeName>H Bas</ForeName>
<Initials>HB</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>14136</GrantID>
<Agency>Cancer Research UK</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>G1000143</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<Agency>British Heart Foundation</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<Agency>Cancer Research UK</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<Agency>Wellcome Trust</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Eur J Epidemiol</MedlineTA>
<NlmUniqueID>8508062</NlmUniqueID>
<ISSNLinking>0393-2990</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002318">Cardiovascular Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D002423">Cause of Death</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004032">Diet</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004034">Diet Surveys</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D005060">Europe</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D005510">Food Habits</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D005638">Fruit</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015994">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008019">Life Style</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016016">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011795">Questionnaires</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D014675">Vegetables</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24676428</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1432-1335</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of cancer research and clinical oncology</Title>
<ISOAbbreviation>J. Cancer Res. Clin. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Role of receptor for hyaluronan-mediated motility (RHAMM) in human head and neck cancers.</ArticleTitle>
<Pagination>
<MedlinePgn>1629-40</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00432-014-1653-z</ELocationID>
<Abstract>
<AbstractText>The receptor for hyaluronan (HA)-mediated motility (RHAMM) is a HA-binding protein located in the cytoskeleton and centrosome. RHAMM has multiple functions that manifest with different cellular localizations, for example, modulation of growth factor receptor, regulation of cell signaling pathways, and mitotic spindle assembly. In addition, its increased expression has major roles in tumorigenesis and can induce genomic instability and cancer progression. In head and neck cancers, increased expression of RHAMM is associated with high proliferation of cancer cells and decreased survival. CD44, a cell-adhesion molecule and HA receptor, can modulate intracellular signaling by forming complexes with RHAMM to promote invasion and metastasis of cancer cells. In this review, we provide an overview of the biological functions of RHAMM in non-neoplastic cells and cancer cells, as well as its association with CD44, and also introduce studies that particularly implicate RHAMM in the pathogenesis of head and neck cancers. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Shigeishi</LastName>
<ForeName>Hideo</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Oral and Maxillofacial Surgery, Division of Cervico-Gnathostomatology, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553, Japan, shige@hiroshima-u.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Higashikawa</LastName>
<ForeName>Koichiro</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takechi</LastName>
<ForeName>Masaaki</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>J Cancer Res Clin Oncol</MedlineTA>
<NlmUniqueID>7902060</NlmUniqueID>
<ISSNLinking>0171-5216</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018960">Antigens, CD44</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497483">CD44 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016326">Extracellular Matrix Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C122167">TPX2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C098946">hyaluronan-mediated motility receptor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9004-61-9</RegistryNumber>
<NameOfSubstance UI="D006820">Hyaluronic Acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018960">Antigens, CD44</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018797">Cell Cycle Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018385">Centrosome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003599">Cytoskeleton</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016326">Extracellular Matrix Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005455">Fluorescent Antibody Technique</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006258">Head and Neck Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006820">Hyaluronic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020935">MAP Kinase Signaling System</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008869">Microtubule-Associated Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25210198</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Electronic-Print">
<Journal>
<ISSN IssnType="Electronic">1460-2105</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>106</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Journal of the National Cancer Institute</Title>
<ISOAbbreviation>J. Natl. Cancer Inst.</ISOAbbreviation>
</Journal>
<ArticleTitle>Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities.</ArticleTitle>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/jnci/dju232</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">dju232</ELocationID>
<Abstract>
<AbstractText>Cardiotoxicity resulting from direct myocyte damage has been a known complication of cancer treatment for decades. More recently, the emergence of hypertension as a clinically significant side effect of several new agents has been recognized as adversely affecting cancer treatment outcomes. With cancer patients living longer, in part because of treatment advances, these adverse events have become increasingly important to address. However, little is known about the cardiovascular pathogenic mechanisms associated with cancer treatment and even less about how to optimally prevent and manage short- and long-term cardiovascular complications, leading to improved patient safety and clinical outcomes. To identify research priorities, allocate resources, and establish infrastructure required to address cardiotoxicity associated with cancer treatment, the National Cancer Institute (NCI) and National Heart, Lung and Blood Institute (NHLBI) sponsored a two-day workshop, "Cancer treatment-related cardiotoxicity: Understanding the current state of knowledge and future research priorities," in March 2013 in Bethesda, MD. Participants included leading oncology and cardiology researchers and health professionals, patient advocates and industry representatives, with expertise ranging from basic to clinical science. Attendees were charged with identifying research opportunities to advance the understanding of cancer treatment-related cardiotoxicity across basic and clinical science. This commentary highlights the key discussion points and overarching recommendations from that workshop. </AbstractText>
<CopyrightInformation>Published by Oxford University Press 2014.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Shelburne</LastName>
<ForeName>Nonniekaye</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Division of Cancer Control and Population Sciences (NS, AF) and Division of Cancer Prevention (JB, LM) and Division of Cancer Treatment and Diagnosis (MD), National Cancer Institute, Rockville, MD; Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD (BA, PDN); Cancer Center, MetroHealth Medical Center and Casewestern Reserve University, Cleveland, OH (JB); Vanderbilt Heart and Vascular Institute, Vanderbilt University School of Medicine, Nashville, TN (TF); Mary Babb Randolph Cancer Center, West Virginia University (SCR), Morgantown, WV. nshelburne@nih.gov.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Adhikari</LastName>
<ForeName>Bishow</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Division of Cancer Control and Population Sciences (NS, AF) and Division of Cancer Prevention (JB, LM) and Division of Cancer Treatment and Diagnosis (MD), National Cancer Institute, Rockville, MD; Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD (BA, PDN); Cancer Center, MetroHealth Medical Center and Casewestern Reserve University, Cleveland, OH (JB); Vanderbilt Heart and Vascular Institute, Vanderbilt University School of Medicine, Nashville, TN (TF); Mary Babb Randolph Cancer Center, West Virginia University (SCR), Morgantown, WV.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Brell</LastName>
<ForeName>Joanna</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Division of Cancer Control and Population Sciences (NS, AF) and Division of Cancer Prevention (JB, LM) and Division of Cancer Treatment and Diagnosis (MD), National Cancer Institute, Rockville, MD; Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD (BA, PDN); Cancer Center, MetroHealth Medical Center and Casewestern Reserve University, Cleveland, OH (JB); Vanderbilt Heart and Vascular Institute, Vanderbilt University School of Medicine, Nashville, TN (TF); Mary Babb Randolph Cancer Center, West Virginia University (SCR), Morgantown, WV.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Davis</LastName>
<ForeName>Myrtle</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Division of Cancer Control and Population Sciences (NS, AF) and Division of Cancer Prevention (JB, LM) and Division of Cancer Treatment and Diagnosis (MD), National Cancer Institute, Rockville, MD; Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD (BA, PDN); Cancer Center, MetroHealth Medical Center and Casewestern Reserve University, Cleveland, OH (JB); Vanderbilt Heart and Vascular Institute, Vanderbilt University School of Medicine, Nashville, TN (TF); Mary Babb Randolph Cancer Center, West Virginia University (SCR), Morgantown, WV.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Desvigne-Nickens</LastName>
<ForeName>Patrice</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Division of Cancer Control and Population Sciences (NS, AF) and Division of Cancer Prevention (JB, LM) and Division of Cancer Treatment and Diagnosis (MD), National Cancer Institute, Rockville, MD; Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD (BA, PDN); Cancer Center, MetroHealth Medical Center and Casewestern Reserve University, Cleveland, OH (JB); Vanderbilt Heart and Vascular Institute, Vanderbilt University School of Medicine, Nashville, TN (TF); Mary Babb Randolph Cancer Center, West Virginia University (SCR), Morgantown, WV.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Freedman</LastName>
<ForeName>Andrew</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Division of Cancer Control and Population Sciences (NS, AF) and Division of Cancer Prevention (JB, LM) and Division of Cancer Treatment and Diagnosis (MD), National Cancer Institute, Rockville, MD; Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD (BA, PDN); Cancer Center, MetroHealth Medical Center and Casewestern Reserve University, Cleveland, OH (JB); Vanderbilt Heart and Vascular Institute, Vanderbilt University School of Medicine, Nashville, TN (TF); Mary Babb Randolph Cancer Center, West Virginia University (SCR), Morgantown, WV.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Minasian</LastName>
<ForeName>Lori</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Division of Cancer Control and Population Sciences (NS, AF) and Division of Cancer Prevention (JB, LM) and Division of Cancer Treatment and Diagnosis (MD), National Cancer Institute, Rockville, MD; Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD (BA, PDN); Cancer Center, MetroHealth Medical Center and Casewestern Reserve University, Cleveland, OH (JB); Vanderbilt Heart and Vascular Institute, Vanderbilt University School of Medicine, Nashville, TN (TF); Mary Babb Randolph Cancer Center, West Virginia University (SCR), Morgantown, WV.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Force</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Division of Cancer Control and Population Sciences (NS, AF) and Division of Cancer Prevention (JB, LM) and Division of Cancer Treatment and Diagnosis (MD), National Cancer Institute, Rockville, MD; Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD (BA, PDN); Cancer Center, MetroHealth Medical Center and Casewestern Reserve University, Cleveland, OH (JB); Vanderbilt Heart and Vascular Institute, Vanderbilt University School of Medicine, Nashville, TN (TF); Mary Babb Randolph Cancer Center, West Virginia University (SCR), Morgantown, WV.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Remick</LastName>
<ForeName>Scot C</ForeName>
<Initials>SC</Initials>
<AffiliationInfo>
<Affiliation>Division of Cancer Control and Population Sciences (NS, AF) and Division of Cancer Prevention (JB, LM) and Division of Cancer Treatment and Diagnosis (MD), National Cancer Institute, Rockville, MD; Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD (BA, PDN); Cancer Center, MetroHealth Medical Center and Casewestern Reserve University, Cleveland, OH (JB); Vanderbilt Heart and Vascular Institute, Vanderbilt University School of Medicine, Nashville, TN (TF); Mary Babb Randolph Cancer Center, West Virginia University (SCR), Morgantown, WV.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016423">Congresses</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Natl Cancer Inst</MedlineTA>
<NlmUniqueID>7503089</NlmUniqueID>
<ISSNLinking>0027-8874</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006282">Health Personnel</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000193">education</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006321">Heart</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006331">Heart Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D032342">Muscle Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054547">National Cancer Institute (U.S.)</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054555">National Heart, Lung, and Blood Institute (U.S.)</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4176042 [Available on 09/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25210199</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Electronic-Print">
<Journal>
<ISSN IssnType="Electronic">1460-2105</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>106</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Journal of the National Cancer Institute</Title>
<ISOAbbreviation>J. Natl. Cancer Inst.</ISOAbbreviation>
</Journal>
<ArticleTitle>Cancer chemoprevention with nuts.</ArticleTitle>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/jnci/dju238</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">dju238</ELocationID>
<Abstract>
<AbstractText>It is well established that increased nut consumption is associated with a reduced risk of major chronic diseases, such as cardiovascular disease and type 2 diabetes mellitus. On the other hand, the association between nut consumption and cancer mortality is less clear. Recent studies have suggested that nut consumption is associated with reduced cancer mortality. This evidence reinforces the interest to investigate the chemopreventive properties of nuts, and it raises questions about the specific cancer type(s) and setting that can be more affected by nut consumption, as well as the cellular mechanisms involved in this protective effect. Here we discuss recent studies on the association of nut consumption and cancer, and we propose specific cellular mechanisms by which nut components can affect cancer progression. </AbstractText>
<CopyrightInformation>Â© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Falasca</LastName>
<ForeName>Marco</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute, Inositide Signalling Group. m.falasca@qmul.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Casari</LastName>
<ForeName>Ilaria</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute, Inositide Signalling Group.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Maffucci</LastName>
<ForeName>Tania</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute, Inositide Signalling Group.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Natl Cancer Inst</MedlineTA>
<NlmUniqueID>7503089</NlmUniqueID>
<ISSNLinking>0027-8874</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016588">Anticarcinogenic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064209">Phytochemicals</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016588">Anticarcinogenic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002318">Cardiovascular Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018890">Chemoprevention</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002908">Chronic Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014943">Global Health</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009754">Nuts</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064209">Phytochemicals</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011322">Primary Prevention</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24594506</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1468-330X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>85</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of neurology, neurosurgery, and psychiatry</Title>
<ISOAbbreviation>J. Neurol. Neurosurg. Psychiatr.</ISOAbbreviation>
</Journal>
<ArticleTitle>Assessment of cancer risk with Î²-interferon treatment for multiple sclerosis.</ArticleTitle>
<Pagination>
<MedlinePgn>1096-102</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2013-307238</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The risk of cancer after exposure to the Î²-interferons (IFNÎ²s) for multiple sclerosis (MS) has not been established. We assessed whether IFNÎ² treatment for MS is associated with cancer risk or the risk of specific cancers in a population-based observational study.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">The British Columbia MS database was linked to the provincial Cancer Registry, Vital Statistics death files and Health Registration files. Using a nested case-control design, MS cancer cases were matched with up to 20 randomly selected MS controls at the date of cancer diagnosis by sex, age (Â± 5 years) and study entry year using incidence density sampling. Associations between treatment exposure and overall or specific (breast, colorectal, lung and prostate) cancers were estimated by conditional logistic regression, adjusted for MS disease duration and age. Tumour size at cancer diagnosis was compared between treated and untreated patients using the stratified Wilcoxon test to explore potential lead time bias.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The cohort included 5146 relapsing-onset MS patients and 48,705 person-years of follow-up, during which 227 cancers were diagnosed. Exposure to IFNÎ² was not significantly different for cases and controls (OR 1.28; 95% CI 0.87 to 1.88). There was a non-significant trend towards an increased risk of IFNÎ² exposure in the breast cancer cases (OR 1.77; 95% CI 0.92 to 3.42), but no evidence of a dose-response effect. Tumour size was similar between IFNÎ² treated and untreated cases.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There was no evidence of an increased cancer risk with exposure to IFNÎ² over a 12-year observation period. However, the trend towards an association between IFNÎ² and breast cancer should be investigated further.</AbstractText>
<CopyrightInformation>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kingwell</LastName>
<ForeName>Elaine</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Faculty of Medicine Division of Neurology, Multiple Sclerosis Program University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Evans</LastName>
<ForeName>Charity</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>Feng</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Faculty of Medicine Division of Neurology, Multiple Sclerosis Program University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oger</LastName>
<ForeName>Joel</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Faculty of Medicine Division of Neurology, Multiple Sclerosis Program University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hashimoto</LastName>
<ForeName>Stanley</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Faculty of Medicine Division of Neurology, Multiple Sclerosis Program University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tremlett</LastName>
<ForeName>Helen</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Faculty of Medicine Division of Neurology, Multiple Sclerosis Program University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>MOP-82738</GrantID>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D064888">Observational Study</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA>
<NlmUniqueID>2985191R</NlmUniqueID>
<ISSNLinking>0022-3050</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C089995">copolymer 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>77238-31-4</RegistryNumber>
<NameOfSubstance UI="D016899">Interferon-beta</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D001955">British Columbia</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016208">Databases, Factual</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016899">Interferon-beta</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016015">Logistic Models</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009103">Multiple Sclerosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010455">Peptides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018570">Risk Assessment</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25208066</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1476-4687</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>513</Volume>
<Issue>7517</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>Immunotherapy: Chemical tricks.</ArticleTitle>
<Pagination>
<MedlinePgn>S10-1</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/513S10a</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Nogrady</LastName>
<ForeName>Bianca</ForeName>
<Initials>B</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000906">Antibodies</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019496">Cancer Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000906">Antibodies</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019496">Cancer Vaccines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007107">Immune System</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007167">Immunotherapy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000592">standards</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000639">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24121272</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>37</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>SRChing for the substrates of Src.</ArticleTitle>
<Pagination>
<MedlinePgn>4537-47</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2013.416</ELocationID>
<Abstract>
<AbstractText>By the mid 1980's, it was clear that the transforming activity of oncogenic Src was linked to the activity of its tyrosine kinase domain and attention turned to identifying substrates, the putative next level of control in the pathway to transformation. Among the first to recognize the potential of phosphotyrosine-specific antibodies, Parsons and colleagues launched a risky shotgun-based approach that led ultimately to the cDNA cloning and functional characterization of many of today's best-known Src substrates (for example, p85-Cortactin, p110-AFAP1, p130Cas, p125FAK and p120-catenin). Two decades and over 6000 citations later, the original goals of the project may be seen as secondary to the enormous impact of these protein substrates in many areas of biology. At the request of the editors, this review is not restricted to the current status of the substrates, but reflects also on the anatomy of the project itself and some of the challenges and decisions encountered along the way. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Reynolds</LastName>
<ForeName>A B</ForeName>
<Initials>AB</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Vanderbilt University, Nashville, TN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kanner</LastName>
<ForeName>S B</ForeName>
<Initials>SB</Initials>
<AffiliationInfo>
<Affiliation>Arrowhead Research Corporation, Madison, WI, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bouton</LastName>
<ForeName>A H</ForeName>
<Initials>AH</Initials>
<AffiliationInfo>
<Affiliation>Departments of Microbiology, Immunology and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schaller</LastName>
<ForeName>M D</ForeName>
<Initials>MD</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, 3124 HSN, Robert C. Byrd Health Sciences Center, West Virginia University School of Medicine, Morgantown, WV, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Weed</LastName>
<ForeName>S A</ForeName>
<Initials>SA</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurobiology and Anatomy, 1833 Mary Babb Randolph Cancer Center, Robert C. Byrd Health Sciences Center, West Virginia University School of Medicine, Morgantown, WV, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Flynn</LastName>
<ForeName>D C</ForeName>
<Initials>DC</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Lab Sciences, College of Health Sciences, University of Delaware, Newark, DE, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Parsons</LastName>
<ForeName>J T</ForeName>
<Initials>JT</Initials>
<AffiliationInfo>
<Affiliation>Departments of Microbiology, Immunology and Cancer Biology, University of Virginia Cancer Center, Charlottesville, VA, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>10</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497360">AFAP1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C493841">BCAR1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495868">CTTN protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051177">Catenins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051356">Cortactin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050719">Crk-Associated Substrate Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008840">Microfilament Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020543">Proteome</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C090470">delta catenin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D051417">Focal Adhesion Kinase 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="C496050">PTK2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D019061">src-Family Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051177">Catenins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002471">Cell Transformation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051356">Cortactin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050719">Crk-Associated Substrate Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051417">Focal Adhesion Kinase 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008840">Microfilament Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020543">Proteome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019061">src-Family Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25211818</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0012-7183</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>130</Volume>
<Issue>15</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Duodecim; lÃ¤Ã¤ketieteellinen aikakauskirja</Title>
<ISOAbbreviation>Duodecim</ISOAbbreviation>
</Journal>
<ArticleTitle>[Pros and cons of cancer screenings].</ArticleTitle>
<Pagination>
<MedlinePgn>1493-9</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Cancer screenings aim to detect latent or oligosymptomatic cancers in the early stage when treatment of the disease can be curative and cancer death may in many cases be prevented. Improved quality of life is a characteristic feature of good screening. Screenings may also lessen human suffering, for instance. For the society, early-stage cancer treatment saves money. Drawbacks of screenings are both false positive and false negative screening results leading to unnecessary further investigations. A latent cancer may also remain undetected due to a false test result.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Malila</LastName>
<ForeName>Nea</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>fin</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<VernacularTitle>SyÃ¶pÃ¤seulonnat, niiden hyÃ¶dyt ja haitat.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>Finland</Country>
<MedlineTA>Duodecim</MedlineTA>
<NlmUniqueID>0373207</NlmUniqueID>
<ISSNLinking>0012-7183</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055088">Early Detection of Cancer</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005188">False Negative Reactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005189">False Positive Reactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008403">Mass Screening</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25214503</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1756-1833</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>349</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>BMJ (Clinical research ed.)</Title>
<ISOAbbreviation>BMJ</ISOAbbreviation>
</Journal>
<ArticleTitle>Peter Clark: public attitudes support a more favourable assessment for cancer treatments.</ArticleTitle>
<Pagination>
<MedlinePgn>g5545</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1136/bmj.g5545</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jack</LastName>
<ForeName>Andrew</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>BMJ</MedlineTA>
<NlmUniqueID>8900488</NlmUniqueID>
<ISSNLinking>0959-535X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>BMJ. 2014;349:g5901</RefSource>
<PMID Version="1">25269627</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001294">Attitude to Health</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011639">Public Opinion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24991880</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1362-3095</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>90</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>International journal of radiation biology</Title>
<ISOAbbreviation>Int. J. Radiat. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Introduction to Michael E. Robbins memorial issue.</ArticleTitle>
<Pagination>
<MedlinePgn>729-30</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3109/09553002.2014.939778</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Greene-Schloessor</LastName>
<ForeName>Dana</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, Wake Forest School of Medicine , Winston-Salem, NC.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Williams</LastName>
<ForeName>Jacqueline P</ForeName>
<Initials>JP</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D019215">Biography</PublicationType>
<PublicationType UI="D016456">Historical Article</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Int J Radiat Biol</MedlineTA>
<NlmUniqueID>8809243</NlmUniqueID>
<ISSNLinking>0955-3002</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CitationSubset>S</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D006113">Great Britain</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049673">History, 20th Century</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049674">History, 21st Century</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000532">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011832">Radiation Injuries</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018787">Radiation Oncology</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<PersonalNameSubjectList>
<PersonalNameSubject>
<LastName>Robbins</LastName>
<ForeName>Michael E</ForeName>
<Initials>ME</Initials>
</PersonalNameSubject>
</PersonalNameSubjectList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25214566</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Electronic-Print">
<Journal>
<ISSN IssnType="Electronic">1460-2105</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>106</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Journal of the National Cancer Institute</Title>
<ISOAbbreviation>J. Natl. Cancer Inst.</ISOAbbreviation>
</Journal>
<ArticleTitle>Alleviating the crisis in cancer care.</ArticleTitle>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/jnci/dju309</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">dju309</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Delude</LastName>
<ForeName>Cathryn M</ForeName>
<Initials>CM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016433">News</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Natl Cancer Inst</MedlineTA>
<NlmUniqueID>7503089</NlmUniqueID>
<ISSNLinking>0027-8874</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000203">Activities of Daily Living</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D000375">Aging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D002755">Choice Behavior</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015897">Comorbidity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D032882">Comprehension</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017051">Hospice Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015969">Institute of Medicine (U.S.)</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009859">Oncology Nursing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D010166">Palliative Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018802">Patient-Centered Care</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000458">organization &amp; administration</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000592">standards</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000639">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011787">Quality of Health Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D011788">Quality of Life</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017741">Survivors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24987873</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1540-7586</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>32</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Journal of psychosocial oncology</Title>
<ISOAbbreviation>J Psychosoc Oncol</ISOAbbreviation>
</Journal>
<ArticleTitle>Predictors of benefit finding in the adult children of patients with cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>535-54</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/07347332.2014.936646</ELocationID>
<Abstract>
<AbstractText>This study aimed to investigate the predictors of benefit finding in 311 adult children of patients with cancer. Participants completed a comprehensive online/pen-and-paper survey measuring benefit finding, gender of parent, outcome and duration of illness, caregiving experience, and emotional experiences including reaction to diagnosis and grief and loss. Greater benefit finding was positively associated with stronger emotional experiences, satisfaction with the caregiving role, and outcome of parental cancer, explaining 15.3% of the variance in benefit finding. Higher emotional reactions and outcome of parental cancer as significant predictors of parental cancer provide some support for the applicability of theories of post-traumatic growth to this cohort. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Levesque</LastName>
<ForeName>Janelle V</ForeName>
<Initials>JV</Initials>
<AffiliationInfo>
<Affiliation>a Ingham Institute for Applied Medical Research, University of New South Wales , South Western Sydney Clinical School , Liverpool , NSW , Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Maybery</LastName>
<ForeName>Darryl J</ForeName>
<Initials>DJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Psychosoc Oncol</MedlineTA>
<NlmUniqueID>8309337</NlmUniqueID>
<ISSNLinking>0734-7332</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D000223">Adaptation, Psychological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D032721">Adult Children</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017028">Caregivers</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016241">Child of Impaired Parents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011582">Psychological Theory</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">adult children</Keyword>
<Keyword MajorTopicYN="N">benefit finding</Keyword>
<Keyword MajorTopicYN="N">caregiving</Keyword>
<Keyword MajorTopicYN="N">emotional experiences</Keyword>
<Keyword MajorTopicYN="N">parental cancer</Keyword>
<Keyword MajorTopicYN="N">post-traumatic growth</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24988134</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1540-7586</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>32</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Journal of psychosocial oncology</Title>
<ISOAbbreviation>J Psychosoc Oncol</ISOAbbreviation>
</Journal>
<ArticleTitle>It's more than dollars and cents: the impact of childhood cancer on parents' occupational and financial health.</ArticleTitle>
<Pagination>
<MedlinePgn>602-21</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/07347332.2014.936653</ELocationID>
<Abstract>
<AbstractText>Few studies have evaluated the impact of childhood cancer on parents' occupational/financial status. This study explored parents' occupational/financial experiences posttreatment. Semistructured interviews were administered to 78 parents (44 mothers) of childhood cancer survivors diagnosed in the preceding 5 years. Transcripts were organized into themes using QSR NVivo8. Parents reported familial, psychological, and practical factors affecting their ability to return to work. Prioritizing family, reinstigating career progression, and negative workplace attitudes were particularly challenging. Parents of children with cancer experience substantial work-family conflict after their child's physical recovery from cancer. Family friendly policies and further research are recommended.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wakefield</LastName>
<ForeName>Claire E</ForeName>
<Initials>CE</Initials>
<AffiliationInfo>
<Affiliation>a School of Women's and Children's Health, UNSW Medicine , University of New South Wales , Kensington , NSW , Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>McLoone</LastName>
<ForeName>Jordana K</ForeName>
<Initials>JK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Evans</LastName>
<ForeName>Nadia T</ForeName>
<Initials>NT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ellis</LastName>
<ForeName>Sarah J</ForeName>
<Initials>SJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cohn</LastName>
<ForeName>Richard J</ForeName>
<Initials>RJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Psychosoc Oncol</MedlineTA>
<NlmUniqueID>8309337</NlmUniqueID>
<ISSNLinking>0734-7332</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D003220">Conflict (Psychology)</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017281">Cost of Illness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005190">Family</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010290">Parents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D036301">Qualitative Research</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D062707">Return to Work</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012959">Socioeconomic Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">cancer</Keyword>
<Keyword MajorTopicYN="N">family friendly policies</Keyword>
<Keyword MajorTopicYN="N">occupation</Keyword>
<Keyword MajorTopicYN="N">oncology</Keyword>
<Keyword MajorTopicYN="N">pediatric</Keyword>
<Keyword MajorTopicYN="N">workâfamily conflict</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24988227</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1540-7586</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>32</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Journal of psychosocial oncology</Title>
<ISOAbbreviation>J Psychosoc Oncol</ISOAbbreviation>
</Journal>
<ArticleTitle>An outdoor adventure program for young adults with cancer: positive effects on body image and psychosocial functioning.</ArticleTitle>
<Pagination>
<MedlinePgn>622-36</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/07347332.2014.936652</ELocationID>
<Abstract>
<AbstractText>This study evaluated the psychological effects of an outdoor adventure program on young adult cancer survivors (ages 18-39). The 6-day adventure program included personal instruction and supervision on the basics of kayaking, surfing, or climbing. Compared to a wait-list control group, participants who took part in the program for the first time had improved (relative to pretest) body image, self-compassion and self-esteem, and less depression and alienation. Participants who took part for the second time, though also helped by the program in similar ways, were no better off psychologically than participants who took part for the first time. Possible explanations for the positive effects and their apparent short duration are offered. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Rosenberg</LastName>
<ForeName>Robin S</ForeName>
<Initials>RS</Initials>
<AffiliationInfo>
<Affiliation>a Department of Psychiatry , University of California-San Francisco , San Francisco , CA , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lange</LastName>
<ForeName>Whitney</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zebrack</LastName>
<ForeName>Brad</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Moulton</LastName>
<ForeName>Samuel</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kosslyn</LastName>
<ForeName>Stephen M</ForeName>
<Initials>SM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D018848">Controlled Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Psychosoc Oncol</MedlineTA>
<NlmUniqueID>8309337</NlmUniqueID>
<ISSNLinking>0734-7332</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001828">Body Image</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003863">Depression</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015397">Program Evaluation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D057173">Recreation Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012649">Self Concept</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017741">Survivors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">adventure therapy</Keyword>
<Keyword MajorTopicYN="N">body image</Keyword>
<Keyword MajorTopicYN="N">cancer survivors</Keyword>
<Keyword MajorTopicYN="N">depression</Keyword>
<Keyword MajorTopicYN="N">self-compassion</Keyword>
<Keyword MajorTopicYN="N">young adult</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24988462</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1540-7586</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>32</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Journal of psychosocial oncology</Title>
<ISOAbbreviation>J Psychosoc Oncol</ISOAbbreviation>
</Journal>
<ArticleTitle>Reciprocal empathy and working alliance in terminal oncological illness: the crucial role of patients' attachment style.</ArticleTitle>
<Pagination>
<MedlinePgn>517-34</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/07347332.2014.936651</ELocationID>
<Abstract>
<AbstractText>Security of attachment is described as an inner resource that may also facilitate the adaptation of individuals during critical life adversity, even when facing end-stage illness and death. This study assessed the relation between attachment styles, patient-caregiver reciprocal empathy, and patient-physician working alliance, in the terminal phase of an oncological disease. We hypothesized that the attachment security of patients, as measured by the Relationship Questionnaire (RQ), is related to the reciprocal empathy with the caregiver, as measured by the Perception of Partner Empathy (PPE) questionnaire, and to the working alliance with the physician, as measured by the Working Alliance Inventory-Short Form (WAI-S). Thirty-seven end-stage cancer patients, their caregivers, and physicians participated in the study. The PPE and WAI-S were administered twice: immediately after the hospice recovery and a week later. Results showed a significant improvement in patient-caregiver empathy and in patient-physician alliance after a week at the hospice. Findings indicated that the patients' attachment style influenced their perception of reciprocal empathy with the caregiver and the working alliance with the physician. Patients with a secure attachment had a greater capacity to show empathic closeness with their caregivers and enjoyed a better working alliance with their physicians. Caregivers' attachment security, otherwise, did not show the same influence on empathy and alliance. Findings support the hypothesis that patients' attachment security plays a crucial role in the relation with their own caregiver and with the physician, even at the terminal phase. Theoretical and clinical implications of these findings are explored in the discussion. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Calvo</LastName>
<ForeName>Vincenzo</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>a Department of Philosophy, Sociology, Pedagogy and Applied Psychology , University of Padova , Padova , Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Palmieri</LastName>
<ForeName>Arianna</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Marinelli</LastName>
<ForeName>Sara</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bianco</LastName>
<ForeName>Francesca</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kleinbub</LastName>
<ForeName>Johann R</ForeName>
<Initials>JR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Psychosoc Oncol</MedlineTA>
<NlmUniqueID>8309337</NlmUniqueID>
<ISSNLinking>0734-7332</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017028">Caregivers</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D004645">Empathy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017051">Hospice Care</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009769">Object Attachment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D010817">Physician-Patient Relations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011582">Psychological Theory</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">attachment</Keyword>
<Keyword MajorTopicYN="N">cancer</Keyword>
<Keyword MajorTopicYN="N">caregiver</Keyword>
<Keyword MajorTopicYN="N">empathy</Keyword>
<Keyword MajorTopicYN="N">working alliance</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25045924</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1540-7586</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>32</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Journal of psychosocial oncology</Title>
<ISOAbbreviation>J Psychosoc Oncol</ISOAbbreviation>
</Journal>
<ArticleTitle>An exploration of the existential experiences of patients following curative treatment for cancer: reflections from a U.K. Sample.</ArticleTitle>
<Pagination>
<MedlinePgn>555-75</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/07347332.2014.936647</ELocationID>
<Abstract>
<AbstractText>The existential experiences associated with cancer diagnosis and treatment are well researched, but the posttreatment phase is relatively underexplored. Using semistructured interviews and theory-led thematic analysis this qualitative study investigated the existential experiences of eight cancer survivors who had successfully completed curative treatment. Being in remission had led to deep existential reflections (i.e., death anxiety, freedom, isolation, and meaning making), and some participants faced considerable challenges that affected their emotional well-being. Understanding cancer survivors' existential challenges should enable health care professionals to engage with the emerging shift from the predominantly medically focused posttreatment care to a more holistic approach. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lagerdahl</LastName>
<ForeName>Anna S K</ForeName>
<Initials>AS</Initials>
<AffiliationInfo>
<Affiliation>a Cancer Services, Great Western Hospital , Swindon , UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Moynihan</LastName>
<ForeName>Manus</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stollery</LastName>
<ForeName>Brian</ForeName>
<Initials>B</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Psychosoc Oncol</MedlineTA>
<NlmUniqueID>8309337</NlmUniqueID>
<ISSNLinking>0734-7332</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005086">Existentialism</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D006113">Great Britain</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D036301">Qualitative Research</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017741">Survivors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">cancer</Keyword>
<Keyword MajorTopicYN="N">curative</Keyword>
<Keyword MajorTopicYN="N">existential</Keyword>
<Keyword MajorTopicYN="N">meaning</Keyword>
<Keyword MajorTopicYN="N">posttreatment</Keyword>
<Keyword MajorTopicYN="N">psychosocial oncology care</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25211044</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1536-5964</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>93</Volume>
<Issue>12</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Medicine</Title>
<ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
</Journal>
<ArticleTitle>Preoperative risk score predicting 90-day mortality after liver resection in a population-based study.</ArticleTitle>
<Pagination>
<MedlinePgn>e59</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000000059</ELocationID>
<Abstract>
<AbstractText>The impact of important preexisting comorbidities, such as liver and renal disease, on the outcome of liver resection remains unclear. Identification of patients at risk of mortality will aid in improving preoperative preparations. The purpose of this study is to develop and validate a population-based score based on available preoperative and predictable parameters predicting 90-day mortality after liver resection using data from a hepatitis endemic country.We identified 13,159 patients who underwent liver resection between 2002 and 2006 in the Taiwan National Health Insurance Research Database. In a randomly selected half of the total patients, multivariate logistic regression analysis was used to develop a prediction score for estimating the risk of 90-day mortality by patient demographics, preoperative liver disease and comorbidities, indication for surgery, and procedure type. The score was validated with the remaining half of the patients.Overall 90-day mortality was 3.9%. Predictive characteristics included in the model were age, preexisting cirrhosis-related complications, ischemic heart disease, heart failure, cerebrovascular disease, renal disease, malignancy, and procedure type. Four risk groups were stratified by mortality scores of 1.1%, 2.2%, 7.7%, and 15%. Preexisting renal disease and cirrhosis-related complications were the strongest predictors. The score discriminated well in both the derivation and validation sets with c-statistics of 0.75 and 0.75, respectively.This population-based score could identify patients at risk of 90-day mortality before liver resection. Preexisting renal disease and cirrhosis-related complications had the strongest influence on mortality. This score enables preoperative risk stratification, decision-making, quality assessment, and counseling for individual patients. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chang</LastName>
<ForeName>Chun-Ming</ForeName>
<Initials>CM</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery (C-MC, W-YY, C-KW, C-HL, J-CC); Department of Otolaryngology (C-CL); Center for Clinical Epidemiology and Biostatistics (S-YJ, C-CL); Division of Hematology-Oncology, Department of Internal Medicine (Y-CS); Cancer Center (Y-CS, C-CL), Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi; School of Medicine, Tzu Chi University, Hualian (C-MC, W-YY, C-KW, C-HL, J-CC, C-CL); and Department of Computer Science and Information Engineering, National Cheng Kung University, Tainan City (Y-TC), Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yin</LastName>
<ForeName>Wen-Yao</ForeName>
<Initials>WY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Su</LastName>
<ForeName>Yu-Chieh</ForeName>
<Initials>YC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wei</LastName>
<ForeName>Chang-Kao</ForeName>
<Initials>CK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Cheng-Hung</ForeName>
<Initials>CH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Juang</LastName>
<ForeName>Shiun-Yang</ForeName>
<Initials>SY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Yi-Ting</ForeName>
<Initials>YT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Jin-Cherng</ForeName>
<Initials>JC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Ching-Chih</ForeName>
<Initials>CC</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Medicine (Baltimore)</MedlineTA>
<NlmUniqueID>2985248R</NlmUniqueID>
<ISSNLinking>0025-7974</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000367">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002318">Cardiovascular Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015897">Comorbidity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006498">Hepatectomy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007674">Kidney Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008103">Liver Cirrhosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016015">Logistic Models</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015233">Models, Statistical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011237">Predictive Value of Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D057234">Preoperative Period</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018570">Risk Assessment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015996">Survival Rate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D013624">Taiwan</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25214590</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1095-9203</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>345</Volume>
<Issue>6202</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>12</Day>
</PubDate>
</JournalIssue>
<Title>Science (New York, N.Y.)</Title>
<ISOAbbreviation>Science</ISOAbbreviation>
</Journal>
<ArticleTitle>Health. Changing behaviors to prevent noncommunicable diseases.</ArticleTitle>
<Pagination>
<MedlinePgn>1243-4</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1259809</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chokshi</LastName>
<ForeName>Dave A</ForeName>
<Initials>DA</Initials>
<AffiliationInfo>
<Affiliation>Departments of Population Health and Medicine, New York University Langone Medical Center, New York, NY 10016, USA. dave.chokshi@nyumc.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Farley</LastName>
<ForeName>Thomas A</ForeName>
<Initials>TA</Initials>
<AffiliationInfo>
<Affiliation>Hunter College, New York, NY 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Science</MedlineTA>
<NlmUniqueID>0404511</NlmUniqueID>
<ISSNLinking>0036-8075</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002318">Cardiovascular Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002908">Chronic Disease</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003920">Diabetes Mellitus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D006293">Health Promotion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008171">Lung Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D012309">Risk-Taking</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016540">Smoking Cessation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25214609</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1095-9203</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>345</Volume>
<Issue>6202</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>12</Day>
</PubDate>
</JournalIssue>
<Title>Science (New York, N.Y.)</Title>
<ISOAbbreviation>Science</ISOAbbreviation>
</Journal>
<ArticleTitle>Halving premature death.</ArticleTitle>
<Pagination>
<MedlinePgn>1272</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1259971</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Peto</LastName>
<ForeName>Richard</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Richard Peto is a professor in the Nuffield Department of Population Health CTSU, University of Oxford, Oxford, UK. rpeto@ctsu.ox.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lopez</LastName>
<ForeName>Alan D</ForeName>
<Initials>AD</Initials>
<AffiliationInfo>
<Affiliation>Alan D. Lopez is a professor at the Melbourne School of Population and Global Health, University of Melbourne, Victoria, Australia. alan.lopez@unimelb.edu.au.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Norheim</LastName>
<ForeName>Ole F</ForeName>
<Initials>OF</Initials>
<AffiliationInfo>
<Affiliation>Ole F. Norheim is a professor in the Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. ole.norheim@igs.uib.no.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016421">Editorial</PublicationType>
<PublicationType UI="D016433">News</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Science</MedlineTA>
<NlmUniqueID>0404511</NlmUniqueID>
<ISSNLinking>0036-8075</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000367">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004646">Emphysema</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014943">Global Health</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000639">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006331">Heart Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061213">Mortality, Premature</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000639">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020521">Stroke</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25201439</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1471-2105</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>15</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>BMC bioinformatics</Title>
<ISOAbbreviation>BMC Bioinformatics</ISOAbbreviation>
</Journal>
<ArticleTitle>Towards accurate characterization of clonal heterogeneity based on structural variation.</ArticleTitle>
<Pagination>
<MedlinePgn>299</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-2105-15-299</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent advances in deep digital sequencing have unveiled an unprecedented degree of clonal heterogeneity within a single tumor DNA sample. Resolving such heterogeneity depends on accurate estimation of fractions of alleles that harbor somatic mutations. Unlike substitutions or small indels, structural variants such as deletions, duplications, inversions and translocations involve segments of DNAs and are potentially more accurate for allele fraction estimations. However, no systematic method exists that can support such analysis.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">In this paper, we present a novel maximum-likelihood method that estimates allele fractions of structural variants integratively from various forms of alignment signals. We develop a tool, BreakDown, to estimate the allele fractions of most structural variants including medium size (from 1 kilobase to 1 megabase) deletions and duplications, and balanced inversions and translocations.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Evaluation based on both simulated and real data indicates that our method systematically enables structural variants for clonal heterogeneity analysis and can greatly enhance the characterization of genomically instable tumors.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Fan</LastName>
<ForeName>Xian</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Wanding</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chong</LastName>
<ForeName>Zechen</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nakhleh</LastName>
<ForeName>Luay</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Ken</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Bioinformatics and Computational Biology, The University of Texas M,D, Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. kchen3@mdanderson.org.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P30-CA016672</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01-CA172652</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U41-HG007497-01</GrantID>
<Acronym>HG</Acronym>
<Agency>NHGRI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>BMC Bioinformatics</MedlineTA>
<NlmUniqueID>100965194</NlmUniqueID>
<ISSNLinking>1471-2105</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>9007-49-2</RegistryNumber>
<NameOfSubstance UI="D004247">DNA</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2009 Dec 24;462(7276):1005-10</RefSource>
<PMID Version="1">20033038</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2010 Jan 14;463(7278):191-6</RefSource>
<PMID Version="1">20016485</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genome Biol. 2009;10(2):R23</RefSource>
<PMID Version="1">19236709</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2010 Apr 15;464(7291):993-8</RefSource>
<PMID Version="1">20393554</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Genet. 2010 Oct;11(10):685-96</RefSource>
<PMID Version="1">20847746</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2010 Oct 28;467(7319):1061-73</RefSource>
<PMID Version="1">20981092</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Genet. 2011 Mar;43(3):269-76</RefSource>
<PMID Version="1">21317889</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2011 Apr 7;472(7341):90-4</RefSource>
<PMID Version="1">21399628</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Genet. 2011 May;12(5):363-76</RefSource>
<PMID Version="1">21358748</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Methods. 2011 Aug;8(8):652-4</RefSource>
<PMID Version="1">21666668</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genome Biol. 2011;12(2):R18</RefSource>
<PMID Version="1">21338519</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Bioinformatics. 2012 Jan 1;28(1):40-7</RefSource>
<PMID Version="1">22039209</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2012 Jan 26;481(7382):506-10</RefSource>
<PMID Version="1">22237025</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>N Engl J Med. 2012 Mar 22;366(12):1090-8</RefSource>
<PMID Version="1">22417201</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2012 May 25;149(5):994-1007</RefSource>
<PMID Version="1">22608083</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2012 May 25;149(5):979-93</RefSource>
<PMID Version="1">22608084</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Biotechnol. 2012 May;30(5):413-21</RefSource>
<PMID Version="1">22544022</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2012 Jun 21;486(7403):395-9</RefSource>
<PMID Version="1">22495314</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Hum Genet. 2012 Sep 7;91(3):408-21</RefSource>
<PMID Version="1">22939633</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Bioinformatics. 2012 Sep 15;28(18):i333-i339</RefSource>
<PMID Version="1">22962449</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Sci Transl Med. 2012 Nov 28;4(162):162ra154</RefSource>
<PMID Version="1">23197571</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Biotechnol. 2013 Mar;31(3):213-9</RefSource>
<PMID Version="1">23396013</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Hum Genet. 2013 Mar 7;92(3):415-21</RefSource>
<PMID Version="1">23395477</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2013 Mar 14;152(6):1226-36</RefSource>
<PMID Version="1">23498933</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2013 Apr 25;153(3):666-77</RefSource>
<PMID Version="1">23622249</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genome Res. 2013 May;23(5):762-76</RefSource>
<PMID Version="1">23410887</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2013 May 9;153(4):919-29</RefSource>
<PMID Version="1">23663786</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Cell. 2013 May 13;23(5):567-9</RefSource>
<PMID Version="1">23680143</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Dev. 2013 Dec 1;27(23):2513-30</RefSource>
<PMID Version="1">24298051</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Bioinformatics. 2014 Jan 1;30(1):50-60</RefSource>
<PMID Version="1">24177718</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Methods. 2014 Apr;11(4):396-8</RefSource>
<PMID Version="1">24633410</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Rep. 2014 Jun 12;7(5):1740-52</RefSource>
<PMID Version="1">24882004</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genome Biol. 2013;14(7):R80</RefSource>
<PMID Version="1">23895164</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS Comput Biol. 2014 Aug;10(8):e1003665</RefSource>
<PMID Version="1">25102416</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genomics. 1988 Apr;2(3):231-9</RefSource>
<PMID Version="1">3294162</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>N Engl J Med. 2008 Aug 14;359(7):722-34</RefSource>
<PMID Version="1">18703475</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2009 Apr 9;458(7239):719-24</RefSource>
<PMID Version="1">19360079</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Bioinformatics. 2009 Jul 15;25(14):1754-60</RefSource>
<PMID Version="1">19451168</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Bioinformatics. 2009 Aug 15;25(16):2078-9</RefSource>
<PMID Version="1">19505943</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Methods. 2009 Sep;6(9):677-81</RefSource>
<PMID Version="1">19668202</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Methods. 2009 Nov;6(11 Suppl):S13-20</RefSource>
<PMID Version="1">19844226</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Bioinformatics. 2009 Nov 1;25(21):2865-71</RefSource>
<PMID Version="1">19561018</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2011 Jan 7;144(1):27-40</RefSource>
<PMID Version="1">21215367</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2011 Feb 10;470(7333):198-203</RefSource>
<PMID Version="1">21307932</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000483">Alleles</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058674">Chromosome Duplication</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007446">Chromosome Inversion</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002999">Clone Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004247">DNA</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023281">Genomics</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059014">High-Throughput Nucleotide Sequencing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016013">Likelihood Functions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016415">Sequence Alignment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017422">Sequence Analysis, DNA</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017384">Sequence Deletion</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012984">Software</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4165998</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25215487</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1097-4172</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>158</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Cell</Title>
<ISOAbbreviation>Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>A dual program for translation regulation in cellular proliferation and differentiation.</ArticleTitle>
<Pagination>
<MedlinePgn>1281-92</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2014.08.011</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0092-8674(14)01042-3</ELocationID>
<Abstract>
<AbstractText>A dichotomous choice for metazoan cells is between proliferation and differentiation. Measuring tRNA pools in various cell types, we found two distinct subsets, one that is induced in proliferating cells, and repressed otherwise, and another with the opposite signature. Correspondingly, we found that genes serving cell-autonomous functions and genes involved in multicellularity obey distinct codon usage. Proliferation-induced and differentiation-induced tRNAs often carry anticodons that correspond to the codons enriched among the cell-autonomous and the multicellularity genes, respectively. Because mRNAs of cell-autonomous genes are induced in proliferation and cancer in particular, the concomitant induction of their codon-enriched tRNAs suggests coordination between transcription and translation. Histone modifications indeed change similarly in the vicinity of cell-autonomous genes and their corresponding tRNAs, and in multicellularity genes and their tRNAs, suggesting the existence of transcriptional programs coordinating tRNA supply and demand. Hence, we describe the existence of two distinct translation programs that operate during proliferation and differentiation. </AbstractText>
<CopyrightInformation>Copyright Â© 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gingold</LastName>
<ForeName>Hila</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tehler</LastName>
<ForeName>Disa</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Biotech Research and Innovation Centre, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Christoffersen</LastName>
<ForeName>Nanna R</ForeName>
<Initials>NR</Initials>
<AffiliationInfo>
<Affiliation>Biotech Research and Innovation Centre, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nielsen</LastName>
<ForeName>Morten M</ForeName>
<Initials>MM</Initials>
<AffiliationInfo>
<Affiliation>Department for Molecular Medicine, Aarhus University Hospital, 8000 Aarhus, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Asmar</LastName>
<ForeName>Fazila</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kooistra</LastName>
<ForeName>Susanne M</ForeName>
<Initials>SM</Initials>
<AffiliationInfo>
<Affiliation>Biotech Research and Innovation Centre, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Christophersen</LastName>
<ForeName>Nicolaj S</ForeName>
<Initials>NS</Initials>
<AffiliationInfo>
<Affiliation>Biotech Research and Innovation Centre, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Christensen</LastName>
<ForeName>Lise Lotte</ForeName>
<Initials>LL</Initials>
<AffiliationInfo>
<Affiliation>Department for Molecular Medicine, Aarhus University Hospital, 8000 Aarhus, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Borre</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Aarhus University Hospital, 8000 Aarhus, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>SÃ¸rensen</LastName>
<ForeName>Karina D</ForeName>
<Initials>KD</Initials>
<AffiliationInfo>
<Affiliation>Department for Molecular Medicine, Aarhus University Hospital, 8000 Aarhus, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Andersen</LastName>
<ForeName>Lars D</ForeName>
<Initials>LD</Initials>
<AffiliationInfo>
<Affiliation>Department for Molecular Medicine, Aarhus University Hospital, 8000 Aarhus, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Andersen</LastName>
<ForeName>Claus L</ForeName>
<Initials>CL</Initials>
<AffiliationInfo>
<Affiliation>Department for Molecular Medicine, Aarhus University Hospital, 8000 Aarhus, Denmark; Department of Surgery, Aarhus University Hospital, 8000 Aarhus, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hulleman</LastName>
<ForeName>Esther</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatric Oncology, Neuro-oncology Research Group, Cancer Center Amsterdam, VU University Medical Center, 1007 MB Amsterdam, the Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wurdinger</LastName>
<ForeName>Tom</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurosurgery, Neuro-oncology Research Group, Cancer Center Amsterdam, VU University Medical Center, 1007 MB Amsterdam, the Netherlands; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>RalfkiÃ¦r</LastName>
<ForeName>Elisabeth</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Helin</LastName>
<ForeName>Kristian</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Biotech Research and Innovation Centre, University of Copenhagen, 2200 Copenhagen, Denmark; Center for Epigenetics, University of Copenhagen, 2200 Copenhagen, Denmark; The Danish Stem Cell Center (Danstem), University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>GrÃ¸nbÃ¦k</LastName>
<ForeName>Kirsten</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Orntoft</LastName>
<ForeName>Torben</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department for Molecular Medicine, Aarhus University Hospital, 8000 Aarhus, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Waszak</LastName>
<ForeName>Sebastian M</ForeName>
<Initials>SM</Initials>
<AffiliationInfo>
<Affiliation>Institute of Bioengineering, School of Life Sciences, Ãcole Polytechnique FÃ©dÃ©rale de Lausanne, 1015 Lausanne, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dahan</LastName>
<ForeName>Orna</ForeName>
<Initials>O</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pedersen</LastName>
<ForeName>Jakob Skou</ForeName>
<Initials>JS</Initials>
<AffiliationInfo>
<Affiliation>Department for Molecular Medicine, Aarhus University Hospital, 8000 Aarhus, Denmark; Bioinformatics Research Centre, Aarhus University Hospital, 8000 Aarhus, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lund</LastName>
<ForeName>Anders H</ForeName>
<Initials>AH</Initials>
<AffiliationInfo>
<Affiliation>Biotech Research and Innovation Centre, University of Copenhagen, 2200 Copenhagen, Denmark. Electronic address: anders.lund@bric.ku.dk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pilpel</LastName>
<ForeName>Yitzhak</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot 76100, Israel. Electronic address: pilpel@weizmann.ac.il.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cell</MedlineTA>
<NlmUniqueID>0413066</NlmUniqueID>
<ISSNLinking>0092-8674</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000926">Anticodon</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003062">Codon</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006657">Histones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9014-25-9</RegistryNumber>
<NameOfSubstance UI="D012343">RNA, Transfer</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Cell. 2014 Sep 11;158(6):1238-9</RefSource>
<PMID Version="1">25215483</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>EMBO J. 2014 Sep 17;33(18):1981-3</RefSource>
<PMID Version="1">25216676</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000926">Anticodon</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D002454">Cell Differentiation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002471">Cell Transformation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003062">Codon</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006657">Histones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D014176">Protein Biosynthesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012343">RNA, Transfer</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059467">Transcriptome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25215498</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1097-4172</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>158</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Cell</Title>
<ISOAbbreviation>Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>SnapShot: FMRP mRNA targets and diseases.</ArticleTitle>
<Pagination>
<MedlinePgn>1446-1446.e1</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2014.08.035</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0092-8674(14)01105-2</ELocationID>
<Abstract>
<AbstractText>FMRP, or fragile X mental retardation protein is an RNA-binding protein. Mutations in the FMRP protein have been associated with neurological disease as have a number of its mRNA-binding targets. This SnapShot presents 40 bona fide FMRP targets for which mRNA binding and protein regulation have been robustly reported in mammals along with the diseases with which they have been associated. </AbstractText>
<CopyrightInformation>Copyright Â© 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pasciuto</LastName>
<ForeName>Emanuela</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>VIB Center for the Biology of Disease, 3000 Leuven, Belgium; Center for Human Genetics and Leuven Institute for Neurodegenerative Diseases (LIND), KU Leuven, 3000 Leuven, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bagni</LastName>
<ForeName>Claudia</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>VIB Center for the Biology of Disease, 3000 Leuven, Belgium; Center for Human Genetics and Leuven Institute for Neurodegenerative Diseases (LIND), KU Leuven, 3000 Leuven, Belgium; Department of Biomedicine and Prevention, University of Rome "Tor Vergata," 00133 Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cell</MedlineTA>
<NlmUniqueID>0413066</NlmUniqueID>
<ISSNLinking>0092-8674</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>139135-51-6</RegistryNumber>
<NameOfSubstance UI="D051860">Fragile X Mental Retardation Protein</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001927">Brain Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051860">Fragile X Mental Retardation Protein</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001523">Mental Disorders</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25217579</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Electronic-Print">
<Journal>
<ISSN IssnType="Electronic">1460-2105</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>106</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of the National Cancer Institute</Title>
<ISOAbbreviation>J. Natl. Cancer Inst.</ISOAbbreviation>
</Journal>
<ArticleTitle>The role of microRNAs in the control of innate immune response in cancer.</ArticleTitle>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/jnci/dju257</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">dju257</ELocationID>
<Abstract>
<AbstractText>Ligands for receptors of natural killer (NK) cells and CD8(+) cytotoxic T lymphocytes (CTL), such as the inhibitory nonclassical HLA-G, the activating stress-induced major histocompatibility complex class I-related antigens MICA and MICB, and/or the UL16-binding proteins (ULBPs), are often aberrantly expressed upon viral infection and neoplastic transformation, thereby preventing virus-infected or malignant-transformed cells from elimination by immune effector cells. Recently, it has been shown that ligands of both NK and CD8(+) T cells are regulated by a number of cellular and/or viral microRNAs (miRs). These miRs are involved in shaping the antiviral and/or antitumoral immune responses as well as neoplastic growth properties. This review summarizes the expression pattern and function of miRs directed against selected NK and T cell receptor ligands, their putative role in shaping immune surveillance and tumorigenicity, and their clinical relevance. In addition, the potential role of RNA-binding proteins in the post-transcriptional gene regulation of these ligands will be discussed. </AbstractText>
<CopyrightInformation>Â© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jasinski-Bergner</LastName>
<ForeName>Simon</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Martin-Luther-University Halle-Wittenberg, Institute of Medical Immunology, Halle (Saale), Germany (SJB, BS); The Hebrew University of Jerusalem, Ein Kerem, The Lautenberg Center for General and Tumor Immunology, IMRIC, Jerusalem, Israel (OM).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mandelboim</LastName>
<ForeName>Ofer</ForeName>
<Initials>O</Initials>
<AffiliationInfo>
<Affiliation>Martin-Luther-University Halle-Wittenberg, Institute of Medical Immunology, Halle (Saale), Germany (SJB, BS); The Hebrew University of Jerusalem, Ein Kerem, The Lautenberg Center for General and Tumor Immunology, IMRIC, Jerusalem, Israel (OM).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Seliger</LastName>
<ForeName>Barbara</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Martin-Luther-University Halle-Wittenberg, Institute of Medical Immunology, Halle (Saale), Germany (SJB, BS); The Hebrew University of Jerusalem, Ein Kerem, The Lautenberg Center for General and Tumor Immunology, IMRIC, Jerusalem, Israel (OM). barbara.seliger@uk-halle.de.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Natl Cancer Inst</MedlineTA>
<NlmUniqueID>7503089</NlmUniqueID>
<ISSNLinking>0027-8874</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058851">GPI-Linked Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D059951">HLA-G Antigens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C099187">MHC class I-related chain A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C098080">MICB antigen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055655">NK Cell Lectin-Like Receptor Subfamily K</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C423231">ULBP1 protein, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056704">Adaptive Immunity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018414">CD8-Positive T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058851">GPI-Linked Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059951">HLA-G Antigens</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015395">Histocompatibility Antigens Class I</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007113">Immunity, Innate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047908">Intracellular Signaling Peptides and Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007694">Killer Cells, Natural</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008024">Ligands</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055655">NK Cell Lectin-Like Receptor Subfamily K</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013602">T-Lymphocytes, Cytotoxic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25217580</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Electronic-Print">
<Journal>
<ISSN IssnType="Electronic">1460-2105</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>106</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of the National Cancer Institute</Title>
<ISOAbbreviation>J. Natl. Cancer Inst.</ISOAbbreviation>
</Journal>
<ArticleTitle>Use of crowdsourcing for cancer clinical trial development.</ArticleTitle>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/jnci/dju258</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">dju258</ELocationID>
<Abstract>
<AbstractText>Patient and physician awareness and acceptance of trials and patient ineligibility are major cancer clinical trial accrual barriers. Yet, trials are typically conceived and designed by small teams of researchers with limited patient input. We hypothesized that through crowdsourcing, the intellectual and creative capacity of a large number of researchers, clinicians, and patients could be harnessed to improve the clinical trial design process. In this study, we evaluated the feasibility and utility of using an internet-based crowdsourcing platform to inform the design of a clinical trial exploring an antidiabetic drug, metformin, in prostate cancer. Over a six-week period, crowd-sourced input was collected from 60 physicians/researchers and 42 patients/advocates leading to several major (eg, eligibility) and minor modifications to the clinical trial protocol as originally designed. Crowdsourcing clinical trial design is feasible, adds value to the protocol development process, and may ultimately improve the efficiency of trial conduct.</AbstractText>
<CopyrightInformation>Â© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Leiter</LastName>
<ForeName>Amanda</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY (AL, WKO, MDG); Platform Development Department, Transparency Life Sciences, New York, NY (TS, MF, AG); Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY (MD); Clinical Trials Department, AMC Health, New York, NY (JH).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sablinski</LastName>
<ForeName>Tomasz</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY (AL, WKO, MDG); Platform Development Department, Transparency Life Sciences, New York, NY (TS, MF, AG); Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY (MD); Clinical Trials Department, AMC Health, New York, NY (JH).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Diefenbach</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY (AL, WKO, MDG); Platform Development Department, Transparency Life Sciences, New York, NY (TS, MF, AG); Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY (MD); Clinical Trials Department, AMC Health, New York, NY (JH).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Foster</LastName>
<ForeName>Marc</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY (AL, WKO, MDG); Platform Development Department, Transparency Life Sciences, New York, NY (TS, MF, AG); Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY (MD); Clinical Trials Department, AMC Health, New York, NY (JH).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Greenberg</LastName>
<ForeName>Alex</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY (AL, WKO, MDG); Platform Development Department, Transparency Life Sciences, New York, NY (TS, MF, AG); Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY (MD); Clinical Trials Department, AMC Health, New York, NY (JH).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Holland</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY (AL, WKO, MDG); Platform Development Department, Transparency Life Sciences, New York, NY (TS, MF, AG); Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY (MD); Clinical Trials Department, AMC Health, New York, NY (JH).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oh</LastName>
<ForeName>William K</ForeName>
<Initials>WK</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY (AL, WKO, MDG); Platform Development Department, Transparency Life Sciences, New York, NY (TS, MF, AG); Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY (MD); Clinical Trials Department, AMC Health, New York, NY (JH).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Galsky</LastName>
<ForeName>Matthew D</ForeName>
<Initials>MD</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY (AL, WKO, MDG); Platform Development Department, Transparency Life Sciences, New York, NY (TS, MF, AG); Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY (MD); Clinical Trials Department, AMC Health, New York, NY (JH). matthew.galsky@mssm.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Natl Cancer Inst</MedlineTA>
<NlmUniqueID>7503089</NlmUniqueID>
<ISSNLinking>0027-8874</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9100L32L2N</RegistryNumber>
<NameOfSubstance UI="D008687">Metformin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D063045">Crowdsourcing</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005240">Feasibility Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020407">Internet</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008687">Metformin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018579">Patient Selection</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D012107">Research Design</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25219036</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0869-866X</ISSN>
<JournalIssue CitedMedium="Print">
<Issue>3</Issue>
<PubDate>
<MedlineDate>2014 May-Jun</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Problemy sotÍ¡sialÊ¹noÄ­ gigieny, zdravookhraneniiÍ¡a i istorii meditÍ¡siny / NII sotÍ¡sialÊ¹noÄ­ gigieny, Äkonomiki i upravleniiÍ¡a zdravookhraneniem im. N.A. Semashko RAMN ; AO "AssotÍ¡siatÍ¡siiÍ¡a 'MeditÍ¡sinskaiÍ¡a literatura'."</Title>
<ISOAbbreviation>Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med</ISOAbbreviation>
</Journal>
<ArticleTitle>[The economic aspects of mortality of population in the Republic of Sakha (Yakutiya)].</ArticleTitle>
<Pagination>
<MedlinePgn>20-3</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The article presents data concerning dynamics of level and structure of mortality of population of the Republic of Sakha (Yakutiya) during 1990-2012. The study revealed gender differences and main causes of population mortality. The standardized indicators of mortality due certain causes are presented. The economic losses because of population mortality in 2006-2011 are calculated. It is established that the most input into economic losses because of population mortality was made by diseases of blood circulation system, external causes and neoplasms.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Timofeyev</LastName>
<ForeName>L F</ForeName>
<Initials>LF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ivanova</LastName>
<ForeName>A A</ForeName>
<Initials>AA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lindenbraten</LastName>
<ForeName>A L</ForeName>
<Initials>AL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Grishina</LastName>
<ForeName>N K</ForeName>
<Initials>NK</Initials>
</Author>
</AuthorList>
<Language>rus</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Russia (Federation)</Country>
<MedlineTA>Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med</MedlineTA>
<NlmUniqueID>101270373</NlmUniqueID>
<ISSNLinking>0869-866X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002318">Cardiovascular Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009026">Mortality</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D012426">Russia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012737">Sex Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25219039</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0869-866X</ISSN>
<JournalIssue CitedMedium="Print">
<Issue>3</Issue>
<PubDate>
<MedlineDate>2014 May-Jun</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Problemy sotÍ¡sialÊ¹noÄ­ gigieny, zdravookhraneniiÍ¡a i istorii meditÍ¡siny / NII sotÍ¡sialÊ¹noÄ­ gigieny, Äkonomiki i upravleniiÍ¡a zdravookhraneniem im. N.A. Semashko RAMN ; AO "AssotÍ¡siatÍ¡siiÍ¡a 'MeditÍ¡sinskaiÍ¡a literatura'."</Title>
<ISOAbbreviation>Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med</ISOAbbreviation>
</Journal>
<ArticleTitle>[The information support of oncological service of the Krasnodar kray].</ArticleTitle>
<Pagination>
<MedlinePgn>32-4</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The clinical oncologic dispensary No 1 of the health Department of the Krasnodar kray, 350040 Krasnodar, Russia The article presents substantiation of actuality of fast receiving of reliable information about prevalence of malignant neoplasms. The characteristic of population cancer registry and results of its implementation in the Krasnodar kray are presented.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kazantseva</LastName>
<ForeName>M V</ForeName>
<Initials>MV</Initials>
</Author>
</AuthorList>
<Language>rus</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Russia (Federation)</Country>
<MedlineTA>Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med</MedlineTA>
<NlmUniqueID>101270373</NlmUniqueID>
<ISSNLinking>0869-866X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008495">Medical Oncology</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015995">Prevalence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012042">Registries</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D012426">Russia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013534">Survival</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25043839</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1521-4141</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>44</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>European journal of immunology</Title>
<ISOAbbreviation>Eur. J. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Hypoxia in the intestine or solid tumors: a beneficial or deleterious alarm signal?</ArticleTitle>
<Pagination>
<MedlinePgn>2550-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/eji.201444719</ELocationID>
<Abstract>
<AbstractText>The transcription factor hypoxia inducible factors (HIF)-1 functions as a master regulator of oxygen homeostasis. There is increasing evidence that HIF has an essential role to prevent tissue damage in physiological and pathological situations in which cells are deprived of O2. Here, we review the effects of decreased oxygen supply on the innate and adaptive immune responses in the gut and in solid tumors in which the oxygenation profile correlates with the grade of inflammation. Data in the literature indicate that some tumors may co-opt immune mechanisms induced by HIF-1 to promote their survival and proliferation. By contrast, HIF-1 stabilization would have a beneficial effect in the intestinal tract as it would dampen inflammation and promote its resolution. Therefore, stabilization of HIF-1 in hypoxia may have opposite effects on the integrity of the host, depending on the tissue microenvironment.</AbstractText>
<CopyrightInformation>Â© 2014 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Shehade</LastName>
<ForeName>Hussein</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Immunobiology, UniversitÃ© Libre de Bruxelles, Gosselies, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oldenhove</LastName>
<ForeName>Guillaume</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Moser</LastName>
<ForeName>Muriel</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Eur J Immunol</MedlineTA>
<NlmUniqueID>1273201</NlmUniqueID>
<ISSNLinking>0014-2980</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051793">Hypoxia-Inducible Factor 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>S88TT14065</RegistryNumber>
<NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000860">Anoxia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051793">Hypoxia-Inducible Factor 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007422">Intestines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000098">blood supply</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000098">blood supply</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010100">Oxygen</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D059016">Tumor Microenvironment</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Hypoxia inducible factors</Keyword>
<Keyword MajorTopicYN="N">Immunity</Keyword>
<Keyword MajorTopicYN="N">Macrophages</Keyword>
<Keyword MajorTopicYN="N">T helper subsets</Keyword>
<Keyword MajorTopicYN="N">Vasculature</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25223100</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1062-3388</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>23</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Managed care (Langhorne, Pa.)</Title>
<ISOAbbreviation>Manag Care</ISOAbbreviation>
</Journal>
<ArticleTitle>Ups and downs at ASCO 2014.</ArticleTitle>
<Pagination>
<MedlinePgn>50-2</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Adams</LastName>
<ForeName>Katherine T</ForeName>
<Initials>KT</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Manag Care</MedlineTA>
<NlmUniqueID>9303583</NlmUniqueID>
<ISSNLinking>1062-3388</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001688">Biological Products</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>H</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D001688">Biological Products</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003226">Congresses as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017277">Drug Approval</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D055808">Drug Discovery</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008495">Medical Oncology</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D012955">Societies, Medical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014486">United States Food and Drug Administration</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25223103</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1062-3388</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>23</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Managed care (Langhorne, Pa.)</Title>
<ISOAbbreviation>Manag Care</ISOAbbreviation>
</Journal>
<ArticleTitle>Immunotherapies can't keep market forces at arm's length.</ArticleTitle>
<Pagination>
<MedlinePgn>55-6</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Morrow</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Manag Care</MedlineTA>
<NlmUniqueID>9303583</NlmUniqueID>
<ISSNLinking>1062-3388</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>H</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D016527">Drug Costs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007167">Immunotherapy</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25223104</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1062-3388</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>23</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Managed care (Langhorne, Pa.)</Title>
<ISOAbbreviation>Manag Care</ISOAbbreviation>
</Journal>
<ArticleTitle>Battle against cancer: the long and short views.</ArticleTitle>
<Pagination>
<MedlinePgn>57</MedlinePgn>
</Pagination>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Manag Care</MedlineTA>
<NlmUniqueID>9303583</NlmUniqueID>
<ISSNLinking>1062-3388</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>H</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017741">Survivors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25223197</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1935-1623</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>29</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>ONS connect</Title>
<ISOAbbreviation>ONS Connect</ISOAbbreviation>
</Journal>
<ArticleTitle>Getting old isn't easy, especially when cancer's involved.</ArticleTitle>
<Pagination>
<MedlinePgn>18-22</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lindberg</LastName>
<ForeName>Deborah</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>ONS Connect</MedlineTA>
<NlmUniqueID>101300056</NlmUniqueID>
<ISSNLinking>1935-1623</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017028">Caregivers</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006699">Home Care Services</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000451">nursing</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009723">Nurse-Patient Relations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009859">Oncology Nursing</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25223198</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1935-1623</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>29</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>ONS connect</Title>
<ISOAbbreviation>ONS Connect</ISOAbbreviation>
</Journal>
<ArticleTitle>Which affects cancer treatment outcomes more: age or comorbidities?</ArticleTitle>
<Pagination>
<MedlinePgn>23</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Merenda</LastName>
<ForeName>Christine</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>ONS Connect</MedlineTA>
<NlmUniqueID>101300056</NlmUniqueID>
<ISSNLinking>1935-1623</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015897">Comorbidity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25223199</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1935-1623</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>29</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>ONS connect</Title>
<ISOAbbreviation>ONS Connect</ISOAbbreviation>
</Journal>
<ArticleTitle>Care coordination helps older adults with cancer continue to live life to the fullest.</ArticleTitle>
<Pagination>
<MedlinePgn>24-8</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Coghill</LastName>
<ForeName>Amy S</ForeName>
<Initials>AS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>ONS Connect</MedlineTA>
<NlmUniqueID>101300056</NlmUniqueID>
<ISSNLinking>1935-1623</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D040561">Assisted Living Facilities</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D003266">Continuity of Patient Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017146">Models, Organizational</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000451">nursing</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012866">Skilled Nursing Facilities</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25223202</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1935-1623</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>29</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>ONS connect</Title>
<ISOAbbreviation>ONS Connect</ISOAbbreviation>
</Journal>
<ArticleTitle>Manage immune-related adverse events associated with cancer immunotherapies.</ArticleTitle>
<Pagination>
<MedlinePgn>36-7</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Becze</LastName>
<ForeName>Elisa</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>ONS Connect</MedlineTA>
<NlmUniqueID>101300056</NlmUniqueID>
<ISSNLinking>1935-1623</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007167">Immunotherapy</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25223204</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1935-1623</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>29</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>ONS connect</Title>
<ISOAbbreviation>ONS Connect</ISOAbbreviation>
</Journal>
<ArticleTitle>Treat cancer pain successfully, even with the epidemic of prescription drug abuse.</ArticleTitle>
<Pagination>
<MedlinePgn>45</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Merenda</LastName>
<ForeName>Christine</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>ONS Connect</MedlineTA>
<NlmUniqueID>101300056</NlmUniqueID>
<ISSNLinking>1935-1623</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000700">Analgesics</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000700">Analgesics</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010146">Pain</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059408">Pain Management</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010353">Patient Education as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019966">Substance-Related Disorders</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25223205</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1935-1623</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>29</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>ONS connect</Title>
<ISOAbbreviation>ONS Connect</ISOAbbreviation>
</Journal>
<ArticleTitle>Get the facts on sexuality and cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>46</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lindberg</LastName>
<ForeName>Deborah</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>ONS Connect</MedlineTA>
<NlmUniqueID>101300056</NlmUniqueID>
<ISSNLinking>1935-1623</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010817">Physician-Patient Relations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019529">Sexuality</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25044365</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-8652</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>89</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>American journal of hematology</Title>
<ISOAbbreviation>Am. J. Hematol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Donor NK cell licensing in control of malignancy in hematopoietic stem cell transplant recipients.</ArticleTitle>
<Pagination>
<MedlinePgn>E176-83</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/ajh.23802</ELocationID>
<Abstract>
<AbstractText>Among cancers treated with allogeneic hematopoietic stem-cell transplantation (HSCT), some are sensitive to natural killer (NK) cell reactivity, described as the "missing self" recognition effect. However, this model disregarded the NK cell licensing effect, which highly increases the NK cell reactivity against tumor and is dependent on the coexpression of inhibitory killer cell immunoglobulin-like receptor (iKIR) and its corresponding HLA Class I ligand. We assessed clinical data, HLA and donor iKIR genotyping in 283 patients with myelo- and lymphoproliferative malignancies who underwent HSCT from unrelated donors. We found dramatically reduced overall survival (OS), progression free survival (PFS), and time to progression (TTP) among patients with malignant diseases with the lack of HLA ligand cognate with this iKIR involved in NK cell licensing in corresponding donor (events 83.3% vs. 39.8%, P = 0.0010; 91.6% vs. 47.7%, P = 0.00010; and 30.0% vs. 17.3%, P = 0.013, for OS, PFS, and TTP, respectively). The extremely adverse PFS have withstand the correction when patient group was restricted to HLA mismatched donor-recipient pairs. The incidence of aGvHD was comparable in two groups of patients. In malignant patients after HSCT the missing HLA ligand for iKIR involved in NK cell licensing in corresponding donor ("missing licensing proof") induced extremely adverse survival of the patients due to the progression of malignancy and not to the aGvHD. Avoiding the selection of HSCT donors with the "missing licensing proof" in the malignant patient is strongly advisable.</AbstractText>
<CopyrightInformation>Â© 2014 Wiley Periodicals, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Nowak</LastName>
<ForeName>Jacek</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunogenetics, Institute of Hematology and Transfusion Medicine, Warsaw.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>KoÅciÅska</LastName>
<ForeName>Katarzyna</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mika-Witkowska</LastName>
<ForeName>Renata</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rogatko-KoroÅ</LastName>
<ForeName>Marta</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mizia</LastName>
<ForeName>Sylwia</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>JaskuÅa</LastName>
<ForeName>Emilia</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Polak</LastName>
<ForeName>MaÅgorzata</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mordak-DomagaÅa</LastName>
<ForeName>Monika</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lange</LastName>
<ForeName>Janusz</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gronkowska</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>JÄdrzejczak</LastName>
<ForeName>WiesÅaw Wiktor</ForeName>
<Initials>WW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kyrcz-KrzemieÅ</LastName>
<ForeName>SÅawomira</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Markiewicz</LastName>
<ForeName>MirosÅaw</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>DzierÅ¼ak-MietÅa</LastName>
<ForeName>Monika</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tomaszewska</LastName>
<ForeName>Agnieszka</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>NasiÅowska-Adamska</LastName>
<ForeName>Barbara</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>SzczepiÅski</LastName>
<ForeName>Andrzej</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>HaÅaburda</LastName>
<ForeName>Kazimierz</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hellmann</LastName>
<ForeName>Andrzej</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Komarnicki</LastName>
<ForeName>MieczysÅaw</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gil</LastName>
<ForeName>Lidia</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>CzyÅ¼</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wachowiak</LastName>
<ForeName>Jacek</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>BaraÅska</LastName>
<ForeName>MaÅgorzata</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kowalczyk</LastName>
<ForeName>Jerzy</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Drabko</LastName>
<ForeName>Katarzyna</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>GoÅºdzik</LastName>
<ForeName>Jolanta</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>WysoczaÅska</LastName>
<ForeName>Barbara</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bogunia-Kubik</LastName>
<ForeName>Katarzyna</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Graczyk-Pol</LastName>
<ForeName>ElÅ¼bieta</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Witkowska</LastName>
<ForeName>Agnieszka</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Marosz-Rudnicka</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nestorowicz</LastName>
<ForeName>Klaudia</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dziopa</LastName>
<ForeName>Joanna</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Szlendak</LastName>
<ForeName>Urszula</ForeName>
<Initials>U</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Warzocha</LastName>
<ForeName>Krzysztof</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lange</LastName>
<ForeName>And Andrzej</ForeName>
<Initials>AA</Initials>
</Author>
<Author ValidYN="Y">
<CollectiveName>Polish Donor-Recipient Matching Study Group</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Hematol</MedlineTA>
<NlmUniqueID>7610369</NlmUniqueID>
<ISSNLinking>0361-8609</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054340">Receptors, KIR</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000208">Acute Disease</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064591">Allografts</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046148">Donor Selection</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005838">Genotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006086">Graft vs Host Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015395">Histocompatibility Antigens Class I</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007694">Killer Cells, Natural</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054340">Receptors, KIR</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D061349">Unrelated Donors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25226624</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1945-6123</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>41</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Season>Summer</Season>
</PubDate>
</JournalIssue>
<Title>Journal of registry management</Title>
<ISOAbbreviation>J Registry Manag</ISOAbbreviation>
</Journal>
<ArticleTitle>Raising the bar: how to strut your cancer registry stuff.</ArticleTitle>
<Pagination>
<MedlinePgn>91</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Webb</LastName>
<ForeName>Michelle</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Registry Manag</MedlineTA>
<NlmUniqueID>9804163</NlmUniqueID>
<ISSNLinking>1945-6131</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007588">Job Satisfaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D012042">Registries</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25226625</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1945-6123</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>41</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Season>Summer</Season>
</PubDate>
</JournalIssue>
<Title>Journal of registry management</Title>
<ISOAbbreviation>J Registry Manag</ISOAbbreviation>
</Journal>
<ArticleTitle>Edits impact statement: North American Association of Central Cancer Registries.</ArticleTitle>
<Pagination>
<MedlinePgn>92-4</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<CollectiveName>Edits Impact Workgroup</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Registry Manag</MedlineTA>
<NlmUniqueID>9804163</NlmUniqueID>
<ISSNLinking>1945-6131</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D033181">Information Dissemination</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012042">Registries</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000592">standards</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25228562</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>17</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1421-9662</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>132</Volume>
<Issue>3-4</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Acta haematologica</Title>
<ISOAbbreviation>Acta Haematol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Nursing care for adolescents and young adults with cancer: literature review.</ArticleTitle>
<Pagination>
<MedlinePgn>363-74</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1159/000360213</ELocationID>
<Abstract>
<AbstractText>Cancer patients belonging to the adolescent and young adult (AYA) age group have unique and very specific needs, which require special attention from the caring staff. The difficulty in maintaining the personal and professional development at this age is both natural and normal. Adding to this, coping with a life-threatening disease turns this stage in life into a period with many dilemmas and challenges of quite a complex nature. AYA patients have to deal with issues above and beyond the disease itself, which create a very complex coping picture. On top of that, prognosis for this age group has not improved in recent years, unlike the situation in other age groups like children and adults. The literature on this subject is extensive and comprehensive. However, most of the papers on this subject are very specific and narrow in their approach, each dealing with a specific topic. In this article, we bring together many different papers which make a wide and comprehensive picture of the subject of AYAs coping with cancer, coupled with recommendations for the caring staff. In this review we focus on the various aspects of the disease and treatments in AYAs, based on the conceptual model of quality of life proposed by Ferrell and colleagues [Cancer Nurs 1992;15:153-160; Cancer Nurs 1992;15:247-253], including physical, social, emotional and spiritual aspects. From the psychological standpoint, most of the papers discuss the negative aspects; however, in this article we try to include some articles from the positive psychology school of thought. From our findings it is apparent that there is an opportunity and need to further explore research in this regard. It is apparent that taking a unique approach to AYA cancer patients is needed in order to deal with the unique needs of this age group. This article aims at putting a framework around this issue, with actionable recommendations for the caring staff.</AbstractText>
<CopyrightInformation>Â© 2014 S. Karger AG, Basel.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dreyer</LastName>
<ForeName>Juliet</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schwartz-Attias</LastName>
<ForeName>Irit</ForeName>
<Initials>I</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Switzerland</Country>
<MedlineTA>Acta Haematol</MedlineTA>
<NlmUniqueID>0141053</NlmUniqueID>
<ISSNLinking>0001-5792</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000223">Adaptation, Psychological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000367">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005195">Family Relations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000451">nursing</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012737">Sex Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012893">Sleep Disorders</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012944">Social Support</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25228565</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>17</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1421-9662</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>132</Volume>
<Issue>3-4</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Acta haematologica</Title>
<ISOAbbreviation>Acta Haematol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Cardiotoxicity and cardioprotection in childhood cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>391-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1159/000360238</ELocationID>
<Abstract>
<AbstractText>Children diagnosed with cancer are now living longer as a result of advances in treatment. However, some commonly used anticancer drugs, although effective in curing cancer, can also cause adverse late effects. The cardiotoxic effects of anthracycline chemotherapy, such as doxorubicin, and radiation can cause persistent and progressive cardiovascular damage, emphasizing a need for effective prevention and treatment to reduce or avoid cardiotoxicity. Examples of risk factors for cardiotoxicity in children include higher anthracycline cumulative dose, higher dose of radiation, younger age at diagnosis, female sex, trisomy 21 and black race. However, not all who are exposed to toxic treatments experience cardiotoxicity, suggesting the possibility of a genetic predisposition. Cardioprotective strategies under investigation include the use of dexrazoxane, which provides short- and long-term cardioprotection in children treated with doxorubicin without interfering with oncological efficacy, the use of less toxic anthracycline derivatives and nutritional supplements. Evidence-based monitoring and screening are needed to identify early signs of cardiotoxicity that have been validated as surrogates of subsequent clinically significant cardiovascular disease before the occurrence of cardiac damage, in patients who may be at higher risk.</AbstractText>
<CopyrightInformation>Â© 2014 S. Karger AG, Basel.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lipshultz</LastName>
<ForeName>Steven E</ForeName>
<Initials>SE</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, University of Miami Miller School of Medicine, Miami, Fla., USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sambatakos</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Maguire</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Karnik</LastName>
<ForeName>Ruchika</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ross</LastName>
<ForeName>Samuel W</ForeName>
<Initials>SW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Franco</LastName>
<ForeName>Vivian I</ForeName>
<Initials>VI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Miller</LastName>
<ForeName>Tracie L</ForeName>
<Initials>TL</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Switzerland</Country>
<MedlineTA>Acta Haematol</MedlineTA>
<NlmUniqueID>0141053</NlmUniqueID>
<ISSNLinking>0001-5792</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018943">Anthracyclines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002316">Cardiotonic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018943">Anthracyclines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002316">Cardiotonic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055317">Evidence-Based Practice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005720">Gamma Rays</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006331">Heart Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000532">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25060164</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>17</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>05</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1934-6638</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>122</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Cancer cytopathology</Title>
<ISOAbbreviation>Cancer Cytopathol</ISOAbbreviation>
</Journal>
<ArticleTitle>A minimum fluid volume of 75 mL is needed to ensure adequacy in a pleural effusion: a retrospective analysis of 2540 cases.</ArticleTitle>
<Pagination>
<MedlinePgn>657-65</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/cncy.21452</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">No consensus exists regarding minimum fluid volume for adequacy of benign pleural effusion specimens. Although any volume is acceptable if cytologic findings are malignant, the distinction between the absence of disease and false-negativity is not straightforward in low-volume specimens. Recent literature has offered conflicting results regarding what minimum volume is necessary. Moreover, no studies to date have evaluated this issue across a large series of specimens with a wide distribution of volumes. The objective of the current study was to determine the minimum volume of pleural fluid necessary for optimal cytopathological diagnosis.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">The authors identified 2540 pleural fluid specimens received between January 2000 and December 2009 and retrospectively reviewed their diagnoses and characteristics. Because of the large range of volumes (1 mL-6500 mL), the cases were binned into 9 groups of roughly equivalent sample sizes. The malignancy fractions (percentage of cases with malignant diagnoses) were compared for each group.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The current study specimens had a median volume of 200 mL and an overall malignancy fraction of 20.1%. The malignancy fraction increased from 10.1% (95% confidence interval, 8.1%-12.1%) for volumes &lt; 5 mL to 23.3% (95% confidence interval, 20.0%-25.8%) for volumes between 50 mL and 75 mL (P = .009). Specimens with volumes â¥ 75 mL had malignancy fractions independent of volume. In addition, ratios of benign or malignant diagnoses versus nondiagnostic and atypical results continued to increase with volume.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A fluid volume of â¥ 75 mL is required to eliminate the influence of specimen size on diagnostic adequacy. Although larger volumes do not appear to impact malignancy fraction, they do correlate with decreased nondiagnostic and atypical results.</AbstractText>
<CopyrightInformation>Â© 2014 American Cancer Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Rooper</LastName>
<ForeName>Lisa M</ForeName>
<Initials>LM</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ali</LastName>
<ForeName>Syed Z</ForeName>
<Initials>SZ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Olson</LastName>
<ForeName>Matthew T</ForeName>
<Initials>MT</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer Cytopathol</MedlineTA>
<NlmUniqueID>101499453</NlmUniqueID>
<ISSNLinking>1934-662X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001706">Biopsy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016066">Pleural Effusion, Malignant</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013048">Specimen Handling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">cytological techniques/methods</Keyword>
<Keyword MajorTopicYN="N">female</Keyword>
<Keyword MajorTopicYN="N">humans</Keyword>
<Keyword MajorTopicYN="N">male</Keyword>
<Keyword MajorTopicYN="N">malignant diagnosis</Keyword>
<Keyword MajorTopicYN="N">pathology</Keyword>
<Keyword MajorTopicYN="N">pleural effusion</Keyword>
<Keyword MajorTopicYN="N">pleural neoplasms</Keyword>
<Keyword MajorTopicYN="N">retrospective studies</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25230429</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>17</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2153-8387</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>20</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>DukeMedicine healthnews</Title>
<ISOAbbreviation>Duke Med Health News</ISOAbbreviation>
</Journal>
<ArticleTitle>Advances in immunotherapy. Using the body's own immune system to fight cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>6</MedlinePgn>
</Pagination>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Duke Med Health News</MedlineTA>
<NlmUniqueID>101510062</NlmUniqueID>
<ISSNLinking>2153-8387</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019496">Cancer Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>K</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000911">Antibodies, Monoclonal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019496">Cancer Vaccines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007167">Immunotherapy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25233530</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0440-8888</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>48</Volume>
<Issue>2</Issue>
<PubDate>
<MedlineDate>2014 Apr-Jun</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Histoire des sciences mÃ©dicales</Title>
<ISOAbbreviation>Hist Sci Med</ISOAbbreviation>
</Journal>
<ArticleTitle>[Aging in the Amazon rainforest: challenges and prospects].</ArticleTitle>
<Pagination>
<MedlinePgn>189-97</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ribeiror</LastName>
<ForeName>Euler Esteves</ForeName>
<Initials>EE</Initials>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType UI="D016456">Historical Article</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>Le vieillissement dans la forÃªt amazonienne: dÃ©fis et perspectives.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>France</Country>
<MedlineTA>Hist Sci Med</MedlineTA>
<NlmUniqueID>0225346</NlmUniqueID>
<ISSNLinking>0440-8888</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>QIS</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D000375">Aging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D001938">Brazil</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002318">Cardiovascular Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002908">Chronic Disease</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004787">Environmental Pollution</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005298">Fertility</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005853">Geriatrics</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049673">History, 20th Century</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049674">History, 21st Century</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007226">Infant Mortality</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007231">Infant, Newborn</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008017">Life Expectancy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011891">Rain</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012140">Respiratory Tract Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045483">Rivers</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014197">Trees</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24141774</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>38</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.</ArticleTitle>
<Pagination>
<MedlinePgn>4623-31</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2013.432</ELocationID>
<Abstract>
<AbstractText>Vaccines that promote protective adaptive immune responses have been successfully developed against a range of infectious diseases, and these are normally administered prior to exposure with the relevant virus or bacteria. Adaptive immunity also plays a critical role in the control of tumors. Immunotherapeutics and vaccines that promote effector T cell responses have the potential to eliminate tumors when used in a therapeutic setting. However, the induction of protective antitumor immunity is compromised by innate immunosuppressive mechanisms and regulatory cells that often dominate the tumor microenvironment. Recent studies have shown that blocking these suppressor cells and immune checkpoints to allow induction of antitumor immunity is a successful immunotherapeutic modality for the treatment of cancer. Furthermore, stimulation of innate and consequently adaptive immune responses with concomitant inhibition of immune suppression, especially that mediated by regulatory T (Treg) cells, is emerging as a promising approach to enhance the efficacy of therapeutic vaccines against cancer. This review describes the immunosuppressive mechanisms controlling antitumor immunity and the novel strategies being employed to design effective immunotherapeutics against tumors based on inhibition of suppressor cells or blockade of immune checkpoints to allow induction of more potent effector T cell responses. This review also discusses the potential of using a combination of adjuvants with inhibition of immune checkpoint or suppressor cells for therapeutic vaccines and the translation of pre-clinical studies to the next-generation vaccines against cancer in humans. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Butt</LastName>
<ForeName>A Q</ForeName>
<Initials>AQ</Initials>
<AffiliationInfo>
<Affiliation>Immune Regulation Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mills</LastName>
<ForeName>K H G</ForeName>
<Initials>KH</Initials>
<AffiliationInfo>
<Affiliation>Immune Regulation Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>10</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019496">Cancer Vaccines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051193">Toll-Like Receptors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000276">Adjuvants, Immunologic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019496">Cancer Vaccines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007165">Immunosuppression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007167">Immunotherapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050378">T-Lymphocytes, Regulatory</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051193">Toll-Like Receptors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24950257</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>19</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1744-7593</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>11</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Expert opinion on drug delivery</Title>
<ISOAbbreviation>Expert Opin Drug Deliv</ISOAbbreviation>
</Journal>
<ArticleTitle>Cytotoxic enhancement of hexapeptide-conjugated micelles in EGFR high-expressed cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>1537-50</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1517/17425247.2014.930433</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to develop the hexapeptide-conjugated active targeting micelles for delivery of doxorubicin (DOX) and paclitaxel (PTX) to EGFR high-expressed cancer cells.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">A hexapeptide, which mimicked the EGFR, was applied as a targeting ligand. The active targeting micelles were prepared using the synthesized poly(D,L-lactide-co-glycolide)-PEG copolymer conjugated with the hexapeptide. The micelles were used for encapsulating DOX and/or PTX, and the cellular uptake, in vitro drug release and cellular viability of drug-loaded peptide-conjugated and peptide-free micelles were investigated.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The particle size of drug-loaded peptide-conjugated and peptide-free micelles was &lt; 150 nm with narrow size distribution. The uptake of peptide-conjugated micelles was more efficient in EGFR high-expressed MDA-MB-468 and SKOV3 cells than in EGFR low-expressed HepG2 cells. The in vitro release of DOX and PTX was faster in pH 4.0 (500 U lipase) than in pH 7.4 release medium. The cytotoxicity in terms of IC50 of DOX/PTX-loaded peptide-conjugated micelles was 4.8-folds lower than that of peptide-free micelles and 18.2-folds lower than DOX/PTX drug solution in SOKV3 cells.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The peptide-conjugated micelles acted as a nanocarrier to increase intracellular accumulation of anticancer drugs in EGFR high-expressed SKOV3 cancer cells to enhance cell cytotoxicity.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Wen Jen</ForeName>
<Initials>WJ</Initials>
<AffiliationInfo>
<Affiliation>National Taiwan University, Graduate Institute of Pharmaceutical Sciences, School of Pharmacy , No. 33 Lin San S. Rd, Taipei 100 , Taiwan +886 2 33668765 ; +886 2 23916126 ; wjlin@ntu.edu.tw.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kao</LastName>
<ForeName>Li Ting</ForeName>
<Initials>LT</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Expert Opin Drug Deliv</MedlineTA>
<NlmUniqueID>101228421</NlmUniqueID>
<ISSNLinking>1742-5247</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000903">Antibiotics, Antineoplastic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008823">Micelles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C043435">polylactic acid-polyglycolic acid copolymer</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>26009-03-0</RegistryNumber>
<NameOfSubstance UI="D011100">Polyglycolic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>33069-62-4</RegistryNumber>
<NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>33X04XA5AT</RegistryNumber>
<NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>80168379AG</RegistryNumber>
<NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000903">Antibiotics, Antineoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000972">Antineoplastic Agents, Phytogenic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D004337">Drug Carriers</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019344">Lactic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008823">Micelles</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017239">Paclitaxel</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010316">Particle Size</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011100">Polyglycolic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011958">Receptor, Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">EGFR</Keyword>
<Keyword MajorTopicYN="N">doxorubicin</Keyword>
<Keyword MajorTopicYN="N">hexapeptide</Keyword>
<Keyword MajorTopicYN="N">micelles</Keyword>
<Keyword MajorTopicYN="N">paclitaxel</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24950343</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>19</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1744-7593</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>11</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Expert opinion on drug delivery</Title>
<ISOAbbreviation>Expert Opin Drug Deliv</ISOAbbreviation>
</Journal>
<ArticleTitle>Extracellularly activatable nanocarriers for drug delivery to tumors.</ArticleTitle>
<Pagination>
<MedlinePgn>1601-18</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1517/17425247.2014.930434</ELocationID>
<Abstract>
<AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Nanoparticles (NPs) for drug delivery to tumors need to satisfy two seemingly conflicting requirements: they should maintain physical and chemical stability during circulation and be able to interact with target cells and release the drug at desired locations with no substantial delay. The unique microenvironment of tumors and externally applied stimuli provide a useful means to maintain a balance between the two requirements.</AbstractText>
<AbstractText Label="AREAS COVERED" NlmCategory="METHODS">We discuss nanoparticulate drug carriers that maintain stable structures in normal conditions but respond to stimuli for the spatiotemporal control of drug delivery. We first define the desired effects of extracellular activation of NPs and frequently used stimuli and then review the examples of extracellularly activated NPs.</AbstractText>
<AbstractText Label="EXPERT OPINION" NlmCategory="CONCLUSIONS">Several challenges remain in developing extracellularly activatable NPs. First, some of the stimuli-responsive NPs undergo incremental changes in response to stimuli, losing circulation stability. Second, the applicability of stimuli in clinical settings is limited due to the occasional occurrence of the activating conditions in normal tissues. Third, the construction of stimuli-responsive NPs involves increasing complexity in NP structure and production methods. Future efforts are needed to identify new targeting conditions and increase the contrast between activated and nonactivated NPs while keeping the production methods simple and scalable.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Abouelmagd</LastName>
<ForeName>Sara A</ForeName>
<Initials>SA</Initials>
<AffiliationInfo>
<Affiliation>Purdue University, Department of Industrial and Physical Pharmacy , 575 Stadium Mall Drive, West Lafayette, IN 47907 , USA +1 765 496 9608 ; +1 765 494 6545 ; yyeo@purdue.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hyun</LastName>
<ForeName>Hyesun</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yeo</LastName>
<ForeName>Yoon</ForeName>
<Initials>Y</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01EB017791</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Expert Opin Drug Deliv</MedlineTA>
<NlmUniqueID>101228421</NlmUniqueID>
<ISSNLinking>1742-5247</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004337">Drug Carriers</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016503">Drug Delivery Systems</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053758">Nanoparticles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">drug delivery</Keyword>
<Keyword MajorTopicYN="N">extracellular activation</Keyword>
<Keyword MajorTopicYN="N">nanocarriers</Keyword>
<Keyword MajorTopicYN="N">nanoparticles</Keyword>
<Keyword MajorTopicYN="N">stimuli-responsive</Keyword>
<Keyword MajorTopicYN="N">tumor microenvironment</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25234529</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>19</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1531-5053</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>72</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons</Title>
<ISOAbbreviation>J. Oral Maxillofac. Surg.</ISOAbbreviation>
</Journal>
<ArticleTitle>American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.</ArticleTitle>
<Pagination>
<MedlinePgn>1938-56</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.joms.2014.04.031</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0278-2391(14)00463-7</ELocationID>
<Abstract>
<AbstractText>Strategies for management of patients with, or at risk for, medication-related osteonecrosis of the jaw (MRONJ) were set forth in the American Association of Oral and Maxillofacial Surgeons (AAOMS) position papers in 2007 and 2009. The position papers were developed by a special committee appointed by the board and composed of clinicians with extensive experience in caring for these patients and basic science researchers. The knowledge base and experience in addressing MRONJ has expanded, necessitating modifications and refinements to the previous position paper. This special committee met in September 2013 to appraise the current literature and revise the guidelines as indicated to reflect current knowledge in this field. This update contains revisions to diagnosis, staging, and management strategies and highlights current research status. The AAOMS considers it vitally important that this information be disseminated to other relevant health care professionals and organizations. </AbstractText>
<CopyrightInformation>Copyright Â© 2014 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ruggiero</LastName>
<ForeName>Salvatore L</ForeName>
<Initials>SL</Initials>
<AffiliationInfo>
<Affiliation>Clinical Professor, Division of Oral and Maxillofacial Surgery, Stony Brook School of Dental Medicine, Hofstra North Shore-LIJ School of Medicine, New York Center for Orthognathic and Maxillofacial Surgery, Lake Success, NY. Electronic address: sruggie@optonline.net.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dodson</LastName>
<ForeName>Thomas B</ForeName>
<Initials>TB</Initials>
<AffiliationInfo>
<Affiliation>Professor and Chair, Associate Dean for Hospital Affairs, Department of Oral and Maxillofacial Surgery, University of Washington School of Dentistry, Seattle, WA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fantasia</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Chief, Division of Oral Pathology, Department of Dental Medicine, Hofstra North Shore-LIJ School of Medicine , New Hyde Park, NY.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Goodday</LastName>
<ForeName>Reginald</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Professor, Department of Oral and Maxillofacial Sciences, Dalhousie University, Halifax, NS, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Aghaloo</LastName>
<ForeName>Tara</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Associate Professor, Oral and Maxillofacial Surgery, Assistant Dean for Clinical Research, UCLA School of Dentistry, Los Angeles, CA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mehrotra</LastName>
<ForeName>Bhoomi</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Director, Cancer Institute at St Francis Hospital, Roslyn, NY.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>O'Ryan</LastName>
<ForeName>Felice</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Director, Division of Maxillofacial Surgery, Kaiser Permanente Oakland Medical Center, Oakland, CA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<CollectiveName>American Association of Oral and Maxillofacial Surgeons</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D017065">Practice Guideline</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Oral Maxillofac Surg</MedlineTA>
<NlmUniqueID>8206428</NlmUniqueID>
<ISSNLinking>0278-2391</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050071">Bone Density Conservation Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>D</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020533">Angiogenesis Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059266">Bisphosphonate-Associated Osteonecrosis of the Jaw</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050071">Bone Density Conservation Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016723">Bone Remodeling</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001862">Bone Resorption</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007571">Jaw Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018919">Neovascularization, Physiologic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019647">Oral Surgical Procedures</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010020">Osteonecrosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010024">Osteoporosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010347">Patient Care Planning</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018570">Risk Assessment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009626">Terminology as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25240083</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1938-3207</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>100</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>The American journal of clinical nutrition</Title>
<ISOAbbreviation>Am. J. Clin. Nutr.</ISOAbbreviation>
</Journal>
<ArticleTitle>Additional analyses in a study on the obesity paradox.</ArticleTitle>
<Pagination>
<MedlinePgn>1208</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3945/ajcn.114.092742</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Winkels</LastName>
<ForeName>Renate M</ForeName>
<Initials>RM</Initials>
<AffiliationInfo>
<Affiliation>Division of Human Nutrition, Wageningen University, PO Box 8129, 6700 EV Wageningen, Netherlands, E-mail: renate.winkels@wur.nl.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gomora</LastName>
<ForeName>Zephenia</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Division of Human Nutrition, Wageningen University, PO Box 8129, 6700 EV Wageningen, Netherlands, E-mail: renate.winkels@wur.nl.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>van Zutphen</LastName>
<ForeName>Moniek</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Division of Human Nutrition, Wageningen University, PO Box 8129, 6700 EV Wageningen, Netherlands, E-mail: renate.winkels@wur.nl.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kampman</LastName>
<ForeName>Ellen</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Division of Human Nutrition, Wageningen University, PO Box 8129, 6700 EV Wageningen, Netherlands, E-mail: renate.winkels@wur.nl.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016420">Comment</PublicationType>
<PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Clin Nutr</MedlineTA>
<NlmUniqueID>0376027</NlmUniqueID>
<ISSNLinking>0002-9165</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Am J Clin Nutr. 2014 Oct;100(4):1208-9</RefSource>
<PMID Version="1">25240084</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentOn">
<RefSource>Am J Clin Nutr. 2014 May;99(5):999-1005</RefSource>
<PMID Version="1">24572565</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001823">Body Composition</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009765">Obesity</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055948">Sarcopenia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25240084</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1938-3207</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>100</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>The American journal of clinical nutrition</Title>
<ISOAbbreviation>Am. J. Clin. Nutr.</ISOAbbreviation>
</Journal>
<ArticleTitle>Reply to RM Winkels et al.</ArticleTitle>
<Pagination>
<MedlinePgn>1208-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3945/ajcn.114.093054</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gonzalez</LastName>
<ForeName>Maria Cristina</ForeName>
<Initials>MC</Initials>
<AffiliationInfo>
<Affiliation>Postgraduate Program of Health and Behavior, Catholic University of Pelotas, Rua Vereador Ariano RequiÃ£o de Carvalho, 301, Pelotas - Rio Grande do Sul CEP 96055-800, Brazil, E-mail: cristinagbs@hotmal.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pastore</LastName>
<ForeName>Carla A</ForeName>
<Initials>CA</Initials>
<AffiliationInfo>
<Affiliation>Nutrition College of Nutrition, Federal University of Pelotas Rio Grande do Sul, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Orlandi</LastName>
<ForeName>Silvana P</ForeName>
<Initials>SP</Initials>
<AffiliationInfo>
<Affiliation>Nutrition College of Nutrition, Federal University of Pelotas Rio Grande do Sul, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Heymsfield</LastName>
<ForeName>Steven B</ForeName>
<Initials>SB</Initials>
<AffiliationInfo>
<Affiliation>Pennington Biomedical Research Center, Baton Rouge, LA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016420">Comment</PublicationType>
<PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Clin Nutr</MedlineTA>
<NlmUniqueID>0376027</NlmUniqueID>
<ISSNLinking>0002-9165</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentOn">
<RefSource>Am J Clin Nutr. 2014 Oct;100(4):1208</RefSource>
<PMID Version="1">25240083</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentOn">
<RefSource>Am J Clin Nutr. 2014 May;99(5):999-1005</RefSource>
<PMID Version="1">24572565</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001823">Body Composition</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009765">Obesity</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055948">Sarcopenia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25238089</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1097-4180</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>41</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Immunity</Title>
<ISOAbbreviation>Immunity</ISOAbbreviation>
</Journal>
<ArticleTitle>Targeting foxp1 for reinstating anticancer immunosurveillance.</ArticleTitle>
<Pagination>
<MedlinePgn>345-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.immuni.2014.09.001</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1074-7613(14)00311-2</ELocationID>
<Abstract>
<AbstractText>Transforming growth factor Î² (TGF-Î²) is a canonical immunosuppressive cytokine secreted by tumors. In this issue of Immunity, Stephen etÂ al. (2014) reveal that tumor-derived TGF-Î² deactivates antitumor CD8(+) TÂ cell responses through TÂ cell upregulation of the FoxP1 transcription factor. </AbstractText>
<CopyrightInformation>Copyright Â© 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zitvogel</LastName>
<ForeName>Laurence</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Gustave Roussy Cancer Campus, Villejuif, France; INSERM U1015, Villejuif, France; UniversitÃ© Paris Sud-XI, FacultÃ© de MÃ©decine, Le Kremlin BicÃªtre, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France. Electronic address: laurence.zitvogel@gustaveroussy.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kroemer</LastName>
<ForeName>Guido</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Gustave Roussy Cancer Campus, Villejuif, France; UniversitÃ© Paris Descartes, Sorbonne Paris CitÃ©, Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France; Equipe 11 labellisÃ©e Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U 1138, Paris, France; PÃ´le de Biologie, HÃ´pital EuropÃ©en Georges Pompidou, AP-HP, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016420">Comment</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Immunity</MedlineTA>
<NlmUniqueID>9432918</NlmUniqueID>
<ISSNLinking>1074-7613</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051858">Forkhead Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C432917">Foxp1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentOn">
<RefSource>Immunity. 2014 Sep 18;41(3):427-39</RefSource>
<PMID Version="1">25238097</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051858">Forkhead Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012097">Repressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013602">T-Lymphocytes, Cytotoxic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016212">Transforming Growth Factor beta</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019139">Tumor Escape</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25238096</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1097-4180</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>41</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Immunity</Title>
<ISOAbbreviation>Immunity</ISOAbbreviation>
</Journal>
<ArticleTitle>The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors.</ArticleTitle>
<Pagination>
<MedlinePgn>389-401</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.immuni.2014.08.015</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1074-7613(14)00309-4</ELocationID>
<Abstract>
<AbstractText>Adaptation of malignant cells to the hostile milieu present in tumors is an important determinant of their survival and growth. However, the interaction between tumor-linked stress and antitumor immunity remains poorly characterized. Here, we show the critical role of the cellular stress sensor C/EBP-homologous protein (Chop) in the accumulation and immune inhibitory activity of tumor-infiltrating myeloid-derived suppressor cells (MDSCs). MDSCs lacking Chop had decreased immune-regulatory functions and showed the ability to prime TÂ cell function and induce antitumor responses. Chop expression in MDSCs was induced by tumor-linked reactive oxygen and nitrogen species and regulated by the activating-transcription factor-4. Chop-deficient MDSCs displayed reduced signaling through CCAAT/enhancer-binding protein-Î², leading to a decreased production of interleukin-6 (IL-6) and low expression of phospho-STAT3. IL-6 overexpression restored immune-suppressive activity of Chop-deficient MDSCs. These findings suggest the role of Chop in tumor-induced tolerance and the therapeutic potential of targeting Chop in MDSCs for cancer immunotherapy. </AbstractText>
<CopyrightInformation>Copyright Â© 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Thevenot</LastName>
<ForeName>Paul T</ForeName>
<Initials>PT</Initials>
<AffiliationInfo>
<Affiliation>Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sierra</LastName>
<ForeName>Rosa A</ForeName>
<Initials>RA</Initials>
<AffiliationInfo>
<Affiliation>Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Raber</LastName>
<ForeName>Patrick L</ForeName>
<Initials>PL</Initials>
<AffiliationInfo>
<Affiliation>Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA; Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Al-Khami</LastName>
<ForeName>Amir A</ForeName>
<Initials>AA</Initials>
<AffiliationInfo>
<Affiliation>Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Trillo-Tinoco</LastName>
<ForeName>Jimena</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zarreii</LastName>
<ForeName>Parisa</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ochoa</LastName>
<ForeName>Augusto C</ForeName>
<Initials>AC</Initials>
<AffiliationInfo>
<Affiliation>Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA; Department of Pediatrics, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cui</LastName>
<ForeName>Yan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA; Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Del Valle</LastName>
<ForeName>Luis</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rodriguez</LastName>
<ForeName>Paulo C</ForeName>
<Initials>PC</Initials>
<AffiliationInfo>
<Affiliation>Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA; Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA. Electronic address: prodri1@lsuhsc.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P20 RR021970</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P20GM103501</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P20GM103518</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21 CA162133</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21CA162133</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Immunity</MedlineTA>
<NlmUniqueID>9432918</NlmUniqueID>
<ISSNLinking>1074-7613</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C081452">Atf4 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D022782">CCAAT-Enhancer-Binding Protein-beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497250">Ddit3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D026361">Reactive Nitrogen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494087">Stat3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>145891-90-3</RegistryNumber>
<NameOfSubstance UI="D051701">Activating Transcription Factor 4</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>147336-12-7</RegistryNumber>
<NameOfSubstance UI="D051742">Transcription Factor CHOP</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Immunity. 2014 Sep 18;41(3):341-2</RefSource>
<PMID Version="1">25238087</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051701">Activating Transcription Factor 4</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001854">Bone Marrow Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016026">Bone Marrow Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D022782">CCAAT-Enhancer-Binding Protein-beta</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042783">Endothelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015850">Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D022423">Myeloid Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009389">Neovascularization, Pathologic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D026361">Reactive Nitrogen Species</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013601">T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051742">Transcription Factor CHOP</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019139">Tumor Escape</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS625838 [Available on 09/18/15]</OtherID>
<OtherID Source="NLM">PMC4171711 [Available on 09/18/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25238097</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1097-4180</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>41</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Immunity</Title>
<ISOAbbreviation>Immunity</ISOAbbreviation>
</Journal>
<ArticleTitle>Transforming growth factor Î²-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression.</ArticleTitle>
<Pagination>
<MedlinePgn>427-39</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.immuni.2014.08.012</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1074-7613(14)00306-9</ELocationID>
<Abstract>
<AbstractText>Tumor-reactive T cells become unresponsive in advanced tumors. Here we have characterized a common mechanism of T cell unresponsiveness in cancer driven by the upregulation of the transcription factor Forkhead box protein P1 (Foxp1), which prevents CD8âº T cells from proliferating and upregulating Granzyme-B and interferon-Î³ in response to tumor antigens. Accordingly, Foxp1-deficient lymphocytes induced rejection of incurable tumors and promoted protection against tumor rechallenge. Mechanistically, Foxp1 interacted with the transcription factors Smad2 and Smad3 in preactivated CD8âº T cells in response to microenvironmental transforming growth factor-Î² (TGF-Î²), and was essential for its suppressive activity. Therefore, Smad2 and Smad3-mediated c-Myc repression requires Foxp1 expression in T cells. Furthermore, Foxp1 directly mediated TGF-Î²-induced c-Jun transcriptional repression, which abrogated T cell activity. Our results unveil a fundamental mechanism of T cell unresponsiveness different from anergy or exhaustion, driven by TGF-Î² signaling on tumor-associated lymphocytes undergoing Foxp1-dependent transcriptional regulation.</AbstractText>
<CopyrightInformation>Copyright Â© 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Stephen</LastName>
<ForeName>Tom L</ForeName>
<Initials>TL</Initials>
<AffiliationInfo>
<Affiliation>Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rutkowski</LastName>
<ForeName>Melanie R</ForeName>
<Initials>MR</Initials>
<AffiliationInfo>
<Affiliation>Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Allegrezza</LastName>
<ForeName>Michael J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Perales-Puchalt</LastName>
<ForeName>Alfredo</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tesone</LastName>
<ForeName>Amelia J</ForeName>
<Initials>AJ</Initials>
<AffiliationInfo>
<Affiliation>Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Svoronos</LastName>
<ForeName>Nikolaos</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nguyen</LastName>
<ForeName>Jenny M</ForeName>
<Initials>JM</Initials>
<AffiliationInfo>
<Affiliation>Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sarmin</LastName>
<ForeName>Fahmida</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Borowsky</LastName>
<ForeName>Mark E</ForeName>
<Initials>ME</Initials>
<AffiliationInfo>
<Affiliation>Helen F. Graham Cancer Center, Christiana Care Health System, 4701 Ogletown-Stanton Road, Newark, DE 19713, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tchou</LastName>
<ForeName>Julia</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrine and Oncologic Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, PA 19104-1693, USA; Rena Rowan Breast Center, University of Pennsylvania, Philadelphia, PA 19104-1693, USA; Abramson Cancer Center Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-1693, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Conejo-Garcia</LastName>
<ForeName>Jose R</ForeName>
<Initials>JR</Initials>
<AffiliationInfo>
<Affiliation>Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA. Electronic address: jrconejo@wistar.org.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA010815</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 CA010815</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA124515</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA157664</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA178687</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA124515</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA157664</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32CA009171</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U54 CA151662</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Immunity</MedlineTA>
<NlmUniqueID>9432918</NlmUniqueID>
<ISSNLinking>1074-7613</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051858">Forkhead Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C432917">Foxp1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C489428">Myc protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016271">Proto-Oncogene Proteins c-myc</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051899">Smad2 Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497783">Smad2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051900">Smad3 Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497791">Smad3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>82115-62-6</RegistryNumber>
<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048031">JNK Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.21.-</RegistryNumber>
<NameOfSubstance UI="D053804">Granzymes</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Immunity. 2014 Sep 18;41(3):345-7</RefSource>
<PMID Version="1">25238089</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019264">Adoptive Transfer</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000951">Antigens, Neoplasm</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015496">CD4-Positive T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051858">Forkhead Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053804">Granzymes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007371">Interferon-gamma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048031">JNK Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008213">Lymphocyte Activation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016271">Proto-Oncogene Proteins c-myc</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012097">Repressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051899">Smad2 Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051900">Smad3 Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013602">T-Lymphocytes, Cytotoxic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000637">transplantation</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014158">Transcription, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015533">Transcriptional Activation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016212">Transforming Growth Factor beta</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019139">Tumor Escape</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059016">Tumor Microenvironment</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS626648 [Available on 09/18/15]</OtherID>
<OtherID Source="NLM">PMC4174366 [Available on 09/18/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25241482</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1542-3050</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>68</Volume>
<Issue>1-2</Issue>
<PubDate>
<MedlineDate>2014 Mar-Jun</MedlineDate>
</PubDate>
</JournalIssue>
<Title>The journal of pastoral care &amp; counseling : JPCC</Title>
<ISOAbbreviation>J Pastoral Care Counsel</ISOAbbreviation>
</Journal>
<ArticleTitle>In the shadow of death: existential and spiritual concerns among persons receiving palliative care.</ArticleTitle>
<Pagination>
<MedlinePgn>4</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>This study explores existential and spiritual concerns from the perspective of people receiving palliative care. It examines the meaning of these concerns, their influence on people's lives and investigates the connections between them. In-depth qualitative interviews were conducted with ten persons. Findings reveal existential and spiritual aspects as interconnected and an integral part of the participants' everyday existence. It concludes with a call for a better understanding of these phenomena in the palliative care context.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Asgeirsdottir</LastName>
<ForeName>Gudlaug Helga</ForeName>
<Initials>GH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>SigurbjÃ¶rnsson</LastName>
<ForeName>Einar</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Traustadottir</LastName>
<ForeName>Rannveig</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sigurdardottir</LastName>
<ForeName>Valgerdur</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gunnarsdottir</LastName>
<ForeName>Sigridur</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kelly</LastName>
<ForeName>Ewan</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Pastoral Care Counsel</MedlineTA>
<NlmUniqueID>101144384</NlmUniqueID>
<ISSNLinking>1542-3050</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>H</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000223">Adaptation, Psychological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000739">Anecdotes as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D001293">Attitude to Death</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007055">Iceland</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007406">Interview, Psychological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010166">Palliative Care</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010342">Patient Acceptance of Health Care</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D012069">Religion and Psychology</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D029181">Spirituality</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25241488</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1542-3050</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>68</Volume>
<Issue>1-2</Issue>
<PubDate>
<MedlineDate>2014 Mar-Jun</MedlineDate>
</PubDate>
</JournalIssue>
<Title>The journal of pastoral care &amp; counseling : JPCC</Title>
<ISOAbbreviation>J Pastoral Care Counsel</ISOAbbreviation>
</Journal>
<ArticleTitle>Increasingly, the skills pastoral and spiritual care providers bring to clinical settings.</ArticleTitle>
<Pagination>
<MedlinePgn>1</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bard</LastName>
<ForeName>Terry R</ForeName>
<Initials>TR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016421">Editorial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Pastoral Care Counsel</MedlineTA>
<NlmUniqueID>101144384</NlmUniqueID>
<ISSNLinking>1542-3050</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>H</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002604">Chaplaincy Service, Hospital</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000451">nursing</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010327">Pastoral Care</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D011368">Professional-Family Relations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D012068">Religion and Medicine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D029181">Spirituality</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24798107</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-0142</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>120</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer</Title>
<ISOAbbreviation>Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Recommendations for the implementation of distress screening programs in cancer centers: report from the American Psychosocial Oncology Society (APOS), Association of Oncology Social Work (AOSW), and Oncology Nursing Society (ONS) joint task force.</ArticleTitle>
<Pagination>
<MedlinePgn>2946-54</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.28750</ELocationID>
<Abstract>
<AbstractText>In 2015, the American College of Surgeons (ACoS) Commission on Cancer will require cancer centers to implement screening programs for psychosocial distress as a new criterion for accreditation. A joint task force from the American Psychosocial Oncology Society, the Association of Oncology Social Work, and the Oncology Nursing Society developed consensus-based recommendations to guide the implementation of this requirement. In this review, the authors provide recommendations regarding each of the 6 components necessary to meet the ACoS standard: 1) inclusion of psychosocial representation on the cancer committee, 2) timing of screening, 3) method/mode of screening, 4) tools for screening, 5) assessment and referral, and 6) documentation.</AbstractText>
<CopyrightInformation>Â© 2014 American Cancer Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pirl</LastName>
<ForeName>William F</ForeName>
<Initials>WF</Initials>
<AffiliationInfo>
<Affiliation>Center for Psychiatric Oncology and Behavioral Sciences at Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fann</LastName>
<ForeName>Jesse R</ForeName>
<Initials>JR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Greer</LastName>
<ForeName>Joseph A</ForeName>
<Initials>JA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Braun</LastName>
<ForeName>Ilana</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Deshields</LastName>
<ForeName>Teresa</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fulcher</LastName>
<ForeName>Caryl</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Harvey</LastName>
<ForeName>Elizabeth</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Holland</LastName>
<ForeName>Jimmie</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kennedy</LastName>
<ForeName>Vicki</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lazenby</LastName>
<ForeName>Mark</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wagner</LastName>
<ForeName>Lynne</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Underhill</LastName>
<ForeName>Meghan</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Walker</LastName>
<ForeName>Deborah K</ForeName>
<Initials>DK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zabora</LastName>
<ForeName>James</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zebrack</LastName>
<ForeName>Bradley</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bardwell</LastName>
<ForeName>Wayne A</ForeName>
<Initials>WA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer</MedlineTA>
<NlmUniqueID>0374236</NlmUniqueID>
<ISSNLinking>0008-543X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001007">Anxiety</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003863">Depression</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008403">Mass Screening</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000458">organization &amp; administration</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000592">standards</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000639">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008499">Medical Records</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000592">standards</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016730">Program Development</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011594">Psychometrics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011795">Questionnaires</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012017">Referral and Consultation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013001">Somatoform Disorders</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013315">Stress, Psychological</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">cancer</Keyword>
<Keyword MajorTopicYN="N">distress screening</Keyword>
<Keyword MajorTopicYN="N">implementation</Keyword>
<Keyword MajorTopicYN="N">neoplasms</Keyword>
<Keyword MajorTopicYN="N">programs</Keyword>
<Keyword MajorTopicYN="N">psychosocial</Keyword>
<Keyword MajorTopicYN="N">psychosocial aspects</Keyword>
<Keyword MajorTopicYN="N">recommendations</Keyword>
<Keyword MajorTopicYN="N">screening</Keyword>
<Keyword MajorTopicYN="N">standards</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24889136</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-0142</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>120</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer</Title>
<ISOAbbreviation>Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>The Children's Oncology Group Childhood Cancer Research Network (CCRN): case catchment in the United States.</ArticleTitle>
<Pagination>
<MedlinePgn>3007-15</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.28813</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Childhood Cancer Research Network (CCRN) was established within the Children's Oncology Group (COG) in July 2008 to provide a centralized pediatric cancer research registry for investigators conducting approved etiologic and survivorship studies. The authors conducted an ecological analysis to characterize CCRN catchment at &gt;200 COG institutions by demographic characteristics, diagnosis, and geographic location to determine whether the CCRN can serve as a population-based registry for childhood cancer.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">During 2009 to 2011, 18,580 US children newly diagnosed with cancer were registered in the CCRN. These observed cases were compared with age-specific, sex-specific, and race/ethnicity-specific expected numbers calculated from Surveillance, Epidemiology, and End Results (SEER) Program cancer incidence rates and 2010 US Census data.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 42% of children (18,580 observed/44,267 expected) who were diagnosed with cancer at age &lt;20 years were registered in the CCRN, including 45%, 57%, 51%, 44%, and 24% of those diagnosed at birth, ages 1 to 4 years, ages 5 to 9 years, ages 10 to 14 years, and ages 15 to 19 years, respectively. Some malignancies were better represented in the CCRN (leukemia, 59%; renal tumors, 67%) than others (retinoblastoma, 34%). There was little evidence of differences by sex or race/ethnicity, although rates in nonwhites were somewhat lower than rates in whites.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Given the low observed-to-expected ratio, it will be important to identify challenges and barriers to registration to improve case ascertainment, especially for rarer diagnoses and older age groups; however, it is encouraging that some diagnoses in younger children are fairly representative of the population. Overall, the CCRN is providing centralized, real-time access to cases for research and could be used as a model for other national cooperative groups.</AbstractText>
<CopyrightInformation>Â© 2014 American Cancer Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Musselman</LastName>
<ForeName>Jessica R B</ForeName>
<Initials>JR</Initials>
<AffiliationInfo>
<Affiliation>Division of Epidemiology and Clinical Research, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Spector</LastName>
<ForeName>Logan G</ForeName>
<Initials>LG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Krailo</LastName>
<ForeName>Mark D</ForeName>
<Initials>MD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Reaman</LastName>
<ForeName>Gregory H</ForeName>
<Initials>GH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Linabery</LastName>
<ForeName>Amy M</ForeName>
<Initials>AM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Poynter</LastName>
<ForeName>Jenny N</ForeName>
<Initials>JN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stork</LastName>
<ForeName>Susan K</ForeName>
<Initials>SK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Adamson</LastName>
<ForeName>Peter C</ForeName>
<Initials>PC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ross</LastName>
<ForeName>Julie A</ForeName>
<Initials>JA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>K05 CA157439</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>K05 CA157439</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 CA099936</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 CA099936</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA098543</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA98543</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer</MedlineTA>
<NlmUniqueID>0374236</NlmUniqueID>
<ISSNLinking>0008-543X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005006">Ethnic Groups</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015994">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000208">ethnology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D012042">Registries</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018426">SEER Program</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015996">Survival Rate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">United States</Keyword>
<Keyword MajorTopicYN="N">catchment</Keyword>
<Keyword MajorTopicYN="N">childhood cancer</Keyword>
<Keyword MajorTopicYN="N">clinical trials</Keyword>
<Keyword MajorTopicYN="N">incidence</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24917509</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-0142</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>120</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer</Title>
<ISOAbbreviation>Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Comorbidities predict worse prognosis in patients with primary myelofibrosis.</ArticleTitle>
<Pagination>
<MedlinePgn>2996-3002</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.28857</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Comorbidities have been shown to play an important role in the prognostic assessment of several hematologic conditions; however, the role of comorbidities in primary myelofibrosis has not been studied. The objective of the current study was to evaluate the prevalence and impact of comorbidities in patients with primary myelofibrosis (PMF) using the Adult Comorbidity Evaluation-27 (ACE-27).</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">In this retrospective observational cohort study, a total of 349 consecutive patients with a confirmed diagnosis of PMF who presented to the study institution from 2000 to 2008 were evaluated. The authors evaluated the frequency and severity of comorbidities in these patients and assessed their impact on survival in a bivariable model that included the ACE-27 and Dynamic International Prognostic Scoring System scores as covariates.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Approximately 64% of patients had at least 1 comorbid condition, and diseases of the cardiovascular system (63%) were most common. Comorbidities had a significant negative impact on survival (P &lt;â.001). Patients with severe comorbidities had twice the risk of death as those with no comorbidities. When stratified by demographic and clinical characteristics, comorbidities were found to be significantly associated with worse survival in patients agedâ&lt; 65 years (P &lt;â.001) and those with an ECOG performance statusâ&lt;â1 (Pâ&lt;â.001). In a multivariable model that included the ACE-27 and Dynamic International Prognostic Scoring System scores, comorbidities retained a significant association with shorter survival (P â¤â.001).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The assessment of comorbid conditions in patients with PMF, particularly those who are younger and with a good performance status, has important implications for overall prognosis and treatment planning.</AbstractText>
<CopyrightInformation>Â© 2014 American Cancer Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Newberry</LastName>
<ForeName>Kate J</ForeName>
<Initials>KJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Naqvi</LastName>
<ForeName>Kiran</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nguyen</LastName>
<ForeName>Khanh T</ForeName>
<Initials>KT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cardenas-Turanzas</LastName>
<ForeName>Marylou</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Florencia Tanaka</LastName>
<ForeName>Maria</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pierce</LastName>
<ForeName>Sherry</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Verstovsek</LastName>
<ForeName>Srdan</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P30 CA016672</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D064888">Observational Study</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer</MedlineTA>
<NlmUniqueID>0374236</NlmUniqueID>
<ISSNLinking>0008-543X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002318">Cardiovascular Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015897">Comorbidity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004700">Endocrine System Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015994">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016017">Odds Ratio</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011237">Predictive Value of Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015995">Prevalence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055728">Primary Myelofibrosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016016">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018570">Risk Assessment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Adult Comorbidity Evaluation-27 score</Keyword>
<Keyword MajorTopicYN="N">Dynamic International Prognostic Scoring System score</Keyword>
<Keyword MajorTopicYN="N">comorbidity</Keyword>
<Keyword MajorTopicYN="N">primary myelofibrosis</Keyword>
<Keyword MajorTopicYN="N">prognosis</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24962202</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-0142</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>120</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer</Title>
<ISOAbbreviation>Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Genomic testing in cancer: patient knowledge, attitudes, and expectations.</ArticleTitle>
<Pagination>
<MedlinePgn>3066-73</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.28807</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Genomic testing in cancer (GTC) characterizes genes that play an important role in the development and growth of a patient's cancer. This form of DNA testing is currently being studied for its ability to guide cancer therapy. The objective of the current study was to describe patients' knowledge, attitudes, and expectations toward GTC.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">A 42-item self-administered GTC questionnaire was developed by a multidisciplinary group and patient pretesting. The questionnaire was distributed to patients with advanced cancer who were referred to the Princess Margaret Cancer Center for a phase 1 clinical trial or GTC testing.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Results were reported from 98 patients with advanced cancer, representing 66% of the patients surveyed. Seventy-six percent of patients were interested in learning more about GTC, and 64% reported that GTC would significantly improve their cancer care. The median score on a 12-item questionnaire to assess knowledge of cancer genomics was 8 of 12 items correct (67%; interquartile range, 7-9 of 12 items correct [58%-75%]). Scores were associated significantly with patients' education level (P &lt;â.0001). Sixty-six percent of patients would consent to a needle biopsy, and 39% would consent to an invasive surgical biopsy if required for GTC. Only 48% of patients reported having sufficient knowledge to make an informed decision to pursue GTC whereas 34% of patients indicated a need for formal genetic counseling.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients with advanced cancer are motivated to participate in GTC. Patients require further education to understand the difference between somatic and germline mutations in the context of GTC. Educational programs are needed to support patients interested in pursuing GTC.</AbstractText>
<CopyrightInformation>Â© 2014 American Cancer Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Blanchette</LastName>
<ForeName>Phillip S</ForeName>
<Initials>PS</Initials>
<AffiliationInfo>
<Affiliation>Division of Medical Oncology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Spreafico</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Miller</LastName>
<ForeName>Fiona A</ForeName>
<Initials>FA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chan</LastName>
<ForeName>Kelvin</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bytautas</LastName>
<ForeName>Jessica</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kang</LastName>
<ForeName>Steve</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bedard</LastName>
<ForeName>Philippe L</ForeName>
<Initials>PL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Eisen</LastName>
<ForeName>Andrea</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Potanina</LastName>
<ForeName>Larissa</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Holland</LastName>
<ForeName>Jack</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kamel-Reid</LastName>
<ForeName>Suzanne</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McPherson</LastName>
<ForeName>John D</ForeName>
<Initials>JD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Razak</LastName>
<ForeName>Albiruni R</ForeName>
<Initials>AR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Siu</LastName>
<ForeName>Lillian L</ForeName>
<Initials>LL</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer</MedlineTA>
<NlmUniqueID>0374236</NlmUniqueID>
<ISSNLinking>0008-543X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001706">Biopsy</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D032882">Comprehension</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D003657">Decision Making</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D005817">Genetic Counseling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D005820">Genetic Testing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007722">Health Knowledge, Attitudes, Practice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007258">Informed Consent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D009864">Ontario</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010361">Patients</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011795">Questionnaires</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057566">Self Report</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">attitude</Keyword>
<Keyword MajorTopicYN="N">cancer</Keyword>
<Keyword MajorTopicYN="N">genomic testing</Keyword>
<Keyword MajorTopicYN="N">knowledge</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25154930</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-0142</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>120</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer</Title>
<ISOAbbreviation>Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Impact of state-specific Medicaid reimbursement and eligibility policies on receipt of cancer screening.</ArticleTitle>
<Pagination>
<MedlinePgn>3016-24</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.28704</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although state Medicaid programs cover cancer screening, Medicaid beneficiaries are less likely to be screened for cancer and are more likely to present with tumors of an advanced stage than are those with other insurance. The current study was performed to determine whether state Medicaid eligibility and reimbursement policies affect the receipt of breast, cervical, and colon cancer screening among Medicaid beneficiaries.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Cross-sectional regression analyses of 2007 Medicaid data from 46 states and the District of Columbia were performed to examine associations between state-specific Medicaid reimbursement/eligibility policies and receipt of cancer screening. The study sample included individuals aged 21 years to 64 years who were enrolled in fee-for-service Medicaid for at least 4 months. Subsamples eligible for each screening test were: Papanicolaou test among 2,136,511 patients, mammography among 792,470 patients, colonoscopy among 769,729 patients, and fecal occult blood test among 753,868 patients. State-specific Medicaid variables included median screening test reimbursement, income/financial asset eligibility requirements, physician copayments, and frequency of eligibility renewal.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Increases in screening test reimbursement demonstrated mixed associations (positive and negative) with the likelihood of receiving screening tests among Medicaid beneficiaries. In contrast, increased reimbursements for office visits were found to be positively associated with the odds of receiving all screening tests examined, including colonoscopy (odds ratio [OR], 1.07; 95% confidence interval [95% CI], 1.06-1.08), fecal occult blood test (OR, 1.09; 95% CI, 1.08-1.10), Papanicolaou test (OR, 1.02; 95% CI, 1.02-1.03), and mammography (OR, 1.02; 95% CI, 1.02-1.03). Effects of other state-specific Medicaid policies varied across the screening tests examined.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Increased reimbursement for office visits was consistently associated with an increased likelihood of being screened for cancer, and may be an important policy tool for increasing screening among this vulnerable population.</AbstractText>
<CopyrightInformation>Â© 2014 American Cancer Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Halpern</LastName>
<ForeName>Michael T</ForeName>
<Initials>MT</Initials>
<AffiliationInfo>
<Affiliation>RTI International, Washington, DC.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Romaire</LastName>
<ForeName>Melissa A</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Haber</LastName>
<ForeName>Susan G</ForeName>
<Initials>SG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tangka</LastName>
<ForeName>Florence K</ForeName>
<Initials>FK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sabatino</LastName>
<ForeName>Susan A</ForeName>
<Initials>SA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Howard</LastName>
<ForeName>David H</ForeName>
<Initials>DH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer</MedlineTA>
<NlmUniqueID>0374236</NlmUniqueID>
<ISSNLinking>0008-543X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003110">Colonic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003113">Colonoscopy</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000656">utilization</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003430">Cross-Sectional Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055088">Early Detection of Cancer</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000191">economics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D004608">Eligibility Determination</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000331">legislation &amp; jurisprudence</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006297">Health Services Accessibility</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000331">legislation &amp; jurisprudence</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019458">Insurance Coverage</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008327">Mammography</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000656">utilization</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008403">Mass Screening</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000191">economics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008484">Medicaid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000331">legislation &amp; jurisprudence</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000208">ethnology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009780">Occult Blood</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016017">Odds Ratio</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009819">Office Visits</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D065006">Papanicolaou Test</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000656">utilization</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002583">Uterine Cervical Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014626">Vaginal Smears</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000656">utilization</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D035862">Vulnerable Populations</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000208">ethnology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Medicaid</Keyword>
<Keyword MajorTopicYN="N">Papanicolaou test</Keyword>
<Keyword MajorTopicYN="N">access to health care</Keyword>
<Keyword MajorTopicYN="N">cancer screening</Keyword>
<Keyword MajorTopicYN="N">colonoscopy</Keyword>
<Keyword MajorTopicYN="N">health care disparities</Keyword>
<Keyword MajorTopicYN="N">health insurance reimbursement</Keyword>
<Keyword MajorTopicYN="N">mammography</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24952243</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7905</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>411</Volume>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Journal of immunological methods</Title>
<ISOAbbreviation>J. Immunol. Methods</ISOAbbreviation>
</Journal>
<ArticleTitle>Isolation of biologically-active exosomes from human plasma.</ArticleTitle>
<Pagination>
<MedlinePgn>55-65</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jim.2014.06.007</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0022-1759(14)00190-2</ELocationID>
<Abstract>
<AbstractText>Effects of exosomes present in human plasma on immune cells have not been examined in detail. Immunological studies with plasma-derived exosomes require their isolation by procedures involving ultracentrifugation. These procedures were largely developed using supernatants of cultured cells. To test biologic activities of plasma-derived exosomes, methods are necessary that ensure adequate recovery of exosome fractions free of contaminating larger vesicles, cell fragments and protein/nucleic acid aggregates. Here, an optimized method for exosome isolation from human plasma/serum specimens of normal controls (NC) or cancer patients and its advantages and pitfalls are described. To remove undesirable plasma-contaminating components, ultrafiltration of differentially-centrifuged plasma/serum followed by size-exclusion chromatography prior to ultracentrifugation facilitated the removal of contaminants. Plasma or serum was equally acceptable as a source of exosomes based on the recovered protein levels (in Î¼g protein/mL plasma) and TEM image quality. Centrifugation on sucrose density gradients led to large exosome losses. Fresh plasma was the best source of morphologically-intact exosomes, while the use of frozen/thawed plasma decreased exosome purity but not their biologic activity. Treatments of frozen plasma with DNAse, RNAse or hyaluronidase did not improve exosome purity and are not recommended. Cancer patients' plasma consistently yielded more isolated exosomes than did NCs' plasma. Cancer patients' exosomes also mediated higher immune suppression as evidenced by decreased CD69 expression on responder CD4+ T effector cells. Thus, the described procedure yields biologically-active, morphologically-intact exosomes that have reasonably good purity without large protein losses and can be used for immunological, biomarker and other studies. </AbstractText>
<CopyrightInformation>Copyright Â© 2014 Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Muller</LastName>
<ForeName>Laurent</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA; Departments of Otolaryngology and Head&amp;Neck Surgery, University Hospital Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hong</LastName>
<ForeName>Chang-Sook</ForeName>
<Initials>CS</Initials>
<AffiliationInfo>
<Affiliation>University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stolz</LastName>
<ForeName>Donna B</ForeName>
<Initials>DB</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15261, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Watkins</LastName>
<ForeName>Simon C</ForeName>
<Initials>SC</Initials>
<AffiliationInfo>
<Affiliation>University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA; Department of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15261, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Whiteside</LastName>
<ForeName>Theresa L</ForeName>
<Initials>TL</Initials>
<AffiliationInfo>
<Affiliation>University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA; Departments of Pathology, Immunology and Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15261, USA. Electronic address: whitesidetl@upmc.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>5P30 CA047904</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA168628</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>J Immunol Methods</MedlineTA>
<NlmUniqueID>1305440</NlmUniqueID>
<ISSNLinking>0022-1759</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000945">Antigens, Differentiation, T-Lymphocyte</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C055855">CD69 antigen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D037181">Lectins, C-Type</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.-</RegistryNumber>
<NameOfSubstance UI="D003851">Deoxyribonucleases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.-</RegistryNumber>
<NameOfSubstance UI="D012260">Ribonucleases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.2.1.35</RegistryNumber>
<NameOfSubstance UI="D006821">Hyaluronoglucosaminidase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015703">Antigens, CD</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000945">Antigens, Differentiation, T-Lymphocyte</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058621">Blood Buffy Coat</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015496">CD4-Positive T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003851">Deoxyribonucleases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D055354">Exosomes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006821">Hyaluronoglucosaminidase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D037181">Lectins, C-Type</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046529">Microscopy, Electron, Transmission</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012260">Ribonucleases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Exosome characteristics</Keyword>
<Keyword MajorTopicYN="N">Exosome isolation</Keyword>
<Keyword MajorTopicYN="N">Human plasma</Keyword>
<Keyword MajorTopicYN="N">Immunological studies</Keyword>
<Keyword MajorTopicYN="N">Size-exclusion chromatography</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25244808</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1293-8505</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>Spec No</Volume>
<PubDate>
<Year>2014</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Revue de l'infirmiÃ¨re</Title>
<ISOAbbreviation>Rev Infirm</ISOAbbreviation>
</Journal>
<ArticleTitle>[Prescriptions by nurse as an act of medical protocol delegation].</ArticleTitle>
<Pagination>
<MedlinePgn>1S13-6</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Baldacci</LastName>
<ForeName>GÃ©raldine</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Baudat</LastName>
<ForeName>Virginie</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cazard</LastName>
<ForeName>Murielle</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Da Mota</LastName>
<ForeName>CÃ©line</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chauveau</LastName>
<ForeName>CÃ©cile</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Maindrault-Goebel</LastName>
<ForeName>FrÃ©dÃ©rique</ForeName>
<Initials>F</Initials>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<VernacularTitle>La prescription infirmiÃ¨re comme acte sur dÃ©lÃ©gation mÃ©dicale protocolaire.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>France</Country>
<MedlineTA>Rev Infirm</MedlineTA>
<NlmUniqueID>1267175</NlmUniqueID>
<ISSNLinking>1293-8505</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002983">Clinical Competence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D032022">Delegation, Professional</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000458">organization &amp; administration</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064420">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000451">nursing</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008495">Medical Oncology</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000364">manpower</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000458">organization &amp; administration</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000451">nursing</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D057184">Nurse's Practice Patterns</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000458">organization &amp; administration</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010348">Patient Care Team</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000458">organization &amp; administration</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055656">Prescriptions</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000451">nursing</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25244814</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0038-3317</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>67</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>South Dakota medicine : the journal of the South Dakota State Medical Association</Title>
<ISOAbbreviation>S D Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Technology radiation technology targets tumors. Surgical precision without the incision.</ArticleTitle>
<Pagination>
<MedlinePgn>362</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Simon</LastName>
<ForeName>James</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>S D Med</MedlineTA>
<NlmUniqueID>101265265</NlmUniqueID>
<ISSNLinking>0038-3317</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004867">Equipment Design</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016634">Radiosurgery</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000295">instrumentation</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25122173</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1438-9010</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>186</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>RÃ¶Fo : Fortschritte auf dem Gebiete der RÃ¶ntgenstrahlen und der Nuklearmedizin</Title>
<ISOAbbreviation>Rofo</ISOAbbreviation>
</Journal>
<ArticleTitle>Radiological evaluation of the therapeutic response of malignant diseases: status quo, innovative developments and requirements for radiology.</ArticleTitle>
<Pagination>
<MedlinePgn>927-36</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0034-1366741</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">In consequence of the rapid development of newer targeted and personalized tumor therapies, radiology as an essential component of the treatment concept of numerous malignant diseases needs to improve in order to adequately capture and evaluate the effects, but also the side effects of these novel therapeutic agents. The early recognition of therapy response or failure is crucial for the optimal planning of the further treatment and can therefore have direct impact on the chances of recovery and the survival time of oncological patients. In previous years, the goal of medical imaging was to just qualitatively assess the increase or reduction in the size of tumors and their metastases, which was often achieved by a simple subjective estimation of the tumor findings by the diagnosing radiologist. Nowadays, radiology is faced with the challenge of evaluating changes during therapy quantitatively and of visualizing therapeutic effects that are more discrete (e.âg. necrosis, altered tumor perfusion). The importance of an adequate assessment of therapy response is further underlined by the fact that in these days, a good portion of oncological patients are enrolled in clinical trials, in which the quantitative radiological evaluation of malignant disorders is an important surrogate parameter. On the basis of this development, the demands for radiology to provide more sophisticated assessments of therapy response and documentation of imaging findings have been constantly growing. The following article provides an overview of the established and still widely spread but in particular also the latest imaging modalities and evaluation criteria with regard to oncological diseases as well as of the increasing demands on radiology that result from these developments. Beyond that, future advancements in tumor imaging are taken into account and the new challenges these developments will bring are discussed.</AbstractText>
<AbstractText Label="KEY POINTS" NlmCategory="CONCLUSIONS">â¢âIn the era of personalized medicine, evaluation criteria that are individually adapted to the respective patient are required.â¢âRadiology needs to substantially contribute to oncological treatment concepts and the evaluation of therapeutic response.</AbstractText>
<CopyrightInformation>Â©Â Georg Thieme Verlag KG Stuttgart Â· New York.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>HÃ¶ink</LastName>
<ForeName>A J</ForeName>
<Initials>AJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Heindel</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Buerke</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Rofo</MedlineTA>
<NlmUniqueID>7507497</NlmUniqueID>
<ISSNLinking>1438-9010</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006528">Carcinoma, Hepatocellular</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003287">Contrast Media</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003952">Diagnostic Imaging</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D038524">Diffusion Magnetic Resonance Imaging</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046152">Gastrointestinal Stromal Tumors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007089">Image Enhancement</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007090">Image Interpretation, Computer-Assisted</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008113">Liver Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008223">Lymphoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008279">Magnetic Resonance Imaging</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009682">Magnetic Resonance Spectroscopy</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049268">Positron-Emission Tomography</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012680">Sensitivity and Specificity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014057">Tomography, X-Ray Computed</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014463">Ultrasonography</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25247546</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1938-808X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>89</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Academic medicine : journal of the Association of American Medical Colleges</Title>
<ISOAbbreviation>Acad Med</ISOAbbreviation>
</Journal>
<ArticleTitle>The Gold-Hope Tang, MD 2014 Humanism in Medicine essay contest: third place: An extension of â¦.</ArticleTitle>
<Pagination>
<MedlinePgn>1360-1</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/ACM.0000000000000443</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Jason</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Mr. Liu is a second-year student, Drexel University College of Medicine, Philadelphia, Pennsylvania; e-mail: jasonliu@drexel.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Acad Med</MedlineTA>
<NlmUniqueID>8904605</NlmUniqueID>
<ISSNLinking>1040-2446</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D035843">Biomedical Research</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D020811">Biomedical Technology</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D006808">Humanism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057285">Individualized Medicine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017056">Medical Laboratory Personnel</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25248863</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1756-1833</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>349</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>BMJ (Clinical research ed.)</Title>
<ISOAbbreviation>BMJ</ISOAbbreviation>
</Journal>
<ArticleTitle>US university plans to close proton therapy center in first of many possible closures.</ArticleTitle>
<Pagination>
<MedlinePgn>g5823</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1136/bmj.g5823</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>McCarthy</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Seattle.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016433">News</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>BMJ</MedlineTA>
<NlmUniqueID>8900488</NlmUniqueID>
<ISSNLinking>0959-535X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D006271">Health Facility Closure</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007196">Indiana</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D061766">Proton Therapy</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25249311</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1756-1833</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>349</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>BMJ (Clinical research ed.)</Title>
<ISOAbbreviation>BMJ</ISOAbbreviation>
</Journal>
<ArticleTitle>Time to vaccinate boys against HPV infection and cancer, say parliamentarians with special interest in public health.</ArticleTitle>
<Pagination>
<MedlinePgn>g5789</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1136/bmj.g5789</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Baron</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>House of Commons, London SW1A 0AA, UK baronj@parliament.uk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Beresford</LastName>
<ForeName>Paul</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>House of Commons, London SW1A 0AA, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gould</LastName>
<ForeName>Joyce</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>House of Lords, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Patel</LastName>
<ForeName>Kamlesh</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>House of Lords, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nash</LastName>
<ForeName>Pamela</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>House of Commons, London SW1A 0AA, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Freer</LastName>
<ForeName>Mike</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>House of Commons, London SW1A 0AA, UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>BMJ</MedlineTA>
<NlmUniqueID>8900488</NlmUniqueID>
<ISSNLinking>0959-535X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019496">Cancer Vaccines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053918">Papillomavirus Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019496">Cancer Vaccines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D006113">Great Britain</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D030361">Papillomavirus Infections</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053918">Papillomavirus Vaccines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011634">Public Health</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25093495</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-1827</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>23</Day>
</PubDate>
</JournalIssue>
<Title>British journal of cancer</Title>
<ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>The risk of cancer in primary care patients with hypercalcaemia: a cohort study using electronic records.</ArticleTitle>
<Pagination>
<MedlinePgn>1410-2</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2014.433</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The risk of cancer with hypercalcaemia in primary care is unknown.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">This was a cohort study using calcium results in patients aged â©¾40 years in a primary care electronic data set. Diagnoses of cancer in the following year were identified.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Participants (54â267) had calcium results: 1674 (3%) were â©¾2.6âmmolâl(-1). Hypercalcaemia was strongly associated with cancer, especially in males: OR 2.92, 95% CI 2.17-3.93, P=&lt;0.001; positive predictive value (PPV) 11.5%; females: OR 1.86, 95% CI 1.39-2.50, P&lt;0.001: PPV 4.1%.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Hypercalcaemia is strongly associated with cancer in primary care, with men at most risk, despite hypercalcaemia being more common in women.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hamilton</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>University of Bristol, Centre for Academic Primary Care, School of Social and Community Medicine, Canyngne Hall, Bristol BS8 2PS, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Carroll</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>University of Bristol, Centre for Academic Primary Care, School of Social and Community Medicine, Canyngne Hall, Bristol BS8 2PS, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hamilton</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>University of Exeter, St Luke's Campus, Exeter EX1 2LU, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Salisbury</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>University of Bristol, Centre for Academic Primary Care, School of Social and Community Medicine, Canyngne Hall, Bristol BS8 2PS, UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Cancer</MedlineTA>
<NlmUniqueID>0370635</NlmUniqueID>
<ISSNLinking>0007-0920</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057286">Electronic Health Records</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006934">Hypercalcemia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015994">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015999">Multivariate Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011320">Primary Health Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4183854 [Available on 09/23/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25101569</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-1827</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>23</Day>
</PubDate>
</JournalIssue>
<Title>British journal of cancer</Title>
<ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Refinement of the symptom screening in pediatrics tool (SSPedi).</ArticleTitle>
<Pagination>
<MedlinePgn>1262-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2014.445</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Objective was to evaluate and refine a new instrument for paediatric cancer symptom screening named the Symptom Screening in Pediatrics Tool (SSPedi).</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Respondents were children 8-18 years of age undergoing active cancer treatment and parents of eligible children. Respondents completed SSPedi once and then responded to semi-structured questions. They rated how easy or difficult SSPedi was to complete. For items containing two concepts, we asked respondents whether concepts should remain together or be separated into two questions. We also asked about each item's importance and whether items were missing. Cognitive probing was conducted in children to evaluate their understanding of items and the response scale. After each group of 10 children and 10 parents, responses were reviewed to determine whether modifications were required. Recruitment ceased with the first group of 10 children in which modifications were not required.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty children and 20 parents were required to achieve a final version of SSPedi. Fifteen items remain in the final version; the score ranges from 0 to 60.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Using opinions of children with cancer and parents of paediatric cancer patients, we successfully developed a symptom screening tool that is easy to complete, is understandable and demonstrates content validity.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>O'Sullivan</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Program in Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan Centre for Research and Learning, 686 Bay Street, Toronto, Ontario M5G 0A4, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dupuis</LastName>
<ForeName>L L</ForeName>
<Initials>LL</Initials>
<AffiliationInfo>
<Affiliation>1] Division of Haematology/Oncology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada [2] Department of Pharmacy, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada [3] Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario M5S 3M2, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gibson</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Division of Haematology/Oncology, Department of Pediatrics, London Health Sciences Centre, 800 Commissioners Road East, London, Ontario N6A 5W9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Johnston</LastName>
<ForeName>D L</ForeName>
<Initials>DL</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology/Oncology, Children's Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, Ontario K1H 8L1, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Baggott</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>School of Nursing, UCSF Medical Center, Parnassus, 2 Koret Way, San Francisco, California 94143, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Portwine</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Division of Haematology/Oncology, McMaster Children's Hospital, Health Sciences Centre, 1280 Main Street West, Hamilton, Ontario L8S 4K1, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Spiegler</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Psychology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kuczynski</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Ontario Parents Advocating for Children With Cancer (OPACC), 99 Citation Drive, Toronto, Ontario M2K 1S9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tomlinson</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Program in Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan Centre for Research and Learning, 686 Bay Street, Toronto, Ontario M5G 0A4, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>de Mol Van Otterloo</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Program in Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan Centre for Research and Learning, 686 Bay Street, Toronto, Ontario M5G 0A4, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tomlinson</LastName>
<ForeName>G A</ForeName>
<Initials>GA</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Toronto General Hospital, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sung</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>1] Program in Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan Centre for Research and Learning, 686 Bay Street, Toronto, Ontario M5G 0A4, Canada [2] Division of Haematology/Oncology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Cancer</MedlineTA>
<NlmUniqueID>0370635</NlmUniqueID>
<ISSNLinking>0007-0920</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001007">Anxiety</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009325">Nausea</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010146">Pain</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D057566">Self Report</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4183858 [Available on 09/23/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25117813</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-1827</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>23</Day>
</PubDate>
</JournalIssue>
<Title>British journal of cancer</Title>
<ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress?</ArticleTitle>
<Pagination>
<MedlinePgn>1305-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2014.448</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The clinical development of new drugs with radiation appears to be limited. We hypothesised that phase I clinical trials with radiation therapy (RT) are initiated too late into a new drug's lifetime, impeding the ability to complete RT-drug development programmes before patent expiration.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We identified novel drug-radiation phase I combination trials performed between 1980 and 2012 within the PubMed and ClinicalTrials.gov databases. Data gathered for each drug included: date the initial phase I trial with/without RT was opened/published, date of the published positive phase III trials, and patent expiration dates. Lag time was defined as the interval between opening of the phase I trial without RT and the opening of the phase I with RT. Linear regression was used to model how the lag time has changed over time.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The median lag time was 6 years. The initial phase I trial with RT was typically published 2 years after the first published positive phase III trial and 11 years before patent expiration. Using a best-fit linear model, lag time decreased from 10 years for phase I trials published in 1990 to 5 years in 2005 (slope significantly non-zero, P&lt;0.001).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Clinical drug development with RT commences late in the life cycle of anti-cancer agents. Taking into account the additional time required for late-phase clinical trials, the delay in initiating clinical testing of drug-RT combinations discourages drug companies from further pursuing RT-based development. Encouragingly, lag time appears to be decreasing. Further reduction in lag time may accelerate RT-based drug development, potentially improving patient outcomes.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Blumenfeld</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, USA [2] Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pfeffer</LastName>
<ForeName>R M</ForeName>
<Initials>RM</Initials>
<AffiliationInfo>
<Affiliation>1] Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel [2] Department of Radiation Oncology, Sheba Medical Center, Ramat Gan, Israel [3] MSR School of Radiotherapy, Ramat Gan, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Symon</LastName>
<ForeName>Z</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>1] Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel [2] Department of Radiation Oncology, Sheba Medical Center, Ramat Gan, Israel [3] MSR School of Radiotherapy, Ramat Gan, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Den</LastName>
<ForeName>R B</ForeName>
<Initials>RB</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dicker</LastName>
<ForeName>A P</ForeName>
<Initials>AP</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Raben</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, University of Colorado Denver, Denver, CO, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lawrence</LastName>
<ForeName>Y R</ForeName>
<Initials>YR</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Radiation Oncology, Sheba Medical Center, Ramat Gan, Israel [2] MSR School of Radiotherapy, Ramat Gan, Israel [3] Department of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Cancer</MedlineTA>
<NlmUniqueID>0370635</NlmUniqueID>
<ISSNLinking>0007-0920</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D059248">Chemoradiotherapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017321">Clinical Trials, Phase I as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058996">Quality Improvement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4183859 [Available on 09/23/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25248886</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0385-0684</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>41</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Gan to kagaku ryoho. Cancer &amp; chemotherapy</Title>
<ISOAbbreviation>Gan To Kagaku Ryoho</ISOAbbreviation>
</Journal>
<ArticleTitle>[Cancer treatment for patients with dementia].</ArticleTitle>
<Pagination>
<MedlinePgn>1051-6</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Cancer is a disease associated with aging. In Japan, the rate of aging is estimated to be over 25%. Further, the prevalence of dementia also increases with age, and cancer patients with dementia are becoming more common. Dementia is a progressive condition characterized by impairment in memory and at least one other cognitive domain(language, praxis, gnosis, or executive function), as well as a compromised ability to perform daily functions. Impairment of short-term memory and executive function in particular are associated with an increased risk for functional decline and mortality. Assessment of cognitive function is necessary to ensure that cancer patients can provide informed consent and understand the risks, benefits, and alternatives of therapeutic treatment. The health care team needs to ascertain whether patients have the mental capacity for cancer treatment, will comply with the treatment schedule, and will understand when to seek help. Elderly cancer patients undergoing treatment need to be assessed for vulnerability with the comprehensive geriatric assessment (CGA).</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ogawa</LastName>
<ForeName>Asao</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Division of Psycho-Oncology, National Cancer Center Hospital East.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>jpn</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Japan</Country>
<MedlineTA>Gan To Kagaku Ryoho</MedlineTA>
<NlmUniqueID>7810034</NlmUniqueID>
<ISSNLinking>0385-0684</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000203">Activities of Daily Living</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000375">Aging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003704">Dementia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017410">Practice Guidelines as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25248887</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0385-0684</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>41</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Gan to kagaku ryoho. Cancer &amp; chemotherapy</Title>
<ISOAbbreviation>Gan To Kagaku Ryoho</ISOAbbreviation>
</Journal>
<ArticleTitle>[Suppression of tumor antigen-specific T cell immune responses by regulatory T cells].</ArticleTitle>
<Pagination>
<MedlinePgn>1057-61</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>CD4âº CD25âº FOXP3âº regulatory T cells(Tregs)play important roles in maintaining self-tolerance in vivo by suppressing self antigen- reactive T cells. In the tumor microenvironment, tumor cells produce several chemokines and attract Tregs, resulting in suppression of tumor antigen-specific cytotoxic CD8âº T cell activation. Controlling the suppressive function of Tregs to recover anti-tumor immune responses in the tumor microenvironment is critical to improve the efficiency of cancer immunotherapy. Many immune-checkpoint blockade reagents, including antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA- 4), programmed cell death (PD)-1, and PD-L1, have been tested in the clinic and elicit clinical responses in several types of cancers. Importantly, clinical responses in melanoma patients treated with an anti-CTLA-4 antibody were associated with a reduced number of Tregs in the tumor microenvironment. Therefore, in addition to activating or expanding antigen-specific cytotoxic T cells, modulating the number and/or function of Tregs in the tumor microenvironment is the next important challenge in the field of cancer immunotherapy.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Shimazu</LastName>
<ForeName>Yutaka</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Dept. of Immunology, Immunology Frontier Research Center, Osaka University.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nishikawa</LastName>
<ForeName>Hiroyoshi</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>jpn</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Japan</Country>
<MedlineTA>Gan To Kagaku Ryoho</MedlineTA>
<NlmUniqueID>7810034</NlmUniqueID>
<ISSNLinking>0385-0684</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000951">Antigens, Neoplasm</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007167">Immunotherapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013601">T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050378">T-Lymphocytes, Regulatory</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25248888</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0385-0684</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>41</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Gan to kagaku ryoho. Cancer &amp; chemotherapy</Title>
<ISOAbbreviation>Gan To Kagaku Ryoho</ISOAbbreviation>
</Journal>
<ArticleTitle>[Development of novel immunotherapy targeting cancer immune evasion].</ArticleTitle>
<Pagination>
<MedlinePgn>1062-5</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Immunotherapy has been developed as an innovative medical intervention against advanced cancer that is refractory to conventional therapies. In recent years, there have been significant advances in our basic knowledge of tumor immunology and ample experience with the clinical application of novel cancer immunotherapies. Accordingly, many of the molecular and cellular mechanisms of the interaction between cancer cells and the immune system have been elucidated. At the initial stage of cancer occurrence, the immune system constantly surveys for the emergence of cancerous cells in order to eliminate them. For cancers that have evaded immune surveillance, the immune system generates anti-tumor responses by recognizing tumor- associated antigens. In response to such immunological pressure, cancer cells edit their immunogenicity and create immunosuppressive conditions in the tumor microenvironment, resulting in cancer immune evasion. Therefore, in order to achieve effective immunotherapy, it is imperative to inactivate mechanisms used by cancer cells to evade and suppress immune responses. In this article, immune checkpoint blockade, one of the most attractive approaches in cancer immunotherapy, will be discussed. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tamada</LastName>
<ForeName>Koji</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Dept. of Immunology, Yamaguchi University Graduate School of Medicine.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>jpn</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Japan</Country>
<MedlineTA>Gan To Kagaku Ryoho</MedlineTA>
<NlmUniqueID>7810034</NlmUniqueID>
<ISSNLinking>0385-0684</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D060908">CTLA-4 Antigen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060908">CTLA-4 Antigen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D057131">Immune Evasion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007167">Immunotherapy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061026">Programmed Cell Death 1 Receptor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059016">Tumor Microenvironment</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25248889</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0385-0684</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>41</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Gan to kagaku ryoho. Cancer &amp; chemotherapy</Title>
<ISOAbbreviation>Gan To Kagaku Ryoho</ISOAbbreviation>
</Journal>
<ArticleTitle>[Regulation of T-cell immune exhaustion and cancer immunotherapy].</ArticleTitle>
<Pagination>
<MedlinePgn>1066-70</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>In chronic infectious diseases and cancer, CD8âº T cells specific for viral and/or tumor antigens undergo repeated T cell receptor (TCR) stimulation due to the persistence of pathogens or cancer cells, gradually losing their ability to secrete interleukin 2 (IL-2), tumor necrosis factor-a (TNF-a), and interferon-g (IFN-g). These CD8âº T cells are finally eliminated by apoptosis, a process referred to as immune exhaustion. The worsening immune function is accompanied by phenotypic changes in CD8âº T cells, for example, by changes in the expression of exhaustion markers such as programmed cell death protein 1(PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), T cell immunoglobulin mucin 3 (TIM-3), and lymphocyte activation gene 3 (LAG-3). The exhaustion molecules on CD8âº T cells interact with their respective ligands and induce negative signals in activated T cells, leading to CD8âº T cell dysfunction. In 2013, the combined use of anti-PD-1 and anti- CTLA-4 antibodies was shown to induce extraordinary anti-tumor effects in patients with advanced melanoma. The regulation of exhausted CD8âº T cells has now emerged as a promising therapy to treat cancer.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Eikawa</LastName>
<ForeName>Shingo</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Dept. of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Udono</LastName>
<ForeName>Heiichiro</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>jpn</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Japan</Country>
<MedlineTA>Gan To Kagaku Ryoho</MedlineTA>
<NlmUniqueID>7810034</NlmUniqueID>
<ISSNLinking>0385-0684</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007167">Immunotherapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013312">Stress, Physiological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013601">T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25248890</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0385-0684</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>41</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Gan to kagaku ryoho. Cancer &amp; chemotherapy</Title>
<ISOAbbreviation>Gan To Kagaku Ryoho</ISOAbbreviation>
</Journal>
<ArticleTitle>[Targeting the PD-1/PD-L1 immune checkpoint signal - a new treatment strategy for cancer].</ArticleTitle>
<Pagination>
<MedlinePgn>1071-6</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Recent studies have revealed that tumor cells can acquire several mechanisms to evade host immunity in the tumor microenvironment, called cancer immune escape. One of the most important mechanisms in this system is an immunosuppressive co- signal, called immune checkpoint, in the programmed cell death-1(PD-1)/programmed death-ligand 1(PD-L1)pathway. PD-1 is mainly expressed on activated T cells, while PD-L1 is frequently expressed on tumor cells. Inhibition of the interaction between PD-1 and PD-L1 enhances T-cell response and mediates antitumor activity. Several clinical trials by several institutions and pharmaceutical companies in the world have shown the antitumor efficacy of PD-1/PD-L1 signal blockade in patients with some solid and hematological malignancies. Production of some drugs for use in anti-PD-1 therapies are on the verge of completion. Herein, we provide a background about the PD-1/PD-L1 signal and describe some previously performed foreign clinical trials, including a trial in our department.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hamanishi</LastName>
<ForeName>Junzo</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Dept. of Gynecology and Obstetrics, Graduate School of Medicine Kyoto University.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Konishi</LastName>
<ForeName>Ikuo</ForeName>
<Initials>I</Initials>
</Author>
</AuthorList>
<Language>jpn</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Japan</Country>
<MedlineTA>Gan To Kagaku Ryoho</MedlineTA>
<NlmUniqueID>7810034</NlmUniqueID>
<ISSNLinking>0385-0684</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D060890">Antigens, CD274</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060890">Antigens, CD274</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057131">Immune Evasion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061026">Programmed Cell Death 1 Receptor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25248895</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0385-0684</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>41</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Gan to kagaku ryoho. Cancer &amp; chemotherapy</Title>
<ISOAbbreviation>Gan To Kagaku Ryoho</ISOAbbreviation>
</Journal>
<ArticleTitle>[Comparison of garenoxacin and levofloxacin for the prophylaxis of febrile neutropenia].</ArticleTitle>
<Pagination>
<MedlinePgn>1119-23</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Placebo-controlled randomized trials have demonstrated that prophylactic levofloxacin (LVFX) significantly reduced the incidence of febrile neutropenia (FN) in patients receiving chemotherapy for advanced solid tumors. Garenoxacin (GRNX) has been reported to be more effective than LVFX against gram-positive bacteria especially Streptococcus pneumoniae. Against this background we conducted a study to compare the efficacy and safety of GRNX with that of LVFX for the prophylaxis of FN. We retrospectively analyzed 127 patients at high risk for FN who were administered GRNX or LVFX for the prophylaxis of FN that occurred during chemotherapy for advanced solid tumors. Our primary outcome of interest was the incidence of febrile episodes. Secondary outcomes included evidence of bacterial infection and infection focus when febrile episodes were observed; adverse drug reactions and mortality were also evaluated. Febrile episodes were observed in 2 patients administered GRNX and 7 patients administered LVFX (p=0.044). Definitive pathogenic bacteria and infection focus could not be identified in any patient with febrile episodes and all cases of fever resolved simultaneously with the recovery from neutropenia. We observed 4 cases of rashes and 3 cases of liver dysfunction in the GRNX group and 2 cases of rashes and 2 cases of liver dysfunctions were observed in the LVFX group(not statistically significant in both the groups). No severe adverse effects or deaths were associated with either of these drugs. These results suggest that GRNX is useful for the prophylaxis of FN.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hata</LastName>
<ForeName>Akito</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Division of Integrated Oncology, Institute of Biomedical Research and Innovation.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Katakami</LastName>
<ForeName>Nobuyuki</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Masuda</LastName>
<ForeName>Yoshio</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takashima</LastName>
<ForeName>Kenji</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takeshita</LastName>
<ForeName>Jumpei</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tanaka</LastName>
<ForeName>Kosuke</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kaji</LastName>
<ForeName>Reiko</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fujita</LastName>
<ForeName>Shiro</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ose</LastName>
<ForeName>Takayuki</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kitajima</LastName>
<ForeName>Naoto</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>jpn</Language>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Japan</Country>
<MedlineTA>Gan To Kagaku Ryoho</MedlineTA>
<NlmUniqueID>7810034</NlmUniqueID>
<ISSNLinking>0385-0684</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D024841">Fluoroquinolones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>6GNT3Y5LMF</RegistryNumber>
<NameOfSubstance UI="D064704">Levofloxacin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>V72H9867WB</RegistryNumber>
<NameOfSubstance UI="C419689">garenoxacin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000900">Anti-Bacterial Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064147">Febrile Neutropenia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D024841">Fluoroquinolones</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064704">Levofloxacin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24136029</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1536-3678</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>36</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of pediatric hematology/oncology</Title>
<ISOAbbreviation>J. Pediatr. Hematol. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Infusional chemotherapy and medication errors in a tertiary care pediatric cancer unit in a resource-limited setting.</ArticleTitle>
<Pagination>
<MedlinePgn>e412-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/MPH.0000000000000044</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Drug administration is a multiprofessional process. The high toxicity and low therapeutic index of chemotherapy drugs make medication errors a significant problem, resulting in excessive patient morbidity and cost.</AbstractText>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">An audit of the delivery of infusional chemotherapy among pediatric inpatients was planned, with the objective of improving practice and minimizing errors.</AbstractText>
<AbstractText Label="METHOD" NlmCategory="METHODS">An observational study was conducted between January and August 2012. Patients were followed up from their premedication until the completion of postchemotherapy hydration and/or rescue drugs. Errors were recorded and classified by error type, cause, severity, unit location, medication involved, and harm caused.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 205 observations were made and 23(13.6%) errors recorded, of which 6 were intercepted. No life-threatening adverse drug event was recorded. The most important risk factor predisposing to errors was admission to nonpediatric ward (P=0.004). Documentation errors and incorrect infusion time were the 2 most common errors, whereas the most frequent error node was administration error. Appropriate steps were taken to prevent their reoccurrence.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study helped provide important information about the rate and epidemiology of medication errors, emphasizing on the role of audit in enabling development of appropriate error-reducing strategies, particularly in the context of quality assurance in hospitals.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dhamija</LastName>
<ForeName>Mayank</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>*Department of Pediatric Hematology and Oncology, Rajiv Gandhi Cancer Institute and Research Centre â National Institute of Medical Statistics, New Delhi, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kapoor</LastName>
<ForeName>Gauri</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Juneja</LastName>
<ForeName>Atul</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D064888">Observational Study</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Pediatr Hematol Oncol</MedlineTA>
<NlmUniqueID>9505928</NlmUniqueID>
<ISSNLinking>1077-4114</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019337">Hematologic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007194">India</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007262">Infusions, Intravenous</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007902">Length of Stay</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008485">Medical Audit</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008508">Medication Errors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009017">Morbidity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016522">Oncology Service, Hospital</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000592">standards</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011785">Quality Assurance, Health Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012308">Risk Management</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000592">standards</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D062606">Tertiary Care Centers</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000592">standards</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24390448</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1536-3678</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>36</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of pediatric hematology/oncology</Title>
<ISOAbbreviation>J. Pediatr. Hematol. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Supporting adolescents and young adults with cancer through transitions: position statement from the Canadian Task Force on Adolescents and Young Adults with cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>545-51</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/MPH.0000000000000103</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This position statement from the Canadian Task Force on Adolescents and Young Adults with cancer aims to (1) conceptualize the numerous transition experiences encountered by adolescents and young adults (AYA) with cancer; and (2) provide recommendations on how to help the AYA regain a sense of control over their lives as they adjust to these transition experiences.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We reviewed and synthesized a heterogeneous sample of studies and recommendations, ranging from well-designed case-controlled investigations to opinions of respected authorities based on clinical experience, and reports of expert committees.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We describe the key factors that have an impact on different transitions during the cancer journey, and the need for developmentally appropriate services for AYA with cancer that consider both the system issues and individual transition issues. Our recommendations are not intended to be prescriptive, but they are broad enough to be applicable in different types of settings (eg, family doctor, cancer center, specialty service) and systems beyond health care (eg, school system, social system).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The Task Force urges health care providers, parents, and AYA with cancer to work together in planning and implementing strategies that will enable individuals to navigate the transitions they encounter along the cancer journey successfully, and strive for meaningful participation in life situations, achieving their potential as fully functional members of society.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wilkins</LastName>
<ForeName>Krista L</ForeName>
<Initials>KL</Initials>
<AffiliationInfo>
<Affiliation>*Faculty of Nursing, University of New Brunswick, Fredericton, NB â Departments of Psychosocial Oncology and Palliative Care, Princess Margaret Cancer Centre â¥Department of Pediatrics, The Hospital for Sick Children and University of Toronto, Toronto Â§Departments of Pediatrics, Pathology and Medicine, McMaster University, Hamilton, ON â¡Department of Hematology/Oncology, IWK Health Centre, Halifax, NS, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>D'Agostino</LastName>
<ForeName>Norma</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Penney</LastName>
<ForeName>Annette M</ForeName>
<Initials>AM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Barr</LastName>
<ForeName>Ronald D</ForeName>
<Initials>RD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nathan</LastName>
<ForeName>Paul C</ForeName>
<Initials>PC</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Pediatr Hematol Oncol</MedlineTA>
<NlmUniqueID>9505928</NlmUniqueID>
<ISSNLinking>1077-4114</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D002170">Canada</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003266">Continuity of Patient Care</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000592">standards</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010166">Palliative Care</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000592">standards</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017410">Practice Guidelines as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000297">Psychology, Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D012944">Social Support</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25176333</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1474-1768</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>14</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Nature reviews. Cancer</Title>
<ISOAbbreviation>Nat. Rev. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Stem cell-based therapies for cancer treatment: separating hope from hype.</ArticleTitle>
<Pagination>
<MedlinePgn>683-91</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nrc3798</ELocationID>
<Abstract>
<AbstractText>Stem cell-based therapies are emerging as a promising strategy to tackle cancer. Multiple stem cell types have been shown to exhibit inherent tropism towards tumours. Moreover, when engineered to express therapeutic agents, these pathotropic delivery vehicles can effectively target sites of malignancy. This perspective considers the current status of stem cell-based treatments for cancer and provides a rationale for translating the most promising preclinical studies into the clinic. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Stuckey</LastName>
<ForeName>Daniel W</ForeName>
<Initials>DW</Initials>
<AffiliationInfo>
<Affiliation>Molecular Neurotherapy and Imaging Laboratory and the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shah</LastName>
<ForeName>Khalid</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Molecular Neurotherapy and Imaging Laboratory and the Departments of Radiology and Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA; and the Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts 02138, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 CA138922</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA173077</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA138922</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA173077</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nat Rev Cancer</MedlineTA>
<NlmUniqueID>101124168</NlmUniqueID>
<ISSNLinking>1474-175X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004337">Drug Carriers</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050130">Oncolytic Virotherapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D033581">Stem Cell Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013234">Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25176334</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1474-1768</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>14</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Nature reviews. Cancer</Title>
<ISOAbbreviation>Nat. Rev. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>DICER1: mutations, microRNAs and mechanisms.</ArticleTitle>
<Pagination>
<MedlinePgn>662-72</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nrc3802</ELocationID>
<Abstract>
<AbstractText>Dicer is central to microRNA-mediated silencing and several other RNA interference phenomena that are profoundly embedded in cancer gene networks. Most recently, both germline and somatic mutations in DICER1 have been identified in diverse types of cancer. Although some of the mutations clearly reduce the dosage of this key enzyme, others dictate surprisingly specific changes in select classes of small RNAs. This Review reflects on the molecular properties of the Dicer enzymes in small RNA silencing pathways, and rationalizes the newly discovered mutations on the basis of the activities and functions of its determinants. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Foulkes</LastName>
<ForeName>William D</ForeName>
<Initials>WD</Initials>
<AffiliationInfo>
<Affiliation>1] Departments of Human Genetics, Medicine and Oncology, McGill University; Lady Davis Institute, Jewish General Hospital and Research Institute, McGill University Health Centre, Montreal, Quebec, Canada. [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Priest</LastName>
<ForeName>John R</ForeName>
<Initials>JR</Initials>
<AffiliationInfo>
<Affiliation>1] [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Duchaine</LastName>
<ForeName>Thomas F</ForeName>
<Initials>TF</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Biochemistry and Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada, H3A 1A3. [2].</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>MOP 86577</GrantID>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nat Rev Cancer</MedlineTA>
<NlmUniqueID>101124168</NlmUniqueID>
<ISSNLinking>1474-175X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.26.3</RegistryNumber>
<NameOfSubstance UI="C408087">DICER1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.26.3</RegistryNumber>
<NameOfSubstance UI="D043244">Ribonuclease III</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.4.13</RegistryNumber>
<NameOfSubstance UI="D053487">DEAD-box RNA Helicases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053487">DEAD-box RNA Helicases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020022">Genetic Predisposition to Disease</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017434">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034622">RNA Interference</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D043244">Ribonuclease III</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25190083</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1474-1768</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>14</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Nature reviews. Cancer</Title>
<ISOAbbreviation>Nat. Rev. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>CUX1, a haploinsufficient tumour suppressor gene overexpressed in advanced cancers.</ArticleTitle>
<Pagination>
<MedlinePgn>673-82</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nrc3805</ELocationID>
<Abstract>
<AbstractText>CUT-like homeobox 1 (CUX1) is a homeobox gene that is implicated in both tumour suppression and progression. The accumulated evidence supports a model of haploinsufficiency whereby reduced CUX1 expression promotes tumour development. Paradoxically, increased CUX1 expression is associated with tumour progression, and ectopic CUX1 expression in transgenic mice increases tumour burden in several tissues. One CUX1 isoform functions as an ancillary factor in base excision repair and the other CUX1 isoforms act as transcriptional activators or repressors. Several transcriptional targets and cellular functions of CUX1 affect tumorigenesis; however, we have yet to develop a mechanistic framework to reconcile the opposite roles of CUX1 in cancer protection and progression. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ramdzan</LastName>
<ForeName>Zubaidah M</ForeName>
<Initials>ZM</Initials>
<AffiliationInfo>
<Affiliation>Goodman Cancer Centre, McGill University, 1160 Pine Avenue West, Montreal, Quebec, H3A 1A3, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nepveu</LastName>
<ForeName>Alain</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>1] Goodman Cancer Centre, McGill University, 1160 Pine Avenue West, Montreal, Quebec, H3A 1A3, Canada. [2] Department of Biochemistry, McGill University, 1160 Pine Avenue West, Montreal, Quebec, H3A 1A3, Canada. [3] Department of Medicine, McGill University, 1160 Pine Avenue West, Montreal, Quebec, H3A 1A3, Canada. [4] Department of Oncology, McGill University, 1160 Pine Avenue West, Montreal, Quebec, H3A 1A3, Canada.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>MOP-98010</GrantID>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nat Rev Cancer</MedlineTA>
<NlmUniqueID>101124168</NlmUniqueID>
<ISSNLinking>1474-175X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C080632">CUX1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063646">Carcinogenesis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056915">DNA Copy Number Variations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016147">Genes, Tumor Suppressor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020022">Genetic Predisposition to Disease</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057895">Haploinsufficiency</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018398">Homeodomain Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012097">Repressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25252508</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0030-9982</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>64</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>JPMA. The Journal of the Pakistan Medical Association</Title>
<ISOAbbreviation>J Pak Med Assoc</ISOAbbreviation>
</Journal>
<ArticleTitle>Utilization of systemic palliative chemotherapy at the end of life: a local experience.</ArticleTitle>
<Pagination>
<MedlinePgn>863-8</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate attitude towards using systemic chemotherapy near the end of life for cancer patients.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective study comprised data of all patients who died with cancer at the Medical Oncology Department of the National Oncology Centre, Muscat, Oman, from January 2009 to December 2011. The records were retrieved from the electronic patient record system of ALSHIFA, Royal Hospital. Demographic data, chemotherapy at end of life, performance status, 'do not resuscitate' status, hospitalisation, and chemotherapy toxicity were analysed.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean age of the 261 patients in the study was 52.3 +/- 14.52 years. Ninety-two (35%) patients did not receive chemotherapy in the last 3 months of their lives. Chemotherapy administered at end of life was 169 (65%), 126 (48%), and 75 (29%) in last 3 months, one month and 2 weeks of life. Those who received more than 3 lines of chemotherapy were 66 (36%).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The end-of-life use of chemotherapy should always be carefully discussed. The patient's right to information should be honoured. The transition from active to best supportive care should be carefully guided.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Abdul Monem</LastName>
<ForeName>Essam</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mehdi</LastName>
<ForeName>Itrat</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Al Bahrani</LastName>
<ForeName>Bassim Jaffa</ForeName>
<Initials>BJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nada</LastName>
<ForeName>Ayman Mohammad</ForeName>
<Initials>AM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Al Kharusi</LastName>
<ForeName>Suad</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Pakistan</Country>
<MedlineTA>J Pak Med Assoc</MedlineTA>
<NlmUniqueID>7501162</NlmUniqueID>
<ISSNLinking>0030-9982</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016223">Advance Directives</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D009850">Oman</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010166">Palliative Care</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000656">utilization</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013727">Terminal Care</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000656">utilization</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24975284</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1349-7006</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Cancer science</Title>
<ISOAbbreviation>Cancer Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Safely targeting cancer stem cells via selective catenin coactivator antagonism.</ArticleTitle>
<Pagination>
<MedlinePgn>1087-92</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.12471</ELocationID>
<Abstract>
<AbstractText>Throughout our life, long-lived somatic stem cells (SSC) regenerate adult tissues both during homeostatic processes and repair after injury. The role of aberrant regulation of SSC has also recently gained prominence in the field of cancer research. Following malignant transformation, so termed cancer stem cells (CSC), endowed with the same properties as SSC (i.e. the ability to both self-renew and generate differentiated progenitors), play a major part in tumor initiation, therapy resistance and ultimately relapse. The same signaling pathways involved in regulating SSC maintenance are involved in the regulation of CSC. CSC exist in a wide array of tumor types, including leukemias, and brain, breast, prostate and colon tumors. Consequently, one of the key goals in cancer research over the past decade has been to develop therapeutic strategies to safely eliminate the CSC population without damaging the endogenous SSC population. A major hurdle to this goal lies in the identification of the key mechanisms that distinguish CSC from the normal endogenous tissue stem cells. This review will discuss the discovery of the specific CBP/catenin antagonist ICG-001 and the ongoing clinical development of the second generation CBP/catenin antagonist PRI-724. Importantly, specific CBP/catenin antagonists appear to have the ability to safely eliminate CSC by taking advantage of an intrinsic differential preference in the way SSC and CSC divide.</AbstractText>
<CopyrightInformation>Â© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lenz</LastName>
<ForeName>Heinz-Josef</ForeName>
<Initials>HJ</Initials>
<AffiliationInfo>
<Affiliation>USC Norris Comprehensive Cancer Center, USC Center for Molecular Pathways and Drug Discovery, University of Southern California, Los Angeles, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kahn</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>1R01 HL112638-01</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>1R01CA166161-01A1</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>1R21AI105057-01</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>1R21NS074392-01</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 CA014089</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA166161</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Cancer Sci</MedlineTA>
<NlmUniqueID>101168776</NlmUniqueID>
<ISSNLinking>1347-9032</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019086">Bicyclo Compounds, Heterocyclic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051177">Catenins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C492448">ICG 001</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011744">Pyrimidinones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012795">Sialoglycoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C571744">bone sialoprotein (35-62), human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019086">Bicyclo Compounds, Heterocyclic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051177">Catenins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014411">Neoplastic Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010446">Peptide Fragments</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011744">Pyrimidinones</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012795">Sialoglycoproteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060449">Wnt Signaling Pathway</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS609713 [Available on 09/06/15]</OtherID>
<OtherID Source="NLM">PMC4175086 [Available on 09/06/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Asymmetric</Keyword>
<Keyword MajorTopicYN="N">CREB-binding protein</Keyword>
<Keyword MajorTopicYN="N">Wnt/catenin</Keyword>
<Keyword MajorTopicYN="N">p300</Keyword>
<Keyword MajorTopicYN="N">symmetric</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24898083</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1420-9071</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>71</Volume>
<Issue>20</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Cellular and molecular life sciences : CMLS</Title>
<ISOAbbreviation>Cell. Mol. Life Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Histone deacetylase inhibitors and cell death.</ArticleTitle>
<Pagination>
<MedlinePgn>3885-901</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00018-014-1656-6</ELocationID>
<Abstract>
<AbstractText>Histone deacetylases (HDACs) are a vast family of enzymes involved in chromatin remodeling and have crucial roles in numerous biological processes, largely through their repressive influence on transcription. In addition to modifying histones, HDACs also target many other non-histone protein substrates to regulate gene expression. Recently, HDACs have gained growing attention as HDAC-inhibiting compounds are being developed as promising cancer therapeutics. Histone deacetylase inhibitors (HDACi) have been shown to induce differentiation, cell cycle arrest, apoptosis, autophagy and necrosis in a variety of transformed cell lines. In this review, we mainly discuss how HDACi may elicit a therapeutic response to human cancers through different cell death pathways, in particular, apoptosis and autophagy. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Jing</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, Center for Autophagy Research, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Room Y9206C, Dallas, TX, 75390-9113, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhong</LastName>
<ForeName>Qing</ForeName>
<Initials>Q</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 CA133228</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA133228</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Switzerland</Country>
<MedlineTA>Cell Mol Life Sci</MedlineTA>
<NlmUniqueID>9705402</NlmUniqueID>
<ISSNLinking>1420-682X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005232">Fatty Acids, Volatile</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D056572">Histone Deacetylase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006877">Hydroxamic Acids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010456">Peptides, Cyclic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.1.98</RegistryNumber>
<NameOfSubstance UI="D006655">Histone Deacetylases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001549">Benzamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016923">Cell Death</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005232">Fatty Acids, Volatile</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056572">Histone Deacetylase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006655">Histone Deacetylases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006877">Hydroxamic Acids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010456">Peptides, Cyclic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25251624</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1533-4406</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>371</Volume>
<Issue>13</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>25</Day>
</PubDate>
</JournalIssue>
<Title>The New England journal of medicine</Title>
<ISOAbbreviation>N. Engl. J. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>Prophylaxis against venous thromboembolism in patients with cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>1263-4</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMc1408866</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Connors</LastName>
<ForeName>Jean M</ForeName>
<Initials>JM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016420">Comment</PublicationType>
<PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>N Engl J Med</MedlineTA>
<NlmUniqueID>0255562</NlmUniqueID>
<ISSNLinking>0028-4793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentOn">
<RefSource>N Engl J Med. 2014 Jun 26;370(26):2515-9</RefSource>
<PMID Version="1">24963570</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentOn">
<RefSource>N Engl J Med. 2014 Sep 25;371(13):1262-3</RefSource>
<PMID Version="1">25251626</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentOn">
<RefSource>N Engl J Med. 2014 Sep 25;371(13):1262</RefSource>
<PMID Version="1">25251625</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000925">Anticoagulants</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054556">Venous Thromboembolism</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25251625</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1533-4406</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>371</Volume>
<Issue>13</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>25</Day>
</PubDate>
</JournalIssue>
<Title>The New England journal of medicine</Title>
<ISOAbbreviation>N. Engl. J. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>Prophylaxis against venous thromboembolism in patients with cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>1262</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMc1408866#SA1</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Verso</LastName>
<ForeName>Melina</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Agnelli</LastName>
<ForeName>Giancarlo</ForeName>
<Initials>G</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016420">Comment</PublicationType>
<PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>N Engl J Med</MedlineTA>
<NlmUniqueID>0255562</NlmUniqueID>
<ISSNLinking>0028-4793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>N Engl J Med. 2014 Sep 25;371(13):1263-4</RefSource>
<PMID Version="1">25251624</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentOn">
<RefSource>N Engl J Med. 2014 Jun 26;370(26):2515-9</RefSource>
<PMID Version="1">24963570</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000925">Anticoagulants</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054556">Venous Thromboembolism</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25251626</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1533-4406</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>371</Volume>
<Issue>13</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>25</Day>
</PubDate>
</JournalIssue>
<Title>The New England journal of medicine</Title>
<ISOAbbreviation>N. Engl. J. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>Prophylaxis against venous thromboembolism in patients with cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>1262-3</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMc1408866#SA2</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Porfidia</LastName>
<ForeName>Angelo</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Morretti</LastName>
<ForeName>Tiziana</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Landolfi</LastName>
<ForeName>Raffaele</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016420">Comment</PublicationType>
<PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>N Engl J Med</MedlineTA>
<NlmUniqueID>0255562</NlmUniqueID>
<ISSNLinking>0028-4793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>N Engl J Med. 2014 Sep 25;371(13):1263-4</RefSource>
<PMID Version="1">25251624</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentOn">
<RefSource>N Engl J Med. 2014 Jun 26;370(26):2515-9</RefSource>
<PMID Version="1">24963570</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000925">Anticoagulants</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054556">Venous Thromboembolism</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24958181</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1759-4782</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>11</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Nature reviews. Clinical oncology</Title>
<ISOAbbreviation>Nat Rev Clin Oncol</ISOAbbreviation>
</Journal>
<ArticleTitle>How does genome sequencing impact surgery?</ArticleTitle>
<Pagination>
<MedlinePgn>610-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nrclinonc.2014.101</ELocationID>
<Abstract>
<AbstractText>Cancer is a leading cause of death worldwide. Great efforts are dedicated to the development of prognostic and predictive biomarkers to improve diagnosis and achieve optimal treatment selection, thereby, introducing precision medicine in the multimodality treatment of cancer. Genomic aberrations are the basis of tumour development, representing excellent candidates for the development of promising clinical biomarkers. Over the past decade, single-gene mutations and genomic profiling have been increasingly used in multidisciplinary consultations for risk-assessment and treatment planning for patients with cancer. We discuss the impact of such genetic-based information on surgical decision-making. Single-gene mutations have already influenced surgical decision-making in breast, colorectal and thyroid cancer. However, the direct impact of genomic profiling on surgical care has not yet been fully established. We discuss the direct and indirect influences of genomic profiling on surgery, and analyse the limitations and unresolved issues of a genotypic-approach to the surgical management of cancer. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Reimers</LastName>
<ForeName>Marlies S</ForeName>
<Initials>MS</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Engels</LastName>
<ForeName>Charla C</ForeName>
<Initials>CC</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kuppen</LastName>
<ForeName>Peter J K</ForeName>
<Initials>PJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>van de Velde</LastName>
<ForeName>Cornelis J H</ForeName>
<Initials>CJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liefers</LastName>
<ForeName>Gerrit J</ForeName>
<Initials>GJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nat Rev Clin Oncol</MedlineTA>
<NlmUniqueID>101500077</NlmUniqueID>
<ISSNLinking>1759-4774</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014644">Genetic Variation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015894">Genome, Human</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023281">Genomics</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057285">Individualized Medicine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018579">Patient Selection</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017422">Sequence Analysis, DNA</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25113839</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1759-4782</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>11</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Nature reviews. Clinical oncology</Title>
<ISOAbbreviation>Nat Rev Clin Oncol</ISOAbbreviation>
</Journal>
<ArticleTitle>Cancer-related fatigue--mechanisms, risk factors, and treatments.</ArticleTitle>
<Pagination>
<MedlinePgn>597-609</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nrclinonc.2014.127</ELocationID>
<Abstract>
<AbstractText>Fatigue is one of the most common adverse effects of cancer that might persist for years after treatment completion in otherwise healthy survivors. Cancer-related fatigue causes disruption in all aspects of quality of life and might be a risk factor of reduced survival. The prevalence and course of fatigue in patients with cancer have been well characterized and there is growing understanding of the underlying biological mechanisms. Inflammation seems to have a key role in fatigue before, during, and after cancer-treatment. However, there is a considerable variability in the presentation of cancer-related fatigue, much of which is not explained by disease-related or treatment-related characteristics, suggesting that host factors might be important in the development and persistence of this symptom. Indeed, longitudinal studies have identified genetic, biological, psychosocial, and behavioural risk factors associated with cancer-related fatigue. Although no current gold-standard treatment for fatigue is available, a variety of intervention approaches have shown beneficial effects in randomized controlled trials, including physical activity, psychosocial, mind-body, and pharmacological treatments. This Review describes the mechanisms, risk factors, and possible interventions for cancer-related fatigue, focusing on recent longitudinal studies and randomized trials that have targeted fatigued patients. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bower</LastName>
<ForeName>Julienne E</ForeName>
<Initials>JE</Initials>
<AffiliationInfo>
<Affiliation>Department of Psychology, University of California, Los Angeles, 1285 Franz Hall, Los Angeles, CA 90095-1563, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>5R01CA160427</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nat Rev Clin Oncol</MedlineTA>
<NlmUniqueID>101500077</NlmUniqueID>
<ISSNLinking>1759-4774</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005221">Fatigue</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008137">Longitudinal Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016032">Randomized Controlled Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017741">Survivors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25255628</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0037-1017</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>86</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Seikagaku. The Journal of Japanese Biochemical Society</Title>
<ISOAbbreviation>Seikagaku</ISOAbbreviation>
</Journal>
<ArticleTitle>[Regulations of YAP transcriptional co-activator].</ArticleTitle>
<Pagination>
<MedlinePgn>464-8</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hata</LastName>
<ForeName>Shoji</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Katada</LastName>
<ForeName>Toshiaki</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nishina</LastName>
<ForeName>Hiroshi</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>jpn</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Japan</Country>
<MedlineTA>Seikagaku</MedlineTA>
<NlmUniqueID>0413564</NlmUniqueID>
<ISSNLinking>0037-1017</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000199">Actins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000199">Actins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011499">Protein Processing, Post-Translational</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25255672</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>09</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1061-3749</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>22</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Journal of nursing measurement</Title>
<ISOAbbreviation>J Nurs Meas</ISOAbbreviation>
</Journal>
<ArticleTitle>Testing measurement invariance of the Chinese version of the Strategies Used by Patients to Promote Health among patients with cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>184-200</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND AND PURPOSE" NlmCategory="OBJECTIVE">The Chinese version of the Strategies Used by Patients to Promote Health (C-SUPPH) is a self-report instrument used to measure self-efficacy among patients with cancer. The purpose of this article is to examine measurement invariance of C-SUPPH using data of 764 cancer patients recruited in China.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Multigroup confirmatory factor analysis (CFA) models were applied across the selected sociodemographic groups of gender, age, education, and monthly income levels.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The factorial structure and factor loadings (relationships between items and their underlying factors) of C-SUPPH were invariant across all sociodemographic groups.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The findings showed that the C-SUPPH measures the same latent constructs/factors in the same way when administered to different sociodemographic groups and thus can be readily applied to studying self-efficacy of cancer patients in China.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yuan</LastName>
<ForeName>Changrong</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wei</LastName>
<ForeName>Chunlan</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Jichuan</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Qian</LastName>
<ForeName>Huijuan</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lev</LastName>
<ForeName>Elise L</ForeName>
<Initials>EL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yuan</LastName>
<ForeName>Avery</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Huiling</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hinds</LastName>
<ForeName>Pamela S</ForeName>
<Initials>PS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Nurs Meas</MedlineTA>
<NlmUniqueID>9318902</NlmUniqueID>
<ISSNLinking>1061-3749</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D044466">Asian Continental Ancestry Group</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001294">Attitude to Health</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000208">ethnology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D002681">China</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003430">Cross-Sectional Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005163">Factor Analysis, Statistical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006293">Health Promotion</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000208">ethnology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011594">Psychometrics</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011795">Questionnaires</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015203">Reproducibility of Results</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D020377">Self Efficacy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D060685">Sense of Coherence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017678">Sex Distribution</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012959">Socioeconomic Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25084322</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-0945</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>97</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Experimental and molecular pathology</Title>
<ISOAbbreviation>Exp. Mol. Pathol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Systemic distribution, subcellular localization and differential expression of sphingosine-1-phosphate receptors in benign and malignant human tissues.</ArticleTitle>
<Pagination>
<MedlinePgn>259-65</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yexmp.2014.07.013</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-4800(14)00126-9</ELocationID>
<Abstract>
<AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Five sphingosine-1-phosphate receptors (S1PR): S1PR1, S1PR2, S1PR3, S1PR4 and S1PR5 (S1PR1-5) have been shown to be involved in the proliferation and progression of various cancers. However, none of the S1PRs have been systemically investigated. In this study, we performed immunohistochemistry (IHC) for S1PR1-S1PR5 on different tissues, in order to simultaneously determine the systemic distribution, subcellular localization and expression level of all five S1PRs.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We constructed tissue microarrays (TMAs) from 384 formalin-fixed paraffin-embedded (FFPE) blocks containing 183 benign and 201 malignant tissues from 34 human organs/systems. Then we performed IHC for all five S1PRs simultaneously on these TMA slides. The distribution, subcellular localization and expression of each S1PR were determined for each tissue. The data in benign and malignant tissues from the same organ/tissue were then compared using the Student's t-test. In order to reconfirm the subcellular localization of each S1PR as determined by IHC, immunocytochemistry (ICC) was performed on several malignant cell lines.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that all five S1PRs are widely distributed in multiple human organs/systems. All S1PRs are expressed in both the cytoplasm and nucleus, except S1PR3, whose IHC signals are only seen in the nucleus. Interestingly, the S1PRs are rarely expressed on cellular membranes. Each S1PR is unique in its organ distribution, subcellular localization and expression level in benign and malignant tissues. Among the five S1PRs, S1PR5 has the highest expression level (in either the nucleus or cytoplasm), with S1PR1, 3, 2 and 4 following in descending order. Strong nuclear expression was seen for S1PR1, S1PR3 and S1PR5, whereas S1PR2 and S1PR4 show only weak staining. Four organs/tissues (adrenal gland, liver, brain and colon) show significant differences in IHC scores for the multiple S1PRs (nuclear and/or cytoplasmic), nine (stomach, lymphoid tissues, lung, ovary, cervix, pancreas, skin, soft tissues and uterus) show differences for only one S1PR (cytoplasmic or nuclear), and twenty three organs/tissues show no significant difference in IHC scores for any S1PR (cytoplasmic or nuclear) between benign and malignant changes.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This is the first study to evaluate the expression level of all S1PRs in benign and malignant tissues from multiple human organs. This study provides data regarding the systemic distribution, subcellular localization and differences in expression of all five S1PRs in benign and malignant changes for each organ/tissue.</AbstractText>
<CopyrightInformation>Copyright Â© 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Chunyi</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China; Department of Pathology, University of Mississippi Medical Center, MS 39216, USA. Electronic address: cwang@umc.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mao</LastName>
<ForeName>Jinghe</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Biology, Tougaloo College, Tougaloo, MS 39174, USA. Electronic address: jmao@tougaloo.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Redfield</LastName>
<ForeName>Samantha</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, University of Mississippi Medical Center, MS 39216, USA. Electronic address: SDRedfield@umc.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mo</LastName>
<ForeName>Yinyuan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Cancer Institute, University of Mississippi Medical Center, MS 39216, USA. Electronic address: ymo@umc.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lage</LastName>
<ForeName>Janice M</ForeName>
<Initials>JM</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, University of Mississippi Medical Center, MS 39216, USA. Electronic address: jlage@umc.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Xinchun</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, University of Mississippi Medical Center, MS 39216, USA; Cancer Institute, University of Mississippi Medical Center, MS 39216, USA. Electronic address: xzhou@umc.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P20 GM103476</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P20GM103476</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Exp Mol Pathol</MedlineTA>
<NlmUniqueID>0370711</NlmUniqueID>
<ISSNLinking>0014-4800</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D049349">Receptors, Lysosphingolipid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056945">Hep G2 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009928">Organ Specificity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021381">Protein Transport</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049349">Receptors, Lysosphingolipid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS618499 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC4177454 [Available on 10/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Adrenal gland</Keyword>
<Keyword MajorTopicYN="N">Cancer</Keyword>
<Keyword MajorTopicYN="N">Colon</Keyword>
<Keyword MajorTopicYN="N">Immunohistochemistry (IHC)</Keyword>
<Keyword MajorTopicYN="N">Liver</Keyword>
<Keyword MajorTopicYN="N">Lung</Keyword>
<Keyword MajorTopicYN="N">Neural system</Keyword>
<Keyword MajorTopicYN="N">Ovary</Keyword>
<Keyword MajorTopicYN="N">Sphingosine-1-phosphate (S1P) receptors (S1PRs)</Keyword>
<Keyword MajorTopicYN="N">Stomach</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25102298</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-0945</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>97</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Experimental and molecular pathology</Title>
<ISOAbbreviation>Exp. Mol. Pathol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Role of microRNA-34 family in cancer with particular reference to cancer angiogenesis.</ArticleTitle>
<Pagination>
<MedlinePgn>298-304</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yexmp.2014.08.002</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-4800(14)00128-2</ELocationID>
<Abstract>
<AbstractText>MicroRNA-34 is involved in pathogenesis in cancer by targeting different tumor-related genes. It could be a biomarker for predicting the prognosis of patients with cancer. In addition, miR-34 is involved in the tumor angiogenesis. Understanding the mechanism of the miR-34 in cancer and tumor angiogenesis will open horizons for development of anti-cancer and anti-angiogenesis drugs. </AbstractText>
<CopyrightInformation>Copyright Â© 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Maroof</LastName>
<ForeName>Hamidreza</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Cancer Molecular Pathology, School of Medicine and Griffith Health Institute, Griffith University, Gold Coast, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Salajegheh</LastName>
<ForeName>Ali</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Cancer Molecular Pathology, School of Medicine and Griffith Health Institute, Griffith University, Gold Coast, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Smith</LastName>
<ForeName>Robert Anthony</ForeName>
<Initials>RA</Initials>
<AffiliationInfo>
<Affiliation>Cancer Molecular Pathology, School of Medicine and Griffith Health Institute, Griffith University, Gold Coast, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lam</LastName>
<ForeName>Alfred King-Yin</ForeName>
<Initials>AK</Initials>
<AffiliationInfo>
<Affiliation>Cancer Molecular Pathology, School of Medicine and Griffith Health Institute, Griffith University, Gold Coast, Queensland, Australia. Electronic address: a.lam@griffith.edu.au.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Exp Mol Pathol</MedlineTA>
<NlmUniqueID>0370711</NlmUniqueID>
<ISSNLinking>0014-4800</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C522425">MIRN34 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009389">Neovascularization, Pathologic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Angiogenesis</Keyword>
<Keyword MajorTopicYN="N">Cancer</Keyword>
<Keyword MajorTopicYN="N">miRNA-34</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25159205</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1552-5783</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>55</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Investigative ophthalmology &amp; visual science</Title>
<ISOAbbreviation>Invest. Ophthalmol. Vis. Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.</ArticleTitle>
<Pagination>
<MedlinePgn>6024-30</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1167/iovs.14-14901</ELocationID>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Hot-spot mutations in the promoter region of telomerase reverse transcriptase (TERT promoter mutations) occur frequently in cutaneous and conjunctival melanoma and are exceedingly rare in uveal melanoma. No information is available on the presence of these mutations in the conjunctival melanocytic precursor lesion primary acquired melanosis (PAM). We tested a cohort of uveal and conjunctival melanomas as well as conjunctival benign and premalignant melanocytic lesions for TERT promoter mutations in order to elucidate the role of these mutations in tumor progression.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">TERT promoter mutation analysis on fresh tumor DNA and DNA from formalin-fixed, paraffin-embedded specimens was performed by SNaPshot analysis in 102 uveal melanomas, 39 conjunctival melanomas, 26 PAM with atypia, 14 PAM without atypia, and 56 conjunctival nevi.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Mutations of the TERT promoter were not identified in conjunctival nevi or PAM without atypia, but were detected in 2/25 (8%) of PAM with atypia and 16/39 (41%) of conjunctival melanomas. A single TERT promoter mutation was detected in 102 uveal melanomas (1%).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We present the second documented case of TERT promoter mutation in uveal melanoma. In comparison with other types of melanoma, TERT promoter mutations occur at extremely low frequency in uveal melanoma. TERT promoter mutations are frequent in conjunctival melanoma and occur at lower frequency in PAM with atypia but were not detected in benign conjunctival melanocytic lesions. These findings favor a pathogenetic tumor progression role for TERT promoter mutations in conjunctival melanocytic lesions.</AbstractText>
<CopyrightInformation>Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Koopmans</LastName>
<ForeName>Anna E</ForeName>
<Initials>AE</Initials>
<AffiliationInfo>
<Affiliation>Department of Ophthalmology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands Department of Clinical Genetics, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ober</LastName>
<ForeName>Kimberley</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dubbink</LastName>
<ForeName>Hendrikus J</ForeName>
<Initials>HJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Paridaens</LastName>
<ForeName>Dion</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>The Rotterdam Eye Hospital, Rotterdam, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Naus</LastName>
<ForeName>Nicole C</ForeName>
<Initials>NC</Initials>
<AffiliationInfo>
<Affiliation>Department of Ophthalmology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Belunek</LastName>
<ForeName>Stephan</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Krist</LastName>
<ForeName>Bart</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Post</LastName>
<ForeName>Edward</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zwarthoff</LastName>
<ForeName>Ellen C</ForeName>
<Initials>EC</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>de Klein</LastName>
<ForeName>Annelies</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Clinical Genetics, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Verdijk</LastName>
<ForeName>Robert M</ForeName>
<Initials>RM</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<CollectiveName>Rotterdam Ocular Melanoma Study Group</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Invest Ophthalmol Vis Sci</MedlineTA>
<NlmUniqueID>7703701</NlmUniqueID>
<ISSNLinking>0146-0404</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>EC 2.7.7.49</RegistryNumber>
<NameOfSubstance UI="C509186">TERT protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.7.49</RegistryNumber>
<NameOfSubstance UI="D019098">Telomerase</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C536494">Uveal melanoma</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003230">Conjunctival Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008545">Melanoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008548">Melanosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009508">Nevus, Pigmented</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011230">Precancerous Conditions</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015995">Prevalence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019098">Telomerase</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014604">Uveal Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">BRAF</Keyword>
<Keyword MajorTopicYN="N">TERT</Keyword>
<Keyword MajorTopicYN="N">conjunctival melanoma</Keyword>
<Keyword MajorTopicYN="N">mutation</Keyword>
<Keyword MajorTopicYN="N">nevus</Keyword>
<Keyword MajorTopicYN="N">primary acquired melanosis</Keyword>
<Keyword MajorTopicYN="N">uveal melanoma</Keyword>
</KeywordList>
<InvestigatorList>
<Investigator ValidYN="Y">
<LastName>Dion</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Paridaens</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Mensink</LastName>
<ForeName>Hanneke W</ForeName>
<Initials>HW</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>van den Bosch</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Naus</LastName>
<ForeName>Nicole C</ForeName>
<Initials>NC</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Kilic</LastName>
<ForeName>Emine</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Koopmans</LastName>
<ForeName>Anna E</ForeName>
<Initials>AE</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>van Beek</LastName>
<ForeName>Jackelien G</ForeName>
<Initials>JG</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Verdijk</LastName>
<ForeName>Robert M</ForeName>
<Initials>RM</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>de Klein</LastName>
<ForeName>Annelies</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Yavuzyigitoglu</LastName>
<ForeName>Serdar</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Vaarwater</LastName>
<ForeName>Jolanda</ForeName>
<Initials>J</Initials>
</Investigator>
</InvestigatorList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25043024</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-4687</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>513</Volume>
<Issue>7519</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>25</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>Functional polarization of tumour-associated macrophages by tumour-derived lactic acid.</ArticleTitle>
<Pagination>
<MedlinePgn>559-63</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13490</ELocationID>
<Abstract>
<AbstractText>Macrophages have an important role in the maintenance of tissue homeostasis. To perform this function, macrophages must have the capacity to monitor the functional states of their 'client cells': namely, the parenchymal cells in the various tissues in which macrophages reside. Tumours exhibit many features of abnormally developed organs, including tissue architecture and cellular composition. Similarly to macrophages in normal tissues and organs, macrophages in tumours (tumour-associated macrophages) perform some key homeostatic functions that allow tumour maintenance and growth. However, the signals involved in communication between tumours and macrophages are poorly defined. Here we show that lactic acid produced by tumour cells, as a by-product of aerobic or anaerobic glycolysis, has a critical function in signalling, through inducing the expression of vascular endothelial growth factor and the M2-like polarization of tumour-associated macrophages. Furthermore, we demonstrate that this effect of lactic acid is mediated by hypoxia-inducible factor 1Î± (HIF1Î±). Finally, we show that the lactate-induced expression of arginase 1 by macrophages has an important role in tumour growth. Collectively, these findings identify a mechanism of communication between macrophages and their client cells, including tumour cells. This communication most probably evolved to promote homeostasis in normal tissues but can also be engaged in tumours to promote their growth. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Colegio</LastName>
<ForeName>Oscar R</ForeName>
<Initials>OR</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06519-1612, USA [2] Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut 06520-8059, USA [3] Yale-New Haven Transplantation Center, Yale University School of Medicine, New Haven, Connecticut 06519-1369, USA [4] Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520-8028, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chu</LastName>
<ForeName>Ngoc-Quynh</ForeName>
<Initials>NQ</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06519-1612, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Szabo</LastName>
<ForeName>Alison L</ForeName>
<Initials>AL</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06519-1612, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chu</LastName>
<ForeName>Thach</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06519-1612, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rhebergen</LastName>
<ForeName>Anne Marie</ForeName>
<Initials>AM</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06519-1612, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jairam</LastName>
<ForeName>Vikram</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06519-1612, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cyrus</LastName>
<ForeName>Nika</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06519-1612, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Brokowski</LastName>
<ForeName>Carolyn E</ForeName>
<Initials>CE</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06519-1612, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Eisenbarth</LastName>
<ForeName>Stephanie C</ForeName>
<Initials>SC</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06519-1612, USA [2] Department of Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut 06520-8035, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Phillips</LastName>
<ForeName>Gillian M</ForeName>
<Initials>GM</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Yale University School of Medicine, New Haven, Connecticut 06520-8107, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cline</LastName>
<ForeName>Gary W</ForeName>
<Initials>GW</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520-8020, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Phillips</LastName>
<ForeName>Andrew J</ForeName>
<Initials>AJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Yale University School of Medicine, New Haven, Connecticut 06520-8107, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Medzhitov</LastName>
<ForeName>Ruslan</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06519-1612, USA [2] Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520-8028, USA [3] Howard Hughes Medical Institute, Chevy Chase, Maryland 20815-6789, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>1 P50 CA121974</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>1K08CA172580-01</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>5KL2RR024138</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>AI046688</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>AI089771</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA157461</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>K08 CA172580</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<Agency>Howard Hughes Medical Institute</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017077">Culture Media, Conditioned</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>33X04XA5AT</RegistryNumber>
<NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.3.1</RegistryNumber>
<NameOfSubstance UI="D001119">Arginase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Immunol Cell Biol. 2014 Sep;92(8):647-9</RefSource>
<PMID Version="1">25091608</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001119">Arginase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018827">Carcinoma, Lewis Lung</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002450">Cell Communication</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002455">Cell Division</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017077">Culture Media, Conditioned</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006019">Glycolysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006706">Homeostasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019344">Lactic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008546">Melanoma, Experimental</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012995">Solubility</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042461">Vascular Endothelial Growth Factor A</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25272572</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>09</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0035-7715</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>65</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Roczniki PaÅstwowego ZakÅadu Higieny</Title>
<ISOAbbreviation>Rocz Panstw Zakl Hig</ISOAbbreviation>
</Journal>
<ArticleTitle>Flavonoids--food sources and health benefits.</ArticleTitle>
<Pagination>
<MedlinePgn>79-85</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Flavonoids are a group of bioactive compounds that are extensively found in foodstuffs of plant origin. Their regular consumption is associated with reduced risk of a number of chronic diseases, including cancer, cardiovascular disease (CVD) and neurodegenerative disorders. Flavonoids are classified into subgroups based on their chemical structure: flavanones, flavones, flavonols, flavan-3-ols, anthocyanins and isoflavones. Their actions at the molecular level include antioxidant effects, as well the ability to modulate several key enzymatic pathways. The growing body of scientific evidence indicates that flavonoids play a beneficial role in disease prevention, however further clinical and epidemiological trials are greatly needed. Among dietary sources of flavonoids there are fruits, vegetables, nuts, seeds and spices. Consumption of these substances with diet appears to be safe. It seems that a diet rich in flavonoids is beneficial and its promotion is thus justifiable.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>KozÅowska</LastName>
<ForeName>Aleksandra</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Szostak-Wegierek</LastName>
<ForeName>Dorota</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Poland</Country>
<MedlineTA>Rocz Panstw Zakl Hig</MedlineTA>
<NlmUniqueID>0414756</NlmUniqueID>
<ISSNLinking>0035-7715</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020011">Protective Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000975">Antioxidants</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002318">Cardiovascular Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005419">Flavonoids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D005502">Food</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005638">Fruit</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019636">Neurodegenerative Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020011">Protective Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D040242">Risk Reduction Behavior</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014675">Vegetables</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25111898</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Gain-of-function of mutant p53: mutant p53 enhances cancer progression by inhibiting KLF17 expression in invasive breast carcinoma cells.</ArticleTitle>
<Pagination>
<MedlinePgn>87-96</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.045</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00424-8</ELocationID>
<Abstract>
<AbstractText>Kruppel-like-factor 17 (KLF17) is a negative regulator of metastasis and epithelial-mesenchymal-transition (EMT). However, its expression is downregulated in metastatic breast cancer that contains p53 mutations. Here, we show that mutant-p53 plays a key role to suppress KLF17 and thereby enhances cancer progression, which defines novel gain-of-function (GOF) of mutant-p53. Mutant-p53 interacts with KLF17 and antagonizes KLF17 mediated EMT genes transcription. Depletion of KLF17 promotes cell viability, decreases apoptosis and induces drug resistance in metastatic breast cancer cells. KLF17 suppresses cell migration and invasion by decreasing CD44, PAI-1 and Cyclin-D1 expressions. Taken together, our results show that KLF17 is important for the suppression of metastasis and could be a potential therapeutic target during chemotherapy. </AbstractText>
<CopyrightInformation>Copyright Â© 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ali</LastName>
<ForeName>Amjad</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai, 200241, China. Electronic address: amjad_486@yahoo.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shah</LastName>
<ForeName>Abdus Saboor</ForeName>
<Initials>AS</Initials>
<AffiliationInfo>
<Affiliation>Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai, 200241, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ahmad</LastName>
<ForeName>Ayaz</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China; Department of Biotechnology, Abdul Wali Khan University, Mardan, 23200, Pakistan. Electronic address: ahdayazb5@awkum.edu.pk.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018960">Antigens, CD44</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C530104">CCND1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497483">CD44 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C510638">KLF17 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017395">Plasminogen Activator Inhibitor 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C051321">SERPINE1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495901">TP53 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>136601-57-5</RegistryNumber>
<NameOfSubstance UI="D019938">Cyclin D1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018960">Antigens, CD44</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002277">Carcinoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019938">Cyclin D1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061986">MCF-7 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017395">Plasminogen Activator Inhibitor 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034622">RNA Interference</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016159">Tumor Suppressor Protein p53</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Breast cancer</Keyword>
<Keyword MajorTopicYN="N">Chemotherapy</Keyword>
<Keyword MajorTopicYN="N">Invasion</Keyword>
<Keyword MajorTopicYN="N">KLF17</Keyword>
<Keyword MajorTopicYN="N">Metastasis</Keyword>
<Keyword MajorTopicYN="N">Mutant p53</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25130173</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors.</ArticleTitle>
<Pagination>
<MedlinePgn>12-20</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.08.010</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00438-8</ELocationID>
<Abstract>
<AbstractText>Epigenetic alterations are strongly associated with cancer development and drug resistance. The use of the DNA methylation inhibitor decitabine (DacogenÂ®) has been approved in the treatment of hematological malignancies, and its clinical effects on solid tumors have gained attention. Here, we present a review of the molecular regulation mechanisms, clinical experiences and biological evaluation for novel decitabine-based therapies in solid tumors. We also discuss the following questions: What is the best administration schedule of decitabine in solid tumors? Is there tumor type specificity for decitabine-based epigenetic therapy? What are the biological function and mechanism of decitabine in suppressing tumor development? Is there a correlation between DNA demethylation and clinical response? Importantly, low-dose decitabine and combined therapy show significant improvement in solid tumor treatment. However, the correlation studies are preliminary, and key biomarkers for prognosis need further investigation. </AbstractText>
<CopyrightInformation>Copyright Â© 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Nie</LastName>
<ForeName>Jing</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biology, Institute of Basic Medical Science, PLA General Hospital, Beijing 100853, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Lin</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, PLA General Hospital, Beijing 100853, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Xiang</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biology, Institute of Basic Medical Science, PLA General Hospital, Beijing 100853, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Han</LastName>
<ForeName>Weidong</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biology, Institute of Basic Medical Science, PLA General Hospital, Beijing 100853, China. Electronic address: hanwdrsw69@yahoo.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000964">Antimetabolites, Antineoplastic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014408">Tumor Markers, Biological</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>776B62CQ27</RegistryNumber>
<NameOfSubstance UI="C014347">decitabine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>M801H13NRU</RegistryNumber>
<NameOfSubstance UI="D001374">Azacitidine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000964">Antimetabolites, Antineoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001374">Azacitidine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019175">DNA Methylation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D044127">Epigenesis, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014408">Tumor Markers, Biological</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Decitabine</Keyword>
<Keyword MajorTopicYN="N">Demethylating drug</Keyword>
<Keyword MajorTopicYN="N">Drug sensitivity</Keyword>
<Keyword MajorTopicYN="N">Tumor therapy</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25265652</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0040-165X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>55</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Technology and culture</Title>
<ISOAbbreviation>Technol Cult</ISOAbbreviation>
</Journal>
<ArticleTitle>Eco-friendly versus cancer causing: perceptions of diesel cars in West Germany and the United States 1970-1990.</ArticleTitle>
<Pagination>
<MedlinePgn>429-60</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Neumaier</LastName>
<ForeName>Christopher</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016456">Historical Article</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Technol Cult</MedlineTA>
<NlmUniqueID>21120500R</NlmUniqueID>
<ISSNLinking>0040-165X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000393">Air Pollutants</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005742">Gasoline</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001335">Vehicle Emissions</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>QIS</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000393">Air Pollutants</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001336">Automobiles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D005742">Gasoline</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D005860">Germany, West</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049673">History, 20th Century</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D033181">Information Dissemination</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D011639">Public Opinion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D001335">Vehicle Emissions</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25265737</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0825-8597</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>30</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Season>Autumn</Season>
</PubDate>
</JournalIssue>
<Title>Journal of palliative care</Title>
<ISOAbbreviation>J Palliat Care</ISOAbbreviation>
</Journal>
<ArticleTitle>Factors associated with fulfilling the preference for dying at home among cancer patients: the role of general practitioners.</ArticleTitle>
<Pagination>
<MedlinePgn>141-50</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="AIM" NlmCategory="OBJECTIVE">This study aimed to explore clinical and care-related factors associated with fulfilling cancer patients' preference for home death across four countries: Belgium (BE), The Netherlands (NL), Italy (IT), and Spain (ES).</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">A mortality follow-back study was undertaken from 2009 to 2011 via representative networks of general practitioners (GPs). The study included all patients aged 18 and over who had died of cancer and whose home death preference and place of death were known by the GP. Factors associated with meeting home death preference were tested using multivariable logistic regressions.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 2,048 deceased patients, preferred and actual place of death was known in 42.6 percent of cases. Home death preference met ranged from 65.5 to 90.9 percent. Country-specific factors included older age in BE, and decision-making capacity and being female in the NL. GPs' provision of palliative care was positively associated with meeting home death preference. Odds ratios (ORs) were: BE: 9.9 (95 percent confidence interval [CI] 3.7-26.6); NL: 9.7 (2.4-39.9); and IT: 2.6 (1.2-5.5). ORs for Spain are not shown because a multivariate model was not performed.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Those who develop policy to facilitate home death need to examine available resources for primary end-of-life care.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ko</LastName>
<ForeName>Winne</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Miccinesi</LastName>
<ForeName>Guido</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Beccaro</LastName>
<ForeName>Monica</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Moreels</LastName>
<ForeName>Sarah</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Donker</LastName>
<ForeName>GÃ© A</ForeName>
<Initials>GA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Onwuteaka-Philipsen</LastName>
<ForeName>Bregje</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Alonso</LastName>
<ForeName>TomÃ¡s V</ForeName>
<Initials>TV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Deliens</LastName>
<ForeName>Luc</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Van den Block</LastName>
<ForeName>Lieve</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<CollectiveName>EURO IMPACT</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Canada</Country>
<MedlineTA>J Palliat Care</MedlineTA>
<NlmUniqueID>8610345</NlmUniqueID>
<ISSNLinking>0825-8597</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D001293">Attitude to Death</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D001530">Belgium</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007558">Italy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D009426">Netherlands</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010166">Palliative Care</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057240">Patient Preference</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D010819">Physician's Role</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010817">Physician-Patient Relations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D010821">Physicians, Family</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D013030">Spain</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013727">Terminal Care</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
</MeshHeadingList>
<InvestigatorList>
<Investigator ValidYN="Y">
<LastName>Van den Block</LastName>
<ForeName>Lieve</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>De Groote</LastName>
<ForeName>Zeger</ForeName>
<Initials>Z</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Brearley</LastName>
<ForeName>Sarah</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Caraceni</LastName>
<ForeName>Augusto</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Cohen</LastName>
<ForeName>Joachim</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Costantini</LastName>
<ForeName>Massimo</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Francke</LastName>
<ForeName>Anneke</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Harding</LastName>
<ForeName>Richard</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Higginson</LastName>
<ForeName>Irene</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Kaasa</LastName>
<ForeName>Stein</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Linden</LastName>
<ForeName>Karen</ForeName>
<Initials>K</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Miccinesi</LastName>
<ForeName>Guido</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Onwuteaka-Philipsen</LastName>
<ForeName>Bregje</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Pardon</LastName>
<ForeName>Koen</ForeName>
<Initials>K</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Pasman</LastName>
<ForeName>Roeline</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Pautex</LastName>
<ForeName>Sophie</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Payne</LastName>
<ForeName>Sheila</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Deliens</LastName>
<ForeName>Luc</ForeName>
<Initials>L</Initials>
</Investigator>
</InvestigatorList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25265740</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0825-8597</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>30</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Season>Autumn</Season>
</PubDate>
</JournalIssue>
<Title>Journal of palliative care</Title>
<ISOAbbreviation>J Palliat Care</ISOAbbreviation>
</Journal>
<ArticleTitle>Initiation of chemotherapy in cancer patients with poor performance status: a population-based analysis.</ArticleTitle>
<Pagination>
<MedlinePgn>166-72</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Practice guidelines indicate that patients who have months to weeks left to live should not be offered chemotherapy. We examined factors associated with clinician-reported poor performance status as determined by the Palliative Performance Scale (PPS) and subsequent initiation of intravenous (IV) chemotherapy in an ambulatory cancer population in Ontario, Canada.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">In this retrospective study, patients who had at least one PPS assessment indicating poor performance status (a PPS score of 50 or lower) comprised the study cohort. Using linked administrative databases, we observed the cohort for initiation of IV chemotherapy within 30 days of the first (index) poor PPS assessment.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We excluded patients for whom IV or oral chemotherapy was ongoing or recently completed or whose performance status improved following the index assessment. Of the remaining cohort, 9.3 percent (264/2,842) received IV chemotherapy within 30 days of the index PPS.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A small number of cancer patients with poor performance status began IV chemotherapy in the month following assessment.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Porter</LastName>
<ForeName>Joan</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Earle</LastName>
<ForeName>Craig</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Atzema</LastName>
<ForeName>Clare</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Ying</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Howell</LastName>
<ForeName>Doris</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Seow</LastName>
<ForeName>Hsien</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sutradhar</LastName>
<ForeName>Rinku</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dudgeon</LastName>
<ForeName>Deborah</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Husain</LastName>
<ForeName>Amna</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sussman</LastName>
<ForeName>Jonathan</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Barbera</LastName>
<ForeName>Lisa</ForeName>
<Initials>L</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Canada</Country>
<MedlineTA>J Palliat Care</MedlineTA>
<NlmUniqueID>8610345</NlmUniqueID>
<ISSNLinking>0825-8597</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D003657">Decision Making</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017567">Karnofsky Performance Status</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D009864">Ontario</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010166">Palliative Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017410">Practice Guidelines as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018570">Risk Assessment</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25265940</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Electronic-Print">
<Journal>
<ISSN IssnType="Electronic">1460-2105</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>106</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Journal of the National Cancer Institute</Title>
<ISOAbbreviation>J. Natl. Cancer Inst.</ISOAbbreviation>
</Journal>
<ArticleTitle>Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).</ArticleTitle>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/jnci/dju244</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">dju244</ELocationID>
<Abstract>
<AbstractText>The standard approach for documenting symptomatic adverse events (AEs) in cancer clinical trials involves investigator reporting using the National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events (CTCAE). Because this approach underdetects symptomatic AEs, the NCI issued two contracts to create a patient-reported outcome (PRO) measurement system as a companion to the CTCAE, called the PRO-CTCAE. This Commentary describes development of the PRO-CTCAE by a group of multidisciplinary investigators and patient representatives and provides an overview of qualitative and quantitative studies of its measurement properties. A systematic evaluation of all 790 AEs listed in the CTCAE identified 78 appropriate for patient self-reporting. For each of these, a PRO-CTCAE plain language term in English and one to three items characterizing the frequency, severity, and/or activity interference of the AE were created, rendering a library of 124 PRO-CTCAE items. These items were refined in a cognitive interviewing study among patients on active cancer treatment with diverse educational, racial, and geographic backgrounds. Favorable measurement properties of the items, including construct validity, reliability, responsiveness, and between-mode equivalence, were determined prospectively in a demographically diverse population of patients receiving treatments for many different tumor types. A software platform was built to administer PRO-CTCAE items to clinical trial participants via the internet or telephone interactive voice response and was refined through usability testing. Work is ongoing to translate the PRO-CTCAE into multiple languages and to determine the optimal approach for integrating the PRO-CTCAE into clinical trial workflow and AE analyses. It is envisioned that the PRO-CTCAE will enhance the precision and patient-centeredness of adverse event reporting in cancer clinical research. </AbstractText>
<CopyrightInformation>Â© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Basch</LastName>
<ForeName>Ethan</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS). ebasch@med.unc.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Reeve</LastName>
<ForeName>Bryce B</ForeName>
<Initials>BB</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mitchell</LastName>
<ForeName>Sandra A</ForeName>
<Initials>SA</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Clauser</LastName>
<ForeName>Steven B</ForeName>
<Initials>SB</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Minasian</LastName>
<ForeName>Lori M</ForeName>
<Initials>LM</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dueck</LastName>
<ForeName>Amylou C</ForeName>
<Initials>AC</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mendoza</LastName>
<ForeName>Tito R</ForeName>
<Initials>TR</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hay</LastName>
<ForeName>Jennifer</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Atkinson</LastName>
<ForeName>Thomas M</ForeName>
<Initials>TM</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Abernethy</LastName>
<ForeName>Amy P</ForeName>
<Initials>AP</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bruner</LastName>
<ForeName>Deborah W</ForeName>
<Initials>DW</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cleeland</LastName>
<ForeName>Charles S</ForeName>
<Initials>CS</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sloan</LastName>
<ForeName>Jeff A</ForeName>
<Initials>JA</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chilukuri</LastName>
<ForeName>Ram</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Baumgartner</LastName>
<ForeName>Paul</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Denicoff</LastName>
<ForeName>Andrea</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>St Germain</LastName>
<ForeName>Diane</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>O'Mara</LastName>
<ForeName>Ann M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Alice</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kelaghan</LastName>
<ForeName>Joseph</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bennett</LastName>
<ForeName>Antonia V</ForeName>
<Initials>AV</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sit</LastName>
<ForeName>Laura</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rogak</LastName>
<ForeName>Lauren</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Barz</LastName>
<ForeName>Allison</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Paul</LastName>
<ForeName>Diane B</ForeName>
<Initials>DB</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schrag</LastName>
<ForeName>Deborah</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>HHSN261201000043C</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>HHSN261201000063C</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Natl Cancer Inst</MedlineTA>
<NlmUniqueID>7503089</NlmUniqueID>
<ISSNLinking>0027-8874</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D016907">Adverse Drug Reaction Reporting Systems</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054547">National Cancer Institute (U.S.)</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063868">Patient Outcome Assessment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011795">Questionnaires</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D057566">Self Report</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009626">Terminology as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4200059 [Available on 09/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25269231</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1708-1890</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>11</Volume>
<Issue>4</Issue>
<PubDate>
<MedlineDate>2014 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Perspective infirmiÃ¨re : revue officielle de l'Ordre des infirmiÃ¨res et infirmiers du QuÃ©bec</Title>
<ISOAbbreviation>Perspect Infirm</ISOAbbreviation>
</Journal>
<ArticleTitle>[Teaching patients about chemotherapy].</ArticleTitle>
<Pagination>
<MedlinePgn>18</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Fiore</LastName>
<ForeName>Francine</ForeName>
<Initials>F</Initials>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>Enseignement en chimiothÃ©rapie.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>Canada</Country>
<MedlineTA>Perspect Infirm</MedlineTA>
<NlmUniqueID>101196674</NlmUniqueID>
<ISSNLinking>1708-1890</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000451">nursing</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D010353">Patient Education as Topic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25269242</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1708-1890</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>11</Volume>
<Issue>4</Issue>
<PubDate>
<MedlineDate>2014 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Perspective infirmiÃ¨re : revue officielle de l'Ordre des infirmiÃ¨res et infirmiers du QuÃ©bec</Title>
<ISOAbbreviation>Perspect Infirm</ISOAbbreviation>
</Journal>
<ArticleTitle>[Oral chemotherapy agents for cancer].</ArticleTitle>
<Pagination>
<MedlinePgn>52-4</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chouinard</LastName>
<ForeName>Audrey</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Adam</LastName>
<ForeName>Jean-Philippe</ForeName>
<Initials>JP</Initials>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>La thÃ©rapie systÃ©mique orale contre le cancer.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>Canada</Country>
<MedlineTA>Perspect Infirm</MedlineTA>
<NlmUniqueID>101196674</NlmUniqueID>
<ISSNLinking>1708-1890</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004340">Drug Contamination</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25271430</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>13</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0893-9675</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>19</Volume>
<Issue>3-4</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Critical reviews in oncogenesis</Title>
<ISOAbbreviation>Crit Rev Oncog</ISOAbbreviation>
</Journal>
<ArticleTitle>Dawn of advanced molecular medicine: nanotechnological advancements in cancer imaging and therapy.</ArticleTitle>
<Pagination>
<MedlinePgn>143-76</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Nanotechnology plays an increasingly important role not only in our everyday life (with all its benefits and dangers) but also in medicine. Nanoparticles are to date the most intriguing option to deliver high concentrations of agents specifically and directly to cancer cells; therefore, a wide variety of these nanomaterials has been developed and explored. These span the range from simple nanoagents to sophisticated smart devices for drug delivery or imaging. Nanomaterials usually provide a large surface area, allowing for decoration with a large amount of moieties on the surface for either additional functionalities or targeting. Besides using particles solely for imaging purposes, they can also carry as a payload a therapeutic agent. If both are combined within the same particle, a theranostic agent is created. The sophistication of highly developed nanotechnology targeting approaches provides a promising means for many clinical implementations and can provide improved applications for otherwise suboptimal formulations. In this review we will explore nanotechnology both for imaging and therapy to provide a general overview of the field and its impact on cancer imaging and therapy. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kaittanis</LastName>
<ForeName>Charalambos</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shaffer</LastName>
<ForeName>Travis M</ForeName>
<Initials>TM</Initials>
<AffiliationInfo>
<Affiliation>Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Thorek</LastName>
<ForeName>Daniel L J</ForeName>
<Initials>DL</Initials>
<AffiliationInfo>
<Affiliation>Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Grimm</LastName>
<ForeName>Jan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>1R01 EB014944</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>5R25CA096945-07</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 CA008748</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 CA008748-44 S5</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 EB014944</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R24 CA083084</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R25 CA096945</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Crit Rev Oncog</MedlineTA>
<NlmUniqueID>8914610</NlmUniqueID>
<ISSNLinking>0893-9675</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008279">Magnetic Resonance Imaging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D062346">Molecular Medicine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053758">Nanoparticles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D036103">Nanotechnology</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049268">Positron-Emission Tomography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015899">Tomography, Emission-Computed, Single-Photon</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS626574 [Available on 01/01/15]</OtherID>
<OtherID Source="NLM">PMC4183929 [Available on 01/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25271432</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>13</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0893-9675</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>19</Volume>
<Issue>3-4</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Critical reviews in oncogenesis</Title>
<ISOAbbreviation>Crit Rev Oncog</ISOAbbreviation>
</Journal>
<ArticleTitle>Nanoparticle drug formulations for cancer diagnosis and treatment.</ArticleTitle>
<Pagination>
<MedlinePgn>223-45</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Over the past ten years, more than a billion dollars in U.S. government funding has been awarded to the development of nanomaterials for clinical diagnosis and therapy. In this article we will focus on one subset of nanotechnology: nanoparticle formulations of drugs intended to diagnose or treat cancer. Several nanoparticle drug preparations are now in widespread clinical use, and dozens are in the pipeline. In some cases the nanoparticles are simply passive drug carriers or contrast agents; in others, the nanoparticles have active therapeutic properties. Cancer, particularly solid tumors, is one of nanotechnology's key targets. The specific challenges involved in cancer treatment are those addressed by multifunctional materials, in particular, inaccessibility, widespread metastasis, low oxygen concentrations, and resistance to drugs and radiation. Nonetheless, major barriers still remain to effective nanoparticle design and approval. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Poon</LastName>
<ForeName>Wilson</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Biomedical Engineering, McGill University, Montreal, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Xuan</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Biomedical Engineering, McGill University, Montreal, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nadeau</LastName>
<ForeName>Jay</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Biomedical Engineering, McGill University, Montreal, Canada.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Crit Rev Oncog</MedlineTA>
<NlmUniqueID>8914610</NlmUniqueID>
<ISSNLinking>0893-9675</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002626">Chemistry, Pharmaceutical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D016503">Drug Delivery Systems</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053758">Nanoparticles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010778">Photochemotherapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014057">Tomography, X-Ray Computed</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25271433</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>13</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0893-9675</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>19</Volume>
<Issue>3-4</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Critical reviews in oncogenesis</Title>
<ISOAbbreviation>Crit Rev Oncog</ISOAbbreviation>
</Journal>
<ArticleTitle>Progress in lipid-based nanoparticles for cancer therapy.</ArticleTitle>
<Pagination>
<MedlinePgn>247-60</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Most conventional cancer therapeutics gain limited access to many types of tumors while having considerable adverse effects, resulting in low therapeutic efficacy and high toxicity. Therefore, research has now focused on the development of novel drug delivery systems (DDS) with the goal of maintaining high therapeutic drug levels at malignant cells and as low as possible drug levels in other cells. The introduction of nanotechnology has addressed some of these problems and opened up new avenues for improved cancer therapy. The design of nanoparticles for DDS takes into consideration issues such as targeting, controlled drug release and enhanced penetration via biological barriers. In this review we describe the design principles of targeted DDS for cancer therapy and the types of nanoparticles that are under development. Emphasis is put on lipid-based nanoparticles, particularly bolaamphiphilic vesicles that have tremendous potential in delivering therapeutic and diagnostic agents to specific cells following systemic administration. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Grinberg</LastName>
<ForeName>Sarina</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Ben-Gurion University of the Negev, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Linder</LastName>
<ForeName>Charles</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Zuckerberg Water Institute and Department of Biotechnology Engineering, Ben-Gurion University of the Negev, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Heldman</LastName>
<ForeName>Eliahu</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Israel.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Crit Rev Oncog</MedlineTA>
<NlmUniqueID>8914610</NlmUniqueID>
<ISSNLinking>0893-9675</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008055">Lipids</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D016503">Drug Delivery Systems</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008055">Lipids</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053758">Nanoparticles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25271618</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1533-4406</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>371</Volume>
<Issue>14</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>2</Day>
</PubDate>
</JournalIssue>
<Title>The New England journal of medicine</Title>
<ISOAbbreviation>N. Engl. J. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>Anticoagulation for central venous catheters in patients with cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>1362-3</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMc1408861</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>D'Ambrosio</LastName>
<ForeName>Lorenzo</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Candiolo Cancer Institute, Candiolo, Italy giovanni.grignani@ircc.it.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Aglietta</LastName>
<ForeName>Massimo</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Grignani</LastName>
<ForeName>Giovanni</ForeName>
<Initials>G</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016422">Letter</PublicationType>
<PublicationType UI="D017418">Meta-Analysis</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>N Engl J Med</MedlineTA>
<NlmUniqueID>0255562</NlmUniqueID>
<ISSNLinking>0028-4793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000925">Anticoagulants</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D062905">Central Venous Catheters</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056824">Upper Extremity Deep Vein Thrombosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25230706</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>08</Day>
</DateCompleted>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1471-2105</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>15</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>BMC bioinformatics</Title>
<ISOAbbreviation>BMC Bioinformatics</ISOAbbreviation>
</Journal>
<ArticleTitle>Personalized Oncology Suite: integrating next-generation sequencing data and whole-slide bioimages.</ArticleTitle>
<Pagination>
<MedlinePgn>306</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-2105-15-306</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cancer immunotherapy has recently entered a remarkable renaissance phase with the approval of several agents for treatment. Cancer treatment platforms have demonstrated profound tumor regressions including complete cure in patients with metastatic cancer. Moreover, technological advances in next-generation sequencing (NGS) as well as the development of devices for scanning whole-slide bioimages from tissue sections and image analysis software for quantitation of tumor-infiltrating lymphocytes (TILs) allow, for the first time, the development of personalized cancer immunotherapies that target patient specific mutations. However, there is currently no bioinformatics solution that supports the integration of these heterogeneous datasets.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We have developed a bioinformatics platform - Personalized Oncology Suite (POS) - that integrates clinical data, NGS data and whole-slide bioimages from tissue sections. POS is a web-based platform that is scalable, flexible and expandable. The underlying database is based on a data warehouse schema, which is used to integrate information from different sources. POS stores clinical data, genomic data (SNPs and INDELs identified from NGS analysis), and scanned whole-slide images. It features a genome browser as well as access to several instances of the bioimage management application Bisque. POS provides different visualization techniques and offers sophisticated upload and download possibilities. The modular architecture of POS allows the community to easily modify and extend the application.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The web-based integration of clinical, NGS, and imaging data represents a valuable resource for clinical researchers and future application in medical oncology. POS can be used not only in the context of cancer immunology but also in other studies in which NGS data and images of tissue sections are generated. The application is open-source and can be downloaded at http://www.icbi.at/POS.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dander</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Baldauf</LastName>
<ForeName>Matthias</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sperk</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pabinger</LastName>
<ForeName>Stephan</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hiltpolt</LastName>
<ForeName>Benjamin</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Trajanoski</LastName>
<ForeName>Zlatko</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Division for Bioinformatics, Biocenter, Innsbruck Medical University, Innrain 80-82, 6020 Innsbruck, Austria. zlatko.trajanoski@i-med.ac.at.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>BMC Bioinformatics</MedlineTA>
<NlmUniqueID>100965194</NlmUniqueID>
<ISSNLinking>1471-2105</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016208">Databases, Factual</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023281">Genomics</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D059014">High-Throughput Nucleotide Sequencing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054643">INDEL Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057285">Individualized Medicine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020407">Internet</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D057054">Molecular Imaging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020641">Polymorphism, Single Nucleotide</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012984">Software</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25278593</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>21</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1095-9203</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>346</Volume>
<Issue>6205</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>3</Day>
</PubDate>
</JournalIssue>
<Title>Science (New York, N.Y.)</Title>
<ISOAbbreviation>Science</ISOAbbreviation>
</Journal>
<ArticleTitle>The littlest patient.</ArticleTitle>
<Pagination>
<MedlinePgn>24-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1126/science.346.6205.24</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Couzin-Frankel</LastName>
<ForeName>Jennifer</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016433">News</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>10</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Science</MedlineTA>
<NlmUniqueID>0404511</NlmUniqueID>
<ISSNLinking>0036-8075</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C117307">KRAS protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D018631">ras Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Science. 2014 Nov 7;346(6210):710</RefSource>
<PMID Version="1">25378612</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005818">Genetic Engineering</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008817">Mice, Mutant Strains</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009374">Neoplasms, Experimental</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010190">Pancreatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011518">Proto-Oncogene Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016159">Tumor Suppressor Protein p53</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018631">ras Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25079331</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-4687</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>514</Volume>
<Issue>7520</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>2</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity.</ArticleTitle>
<Pagination>
<MedlinePgn>54-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13556</ELocationID>
<Abstract>
<AbstractText>Cancers arise through a process of somatic evolution that can result in substantial sub-clonal heterogeneity within tumours. The mechanisms responsible for the coexistence of distinct sub-clones and the biological consequences of this coexistence remain poorly understood. Here we used a mouse xenograft model to investigate the impact of sub-clonal heterogeneity on tumour phenotypes and the competitive expansion of individual clones. We found that tumour growth can be driven by a minor cell subpopulation, which enhances the proliferation of all cells within a tumour by overcoming environmental constraints and yet can be outcompeted by faster proliferating competitors, resulting in tumour collapse. We developed a mathematical modelling framework to identify the rules underlying the generation of intra-tumour clonal heterogeneity. We found that non-cell-autonomous driving of tumour growth, together with clonal interference, stabilizes sub-clonal heterogeneity, thereby enabling inter-clonal interactions that can lead to new phenotypic traits. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Marusyk</LastName>
<ForeName>Andriy</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA [2] Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA [3] Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tabassum</LastName>
<ForeName>Doris P</ForeName>
<Initials>DP</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA [2] BBS Program, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Altrock</LastName>
<ForeName>Philipp M</ForeName>
<Initials>PM</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA [2] Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA [3] Program for Evolutionary Dynamics, Harvard University, Cambridge, Massachusetts 02138, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Almendro</LastName>
<ForeName>Vanessa</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA [2] Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA [3] Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Michor</LastName>
<ForeName>Franziska</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA [2] Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Polyak</LastName>
<ForeName>Kornelia</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA [2] Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA [3] Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA [4] BBS Program, Harvard Medical School, Boston, Massachusetts 02115, USA [5] Harvard Stem Cell Institute and the Broad Institute, Cambridge, Massachusetts 02138, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>U54 CA143798</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U54CA143798</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017370">Interleukin-11</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002999">Clone Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044127">Epigenesis, Genetic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017370">Interleukin-11</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008954">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059016">Tumor Microenvironment</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS601972 [Available on 04/02/15]</OtherID>
<OtherID Source="NLM">PMC4184961 [Available on 04/02/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25079333</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-4687</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>514</Volume>
<Issue>7520</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>2</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy.</ArticleTitle>
<Pagination>
<MedlinePgn>112-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13541</ELocationID>
<Abstract>
<AbstractText>Chemoresistance is a serious limitation of cancer treatment. Until recently, almost all the work done to study this limitation has been restricted to tumour cells. Here we identify a novel molecular mechanism by which endothelial cells regulate chemosensitivity. We establish that specific targeting of focal adhesion kinase (FAK; also known as PTK2) in endothelial cells is sufficient to induce tumour-cell sensitization to DNA-damaging therapies and thus inhibit tumour growth in mice. The clinical relevance of this work is supported by our observations that low blood vessel FAK expression is associated with complete remission in human lymphoma. Our study shows that deletion of FAK in endothelial cells has no apparent effect on blood vessel function per se, but induces increased apoptosis and decreased proliferation within perivascular tumour-cell compartments of doxorubicin- and radiotherapy-treated mice. Mechanistically, we demonstrate that endothelial-cell FAK is required for DNA-damage-induced NF-ÎºB activation in vivo and in vitro, and the production of cytokines from endothelial cells. Moreover, loss of endothelial-cell FAK reduces DNA-damage-induced cytokine production, thus enhancing chemosensitization of tumour cells to DNA-damaging therapies in vitro and in vivo. Overall, our data identify endothelial-cell FAK as a regulator of tumour chemosensitivity. Furthermore, we anticipate that this proof-of-principle data will be a starting point for the development of new possible strategies to regulate chemosensitization by targeting endothelial-cell FAK specifically. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tavora</LastName>
<ForeName>Bernardo</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Adhesion and Angiogenesis Laboratory, Centre for Tumour Biology, Barts Cancer Institute, CR-UK Centre of Excellence, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Reynolds</LastName>
<ForeName>Louise E</ForeName>
<Initials>LE</Initials>
<AffiliationInfo>
<Affiliation>1] Adhesion and Angiogenesis Laboratory, Centre for Tumour Biology, Barts Cancer Institute, CR-UK Centre of Excellence, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Batista</LastName>
<ForeName>Silvia</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>1] Adhesion and Angiogenesis Laboratory, Centre for Tumour Biology, Barts Cancer Institute, CR-UK Centre of Excellence, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Demircioglu</LastName>
<ForeName>Fevzi</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>1] Adhesion and Angiogenesis Laboratory, Centre for Tumour Biology, Barts Cancer Institute, CR-UK Centre of Excellence, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fernandez</LastName>
<ForeName>Isabelle</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>1] Adhesion and Angiogenesis Laboratory, Centre for Tumour Biology, Barts Cancer Institute, CR-UK Centre of Excellence, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lechertier</LastName>
<ForeName>Tanguy</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>1] Adhesion and Angiogenesis Laboratory, Centre for Tumour Biology, Barts Cancer Institute, CR-UK Centre of Excellence, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lees</LastName>
<ForeName>Delphine M</ForeName>
<Initials>DM</Initials>
<AffiliationInfo>
<Affiliation>1] Adhesion and Angiogenesis Laboratory, Centre for Tumour Biology, Barts Cancer Institute, CR-UK Centre of Excellence, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wong</LastName>
<ForeName>Ping-Pui</ForeName>
<Initials>PP</Initials>
<AffiliationInfo>
<Affiliation>1] Adhesion and Angiogenesis Laboratory, Centre for Tumour Biology, Barts Cancer Institute, CR-UK Centre of Excellence, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Alexopoulou</LastName>
<ForeName>Annika</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Adhesion and Angiogenesis Laboratory, Centre for Tumour Biology, Barts Cancer Institute, CR-UK Centre of Excellence, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Elia</LastName>
<ForeName>George</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Barts Cancer Institute, CR-UK Centre of Excellence, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Clear</LastName>
<ForeName>Andrew</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Centre for Haemato-Oncology, Barts Cancer Institute, CR-UK Centre of Excellence, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ledoux</LastName>
<ForeName>Adeline</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Institute for Cell and Molecular Biosciences (ICaMB), Medical School, Newcastle University, Catherine Cookson Building, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hunter</LastName>
<ForeName>Jill</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Institute for Cell and Molecular Biosciences (ICaMB), Medical School, Newcastle University, Catherine Cookson Building, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Perkins</LastName>
<ForeName>Neil</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Institute for Cell and Molecular Biosciences (ICaMB), Medical School, Newcastle University, Catherine Cookson Building, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gribben</LastName>
<ForeName>John G</ForeName>
<Initials>JG</Initials>
<AffiliationInfo>
<Affiliation>Centre for Haemato-Oncology, Barts Cancer Institute, CR-UK Centre of Excellence, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hodivala-Dilke</LastName>
<ForeName>Kairbaan M</ForeName>
<Initials>KM</Initials>
<AffiliationInfo>
<Affiliation>Adhesion and Angiogenesis Laboratory, Centre for Tumour Biology, Barts Cancer Institute, CR-UK Centre of Excellence, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>C9218/A12007</GrantID>
<Agency>Cancer Research UK</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>G0901609</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>P01 CA95426</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>80168379AG</RegistryNumber>
<NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D051416">Focal Adhesion Protein-Tyrosine Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021581">Active Transport, Cell Nucleus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002467">Cell Nucleus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D004249">DNA Damage</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042783">Endothelial Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051416">Focal Adhesion Protein-Tyrosine Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000532">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25282753</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>24</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0342-9601</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>37</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Medizinische Monatsschrift fÃ¼r Pharmazeuten</Title>
<ISOAbbreviation>Med Monatsschr Pharm</ISOAbbreviation>
</Journal>
<ArticleTitle>[Immunotherapy seems to help in the fight against cancer].</ArticleTitle>
<Pagination>
<MedlinePgn>342-3</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Vetter</LastName>
<ForeName>Christine</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>ger</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>Immuntherapie verspricht Fortschritte im Kampf gegen Krebs.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Med Monatsschr Pharm</MedlineTA>
<NlmUniqueID>7802665</NlmUniqueID>
<ISSNLinking>0342-9601</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000906">Antibodies</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000906">Antibodies</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007167">Immunotherapy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000639">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057285">Individualized Medicine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25282806</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1026-9428</ISSN>
<JournalIssue CitedMedium="Print">
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Meditsina truda i promyshlennaia ekologiia</Title>
<ISOAbbreviation>Med Tr Prom Ekol</ISOAbbreviation>
</Journal>
<ArticleTitle>[Evaluation of carcinogenic risk assessment of metallurgic copper production based on mortality studies and predictive risk values].</ArticleTitle>
<Pagination>
<MedlinePgn>9-12</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Comparative evaluation covered carcinogenic jeopardy at metallurgic copper production through studies of the workers' mortality with malignancies and calculation of individual carcinogenic risks. Findings are that the individual carcinogenic risks calucations correspond to the data obtained in epidemiologic study of the mortality with malignancies and could be used for evaluation of carcinogenic jeopardy.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Russkikh</LastName>
<ForeName>K Iu</ForeName>
<Initials>KIu</Initials>
</Author>
<Author ValidYN="Y">
<LastName>AdrianovskiÄ­</LastName>
<ForeName>V I</ForeName>
<Initials>VI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kuz'mina</LastName>
<ForeName>E A</ForeName>
<Initials>EA</Initials>
</Author>
</AuthorList>
<Language>rus</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Russia (Federation)</Country>
<MedlineTA>Med Tr Prom Ekol</MedlineTA>
<NlmUniqueID>9434213</NlmUniqueID>
<ISSNLinking>1026-9428</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000395">Air Pollutants, Occupational</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002273">Carcinogens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>789U1901C5</RegistryNumber>
<NameOfSubstance UI="D003300">Copper</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000395">Air Pollutants, Occupational</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002273">Carcinogens</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002947">Cities</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D003300">Copper</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008669">Metallurgy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009026">Mortality</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000639">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009784">Occupational Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016272">Occupational Health</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000639">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018570">Risk Assessment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D012426">Russia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012737">Sex Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25285353</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>16</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1062-3388</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>23</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Managed care (Langhorne, Pa.)</Title>
<ISOAbbreviation>Manag Care</ISOAbbreviation>
</Journal>
<ArticleTitle>Health plans' success mixed in managing cancer care programs.</ArticleTitle>
<Pagination>
<MedlinePgn>32-4</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Reinke</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Manag Care</MedlineTA>
<NlmUniqueID>9303583</NlmUniqueID>
<ISSNLinking>1062-3388</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>H</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007348">Insurance, Health</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000458">organization &amp; administration</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008329">Managed Care Programs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000458">organization &amp; administration</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016522">Oncology Service, Hospital</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000458">organization &amp; administration</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015397">Program Evaluation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058996">Quality Improvement</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000458">organization &amp; administration</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011787">Quality of Health Care</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000458">organization &amp; administration</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25282885</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1001-5302</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>39</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica</Title>
<ISOAbbreviation>Zhongguo Zhong Yao Za Zhi</ISOAbbreviation>
</Journal>
<ArticleTitle>[Preparation and characterization of cucurbitacin B sodium deoxycholate/phospholipid-mixed oral fast dissolving film and antitumor activity study].</ArticleTitle>
<Pagination>
<MedlinePgn>1799-804</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>A novel drug delivery system combining oral fast dissolving film with sodium deoxycholate/phospholipid mixed micelles was prepared to increase the absorption of cucurbitacin B that is a poor aqueous solubility substance. Encapsulation efficiency, particle size, zeta potential, polydispersity coefficient, investigated the morphology, disintegration time of oral fast dissolving film and the pharmacodynamic properties of cucurbitacin B sodium deoxycholate/phospholipid-mixed micelles before and after solidified in mice were evaluated and compared. The oral fast dissolving film prepared in this study showed a homogeneous pale yellow and could completely disintegrated in the 30 s. It could meet the requirements of rapidly disintegrating fully. The encapsulation efficiency, particle size, zeta potential, polydispersity coefficient of cucurbitacin B sodium deoxycholate/phospholipid-mixed micelles loaded in oral fast dissolving film were (43.36 +/- 2.12)%, (108.82 +/- 5.2) nm, (-34.18 +/- 1.07) mV, 0.088 +/- 0.012, respectively. The encapsulation efficiency, particle size, zeta potential, polydispersity coefficient of cucurbitacin B sodium deoxycholate/phospholipid-mixed micelles in solution were (41.26 +/- 2.22)%, (181.82 +/- 4.48) nm, (-30.67 +/- 0.81) mV, 0.092 +/- 0.012, respectively. The difference of pharmacodynamics among film of cucurbitacin B-loaded micelles, cucurbitacin B-loaded micelles and free cucurbitacin B in vivo was compared. Solubility of cucurbitacin B loaded in sodium deoxycholate/phospholipid-mixed micelles has also been greatly improved. The tumor inhibition rate of cucurbitacin B loaded in sodium deoxycholate/phospholipid-mixed micelles was significantly improved and did not change significantly before and after solidified. These showed that the sodium deoxycholate/phospholipid-mixed micelles could enhance the antitumor activities of cucurbitacin B and the stability of cucurbitacin B sodium deoxycholate/phospholipid-mixed micelles was improved significantly after solidified by oral fast dissolving film technology without pharmacodynamic properties changed significantly.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>Chao</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xiao</LastName>
<ForeName>Yun-Zhi</ForeName>
<Initials>YZ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xun</LastName>
<ForeName>Ping-Hua</ForeName>
<Initials>PH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dai</LastName>
<ForeName>Ling</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Han</LastName>
<ForeName>Jin</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yuan</LastName>
<ForeName>Hai-Long</ForeName>
<Initials>HL</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>China</Country>
<MedlineTA>Zhongguo Zhong Yao Za Zhi</MedlineTA>
<NlmUniqueID>8913656</NlmUniqueID>
<ISSNLinking>1001-5302</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010743">Phospholipids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014315">Triterpenes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>005990WHZZ</RegistryNumber>
<NameOfSubstance UI="D003840">Deoxycholic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>6199-67-3</RegistryNumber>
<NameOfSubstance UI="C041246">cucurbitacin B</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003840">Deoxycholic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004337">Drug Carriers</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010743">Phospholipids</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012995">Solubility</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014315">Triterpenes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25283007</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0016-254X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>105</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Fukuoka igaku zasshi = Hukuoka acta medica</Title>
<ISOAbbreviation>Fukuoka Igaku Zasshi</ISOAbbreviation>
</Journal>
<ArticleTitle>[Alcohol drinking as a risk factor for cancer].</ArticleTitle>
<Pagination>
<MedlinePgn>111-6</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Matsuo</LastName>
<ForeName>Keitaro</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>jpn</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Japan</Country>
<MedlineTA>Fukuoka Igaku Zasshi</MedlineTA>
<NlmUniqueID>9423321</NlmUniqueID>
<ISSNLinking>0016-254X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>EC 1.2.1.3</RegistryNumber>
<NameOfSubstance UI="C096127">ALDH2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.2.1.3</RegistryNumber>
<NameOfSubstance UI="D000444">Aldehyde Dehydrogenase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000428">Alcohol Drinking</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000444">Aldehyde Dehydrogenase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011110">Polymorphism, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25296439</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2191-7043</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>99</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Progress in the chemistry of organic natural products</Title>
<ISOAbbreviation>Prog Chem Org Nat Prod</ISOAbbreviation>
</Journal>
<ArticleTitle>Bioactive heterocyclic natural products from actinomycetes having effects on cancer-related signaling pathways.</ArticleTitle>
<Pagination>
<MedlinePgn>147-98</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ishibashi</LastName>
<ForeName>Masami</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Austria</Country>
<MedlineTA>Prog Chem Org Nat Prod</MedlineTA>
<NlmUniqueID>101605200</NlmUniqueID>
<ISSNLinking>0071-7886</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001688">Biological Products</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006571">Heterocyclic Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009285">Naphthoquinones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010619">Phenazines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053221">TNF-Related Apoptosis-Inducing Ligand</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D039903">Actinobacteria</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001688">Biological Products</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006571">Heterocyclic Compounds</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009285">Naphthoquinones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010619">Phenazines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053221">TNF-Related Apoptosis-Inducing Ligand</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060449">Wnt Signaling Pathway</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25119042</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-4687</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>514</Volume>
<Issue>7521</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>9</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies.</ArticleTitle>
<Pagination>
<MedlinePgn>247-51</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13561</ELocationID>
<Abstract>
<AbstractText>The polycomb repressive complex 2 (PRC2) exerts oncogenic effects in many tumour types. However, loss-of-function mutations in PRC2 components occur in a subset of haematopoietic malignancies, suggesting that this complex plays a dichotomous and poorly understood role in cancer. Here we provide genomic, cellular, and mouse modelling data demonstrating that the polycomb group gene SUZ12 functions as tumour suppressor in PNS tumours, high-grade gliomas and melanomas by cooperating with mutations in NF1. NF1 encodes a Ras GTPase-activating protein (RasGAP) and its loss drives cancer by activating Ras. We show that SUZ12 loss potentiates the effects of NF1 mutations by amplifying Ras-driven transcription through effects on chromatin. Importantly, however, SUZ12 inactivation also triggers an epigenetic switch that sensitizes these cancers to bromodomain inhibitors. Collectively, these studies not only reveal an unexpected connection between the PRC2 complex, NF1 and Ras, but also identify a promising epigenetic-based therapeutic strategy that may be exploited for a variety of cancers. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>De Raedt</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>1] Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA [2] Harvard Medical School, Boston, Massachusetts 02115, USA [3] Ludwig Center at Dana-Farber/Harvard Cancer Center, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Beert</LastName>
<ForeName>Eline</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Human Genetics, Catholic University Leuven, 3000 Leuven, Belgium [2] [3] Laboratory of Aquatic Biology, Interdisciplinary Research Facility Life Sciences, Katholieke Universiteit, Leuven Afdeling Kortrijk, 8500 Kortrijk, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pasmant</LastName>
<ForeName>Eric</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>1] INSERM UMR_S745 et EA7331, UniversitÃ© Paris Descartes, Sorbonne Paris CitÃ©, FacultÃ© des Sciences Pharmaceutiques et Biologiques, 75006 Paris, France [2] Service de Biochimie et GÃ©nÃ©tique MolÃ©culaire, HÃ´pital Cochin, Assistance Publique-HÃ´pitaux de Paris, 75014 Paris, France [3].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Luscan</LastName>
<ForeName>Armelle</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>1] INSERM UMR_S745 et EA7331, UniversitÃ© Paris Descartes, Sorbonne Paris CitÃ©, FacultÃ© des Sciences Pharmaceutiques et Biologiques, 75006 Paris, France [2] Service de Biochimie et GÃ©nÃ©tique MolÃ©culaire, HÃ´pital Cochin, Assistance Publique-HÃ´pitaux de Paris, 75014 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Brems</LastName>
<ForeName>Hilde</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Human Genetics, Catholic University Leuven, 3000 Leuven, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ortonne</LastName>
<ForeName>Nicolas</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>1] INSERM UMR_S745 et EA7331, UniversitÃ© Paris Descartes, Sorbonne Paris CitÃ©, FacultÃ© des Sciences Pharmaceutiques et Biologiques, 75006 Paris, France [2] Service de Biochimie et GÃ©nÃ©tique MolÃ©culaire, HÃ´pital Cochin, Assistance Publique-HÃ´pitaux de Paris, 75014 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Helin</LastName>
<ForeName>Kristian</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>1] Biotech Research and Innovation Centre (BRIC), University of Copenhagen, 2200 Copenhagen, Denmark [2] Center for Epigenetics, University of Copenhagen, 2200 Copenhagen, Denmark [3] The Danish Stem Cell Center (Danstem), University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hornick</LastName>
<ForeName>Jason L</ForeName>
<Initials>JL</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mautner</LastName>
<ForeName>Victor</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Department of Maxillofacial Surgery, University Medical Centre, Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kehrer-Sawatzki</LastName>
<ForeName>Hildegard</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Institute of Human Genetics, University of Ulm, 89081 Ulm, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Clapp</LastName>
<ForeName>Wade</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Herman Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, 46202 Indianapolis, Indiana, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bradner</LastName>
<ForeName>James</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>1] Harvard Medical School, Boston, Massachusetts 02115, USA [2] Department of Medical Oncology, Dana-Farber Cancer Institute, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Vidaud</LastName>
<ForeName>Michel</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>1] INSERM UMR_S745 et EA7331, UniversitÃ© Paris Descartes, Sorbonne Paris CitÃ©, FacultÃ© des Sciences Pharmaceutiques et Biologiques, 75006 Paris, France [2] Service de Biochimie et GÃ©nÃ©tique MolÃ©culaire, HÃ´pital Cochin, Assistance Publique-HÃ´pitaux de Paris, 75014 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Upadhyaya</LastName>
<ForeName>Meena</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Institute of Medical Genetics, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Legius</LastName>
<ForeName>Eric</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Human Genetics, Catholic University Leuven, 3000 Leuven, Belgium [2] Center for Human Genetics, University Hospital Leuven, 3000 Leuven Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cichowski</LastName>
<ForeName>Karen</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>1] Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA [2] Harvard Medical School, Boston, Massachusetts 02115, USA [3] Ludwig Center at Dana-Farber/Harvard Cancer Center, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>GEO</DataBankName>
<AccessionNumberList>
<AccessionNumber>GSE52777</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C561695">(+)-JQ1 compound</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001381">Azepines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C441289">BRD4 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002843">Chromatin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025542">Neurofibromin 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C488432">SUZ12 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494163">Suz12 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.1.1.43</RegistryNumber>
<NameOfSubstance UI="D063151">Polycomb Repressive Complex 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.12.2</RegistryNumber>
<NameOfSubstance UI="D020929">Mitogen-Activated Protein Kinase Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D018631">ras Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001381">Azepines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016923">Cell Death</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002843">Chromatin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044127">Epigenesis, Genetic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005910">Glioma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008545">Melanoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020929">Mitogen-Activated Protein Kinase Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018317">Nerve Sheath Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025542">Neurofibromin 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063151">Polycomb Repressive Complex 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000172">deficiency</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D014158">Transcription, Genetic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014230">Triazoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025521">Tumor Suppressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018631">ras Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25302366</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0065-2598</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>809</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Advances in experimental medicine and biology</Title>
<ISOAbbreviation>Adv. Exp. Med. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>A20 expressing tumors and anticancer drug resistance.</ArticleTitle>
<Pagination>
<MedlinePgn>65-81</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Resistance to anticancer drugs is a major impediment to treating patients with cancer. The molecular mechanisms deciding whether a tumor cell commits to cell death or survives under chemotherapy are complex. Mounting evidence indicates a critical role of cell death and survival pathways in determining the response of human cancers to chemotherapy. Nuclear factor-kappaB (NF-kappaB) is a eukaryotic transcription factor on the crossroad of a cell's decision to live or die. Under physiological conditions, NF-kappaB is regulated by a complex network of endogenous pathway modulators. Tumor necrosis factor alpha induced protein 3 (tnfaip3), a gene encoding the A20 protein, is one of the cell's own inhibitory molecule, which regulates canonical NF-kappaB activation by interacting with upstream signaling pathway components. Interestingly, A20 is also itself a NF-kappaB dependent gene, that has been shown to also exert cell-type specific anti- or pro-apoptotic functions. Recent reports suggest that A20 expression is increased in a number of solid human tumors. This likely contributes to both carcinogenesis and response to chemotherapy. These data uncover the complexities of the mechanisms involved in A20's impact on tumor development and response to treatment, highlighting tumor and drug-type specific outcomes. While A20-targeted therapies may certainly add to the chemotherapeutic armamentarium, better understanding of A20 regulation, molecular targets and function(s) in every single tumor and in response to any given drug is required prior to any clinical implementation. Current renewed appreciation of the unique molecular signature of each tumor holds promise for personalized chemotherapeutic regimen hopefully comprising specific A20-targeting agents i.e., both inhibitors and enhancers.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>da Silva</LastName>
<ForeName>Cleide GonÃ§alves</ForeName>
<Initials>CG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Minussi</LastName>
<ForeName>Darlan Conterno</ForeName>
<Initials>DC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ferran</LastName>
<ForeName>Christiane</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bredel</LastName>
<ForeName>Markus</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 DK063275</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 HL021796</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 HL080130</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21 DK091822</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Adv Exp Med Biol</MedlineTA>
<NlmUniqueID>0121103</NlmUniqueID>
<ISSNLinking>0065-2598</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="C076529">TNFAIP3 protein, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047908">Intracellular Signaling Peptides and Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25317592</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1476-4687</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>514</Volume>
<Issue>7522</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>16</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>Molecular biology: Remove, reuse, recycle.</ArticleTitle>
<Pagination>
<MedlinePgn>S2-4</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/514S2a</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Eisenstein</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010080">Oxazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>54187-04-1</RegistryNumber>
<NameOfSubstance UI="C032302">rilmenidine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000375">Aging</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000544">Alzheimer Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001343">Autophagy</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035843">Biomedical Research</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000639">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D031204">Caloric Restriction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006678">HIV</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000254">growth &amp; development</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008136">Longevity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010080">Oxazoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010588">Phagosomes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25317593</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1476-4687</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>514</Volume>
<Issue>7522</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>16</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>Q&amp;A: Jules Hoffmann. Fighting fit.</ArticleTitle>
<Pagination>
<MedlinePgn>S5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/514S5a</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hoffmann</LastName>
<ForeName>Jules</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>TÃ¡rnoki</LastName>
<ForeName>AdÃ¡m</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>TÃ¡rnoki</LastName>
<ForeName>DÃ¡vid</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D017203">Interview</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004352">Drug Resistance, Microbial</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008611">Mentors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009613">Nobel Prize</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009765">Obesity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012108">Research Personnel</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013850">Thinking</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014611">Vaccination</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000639">trends</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25317596</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1476-4687</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>514</Volume>
<Issue>7522</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>16</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>Q&amp;A: Michael Bishop. Free thinker.</ArticleTitle>
<Pagination>
<MedlinePgn>S9-10</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/514S9a</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bishop</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Weiskopf</LastName>
<ForeName>Kipp</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D020493">Autobiography</PublicationType>
<PublicationType UI="D019215">Biography</PublicationType>
<PublicationType UI="D016456">Historical Article</PublicationType>
<PublicationType UI="D017203">Interview</PublicationType>
<PublicationType UI="D019477">Portraits</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>EC 2.7.7.49</RegistryNumber>
<NameOfSubstance UI="D012194">RNA-Directed DNA Polymerase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035843">Biomedical Research</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D002140">California</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019295">Computational Biology</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055808">Drug Discovery</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000458">organization &amp; administration</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000639">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004345">Drug Industry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049673">History, 20th Century</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009613">Nobel Prize</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012194">RNA-Directed DNA Polymerase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000266">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012190">Retroviridae</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012907">Smoking</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<PersonalNameSubjectList>
<PersonalNameSubject>
<LastName>Bishop</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</PersonalNameSubject>
</PersonalNameSubjectList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25321898</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>17</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1538-3598</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>312</Volume>
<Issue>15</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>JAMA</Title>
<ISOAbbreviation>JAMA</ISOAbbreviation>
</Journal>
<ArticleTitle>Researchers ponder aspirin's potential in preventing cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>1501-2</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2014.12407</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Rubin</LastName>
<ForeName>Rita</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016433">News</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>JAMA</MedlineTA>
<NlmUniqueID>7501160</NlmUniqueID>
<ISSNLinking>0098-7484</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>R16CO5Y76E</RegistryNumber>
<NameOfSubstance UI="D001241">Aspirin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001241">Aspirin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006471">Gastrointestinal Hemorrhage</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011322">Primary Prevention</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012306">Risk</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25333110</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>21</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>13</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<JournalIssue CitedMedium="Print">
<Volume>17</Volume>
<Issue>Pt 1</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention</Title>
<ISOAbbreviation>Med Image Comput Comput Assist Interv</ISOAbbreviation>
</Journal>
<ArticleTitle>Optimally stabilized PET image denoising using trilateral filtering.</ArticleTitle>
<Pagination>
<MedlinePgn>130-7</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Low-resolution and signal-dependent noise distribution in positron emission tomography (PET) images makes denoising process an inevitable step prior to qualitative and quantitative image analysis tasks. Conventional PET denoising methods either over-smooth small-sized structures due to resolution limitation or make incorrect assumptions about the noise characteristics. Therefore, clinically important quantitative information may be corrupted. To address these challenges, we introduced a novel approach to remove signal-dependent noise in the PET images where the noise distribution was considered as Poisson-Gaussian mixed. Meanwhile, the generalized Anscombe's transformation (GAT) was used to stabilize varying nature of the PET noise. Other than noise stabilization, it is also desirable for the noise removal filter to preserve the boundaries of the structures while smoothing the noisy regions. Indeed, it is important to avoid significant loss of quantitative information such as standard uptake value (SUV)-based metrics as well as metabolic lesion volume. To satisfy all these properties, we extended bilateral filtering method into trilateral filtering through multiscaling and optimal Gaussianization process. The proposed method was tested on more than 50 PET-CT images from various patients having different cancers and achieved the superior performance compared to the widely used denoising techniques in the literature.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mansoor</LastName>
<ForeName>Awais</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bagci</LastName>
<ForeName>Ulas</ForeName>
<Initials>U</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mollura</LastName>
<ForeName>Daniel J</ForeName>
<Initials>DJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Med Image Comput Comput Assist Interv</MedlineTA>
<NlmUniqueID>101249582</NlmUniqueID>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D000465">Algorithms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007089">Image Enhancement</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007090">Image Interpretation, Computer-Assisted</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021621">Imaging, Three-Dimensional</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049268">Positron-Emission Tomography</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015203">Reproducibility of Results</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012680">Sensitivity and Specificity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D012815">Signal Processing, Computer-Assisted</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059629">Signal-To-Noise Ratio</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25333156</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>21</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>13</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<JournalIssue CitedMedium="Print">
<Volume>17</Volume>
<Issue>Pt 1</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention</Title>
<ISOAbbreviation>Med Image Comput Comput Assist Interv</ISOAbbreviation>
</Journal>
<ArticleTitle>Towards personalized interventional SPECT-CT imaging.</ArticleTitle>
<Pagination>
<MedlinePgn>504-11</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The development of modern robotics and compact imaging detectors allows the transfer of diagnostic imaging modalities to the operating room, supporting surgeons to perform faster and safer procedures. An intervention that currently suffers from a lack of interventional imaging is radioembolization, a treatment for hepatic carcinoma. Currently, this procedure requires moving the patient from an angiography suite for preliminary catheterization and injection to a whole-body SPECT/CT for leakage detection, necessitating a second catheterization back in the angiography suite for the actual radioembolization. We propose an imaging setup that simplifies this procedure using a robotic approach to directly acquire an interventional SPECT/CT in the angiography suite. Using C-arm CT and a co-calibrated gamma camera mounted on a robotic arm, a personalized trajectory of the gamma camera is generated from the C-arm CT, enabling an interventional SPECT reconstruction that is inherently co-registered to the C-arm CT. In this work we demonstrate the feasibility of this personalized interventional SPECT/CT imaging approach in a liver phantom study.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gardiazabal</LastName>
<ForeName>JosÃ©</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Esposito</LastName>
<ForeName>Marco</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Matthies</LastName>
<ForeName>Philipp</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Okur</LastName>
<ForeName>Asli</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vogel</LastName>
<ForeName>Jakob</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kraft</LastName>
<ForeName>Silvan</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Frisch</LastName>
<ForeName>Benjamin</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lasser</LastName>
<ForeName>Tobias</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Navab</LastName>
<ForeName>Nassir</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Med Image Comput Comput Assist Interv</MedlineTA>
<NlmUniqueID>101249582</NlmUniqueID>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001918">Brachytherapy</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000295">instrumentation</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007090">Image Interpretation, Computer-Assisted</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057285">Individualized Medicine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064847">Multimodal Imaging</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000532">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019919">Prosthesis Implantation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015641">Radiography, Interventional</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011881">Radiotherapy, Computer-Assisted</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015203">Reproducibility of Results</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012680">Sensitivity and Specificity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015899">Tomography, Emission-Computed, Single-Photon</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014057">Tomography, X-Ray Computed</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25335246</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>13</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0255-2930</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>34</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Zhongguo zhen jiu = Chinese acupuncture &amp; moxibustion</Title>
<ISOAbbreviation>Zhongguo Zhen Jiu</ISOAbbreviation>
</Journal>
<ArticleTitle>[Acupuncture on Tiantu (CV 22) combined with pressing acupiont Danzhong (CV 17) for 26 cancer patients suffering from hiccup].</ArticleTitle>
<Pagination>
<MedlinePgn>746</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ding</LastName>
<ForeName>Xiu-Fang</ForeName>
<Initials>XF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Fang-Ming</ForeName>
<Initials>FM</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>China</Country>
<MedlineTA>Zhongguo Zhen Jiu</MedlineTA>
<NlmUniqueID>8600658</NlmUniqueID>
<ISSNLinking>0255-2930</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019050">Acupressure</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015669">Acupuncture Points</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015670">Acupuncture Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006606">Hiccup</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25338459</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0869-2084</ISSN>
<JournalIssue CitedMedium="Print">
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Klinicheskaia laboratornaia diagnostika</Title>
<ISOAbbreviation>Klin. Lab. Diagn.</ISOAbbreviation>
</Journal>
<ArticleTitle>[The possibilities of modern automated clinical blood analysis in differentiated diagnostic of true and redistributing (functional) iron deficiency under anemic syndrome in oncologic patients].</ArticleTitle>
<Pagination>
<MedlinePgn>21-5</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The clinical blood analysis implemented at modern hematological analyzers can be used as a foundation for primary differentiated diagnostic of anemic syndrome related to true and functional iron deficiency in oncologic patients. The normocyte normochromic anemia with normal and higher level of hemoglobin of reticulocytes (RET-HE) testifies presence in higher degree of anemia of chronic diseases which is more often combined with higher content of serum ferritin (Ferr), lower level of soluble receptors of ferritin (sTfR) and production of erythropoietin (EPO) inadequate to anemia degree. The microcyte hypochromic anemia can be present both under iron-deficient anemia and under functional iron deficiency as a result of its blocking in macrophages under anemia of chronic diseases in oncologic patients. Hence the differentiated diagnostic of these states demands additional analysis of content of serum ferritin, soluble receptors of ferritin and production of erythropoietin.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zubrikhina</LastName>
<ForeName>G N</ForeName>
<Initials>GN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Blinder</LastName>
<ForeName>V N</ForeName>
<Initials>VN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Matveyeva</LastName>
<ForeName>I I</ForeName>
<Initials>II</Initials>
</Author>
</AuthorList>
<Language>rus</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Russia (Federation)</Country>
<MedlineTA>Klin Lab Diagn</MedlineTA>
<NlmUniqueID>9432021</NlmUniqueID>
<ISSNLinking>0869-2084</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D033862">Iron-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C027293">ferritin receptor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>11096-26-7</RegistryNumber>
<NameOfSubstance UI="D004921">Erythropoietin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-73-2</RegistryNumber>
<NameOfSubstance UI="D005293">Ferritins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018798">Anemia, Iron-Deficiency</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057205">Automation, Laboratory</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001774">Blood Chemical Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004921">Erythropoietin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005293">Ferritins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D033862">Iron-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011956">Receptors, Cell Surface</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25344986</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>27</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>13</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0065-2423</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>66</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Advances in clinical chemistry</Title>
<ISOAbbreviation>Adv Clin Chem</ISOAbbreviation>
</Journal>
<ArticleTitle>Procollagen assays in cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>79-100</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The synthesis rates of fibrillar collagens can be assessed in blood by measuring propeptides set free from corresponding procollagens before fiber formation. Type I collagen is the major component of the organic matrix of bone, but it is also found in other connective tissues. The serum concentration of the amino-terminal propeptide of type I procollagen, PINP, functions as a measure of type I collagen synthesis during normal bone turnover, but it is also released from bone metastases that involve an osteoblastic component. Type III collagen is a major constituent of soft tissues and the corresponding amino-terminal propeptide, PIIINP, reflects collagen synthesis. Circulating PIIINP tends to be affected by malignomas that grow in the peritoneal cavity or affect bone marrow. Many studies on procollagen markers in cancer have been cross-sectional or demonstrated treatment effects in patient groups. Markers that originate from bone turnover have wide reference intervals, but low biologic variability in individuals. Thus, they appear better suited for monitoring versus diagnostic purposes. There is still definite need for research on the use of procollagen markers in the followup of individual patients undergoing cancer treatment or being monitored after such treatment.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Risteli</LastName>
<ForeName>Leila</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Koivula</LastName>
<ForeName>Marja-Kaisa</ForeName>
<Initials>MK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Risteli</LastName>
<ForeName>Juha</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Adv Clin Chem</MedlineTA>
<NlmUniqueID>2985173R</NlmUniqueID>
<ISSNLinking>0065-2423</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011347">Procollagen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C047202">procollagen Type I N-terminal peptide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C041876">procollagen Type III-N-terminal peptide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016723">Bone Remodeling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010446">Peptide Fragments</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011347">Procollagen</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25360466</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1439-4413</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>139</Volume>
<Issue>39</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Deutsche medizinische Wochenschrift (1946)</Title>
<ISOAbbreviation>Dtsch. Med. Wochenschr.</ISOAbbreviation>
</Journal>
<ArticleTitle>[Gene therapy - successes and many unsolved questions].</ArticleTitle>
<Pagination>
<MedlinePgn>1916-7</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bruhn</LastName>
<ForeName>Claudia</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>ger</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>Gentherapie--Erfolge und viele ungelÃ¶ste Fragen.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Dtsch Med Wochenschr</MedlineTA>
<NlmUniqueID>0006723</NlmUniqueID>
<ISSNLinking>0012-0472</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000639">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003299">Cooperative Behavior</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005544">Forecasting</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018014">Gene Transfer Techniques</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000639">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005814">Genes, Viral</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015316">Genetic Therapy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000639">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005822">Genetic Vectors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D005858">Germany</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D033183">Interdisciplinary Communication</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057130">Leber Congenital Amaurosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007938">Leukemia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010043">Outcome and Process Assessment (Health Care)</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25354106</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1533-4406</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>371</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>30</Day>
</PubDate>
</JournalIssue>
<Title>The New England journal of medicine</Title>
<ISOAbbreviation>N. Engl. J. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>Applying synthetic lethality for the selective targeting of cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>1725-35</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMra1407390</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>McLornan</LastName>
<ForeName>Donal P</ForeName>
<Initials>DP</Initials>
<AffiliationInfo>
<Affiliation>From King's College Hospital NHS Foundation Trust, London (D.P.M., G.J.M.); and Moffitt Cancer Center, Tampa, FL (A.L.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>List</LastName>
<ForeName>Alan</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mufti</LastName>
<ForeName>Ghulam J</ForeName>
<Initials>GJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>N Engl J Med</MedlineTA>
<NlmUniqueID>0255562</NlmUniqueID>
<ISSNLinking>0028-4793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C117307">KRAS protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.4.2.30</RegistryNumber>
<NameOfSubstance UI="D011065">Poly(ADP-ribose) Polymerases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D018631">ras Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D004260">DNA Repair</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055808">Drug Discovery</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D005804">Genes, Lethal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016259">Genes, myc</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011065">Poly(ADP-ribose) Polymerases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011518">Proto-Oncogene Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018631">ras Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
